PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30800058-8	2019	While sub-threshold of 5-HT1A receptor agonist 8-OH-DPAT potentiated the effects of low dose of resveratrol (10 mg/kg) on CACS-related behavioral abnormalities.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	23-29
30366073-9	2019	Therefore, we suggest that 8-OH-DPAT-induced serotonergic behaviors requires oxidative stress, pro-inflammatory, and pro-apoptotic changes, that PKCdelta or p47phox mediates the serotonergic behaviors induced by 8-OH-DPAT, and that the inhibition of PKCdelta-dependent p47phox activation is critical for protecting against serotonergic behaviors.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	protein kinase C, delta	Mus musculus	145-153
30366073-9	2019	Therefore, we suggest that 8-OH-DPAT-induced serotonergic behaviors requires oxidative stress, pro-inflammatory, and pro-apoptotic changes, that PKCdelta or p47phox mediates the serotonergic behaviors induced by 8-OH-DPAT, and that the inhibition of PKCdelta-dependent p47phox activation is critical for protecting against serotonergic behaviors.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	neutrophil cytosolic factor 1	Mus musculus	157-164
30366073-9	2019	Therefore, we suggest that 8-OH-DPAT-induced serotonergic behaviors requires oxidative stress, pro-inflammatory, and pro-apoptotic changes, that PKCdelta or p47phox mediates the serotonergic behaviors induced by 8-OH-DPAT, and that the inhibition of PKCdelta-dependent p47phox activation is critical for protecting against serotonergic behaviors.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	protein kinase C, delta	Mus musculus	250-258
30366073-9	2019	Therefore, we suggest that 8-OH-DPAT-induced serotonergic behaviors requires oxidative stress, pro-inflammatory, and pro-apoptotic changes, that PKCdelta or p47phox mediates the serotonergic behaviors induced by 8-OH-DPAT, and that the inhibition of PKCdelta-dependent p47phox activation is critical for protecting against serotonergic behaviors.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	neutrophil cytosolic factor 1	Mus musculus	269-276
30366073-9	2019	Therefore, we suggest that 8-OH-DPAT-induced serotonergic behaviors requires oxidative stress, pro-inflammatory, and pro-apoptotic changes, that PKCdelta or p47phox mediates the serotonergic behaviors induced by 8-OH-DPAT, and that the inhibition of PKCdelta-dependent p47phox activation is critical for protecting against serotonergic behaviors.	8-Hydroxy-2-(di-n-propylamino)tetralin	212-221	protein kinase C, delta	Mus musculus	145-153
30565963-3	2018	Administration of serotonin or the serotonin 1A receptor agonist, (+-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), into the prefrontal cortex, inhibits anxiety-like responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-56
30565963-3	2018	Administration of serotonin or the serotonin 1A receptor agonist, (+-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), into the prefrontal cortex, inhibits anxiety-like responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-56
30618734-7	2018	To further unravel this phenomenon, we employed the 5-HT1A receptor agonist [(R)-(+)-8-Hydroxy-DPAT hydrobromide] as a topical cream treatment in an excisional punch biopsy model.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-112	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	52-67
30301302-4	2018	14 days after the surgery, rats were assessed their performance in FST with or without the challenge with a 5-HT1A agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
30366073-0	2019	5-HT1A receptor agonist 8-OH-DPAT induces serotonergic behaviors in mice via interaction between PKCdelta and p47phox.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-15
30366073-0	2019	5-HT1A receptor agonist 8-OH-DPAT induces serotonergic behaviors in mice via interaction between PKCdelta and p47phox.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	protein kinase C, delta	Mus musculus	97-105
30366073-0	2019	5-HT1A receptor agonist 8-OH-DPAT induces serotonergic behaviors in mice via interaction between PKCdelta and p47phox.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	neutrophil cytosolic factor 1	Mus musculus	110-117
30366073-2	2019	The full 5-HT1A receptor (5-HT1AR) agonist (+-)-8-hydroxy-dipropylaminotetralin (8-OH-DPAT) has been recognized to elicit traditional serotonergic behaviors.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	9-24
30366073-2	2019	The full 5-HT1A receptor (5-HT1AR) agonist (+-)-8-hydroxy-dipropylaminotetralin (8-OH-DPAT) has been recognized to elicit traditional serotonergic behaviors.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	26-33
30366073-3	2019	Treatment with 8-OH-DPAT selectively increased PKCdelta expression out of PKC isoforms and 5-HT turnover rate in the hypothalamus of wild-type mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	protein kinase C, delta	Mus musculus	47-55
30366073-4	2019	Treatment with 8-OH-DPAT resulted in oxidative burdens, co-immunoprecipitation of 5-HT1AR and PKCdelta, and phosphorylation and membrane translocation of p47phox.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	protein kinase C, delta	Mus musculus	82-102
30366073-4	2019	Treatment with 8-OH-DPAT resulted in oxidative burdens, co-immunoprecipitation of 5-HT1AR and PKCdelta, and phosphorylation and membrane translocation of p47phox.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	neutrophil cytosolic factor 1	Mus musculus	154-161
30366073-5	2019	Importantly, p47phox also interacted with 5-HT1AR or PKCdelta in the presence of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	neutrophil cytosolic factor 1	Mus musculus	13-20
30366073-5	2019	Importantly, p47phox also interacted with 5-HT1AR or PKCdelta in the presence of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	42-49
30366073-5	2019	Importantly, p47phox also interacted with 5-HT1AR or PKCdelta in the presence of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	protein kinase C, delta	Mus musculus	53-61
30138765-1	2018	The aims of this study were (1) to behaviorally phenotype rats at different ages for both cognitive performance and affect, (2) to evaluate the possible beneficial effects of 8-OH-DPAT (a 5-HT1A receptor agonist) treatments on improving age-related behavioral deficits, and (3) to uncover putative key brain targets (e.g., Fas-associated protein with death domain [FADD] and related partners) that might contribute to the observed age-related behavioral changes.	8-Hydroxy-2-(di-n-propylamino)tetralin	175-184	5-hydroxytryptamine receptor 1A	Rattus norvegicus	188-194
30138765-3	2018	Moreover, multifunctional FADD protein decreased with age specifically in the hippocampus (as compared to the prefrontal cortex) and was further decreased following acute 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	Fas associated via death domain	Rattus norvegicus	26-30
30205142-5	2018	Bath application of 5-CT or 8-OH-DPAT (the 5-HT1A and 5-HT7 receptor agonist) mimicked 5-HT in its effect on mEPSCs.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
30205142-5	2018	Bath application of 5-CT or 8-OH-DPAT (the 5-HT1A and 5-HT7 receptor agonist) mimicked 5-HT in its effect on mEPSCs.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	basigin (Ok blood group)	Rattus norvegicus	56-59
30347827-2	2018	Almost all of the studied compounds (except 5-HT1A receptor agonist (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT)) exhibited absolute cytotoxic activity against the examined cancer cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-128	5-hydroxytryptamine receptor 1A	Homo sapiens	44-59
30347827-2	2018	Almost all of the studied compounds (except 5-HT1A receptor agonist (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT)) exhibited absolute cytotoxic activity against the examined cancer cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Homo sapiens	44-59
30235871-7	2018	Furthermore, we found that both 8-OH-DPAT and DBS treatment rescued autistic behaviors by decreasing the expressions of NR2B subunit of N-methyl-D-aspartate receptors (NMDARs) and the beta3 subunit of gamma-aminobutyric acid type A receptors (GABAAR) in the PFC region.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	120-124
29660440-6	2018	5-HT1A receptor function, as measured by quantitative autoradiography of 8-OH-DPAT (1 muM)-stimulated [35S]GTPgammaS binding, was markedly reduced in hippocampus of weanling female, but not male offspring (postnatal day, PND 21) of dams fed the low protein diet.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15
30209293-6	2018	OXT or the 5-HT1A receptor agonist 8OH-DPAT treatment from postnatal day 7 (PD7) to PD21 ameliorated social abnormality in the three-chamber social interaction test in adult 15q dup mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-43	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	11-26
30209293-7	2018	The effect of 8OH-DPAT was inhibited by blockade of OXT receptors in 15q dup mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-22	oxytocin	Mus musculus	52-55
29660440-6	2018	5-HT1A receptor function, as measured by quantitative autoradiography of 8-OH-DPAT (1 muM)-stimulated [35S]GTPgammaS binding, was markedly reduced in hippocampus of weanling female, but not male offspring (postnatal day, PND 21) of dams fed the low protein diet.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	latexin	Homo sapiens	86-89
29885535-4	2018	administration of histamine precursor, l-histidine significantly attenuated the number of marble buried in marble burying behavior (MBB) test as well as obliterated the persistent behavior induced by 5-HT1A receptor agonist, 8-OH-DPAT in T-Maze test.	8-Hydroxy-2-(di-n-propylamino)tetralin	225-234	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	200-215
29521667-6	2018	The inhibition of 5-HT1A receptors after pretreatment with WAY-100635 blocked the hyperphagic effects evoked by 8-OH-DPAT in OVX.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
30046455-8	2018	We report that male and female offspring of CORT-treated fathers are hypersensitive to sertraline but have normal hypothermic responses to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	cortistatin	Homo sapiens	44-48
29617215-12	2018	In this study, acute intermittent hypercapnia evoked development of phrenic long-term depression (pLTD) 60 min after the last hypercapnic episode that was preserved if the selective 5-HT1A receptor agonist 8-hydroxy-2-(dipropylamino)tetralin hydrobromide was microinjected in the caudal raphe region before the hypercapnic stimulus.	8-Hydroxy-2-(di-n-propylamino)tetralin	206-254	5-hydroxytryptamine receptor 1A	Rattus norvegicus	182-188
29730825-13	2018	Although 18F-F13640 in vivo binding was blocked by the 5-HT1A antagonist WAY-100635 and the 5-HT1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98
29730825-13	2018	Although 18F-F13640 in vivo binding was blocked by the 5-HT1A antagonist WAY-100635 and the 5-HT1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98
29555828-5	2018	5-CT and 8-OH-DPAT significantly decreased the activity and expression of CYP2C11 at both the mRNA and protein levels, which was accompanied by an increase in pituitary and hypothalamic somatostatin levels and a decrease in the serum growth hormone concentration.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	74-81
29555828-5	2018	5-CT and 8-OH-DPAT significantly decreased the activity and expression of CYP2C11 at both the mRNA and protein levels, which was accompanied by an increase in pituitary and hypothalamic somatostatin levels and a decrease in the serum growth hormone concentration.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	gonadotropin releasing hormone receptor	Rattus norvegicus	234-248
29649502-7	2018	The 5-HT1A receptor specificity of 8-OH-DPAT"s action was confirmed as its maternal disruption effect was reversed by pretreatment of WAY-100635 (a highly selective 5-HT1A receptor antagonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
29649502-7	2018	The 5-HT1A receptor specificity of 8-OH-DPAT"s action was confirmed as its maternal disruption effect was reversed by pretreatment of WAY-100635 (a highly selective 5-HT1A receptor antagonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	165-171
29649502-11	2018	These findings suggest that stimulation of 5-HT1A receptors by 8-OH-DPAT impairs maternal care by partially interfering with the attentional processing or basal anxiety.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
31194055-8	2018	Conversely, 8-OH-DPAT (5-HT1A agonist) decreased the antinociceptive effect of paracetamol at 500-1000 mg/kg doses.	8-Hydroxy-2-(di-n-propylamino)tetralin	12-21	5-hydroxytryptamine receptor 1A	Rattus norvegicus	23-29
29339052-2	2018	To provide more detailed information on the processes underlying the alleviation of dyskinesia, we have here investigated changes in the spectral contents of local field potentials in cortico-basal ganglia-thalamic circuits following treatment with this novel group of 5-HT1A agonists or the prototypical agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	314-323	5-hydroxytryptamine receptor 1A	Homo sapiens	269-275
29695693-2	2018	Chronic treatment with 8-Hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) led to a significant decrease in the hypothermic response to acute administration of 8-OH-DPAT in CBA and C57BL/6 mice, which indicates the desensiti-zation of 5-HT1A receptors in both strains.	8-Hydroxy-2-(di-n-propylamino)tetralin	23-62	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	261-267
29695693-2	2018	Chronic treatment with 8-Hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) led to a significant decrease in the hypothermic response to acute administration of 8-OH-DPAT in CBA and C57BL/6 mice, which indicates the desensiti-zation of 5-HT1A receptors in both strains.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	261-267
29475221-5	2018	Seven days later rats entered a protocol of 8-OH-DPAT, a 5-HT1A agonist, in which locomotor activity, ASR and PPI and their tissue levels of 5-HT were measured.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
29057454-2	2018	EXPERIMENTAL APPROACH: We investigated the effects of HU-580 and CBDA on (i) activation by 8-hydroxy-2-(di-n-propylamino)tetralin of human 5-HT1A receptors in CHO cell membranes, using [35 S]-GTPgammaS binding assays, (ii) gaping by rats in acute and anticipatory nausea models, and (iii) stress-induced anxiety-like behaviour, as indicated by exit time from the light compartment of a light-dark box of rats subjected 24 h earlier to six tone-paired foot shocks.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-129	5-hydroxytryptamine receptor 1A	Homo sapiens	139-145
28919453-1	2017	This study was designed to examine an anxiety-like behavior in the adult gonadectomized (GDX) male rats subjected to testosterone propionate (TP) treatment alone or in combination with 8-OH-DPAT, a 5-HT1A receptor agonist, or with NAN-190, 5-HT1A receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	185-194	5-hydroxytryptamine receptor 1A	Rattus norvegicus	198-204
29369737-5	2018	Interestingly, both 8-OH-DPAT (5HT1A agonist) and quipazine (5HT3 agonist) did not elicit contractions in BPCAs.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Bos taurus	31-36
29017144-6	2017	Then, AtF1 was co-administered with different drugs, which act on GABAergic (bicuculline, picrotoxin, pentylenetetrazol, baclofen and phaclofen), or serotononinergic (DOI, 8-OH-DPAT, WAY 100635 and ketanserine) or glutamatergic (NMDA, MPEP and MK-801) systems.	8-Hydroxy-2-(di-n-propylamino)tetralin	172-181	thioredoxin F-type 1	Arabidopsis thaliana	6-10
29088731-10	2017	5-HT1a receptor was located on warm-sensitive neurons in PO/AH area and 8-OH-DPAT (5-HT1a receptor agonist) significantly enhanced the firing rate of warm-sensitive neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
29066953-4	2017	FGF-2 and the 5-HT1A agonist 8-OH-DPAT produced enhanced antidepressant effects in the forced swim test (FST).	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
29066953-6	2017	In control SD rats, the FGFR1 agonist SUN11602 and FGF2 produced a significant reduction of G protein-coupled inwardly rectifying K+ channel (GIRK) currents induced by 8-OH-DPAT in the CA1 area of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	Fibroblast growth factor receptor 1	Rattus norvegicus	24-29
29066953-6	2017	In control SD rats, the FGFR1 agonist SUN11602 and FGF2 produced a significant reduction of G protein-coupled inwardly rectifying K+ channel (GIRK) currents induced by 8-OH-DPAT in the CA1 area of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	fibroblast growth factor 2	Rattus norvegicus	51-55
29066953-6	2017	In control SD rats, the FGFR1 agonist SUN11602 and FGF2 produced a significant reduction of G protein-coupled inwardly rectifying K+ channel (GIRK) currents induced by 8-OH-DPAT in the CA1 area of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	carbonic anhydrase 1	Rattus norvegicus	185-188
29066953-13	2017	8-OH-DPAT treatment alone in the CA2 and CA3 areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	carbonic anhydrase 2	Rattus norvegicus	33-36
29066953-13	2017	8-OH-DPAT treatment alone in the CA2 and CA3 areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	carbonic anhydrase 3	Rattus norvegicus	41-44
29066953-18	2017	The results indicate that in FSL rats compared with SD rats alterations may develop in the ability of 8-OH-DPAT and combined FGFR1 and 5-HT1A agonist treatment to increase the density of FGFR1-5-HT1A heteroreceptor complexes of the dorsal raphe.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
28799955-7	2017	An intra-dPAG injection of the 5-HT1A receptor agonist (+-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) increased the [INCREMENT] threshold in both DBT and NGL, suggesting a panicolytic-like effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
28799955-7	2017	An intra-dPAG injection of the 5-HT1A receptor agonist (+-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) increased the [INCREMENT] threshold in both DBT and NGL, suggesting a panicolytic-like effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
28799955-8	2017	DBT animals presented a more pronounced panicolytic-like response compared with NGL as a higher [INCREMENT] threshold was observed after 8-OH-DPAT treatment, which could be a consequence of the increased expression of the 5-HT1A receptor in the dPAG from DBT animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	137-146	5-hydroxytryptamine receptor 1A	Rattus norvegicus	222-228
29088731-10	2017	5-HT1a receptor was located on warm-sensitive neurons in PO/AH area and 8-OH-DPAT (5-HT1a receptor agonist) significantly enhanced the firing rate of warm-sensitive neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
28483674-5	2017	Treatment with the selective 5-HT reuptake inhibitor (fluoxetine) and 5-HT1A receptor agonist (8-OH-DPAT) during the postnatal period decreased anxiety-like behavior in adulthood, whereas only 8-OH-DPAT treatment increased depression-like behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-104	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	70-85
28606822-7	2017	This point was further validated by the fact that genistein action was potentiated by co-treatment with 8-OH-DPAT, a selective 5-HT1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	127-142
28483674-6	2017	Concomitantly with the behavioral effects, postnatal treatment with fluoxetine and 8-OH-DPAT decreased the mRNA expression of the GABAA receptor alpha3 subunit in the mPFC and ventral hippocampus in adulthood, while 8-OH-DPAT, but not fluoxetine, decreased the mRNA expression of the 5-HT1A receptor and BDNF in the mPFC and the GABAA receptor alpha2 subunit in the mPFC and ventral hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	284-299
28483674-6	2017	Concomitantly with the behavioral effects, postnatal treatment with fluoxetine and 8-OH-DPAT decreased the mRNA expression of the GABAA receptor alpha3 subunit in the mPFC and ventral hippocampus in adulthood, while 8-OH-DPAT, but not fluoxetine, decreased the mRNA expression of the 5-HT1A receptor and BDNF in the mPFC and the GABAA receptor alpha2 subunit in the mPFC and ventral hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	brain derived neurotrophic factor	Mus musculus	304-308
28583050-5	2017	Pretreatment with the selective mu-opioid receptor (MOR) antagonist CTOP (1 nmol) blocked the panicolytic-like effect of the 5-HT1AR agonist 8-OHDPAT (8 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	141-149	opioid receptor mu 1	Homo sapiens	32-50
28347824-10	2017	Association of ineffective doses of Nor-BNI and the 5-HT1A-R agonist 8-OH-DPAT caused panicolytic-like effect in these two tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	52-58
28647281-4	2017	The 5-HT1A agonist, 8-hydroxydipropylaminotetraline (8-OH-DPAT), significantly enhanced nicotine-induced tremor and the action of 8-OH-DPAT was antagonized by WAY-100135 (5-HT1A antagonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-10
28583050-5	2017	Pretreatment with the selective mu-opioid receptor (MOR) antagonist CTOP (1 nmol) blocked the panicolytic-like effect of the 5-HT1AR agonist 8-OHDPAT (8 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	141-149	opioid receptor mu 1	Homo sapiens	52-55
28647281-4	2017	The 5-HT1A agonist, 8-hydroxydipropylaminotetraline (8-OH-DPAT), significantly enhanced nicotine-induced tremor and the action of 8-OH-DPAT was antagonized by WAY-100135 (5-HT1A antagonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	171-177
28647281-4	2017	The 5-HT1A agonist, 8-hydroxydipropylaminotetraline (8-OH-DPAT), significantly enhanced nicotine-induced tremor and the action of 8-OH-DPAT was antagonized by WAY-100135 (5-HT1A antagonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-10
28647281-4	2017	The 5-HT1A agonist, 8-hydroxydipropylaminotetraline (8-OH-DPAT), significantly enhanced nicotine-induced tremor and the action of 8-OH-DPAT was antagonized by WAY-100135 (5-HT1A antagonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	171-177
28540176-7	2017	The results indicate that the expression of Drd1 and Slc6a3 was significantly different after treatment with 8-OH-DPAT, whereas the expression of Drd4 was significantly different after treatment with dapoxetine.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	dopamine receptor D1	Rattus norvegicus	44-48
28540176-7	2017	The results indicate that the expression of Drd1 and Slc6a3 was significantly different after treatment with 8-OH-DPAT, whereas the expression of Drd4 was significantly different after treatment with dapoxetine.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	solute carrier family 6 member 3	Rattus norvegicus	53-59
28070618-10	2017	Furthermore, 8-OH-DPAT-induced corticosterone and adrenocorticotropic hormone (ACTH) release were both attenuated in GABAB1a-/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-22	pro-opiomelanocortin-alpha	Mus musculus	50-77
28237803-4	2017	ACh-induced [Ca2+]i increases in chromaffin cells were also inhibited by the 5-HT1A receptor agonist, 8-hydroxy-2-(dipropylamino) tetralin hydrobromide, but were not changed by the 5-HT1B, 5-HT2, or 5-HT3 receptor agonists, CP93129, alpha-methyl-5-HT, or 1-(m-chlorophenyl) biguanide, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-151	5-hydroxytryptamine receptor 3A	Rattus norvegicus	199-213
27676327-5	2017	The IV administration of 5-HT (10-200 mug/kg) dose dependently decreased the vagally induced bradycardia, and agonists 5-CT (5-HT1/7), 8-OH-DPAT (5-HT1A), or AS-19 (5-HT7) (50 mug/kg each) mimicked the 5-HT-induced inhibitory effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	146-152
28345385-6	2017	To test this hypothesis, we surgically implanted chronic jugular cannulae in adult male rats and conducted bilateral microinjection of vehicle or the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT; 8 nmol, 0.2 muL, 0.1 muL/min, per side) into the dorsomedial hypothalamus (DMH) immediately prior to a 40 min period of restraint stress.	8-Hydroxy-2-(di-n-propylamino)tetralin	175-227	5-hydroxytryptamine receptor 1A	Rattus norvegicus	150-156
27702575-3	2017	Neurons at embryonic day 18 were cultured for 3days or 14days and then treated with 5-HT1A receptor agonist (8-OH-DPAT) for 3h or 24h.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	84-99
27702575-4	2017	In neurons cultured for 3 days, 8-OH-DPAT treatment for both 3h and 24h increased the mRNA levels of BDNF and GluR1, but not GluR2.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	brain derived neurotrophic factor	Mus musculus	101-105
27702575-4	2017	In neurons cultured for 3 days, 8-OH-DPAT treatment for both 3h and 24h increased the mRNA levels of BDNF and GluR1, but not GluR2.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	glutamate receptor, ionotropic, AMPA1 (alpha 1)	Mus musculus	110-115
27702575-4	2017	In neurons cultured for 3 days, 8-OH-DPAT treatment for both 3h and 24h increased the mRNA levels of BDNF and GluR1, but not GluR2.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	125-130
27702575-7	2017	Twenty-four hours after the oral administration of 8-OH-DPAT, the mRNA expression of BDNF was decreased in the frontal cortex, but had no effects on the mRNA expression of GluR1 and GluR2.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	brain derived neurotrophic factor	Mus musculus	85-89
28012414-8	2017	CONCLUSIONS: These findings support the anticonvulsant effect of SSRIs and selective 5HT1A receptors, although serotonin receptors other than 5HT1A subtype may be involved and also it is probable that some anticonvulsant effects of the sertraline and 8-OH-DPAT are through the modulation of nitrergic system.	8-Hydroxy-2-(di-n-propylamino)tetralin	251-260	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	85-90
27461084-8	2017	In vivo electrophysiology in behaving mice showed that long-term potentiation in the hippocampus of 5-HT-deficient mice was altered, and administration of the 5-HT1A agonist 8-OHDPAT rescued the memory deficits.	8-Hydroxy-2-(di-n-propylamino)tetralin	174-182	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	159-165
27544824-7	2016	The 5-HT1A receptor antagonist WAY100635 blocked the inhibition by 5-HT which was mimicked by the 5-HT1A agonist 8-OH-DPAT but not the 5-HT1B agonist CP93129.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-19
26792005-0	2016	Galanin (1-15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	galanin and GMAP prepropeptide	Rattus norvegicus	0-7
26792005-3	2016	GAL(1-15) enhanced the antidepressant effects induced by the 5-HT1AR agonist 8-OH-DPAT in the forced swimming test.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	galanin and GMAP prepropeptide	Rattus norvegicus	0-3
26792005-8	2016	The current results indicate that GAL(1-15) enhances the antidepressant effects induced by 8-OH-DPAT acting on 5-HT1AR operating as postjunctional or as autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	galanin and GMAP prepropeptide	Rattus norvegicus	34-37
27461536-11	2016	The induction of head-twitch response and potentiation of forepaw treading induced by 8-OH-DPAT indicate that hallucinogenic activity seems to be mediated through the stimulation of 5-HT2A and 5-HT1A receptors by 5-MeO-DIPT.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 2A	Rattus norvegicus	182-188
27461536-11	2016	The induction of head-twitch response and potentiation of forepaw treading induced by 8-OH-DPAT indicate that hallucinogenic activity seems to be mediated through the stimulation of 5-HT2A and 5-HT1A receptors by 5-MeO-DIPT.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
27544824-7	2016	The 5-HT1A receptor antagonist WAY100635 blocked the inhibition by 5-HT which was mimicked by the 5-HT1A agonist 8-OH-DPAT but not the 5-HT1B agonist CP93129.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-10
27264435-8	2016	The 5-HT1A agonist, 8-OH-DPAT (0.1-1.0mg/kg), but not the 5-HT1B/1A agonist, RU 24969 (0.3-3.0mg/kg), decreased drug-seeking produced by the reintroduction of a light stimulus that had been paired with self-administered MDMA infusions.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
26227539-6	2016	Experiment 3: Following SSRI administration, 5-HT1A agonist (8-OH-DPAT, 300 microM), which has the effect of decreasing the level of serotonin (5-HT) in the PFC, was administered into the PFC, and microdyalysis and CMG were performed simultaneously.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
26227539-6	2016	Experiment 3: Following SSRI administration, 5-HT1A agonist (8-OH-DPAT, 300 microM), which has the effect of decreasing the level of serotonin (5-HT) in the PFC, was administered into the PFC, and microdyalysis and CMG were performed simultaneously.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	complement factor properdin	Rattus norvegicus	157-160
26227539-6	2016	Experiment 3: Following SSRI administration, 5-HT1A agonist (8-OH-DPAT, 300 microM), which has the effect of decreasing the level of serotonin (5-HT) in the PFC, was administered into the PFC, and microdyalysis and CMG were performed simultaneously.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	complement factor properdin	Rattus norvegicus	188-191
26612522-4	2016	An approach that has undergone considerable empirical research after TBI is pharmacological targeting of 5-HT1A receptors with agonists such as repinotan HCl, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	159-198	5-hydroxytryptamine receptor 1A	Homo sapiens	105-111
27029212-6	2016	The dopamine and noradrenaline responses were suppressed by local infusion of a 5-HT1A receptor agonist, 7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol;hydrobromide, into the prefrontal cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-156	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
26145183-6	2016	Microinjection of the 5-HT1A receptor agonist 8-OH-DPAT caused the opposite effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
27004983-6	2016	Acute administration of the 5-HT1A receptor agonist 8-OH-DPAT resulted in dose-dependent hypothermia and in decreased locomotion in both lines.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	28-43
27004983-7	2016	Chronic 8-OH-DPAT administration abolished the 5-HT1A receptor-mediated hypothermic response in B6-M76C mice and increased locomotor activity in B6-M76B mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	8-17	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	47-62
26612522-4	2016	An approach that has undergone considerable empirical research after TBI is pharmacological targeting of 5-HT1A receptors with agonists such as repinotan HCl, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	200-209	5-hydroxytryptamine receptor 1A	Homo sapiens	105-111
27068481-0	2016	Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	hypocretin	Mus musculus	37-43
27068481-0	2016	Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	80-95
27068481-4	2016	RESULTS: A decrease in locomotor activity in the dark phase was observed in orexin KO mice, and psychostimulants and 5-HT-related compounds, such as 8-OH-DPAT (5-HT1A receptor agonist) and DOI (5-HT2 receptor agonist), inhibited this hypolocomotion.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	160-175
27068481-4	2016	RESULTS: A decrease in locomotor activity in the dark phase was observed in orexin KO mice, and psychostimulants and 5-HT-related compounds, such as 8-OH-DPAT (5-HT1A receptor agonist) and DOI (5-HT2 receptor agonist), inhibited this hypolocomotion.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	hypothermia due to alcohol sensitivity 2	Mus musculus	196-199
27068481-6	2016	In addition, the sleep disorder in orexin KO mice, as analyzed by a polysomnography during the dark period, was completely normalized by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	137-146	hypocretin	Mus musculus	35-41
26856853-7	2016	Dose-effect curves for the 5-HT1A-mediated hyperactivity produced by the 5-HT1A agonist, 8-OH-DPAT, and the 5-HT1B-mediated adipsic response produced by RU 24969 were shifted rightward, suggesting a desensitization of 5-HT1A and 5-HT1B receptor mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Homo sapiens	27-33
26876117-6	2016	Interestingly, co-incubation of heterodimer-expressing HEK 293 cells with clozapine and the 5-HT1 A R agonist 8-OH DPAT potentiated post-synaptic effects, especially with respect to ERK activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Homo sapiens	92-99
26876117-6	2016	Interestingly, co-incubation of heterodimer-expressing HEK 293 cells with clozapine and the 5-HT1 A R agonist 8-OH DPAT potentiated post-synaptic effects, especially with respect to ERK activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	mitogen-activated protein kinase 1	Homo sapiens	182-185
26868970-11	2016	Direct injection of NPY or 8-OH-DPAT (a 5-HT1A receptor agonist that inhibits the activity of 5-HT neurons) into the DRN inhibited male sexual behavior in fed males.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	40-55
26987721-4	2016	The selective noradrenergic and serotonergic uptake blocker duloxetine (20mg/kg) and the selective 5-HT1A agonist 8-OH-DPAT (0.5mg/kg) significantly reversed both mechanical hypersensitivity and depression-like behaviour in CCI animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
26856854-4	2016	OBJECTIVES: This study aimed to determine the effect of extensive MDMA self-administration on behavioral responses to the 5-HT(1A) agonist, 8-hydroxy-2-(n-dipropylamino)tetralin (8-OH-DPAT), and the 5-HT(1B/1A) agonist, RU 24969.	8-Hydroxy-2-(di-n-propylamino)tetralin	179-188	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-129
26856854-4	2016	OBJECTIVES: This study aimed to determine the effect of extensive MDMA self-administration on behavioral responses to the 5-HT(1A) agonist, 8-hydroxy-2-(n-dipropylamino)tetralin (8-OH-DPAT), and the 5-HT(1B/1A) agonist, RU 24969.	8-Hydroxy-2-(di-n-propylamino)tetralin	179-188	5-hydroxytryptamine receptor 1B	Rattus norvegicus	199-206
26950279-5	2016	Moreover, the 5-HT1A receptor agonist 8-OH-DPAT also activated the Akt/GSK-3beta pathway and decreased Abeta1-42-induced tau hyperphosphorylation.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	AKT serine/threonine kinase 1	Rattus norvegicus	67-70
26950279-5	2016	Moreover, the 5-HT1A receptor agonist 8-OH-DPAT also activated the Akt/GSK-3beta pathway and decreased Abeta1-42-induced tau hyperphosphorylation.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	glycogen synthase kinase 3 beta	Rattus norvegicus	71-80
26499475-4	2016	Rats were s.c. injected with 0.75 mg/kg 8-OH-DPAT, a full 5-HT1A agonist, as an animal model of serotonin syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
26749090-7	2016	DMH treatment with 8-OH-DPAT decreased escape responses, which strongly suggests that the 5-HT1A receptor modulates the defensive responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	90-105
25596946-5	2015	Animals were subcutaneously injected with 0.75 mg/kg 8-OH-DPAT, a full 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
26428905-5	2016	Aged (months) VMAT2 LO mice exhibited abolished 5-HT1A autoreceptor sensitivity, as determined by 8-OH-DPAT (0.1 mg/kg) induction of hypothermia.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	14-19
26819921-0	2015	Effect of Buspirone, Fluoxetine and 8-OH-DPAT on Striatal Expression of Bax, Caspase-3 and Bcl-2 Proteins in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	BCL2 associated X, apoptosis regulator	Rattus norvegicus	72-75
26819921-0	2015	Effect of Buspirone, Fluoxetine and 8-OH-DPAT on Striatal Expression of Bax, Caspase-3 and Bcl-2 Proteins in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	caspase 3	Rattus norvegicus	77-86
26819921-0	2015	Effect of Buspirone, Fluoxetine and 8-OH-DPAT on Striatal Expression of Bax, Caspase-3 and Bcl-2 Proteins in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	BCL2, apoptosis regulator	Rattus norvegicus	91-96
26819921-3	2015	In this study we investigated the effect of sub-chronic administration of buspirone, fluoxetine and 8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT) in 6-hydroxydopamine (6-OHDA)-lesioned rats and assayed striatal concentrations of apoptotic (Bax, Caspase3) and anti-apoptotic (Bcl-2) proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	BCL2 associated X, apoptosis regulator	Rattus norvegicus	245-248
26819921-3	2015	In this study we investigated the effect of sub-chronic administration of buspirone, fluoxetine and 8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT) in 6-hydroxydopamine (6-OHDA)-lesioned rats and assayed striatal concentrations of apoptotic (Bax, Caspase3) and anti-apoptotic (Bcl-2) proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	caspase 3	Rattus norvegicus	250-258
26819921-3	2015	In this study we investigated the effect of sub-chronic administration of buspirone, fluoxetine and 8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT) in 6-hydroxydopamine (6-OHDA)-lesioned rats and assayed striatal concentrations of apoptotic (Bax, Caspase3) and anti-apoptotic (Bcl-2) proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	BCL2, apoptosis regulator	Rattus norvegicus	280-285
26819921-6	2015	RESULTS: The results showed that the expression of Bax and caspase3 proteins was increased three weeks after 6-OHDA injection while they were decreased significantly in parkinsonian rats which were treated by buspirone, fluoxetine and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	235-244	BCL2 associated X, apoptosis regulator	Rattus norvegicus	51-54
26819921-6	2015	RESULTS: The results showed that the expression of Bax and caspase3 proteins was increased three weeks after 6-OHDA injection while they were decreased significantly in parkinsonian rats which were treated by buspirone, fluoxetine and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	235-244	caspase 3	Rattus norvegicus	59-67
26819921-7	2015	Bcl-2 was decreased and increased in parkinsonian rats and parkinsonian rats treated with buspirone, fluoxetine and 8-OH-DPAT, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	BCL2, apoptosis regulator	Rattus norvegicus	0-5
25596946-6	2015	8-OH-DPAT-treated rats showed serotonin syndrome-like behaviors (low body posture, forepaw treading), hyperlocomotion, and decreased body temperature, which were completely inhibited by pretreatment with WAY 100635, a selective 5-HT1A antagonist (n = 8).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	228-234
25797491-4	2015	Intra-CeM injection of the selective 5-HT1A receptor agonist 8-OH-DPAT produced anxiolytic effects in the lesioned rats, and decreased the firing rate of CeM GABAergic neurons in two groups of rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
25956878-7	2015	5-HT1A receptors were desensitized in GIRK2 knockout mice, as demonstrated by a lower sensitivity of dorsal raphe neurons to the inhibitory effect of the 5-HT1A receptor agonist, 8-OH-DPAT, and the antidepressant citalopram.	8-Hydroxy-2-(di-n-propylamino)tetralin	179-188	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-6
25957476-7	2015	treatment with FGF-2 and the 5-HT1A agonist 8-OHDPAT synergistically increased FGFR1 and ERK1/2 phosphorylation in the raphe midline area of the midbrain and in the RN33B cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
25957476-7	2015	treatment with FGF-2 and the 5-HT1A agonist 8-OHDPAT synergistically increased FGFR1 and ERK1/2 phosphorylation in the raphe midline area of the midbrain and in the RN33B cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-52	Fibroblast growth factor receptor 1	Rattus norvegicus	79-84
25957476-7	2015	treatment with FGF-2 and the 5-HT1A agonist 8-OHDPAT synergistically increased FGFR1 and ERK1/2 phosphorylation in the raphe midline area of the midbrain and in the RN33B cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-52	mitogen activated protein kinase 3	Rattus norvegicus	89-95
25781502-5	2015	The known hyperphagic effect of the 5-HT1A receptor full agonist 8-OH-DPAT ((+-)-8-hydroxy-N,N-dipropyl-2-aminotetralin) in non-food-deprived animals was demonstrated in male NMRI wild-type mice and could be antagonized by the selective 5-HT1A receptor antagonist WAY100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	36-51
25781502-5	2015	The known hyperphagic effect of the 5-HT1A receptor full agonist 8-OH-DPAT ((+-)-8-hydroxy-N,N-dipropyl-2-aminotetralin) in non-food-deprived animals was demonstrated in male NMRI wild-type mice and could be antagonized by the selective 5-HT1A receptor antagonist WAY100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	237-252
25781502-5	2015	The known hyperphagic effect of the 5-HT1A receptor full agonist 8-OH-DPAT ((+-)-8-hydroxy-N,N-dipropyl-2-aminotetralin) in non-food-deprived animals was demonstrated in male NMRI wild-type mice and could be antagonized by the selective 5-HT1A receptor antagonist WAY100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-119	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	36-51
25781502-5	2015	The known hyperphagic effect of the 5-HT1A receptor full agonist 8-OH-DPAT ((+-)-8-hydroxy-N,N-dipropyl-2-aminotetralin) in non-food-deprived animals was demonstrated in male NMRI wild-type mice and could be antagonized by the selective 5-HT1A receptor antagonist WAY100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-119	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	237-252
25925320-8	2015	The 5-HT(2C) receptor antagonist, RS-102221, and the 5-HT1A receptor agonist, 8-OH-DPAT, attenuated but did not completely block CO2-induced arousal.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	53-68
25922422-10	2015	In contrast, MRN administration of 8-OH-DPAT potentiated the eating-stimulant effect of PVN ghrelin.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	ghrelin and obestatin prepropeptide	Rattus norvegicus	92-99
25850079-3	2015	This study sought to determine whether 5-HT1A receptors within the preBotC and ventral respiratory column (VRC) mediate the tachypneic response induced by intravenous (IV) (+-)-8-Hydroxy-2-diproplyaminotetralin hydrobromide (8-OH-DPAT) in a decerebrated dog model.	8-Hydroxy-2-(di-n-propylamino)tetralin	225-234	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	39-45
25687330-4	2015	Unexpectedly, 5-hydroxytryptamine 1A receptor (5-HT1A) agonist 8-OH-DPAT did not decrease forskolin-induced tau hyperphosphorylation.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Homo sapiens	47-53
25956878-7	2015	5-HT1A receptors were desensitized in GIRK2 knockout mice, as demonstrated by a lower sensitivity of dorsal raphe neurons to the inhibitory effect of the 5-HT1A receptor agonist, 8-OH-DPAT, and the antidepressant citalopram.	8-Hydroxy-2-(di-n-propylamino)tetralin	179-188	potassium inwardly-rectifying channel, subfamily J, member 6	Mus musculus	38-43
25956878-7	2015	5-HT1A receptors were desensitized in GIRK2 knockout mice, as demonstrated by a lower sensitivity of dorsal raphe neurons to the inhibitory effect of the 5-HT1A receptor agonist, 8-OH-DPAT, and the antidepressant citalopram.	8-Hydroxy-2-(di-n-propylamino)tetralin	179-188	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-15
26012255-6	2015	HE staining showed that 8-OH-DPAT treatment could alleviate the occurrence of injury in rats CA3 hippocampus and PFC.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	carbonic anhydrase 3	Rattus norvegicus	93-96
25557801-8	2015	Both the increase and decrease of hypersensitivity induced by amygdaloid glutamate treatment were reversed by medullary administration of a 5-HT1A agonist, 8-OH-DPAT, that presumably produced autoinhibition of serotonergic cell bodies in the medullary raphe.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-146
26012255-7	2015	The neuronal apoptosis index decreased in the 8-OH-DPAT treatment group compared with the NS group (P< 0.05) and gradually increased at 6 h, reached the peak level at 72 h and still had a high performance at 168 h in not only CA3 hippocampus but also PFC.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	carbonic anhydrase 3	Rattus norvegicus	229-232
25288485-3	2015	Using a pharmacological approach, we found that the 5-HT1A agonist 8-OH-DPAT also potentiated the antidepressant-like effects of cytisine, suggesting that this subtype might mediate the interaction between the serotonergic and cholinergic systems.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Homo sapiens	52-58
25482075-6	2015	Furthermore, the application of the selective agonist of 5-HT1A receptors, 8-(OH)-DPAT (10 microM), produced PPR facilitation, while DOI application (5-HT2A agonist) did not change the PPR.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
26080602-1	2015	We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Homo sapiens	33-48
26080602-1	2015	We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 2A	Homo sapiens	152-167
26080602-1	2015	We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Homo sapiens	200-215
26080602-1	2015	We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 2A	Homo sapiens	329-344
26012255-8	2015	Expression of Bax and Bcl-2 increased after DBI + SBI, however, with 8-OH-DPAT treatment Bcl-2 expression increased while Bax expression decreased.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	BCL2 associated X, apoptosis regulator	Rattus norvegicus	14-17
26012255-8	2015	Expression of Bax and Bcl-2 increased after DBI + SBI, however, with 8-OH-DPAT treatment Bcl-2 expression increased while Bax expression decreased.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	BCL2, apoptosis regulator	Rattus norvegicus	22-27
26012255-8	2015	Expression of Bax and Bcl-2 increased after DBI + SBI, however, with 8-OH-DPAT treatment Bcl-2 expression increased while Bax expression decreased.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	BCL2, apoptosis regulator	Rattus norvegicus	89-94
26012255-9	2015	8-OH-DPAT had an inhibitory effect on the rat neuronal apoptosis in CA3 hippocampus and PFC after DBI coupled with SBI.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	carbonic anhydrase 3	Rattus norvegicus	68-71
25359190-0	2015	Moderate role of oxytocin in the pro-ejaculatory effect of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	oxytocin/neurophysin I prepropeptide	Rattus norvegicus	17-25
25451298-6	2015	Intra-PrL injections of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and the GABAA receptor-selective agonist muscimol reduced contextual FPS and freezing responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
26681968-7	2015	Furthermore, (+-)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT; a 5-HT1A receptor agonist) was injected intraperitoneally, and rearing behavior was examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-66	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	81-96
26681968-7	2015	Furthermore, (+-)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT; a 5-HT1A receptor agonist) was injected intraperitoneally, and rearing behavior was examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	81-96
25359190-0	2015	Moderate role of oxytocin in the pro-ejaculatory effect of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
25359190-14	2015	CONCLUSIONS: Activation of OXT neurons plays a moderate role in the pro-ejaculatory effects of systemic 8-OH-DPAT, but extracellular 5-HT levels may influence the strength of the effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	oxytocin/neurophysin I prepropeptide	Rattus norvegicus	27-30
24917195-6	2014	Next, a 5-HT1A agonist, 8-OH-DPAT, was coadministered with CP-154,526 into the DRN to temporarily disrupt 5-HT activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	8-14
25012236-8	2015	Moreover, the concomitant administration of sub-effective doses of Lu AF21934 and a sub-effective dose of the selective 5-HT1A receptor agonist tool compound (R)-(+)-8-hydroxy-DPAT hydrobromide (0.01 mg/kg) induced a clear antipsychotic-like effect in all the procedures used.	8-Hydroxy-2-(di-n-propylamino)tetralin	158-193	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	120-135
26016238-5	2015	Then the antagonist (WAY-100635) or agonist (8-OH-DPAT) of the 5-HT1A receptors were microinjected into the DG region, and the active avoidance learning was measured.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
26016238-8	2015	(3) The microinjection of 8-OH-DPAT(an agonist of 5-HT1A receptor) into the DG significantly facilitated the establishment process and inhibited the extinction process during active avoidance conditioned reflex.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-56
25446927-5	2014	Intracerebroventricular coadministration of a 5HT1A antagonist with 8-OH-DPAT prevented the increase in plasma glucose establishing this response as a centrally mediated response in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	46-51
25220702-8	2014	In contrast, prolactin levels remained similar to those of controls both in hyperestrogenic animals treated with 8-OH-DPAT and pindolol and in hypoestrogenic rats administered the same treatments.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	prolactin	Rattus norvegicus	13-22
25290207-6	2014	Results showed that intra-DMH administration of the 5-HT1A receptor agonist 8-OH-DPAT inhibited escape expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	52-58
25304920-5	2014	The purpose of the present study is to determine 5-HT1A receptor-induced G-protein functional activation by 8-OH-DPAT-stimulated [(35)S]GTPgammaS binding assay in hippocampal tissue of surgical patients with mTLE.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Homo sapiens	49-64
25290207-7	2014	Local administration of the 5-HT1A antagonist WAY-100635 by its own was ineffective, but blocked the panicolytic-like effect of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
25710072-5	2014	Selective 5-HT(1A) receptor agonist 8-OH-DPAT (0.25, 0.5, 1.0 mg/kg (0.76, 1.5 and 3.0 mumol/kg correspondingly), i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	10-27
24679950-7	2014	The PKMzeta peptide blocker ZIP and MEK inhibitor U0126 significantly inhibited the increase in extracellular signal-regulated kinase 1/2 and cyclic adenosine monophosphate response element binding protein phosphorylation in the mitogen-activated protein kinase (MAPK) pathway and hippocampal NSC neurogenesis in response to fluoxetine and the 5-HT1A receptor agonist 8-OH DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	368-377	sequestosome 1	Rattus norvegicus	28-31
24679950-7	2014	The PKMzeta peptide blocker ZIP and MEK inhibitor U0126 significantly inhibited the increase in extracellular signal-regulated kinase 1/2 and cyclic adenosine monophosphate response element binding protein phosphorylation in the mitogen-activated protein kinase (MAPK) pathway and hippocampal NSC neurogenesis in response to fluoxetine and the 5-HT1A receptor agonist 8-OH DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	368-377	mitogen activated protein kinase 3	Rattus norvegicus	96-137
24679950-7	2014	The PKMzeta peptide blocker ZIP and MEK inhibitor U0126 significantly inhibited the increase in extracellular signal-regulated kinase 1/2 and cyclic adenosine monophosphate response element binding protein phosphorylation in the mitogen-activated protein kinase (MAPK) pathway and hippocampal NSC neurogenesis in response to fluoxetine and the 5-HT1A receptor agonist 8-OH DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	368-377	mitogen activated protein kinase 3	Rattus norvegicus	263-267
25191231-3	2014	Here we used agonists that are efficient in promoting locomotor recovery in paraplegic rats, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OHDPAT) (acting on 5-HT1A/7 receptors) and quipazine (acting on 5-HT2 receptors), to examine this issue.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	155-161
25191231-3	2014	Here we used agonists that are efficient in promoting locomotor recovery in paraplegic rats, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OHDPAT) (acting on 5-HT1A/7 receptors) and quipazine (acting on 5-HT2 receptors), to examine this issue.	8-Hydroxy-2-(di-n-propylamino)tetralin	134-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	155-161
25191231-3	2014	Here we used agonists that are efficient in promoting locomotor recovery in paraplegic rats, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OHDPAT) (acting on 5-HT1A/7 receptors) and quipazine (acting on 5-HT2 receptors), to examine this issue.	8-Hydroxy-2-(di-n-propylamino)tetralin	134-142	hypothermia due to alcohol sensitivity 2	Mus musculus	202-205
24830553-7	2014	Previously, it was shown that Ktl is in a complex with the Drosophila 5-HT receptor 5-HT7, and we observed that both Ktl and the 5-HT1A receptor are required in insulin-producing cells (IPCs) for proper adult male behaviour, as well as for hyperaggressive activity induced by the mammalian 5-HT1A receptor agonist 8-hydroxy-2-dipropylaminotetralin-hydrobromide.	8-Hydroxy-2-(di-n-propylamino)tetralin	314-360	Kctd12-like	Drosophila melanogaster	30-33
24830553-7	2014	Previously, it was shown that Ktl is in a complex with the Drosophila 5-HT receptor 5-HT7, and we observed that both Ktl and the 5-HT1A receptor are required in insulin-producing cells (IPCs) for proper adult male behaviour, as well as for hyperaggressive activity induced by the mammalian 5-HT1A receptor agonist 8-hydroxy-2-dipropylaminotetralin-hydrobromide.	8-Hydroxy-2-(di-n-propylamino)tetralin	314-360	Kctd12-like	Drosophila melanogaster	117-120
24830553-7	2014	Previously, it was shown that Ktl is in a complex with the Drosophila 5-HT receptor 5-HT7, and we observed that both Ktl and the 5-HT1A receptor are required in insulin-producing cells (IPCs) for proper adult male behaviour, as well as for hyperaggressive activity induced by the mammalian 5-HT1A receptor agonist 8-hydroxy-2-dipropylaminotetralin-hydrobromide.	8-Hydroxy-2-(di-n-propylamino)tetralin	314-360	5-hydroxytryptamine receptor 1A	Homo sapiens	129-144
24831566-8	2014	The antinociception produced by bicuculline (0.5 nmol) in the DRN was blocked by prior administration of 8-OH-DPAT (0.5 nmol), a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Cavia porcellus	129-135
24258351-4	2014	METHODS: One hundred forty-four Sprague-Dawley rats received injections of para-chlorophenylalanine to partially deplete 5-HT then were given daily systemic pretreatment with the 5-HT1A receptor agonist, 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT), the antagonist, WAY 100635, or vehicle prior to either restraint stress (6 h/day for 10 daily sessions) or control conditions.	8-Hydroxy-2-(di-n-propylamino)tetralin	204-244	5-hydroxytryptamine receptor 1A	Rattus norvegicus	179-185
25720289-1	2014	We found that the inhibitor of Rho-kinase fasudil selectively inhibited constriction of isolated rings of the aorta and mesenteric artery in rats in response to application of the agonists of 5HT2A-(DOI and TBC-2) and 5HT1A-receptors (8-OH-DPAT) and did not influence vasoconstriction induced by serotonin.	8-Hydroxy-2-(di-n-propylamino)tetralin	235-244	5-hydroxytryptamine receptor 2A	Rattus norvegicus	192-197
24090638-7	2014	Concomitant with this elevated receptor expression, the 5-HT1A receptor agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) led to an increased hypothermic response in rictor KO mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-118	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	56-71
24090638-7	2014	Concomitant with this elevated receptor expression, the 5-HT1A receptor agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) led to an increased hypothermic response in rictor KO mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	56-71
24732636-5	2014	We then investigated the effects of (+)-8-OH-DPAT on the expression of brain-derived neurotrophic factor (BDNF) and cyclin D1 (elements of cyclic adenosine monophosphate response element-binding protein (CREB)-BDNF and Wnt signaling pathways, respectively) in the hippocampus of saline- and ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-49	brain-derived neurotrophic factor	Rattus norvegicus	71-104
24732636-5	2014	We then investigated the effects of (+)-8-OH-DPAT on the expression of brain-derived neurotrophic factor (BDNF) and cyclin D1 (elements of cyclic adenosine monophosphate response element-binding protein (CREB)-BDNF and Wnt signaling pathways, respectively) in the hippocampus of saline- and ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-49	brain-derived neurotrophic factor	Rattus norvegicus	106-110
24732636-5	2014	We then investigated the effects of (+)-8-OH-DPAT on the expression of brain-derived neurotrophic factor (BDNF) and cyclin D1 (elements of cyclic adenosine monophosphate response element-binding protein (CREB)-BDNF and Wnt signaling pathways, respectively) in the hippocampus of saline- and ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-49	cyclin D1	Rattus norvegicus	116-125
24732636-6	2014	ACTH treatment significantly decreased the expression of cyclin D1, while treatment with (+)-8-OH-DPAT normalized the expression of cyclin D1 in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-102	cyclin D1	Rattus norvegicus	132-141
24732636-8	2014	These findings suggest that the antidepressant effects of (+)-8-OH-DPAT in treatment-resistant animals may be attributed to an enhancement of hippocampal cell proliferation, at least in part due to an enhancement of cyclin D1 expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-71	cyclin D1	Rattus norvegicus	216-225
24351104-2	2014	A previous study showed that the 5-HT1a receptor agonist (R)-(+)-8-hydroxy-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) significantly reduced the incidence of apnea and the irregular breathing pattern in a mouse model of the disorder.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	33-48
24584836-3	2014	Autoradiographic studies demonstrated down-regulation of 5-HT transporters ([(3)H]citalopram binding) and decreased functionality of 5-HT1A receptors (8-OH-DPAT-stimulated [(35)S]GTPgammaS binding) in the dorsal horn of the lumbar spinal cord in OB rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Rattus norvegicus	133-139
24751161-6	2014	Altered avoidance behaviour of the conditional NCAM mutants was associated with a deficit in serotonergic signalling, as indicated by their reduced responsiveness to (+-)-8-hydroxy-2-(dipropylamino)-tetralin-induced hypothermia.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-207	neural cell adhesion molecule 1	Mus musculus	47-51
24345571-6	2014	First, basal sexual performance was studied after saline treatment followed by treatment of two different doses of the 5-HT1A receptor agonist +-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	143-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
24345571-10	2014	The blunted response of FSL rats to the effects of +-8-OH-DPAT may be due to lower densities of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	96-102
24258351-7	2014	RESULTS: 8-OH-DPAT pretreatment prior to stress exposure attenuated later stress-induced anxiety- and depression-like behaviors and increased GR and BDNF mRNA expression in the hippocampus relative to vehicle- and WAY 100635-pretreated, stressed animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	brain-derived neurotrophic factor	Rattus norvegicus	149-153
24271033-6	2014	The systemic administration of the 5-HT(1A) agonist, 8-OH-DPAT, decreased the firing rate and increased the coefficient of variation of STN neurons in pCPA-treated rats but not in control animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-42
24429224-5	2014	The results showed that both clozapine and norclozapine, although with a 20-fold lower affinity, displaced [3H]8-OH-DPAT binding in all of the brain regions analysed, suggesting their interaction with 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Homo sapiens	201-208
24582850-10	2014	of 8-hydroxy-2-(di-N-propylamino)tetralin, a 5-HT1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	3-41	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	45-60
24381267-5	2014	8-OH-DPAT transiently increased respiratory burst frequency in Lmx1b(f/f/p) preparations, but not in WT slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	LIM homeobox transcription factor 1 beta	Mus musculus	63-68
24421401-7	2014	Effects of the SSRI fluvoxamine and 5-HT(1A)R agonist 8-OH-DPAT were also potentiated in RGS6(+/-) mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	regulator of G-protein signaling 6	Mus musculus	89-93
24174292-5	2014	Systemic administration of 5-HT1A receptor agonist 8-OH-DPAT (0.5-128 microg/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
24528136-4	2014	Coadministration of an NMDA antagonist or 8-hydroxy-2-di-n-propylamino-tetralin [a serotonin (5-HT)1A,7 agonist, DPAT] with GRP limited c-fos expression in the SCN to a region dorsal to GRP cell bodies.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-79	proto-oncogene c-Fos	Mesocricetus auratus	136-141
24211235-9	2014	At 3-4months of age, one set of rats from each group (CON, CMI) was evaluated for the effect of a selective agonist to the 5-HT1A receptor subtype, 8-OH-DPAT, by testing in the FST.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
24211235-10	2014	Also determined was the participation of the pre- or post-synaptic 5-HT1A receptor in the antidepressant-like action of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
24516875-4	2014	In another 10 SG neurons, 8-OH-DPAT in the presence of 5-HT(1A) receptor antagonist WAY-100635 (1 muM) elicited either depolarization (n=6) or no response (n=4); hyperpolarization was not observed.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	55-72
24385311-8	2014	Instead, CUMI-101 behaved as a potent 5-HT1A receptor antagonist by dose-dependently inhibiting 8-OH-DPAT-stimulated (35)S-GTPgammaS binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	38-53
24157794-4	2013	The findings show that coagonist treatment with 8-OH-DPAT and FGF2 but not treatment with the 5-HT1A agonist alone markedly increases the BRETmax values and significantly reduces the BRET50 values of 5HT1A homodimerization.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Homo sapiens	200-205
24570834-0	2013	8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	11-17
24570834-7	2013	Levels of TNF-alpha in CSF increased three weeks after 6-OHDA injection while there was a significant decrease in TNF-alpha level of parkinsonian animals treated with 8-OH-DPAT (1 mg/kg, IP for 10 days).	8-Hydroxy-2-(di-n-propylamino)tetralin	167-176	tumor necrosis factor	Rattus norvegicus	114-123
24570834-8	2013	IL-1beta and IL-6 decreased and increased in parkinsonian rats and in 8-OH-DPAT-treated parkinsonian rats, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	interleukin 1 beta	Rattus norvegicus	0-8
24570834-8	2013	IL-1beta and IL-6 decreased and increased in parkinsonian rats and in 8-OH-DPAT-treated parkinsonian rats, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	interleukin 6	Rattus norvegicus	13-17
23787365-5	2013	The results showed that intra-DMH injection of the 5-HT1A receptor agonist 8-OH-DPAT, the preferential 5-HT2A receptor agonist DOI, but not the 5-HT2C agonist MK-212, inhibited the escape reaction of male Wistar rats evoked by electrical stimulation of the DMH.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	51-57
23787365-5	2013	The results showed that intra-DMH injection of the 5-HT1A receptor agonist 8-OH-DPAT, the preferential 5-HT2A receptor agonist DOI, but not the 5-HT2C agonist MK-212, inhibited the escape reaction of male Wistar rats evoked by electrical stimulation of the DMH.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 2A	Rattus norvegicus	103-109
23924692-7	2013	doses of CBD with the selective 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; i.p.).	8-Hydroxy-2-(di-n-propylamino)tetralin	57-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
24201052-5	2013	Both 8-OH-DPAT (5-HT1A agonist) and quinpirole (D2 agonist) also reduced the immobility time.	8-Hydroxy-2-(di-n-propylamino)tetralin	5-14	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	16-22
24157794-8	2013	Furthermore, FGF2 alone produced a small increase in the BRET(2) signal from the 5-HT1A-beta-arrestin2 receptor-protein complex which was additive to the marked effect of 8-OH-DPAT alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	fibroblast growth factor 2	Homo sapiens	13-17
24157794-8	2013	Furthermore, FGF2 alone produced a small increase in the BRET(2) signal from the 5-HT1A-beta-arrestin2 receptor-protein complex which was additive to the marked effect of 8-OH-DPAT alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	5-hydroxytryptamine receptor 1A	Homo sapiens	81-87
24157794-8	2013	Furthermore, FGF2 alone produced a small increase in the BRET(2) signal from the 5-HT1A-beta-arrestin2 receptor-protein complex which was additive to the marked effect of 8-OH-DPAT alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	arrestin beta 2	Homo sapiens	88-102
23959140-3	2013	Serotonin 1A (5-HT1A) agonist 8-OH-DPAT induced astrocyte proliferation and increased metallothionein-1/-2 (MT-1/-2), antioxidative molecules, in cultured astrocytes and the striatum of mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	metallothionein 1	Mus musculus	86-106
23959140-3	2013	Serotonin 1A (5-HT1A) agonist 8-OH-DPAT induced astrocyte proliferation and increased metallothionein-1/-2 (MT-1/-2), antioxidative molecules, in cultured astrocytes and the striatum of mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	metallothionein 1	Mus musculus	108-115
23786880-0	2013	Estradiol potentiates 8-OH-DPAT-induced sumoylation of 5-HT1A receptor: characterization and subcellular distribution of sumoylated 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
24125784-5	2013	Stimulation of 5-HT1A receptors with 8-OH-DPAT (at 0.0, 2.0, 4.0, and 8.0 mug/0.5 mul/side) caused a dose-dependent decrease in food and water intake, and reduced rearing behavior but not ambulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
23786880-0	2013	Estradiol potentiates 8-OH-DPAT-induced sumoylation of 5-HT1A receptor: characterization and subcellular distribution of sumoylated 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	132-138
23786880-9	2013	Furthermore, SUMO1-5-HT1A-Rs in the DRM were increased by treatment with a 5-HT1A-R agonist, 8-OH-DPAT ((+)8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	small ubiquitin-like modifier 1	Rattus norvegicus	13-18
23786880-9	2013	Furthermore, SUMO1-5-HT1A-Rs in the DRM were increased by treatment with a 5-HT1A-R agonist, 8-OH-DPAT ((+)8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
23786880-9	2013	Furthermore, SUMO1-5-HT1A-Rs in the DRM were increased by treatment with a 5-HT1A-R agonist, 8-OH-DPAT ((+)8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-81
23902597-5	2013	Pretest 5-HT1A receptor activation by 8-OH-DPAT (0.5 but not 0.1 and 0.02 mg kg(-1) ) caused bradycardia and increased HR variability.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	8-23
23786880-9	2013	Furthermore, SUMO1-5-HT1A-Rs in the DRM were increased by treatment with a 5-HT1A-R agonist, 8-OH-DPAT ((+)8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	107-140	small ubiquitin-like modifier 1	Rattus norvegicus	13-18
23786880-9	2013	Furthermore, SUMO1-5-HT1A-Rs in the DRM were increased by treatment with a 5-HT1A-R agonist, 8-OH-DPAT ((+)8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	107-140	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
23786880-9	2013	Furthermore, SUMO1-5-HT1A-Rs in the DRM were increased by treatment with a 5-HT1A-R agonist, 8-OH-DPAT ((+)8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	107-140	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-81
23141373-7	2013	Notably, the PPI deficits induced by 8-OH-DPAT in TR- rats were significantly milder than those observed in their TR+ counterparts; these effects were fully prevented by the 5-HT(1A) antagonist WAY-100135 (10 mg/kg, intraperitoneal).	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	174-181
23780309-2	2013	The present study was therefore designed firstly to investigate the acute effect of 8-OH-DPAT, a mixed 5-HT1A/7 receptor agonist, at a high dose (1 mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	103-109
23774134-10	2013	Fluoxetine (10 mg/kg) stimulated greater increases in c-Fos expression across the extended amygdala in adults than in adolescents, and 8-OH DPAT (0.5 mg/kg) produced greater increases in c-Fos in the lateral orbital cortex and central nucleus of the amygdala in adults.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	187-192
23902597-9	2013	The 5-HT1A receptor antagonist WAY-100635 (0.03 mg kg(-1) ) blocked these effects of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-19
23902597-10	2013	CONCLUSIONS AND IMPLICATIONS: Pre-training 5-HT1A receptor activation by 8-OH-DPAT (0.5 mg kg(-1) ) impaired memory of conditioned auditory fear based on an attenuated HR increase, whereas pretest administration did not prevent the fear-conditioned HR increase but induced pathological HR dynamics through central ANS dysregulation with cardiac effects similar to acute SSRI overdose.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	43-58
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-28
23838274-6	2013	A selective 5-HT1A antagonist (s)-WAY-100135 completely reversed the anti-EPS action of (+-)-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-18
23841816-7	2013	Furthermore, a 1-week administration of the 5-HT1A receptor agonist 8-OH-DPAT in Pet1(-/-) and PCPA-treated mice normalised hippocampal cell survival.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-59
23841816-7	2013	Furthermore, a 1-week administration of the 5-HT1A receptor agonist 8-OH-DPAT in Pet1(-/-) and PCPA-treated mice normalised hippocampal cell survival.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	plasmacytoma expressed transcript 1	Mus musculus	81-85
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	glial fibrillary acidic protein	Mus musculus	99-130
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	glial fibrillary acidic protein	Mus musculus	132-136
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	211-217
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-28
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	glial fibrillary acidic protein	Mus musculus	99-130
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	glial fibrillary acidic protein	Mus musculus	132-136
23692952-4	2013	Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	211-217
23692952-5	2013	The reduction in GFAP staining by 8-OH-DPAT remained significant when a single dose was administered 2h after the toxic challenge.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	glial fibrillary acidic protein	Mus musculus	17-21
23692952-6	2013	In addition, 8-OH-DPAT reversed the increase in the inflammatory factor IL-1beta in the dentate gyrus and amygdala but did not reduce positive TUNEL staining in the dentate gyrus.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-22	interleukin 1 beta	Mus musculus	72-80
23219224-11	2013	Stimulation of 5-HT1A receptors with 8-OH-DPAT increases the sumoylation of Galphaz proteins and reduces the 33 kD Galphaz proteins, suggesting that these responses may be related to the desensitization of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
23680575-2	2013	This study addressed the therapeutic potential of 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a selective 5-HT1A/7 receptor agonist, after mechanical brain injury, and evaluated its effects in terms of acquisition of an allocentric place learning task in a water maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	113-119
23680575-2	2013	This study addressed the therapeutic potential of 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a selective 5-HT1A/7 receptor agonist, after mechanical brain injury, and evaluated its effects in terms of acquisition of an allocentric place learning task in a water maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	113-119
23454471-4	2013	Functional connectivity elicited by administration of the 5-HT(1A)-R agonist 8-OH-DPAT can be described by networks characterized by small-world attributes with nodes displaying highly concerted response patterns.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	58-65
23454471-7	2013	Administration of a specific 5-HT(1A)-R antagonist or use of heterozygous 5-HT(1A)-R knockout mice significantly reduced functional connectivity elicited by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	157-166	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	29-36
23454471-7	2013	Administration of a specific 5-HT(1A)-R antagonist or use of heterozygous 5-HT(1A)-R knockout mice significantly reduced functional connectivity elicited by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	157-166	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	74-81
23219224-11	2013	Stimulation of 5-HT1A receptors with 8-OH-DPAT increases the sumoylation of Galphaz proteins and reduces the 33 kD Galphaz proteins, suggesting that these responses may be related to the desensitization of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	206-212
23473877-9	2013	8-OHDPAT induced OCD was associated with a concomitant decrease in basal 5-HT levels (88%) and depletion of basal CREB (32%) in the frontal cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-8	cAMP responsive element binding protein 1	Mus musculus	114-118
23481219-7	2013	After acute treatment with Julibroside C1 (0.5 mg/kg), [(3)H]-8-OH-DPAT binding was significantly decreased in the CA1 region of the hippocampus and [(3)H]-flunitrazepam binding was decreased remarkably in the cingulate cortex region.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	carbonic anhydrase 1	Mus musculus	115-118
23499701-4	2013	The results showed that intra-BLA injection of the 5-HT1A-R agonist 8-OH-DPAT (0.4-16nmol) in male Wistar rats impaired the acquisition of inhibitory avoidance in the elevated T-maze, increased the percentage of time spent in the lit compartment of the light-dark transition model and enhanced the number of punished drinking events in the Vogel conflict test, all changes compatible with an anxiolytic effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	51-57
23499701-6	2013	8-OH-DPAT-induced changes in the elevated T-maze and light-dark tests were blocked by previous local administration of the 5-HT1A-R antagonist WAY-100635 (0.37nmol) and were also observed after intra-BLA microinjection of the benzodiazepine receptor agonist midazolam (10-40nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
23551660-8	2013	Oxytocin (OXT) in the mPOA and 5-HTT in the DRN were strongly increased by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	oxytocin-neurophysin 1	Callithrix jacchus	0-8
23515792-4	2013	The 5-HT(1A) agonist R(+)-8-OH-DPAT (1 muM) produced outward currents in subpopulations of PAG neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
23551660-8	2013	Oxytocin (OXT) in the mPOA and 5-HTT in the DRN were strongly increased by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	oxytocin-neurophysin 1	Callithrix jacchus	10-13
23551660-8	2013	Oxytocin (OXT) in the mPOA and 5-HTT in the DRN were strongly increased by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	huntingtin	Callithrix jacchus	33-36
23417514-7	2013	Following administration of the 5-HT1A/7 agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), stereotypical head weaving and forepaw treading were increased more in DAT-KO mice than in DAT-WT or -HET mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-87	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-38
23417514-7	2013	Following administration of the 5-HT1A/7 agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), stereotypical head weaving and forepaw treading were increased more in DAT-KO mice than in DAT-WT or -HET mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-87	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	172-175
23417514-7	2013	Following administration of the 5-HT1A/7 agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), stereotypical head weaving and forepaw treading were increased more in DAT-KO mice than in DAT-WT or -HET mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-87	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	192-195
23417514-7	2013	Following administration of the 5-HT1A/7 agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), stereotypical head weaving and forepaw treading were increased more in DAT-KO mice than in DAT-WT or -HET mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-38
23417514-7	2013	Following administration of the 5-HT1A/7 agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), stereotypical head weaving and forepaw treading were increased more in DAT-KO mice than in DAT-WT or -HET mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	172-175
23417514-7	2013	Following administration of the 5-HT1A/7 agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), stereotypical head weaving and forepaw treading were increased more in DAT-KO mice than in DAT-WT or -HET mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	192-195
23354536-4	2013	The response to the 5-HT1a agonist, 8-OHDPAT (0.003-0.5 mg/kg, SC), was assessed using lower lip retraction (LLR), hypoactivity, and 5-hydroxytryptophan (5-HTP) accumulation following decarboxylase inhibition.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-44	5-hydroxytryptamine receptor 1A	Homo sapiens	20-26
23629688-3	2013	The 5-HT-induced inhibition of excitatory postsynaptic currents was partially occluded by NAN-190, a 5-HT1A receptor antagonist, and mimicked by 8-OH-DPAT, a 5-HT1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	158-164
23524167-13	2013	Pretreatment with the serotonin 5-HT1A receptor antagonist WAY100635 (3mg/kg) blocked the anxiolytic-like effect of lavender essential oil and the 5-HT1A receptor agonist 8-OH-DPAT (3mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-47
23524167-13	2013	Pretreatment with the serotonin 5-HT1A receptor antagonist WAY100635 (3mg/kg) blocked the anxiolytic-like effect of lavender essential oil and the 5-HT1A receptor agonist 8-OH-DPAT (3mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	147-162
23486969-5	2013	Direct cortical application of the 5-HT1A/7 agonist 8-OH-DPAT lowered movement thresholds in vivo and increased map size in 5-HT-depleted rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
23299041-7	2013	5-HT1A receptor agonist 8-OH-DPAT (0.2 and 0.5mg/kg) decreased aggressive behavior in both A infant and adult rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15
23121934-7	2013	In cortical neuronal cells, (+)8-OH-DPAT (1 muM) produced an elevation of the pERK 1/2 expression, and the elevated pERK levels were inhibited by WAY 100635, a 5-HT(1A) receptor-specific antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	78-82
23121934-7	2013	In cortical neuronal cells, (+)8-OH-DPAT (1 muM) produced an elevation of the pERK 1/2 expression, and the elevated pERK levels were inhibited by WAY 100635, a 5-HT(1A) receptor-specific antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	116-120
23121934-7	2013	In cortical neuronal cells, (+)8-OH-DPAT (1 muM) produced an elevation of the pERK 1/2 expression, and the elevated pERK levels were inhibited by WAY 100635, a 5-HT(1A) receptor-specific antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	160-177
22591911-9	2013	However, 5-HT1A receptor levels, as measured by [(3)H]-8-OH-DPAT binding, diminished significantly only in dentate gyrus.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	9-15
23303936-13	2013	Bath application of 5-HT and injection of 8-OH-DPAT [(+-)-8-hydroxy-2-di-(n-propylamino) tetralin hydrobromide; 5-HT(1A) agonist; in vivo] reduced respiratory instability and apneas; these effects were greater in stressed pups than controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-119
23164613-3	2013	Here we show that treatment of murine striatal and cortical neuronal cultures with 5-HTR7 agonists (8-OH-DPAT and LP-211) significantly enhances neurite outgrowth.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine (serotonin) receptor 7	Mus musculus	85-89
22993050-6	2013	These effects of 8-OH-DPAT were prevented by the 5-HT(1A) receptor-selective antagonist WAY100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-56
23336054-3	2013	Although the full 5-HT(1A) receptor agonist, 8-OH-DPAT, induced markedly different strain-specific responses in PPI, other selective 5-HT(1A) receptor ligands with partial agonist or antagonist activity elicited similar effects across strains.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	18-35
25206483-10	2013	These results suggest that 8-OH-DPAT inhibits Bax and caspase-3 expression, increases Bcl-2 expression, and reduces neural cell apoptosis, resulting in neuroprotection against diffuse axonal injury.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	BCL2 associated X, apoptosis regulator	Rattus norvegicus	46-49
25206483-10	2013	These results suggest that 8-OH-DPAT inhibits Bax and caspase-3 expression, increases Bcl-2 expression, and reduces neural cell apoptosis, resulting in neuroprotection against diffuse axonal injury.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	caspase 3	Rattus norvegicus	54-63
25206483-10	2013	These results suggest that 8-OH-DPAT inhibits Bax and caspase-3 expression, increases Bcl-2 expression, and reduces neural cell apoptosis, resulting in neuroprotection against diffuse axonal injury.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	BCL2, apoptosis regulator	Rattus norvegicus	86-91
23303936-13	2013	Bath application of 5-HT and injection of 8-OH-DPAT [(+-)-8-hydroxy-2-di-(n-propylamino) tetralin hydrobromide; 5-HT(1A) agonist; in vivo] reduced respiratory instability and apneas; these effects were greater in stressed pups than controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-119
22817866-5	2012	RESULTS: Application of 5-HT or 8-OH-DPAT (a mixed 5-HT1A/5-HT7 agonist) reversed mGluR-LTD in hippocampal slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	51-57
23045340-15	2013	Interestingly, by comparing in vivo and in vitro results, our findings suggest that 8-OH-DPAT-induced hypothermia could be mediated by other targets besides the 5-HT(1A) autoreceptor, including hippocampal 5-HT(7) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	161-168
22809709-10	2013	Finally, we observed that administration of the 5-HT1A receptor agonist 8-OH-DPAT also ameliorated the deficit in PPI observed in DAT KO mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	48-63
22817866-6	2012	Reversal of mGluR-LTD by 8-OH-DPAT persisted in the presence of the 5-HT1A receptor antagonist WAY-100635, was abolished by SB-269970 (5-HT7 receptor antagonist), and was mimicked by LP-211, a novel selective 5-HT7 receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	68-83
22817866-7	2012	Consistently, 8-OH-DPAT decreased mGluR-mediated reduction of AMPA glutamate receptor 2 (GluR2) subunit surface expression in hippocampal slices and cultured hippocampal neurons, an effect mimicked by LP-211 and blocked by SB-269970.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	89-94
22940695-6	2012	As measured by autoradiography with [(3)H]8-hydroxy-2-(di-n-propyl) aminotetralin (8-OH-DPAT), a decrease of 5-HT(1A) receptor specific binding was observed in the posterior/dorsal region of the anterior cingulate gyrus and posterior/ventral area of the superior frontal gyrus of MPTP monkeys compared to controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	109-126
22817866-8	2012	In Fmr1 KO mice, mGluR-LTD was abnormally enhanced; similarly to wild-type, 8-OH-DPAT reversed mGluR-LTD and decreased mGluR-induced reduction of surface AMPA receptors, an effect antagonized by SB-269970.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	fragile X messenger ribonucleoprotein 1	Mus musculus	3-7
22884499-4	2012	Like others, we show that systemic treatment with the active R-enantiomer of the 5-HT1A agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)(5) induces proliferation in the SGZ in rats using unbiased stereology of 5-Bromo-2"-deoxyuridine (BrdU)(6) positive nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
22884499-4	2012	Like others, we show that systemic treatment with the active R-enantiomer of the 5-HT1A agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)(5) induces proliferation in the SGZ in rats using unbiased stereology of 5-Bromo-2"-deoxyuridine (BrdU)(6) positive nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
22884499-5	2012	However, despite the bioactivity of R-8-OH-DPAT, as also shown by a decrease in hippocampal nNOS(7) mRNA levels, it did not increase CNTF mRNA as shown by highly specific quantitative RT-PCR (qPCR)(8).	8-Hydroxy-2-(di-n-propylamino)tetralin	36-47	nitric oxide synthase 1	Rattus norvegicus	92-96
22040681-6	2012	The possible involvement of raphe nucleus 5-HT1A receptors in these behavioural features was examined by 8-OH-DPAT-induced hypothermia.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	42-48
22579773-8	2012	In addition, activation of 5-HT(1A) and 5-HT(1B) receptors by 8-OH-DPAT and CP 94253, known to inhibit the activity of 5-HT neurons, significantly reduced GID, whereas induction of neurotransmitter release by fenfluramine administration significantly increased GID, indicating an involvement of the 5-HT system in the modulation of GID.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-34
22735975-5	2012	Food intake was measured in chickens after centrally administered lipopolysaccharide (LPS) (20 ng) (0 h), followed by intracerebroventricular (ICV) injection of the 5-HT(1A) autoreceptor agonist (8-OH-DPAT, 61 nmol), 5-HT(2c) receptor antagonist (SB 242084, 30 nm), and NMDA receptor antagonist (DL-AP5, 5 nm) at the onset of anorexia (4 h).	8-Hydroxy-2-(di-n-propylamino)tetralin	196-205	5-hydroxytryptamine receptor 1A	Homo sapiens	165-172
22696579-9	2012	We conclude that the vagal-mediated apneic response to MOR activation depends on PCFs, which is fully antagonized by systemic 8-OH-DPAT challenge largely via acting on mNTS 5HT(1A)Rs.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	173-179
22265196-7	2012	Reduction of GPR30 prevented estradiol-induced desensitization of 5-HT(1A) receptor as measured by hormonal responses to the selective 5-HT(1A) receptor agonist, (+)8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	165-174	G protein-coupled estrogen receptor 1	Rattus norvegicus	13-18
22265196-7	2012	Reduction of GPR30 prevented estradiol-induced desensitization of 5-HT(1A) receptor as measured by hormonal responses to the selective 5-HT(1A) receptor agonist, (+)8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	165-174	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-73
22516841-10	2012	The serotoninergic 5-HT(1A) and 5-HT(1B) agonists (8-OH-DPAT and CP94253 respectively) altered the temporal profile of the rotational behaviour supporting a regulatory role.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-26
22705909-6	2012	or selective agonist of 5-HT(1A) receptor (8-hydroxy-2-(di-n-propylamino)tetralin) (8-OH-DPAT, 1mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	43-81	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	24-41
22705909-6	2012	or selective agonist of 5-HT(1A) receptor (8-hydroxy-2-(di-n-propylamino)tetralin) (8-OH-DPAT, 1mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	24-41
22180148-7	2012	Selective inactivation of serotonergic median raphe outputs with the 5-HT-1A agonist (8-OH-DPAT) induced theta that was also abolished by medial septal inactivation using procaine.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-76
22494991-1	2012	Disruption of spontaneous alternation behavior (SAB) by the serotonin 1A (5-HT-1A) receptor agonist, 8-hydroxy-dipropylaminotetraline (8-OH-DPAT), results in repetitive behaviors that have been used to model the perseveration and indecisiveness of human obsessive-compulsive disorder (OCD).	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-81
22988760-2	2012	Calmodulin inhibitors trifluoperazine and W-13 suppress vasoconstriction of the rat aorta in response to norepinephrine, serotonin, and serotonin 5HT1A- and 5HT2A-receptor agonists (8-OH-DPAT and DOI, respectively) and do not affect the vasodilatory effect of 5HT1B-, 5HT2B-, and 5HT4-receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	182-191	calmodulin 1	Rattus norvegicus	0-10
22494991-8	2012	The 5-HT-1A antagonist WAY 100365 blocked the effect 8-OH-DPAT on repetitive choice of arms but not the effect of buspirone on VTE behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
21524335-8	2012	Interestingly, 8-OH-DPAT and MDL11939 partially prevented haloperidol-induced Nur77 up-regulation, while MDL11939 completely abolished Nor-1 expression in the striatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	nuclear receptor subfamily 4, group A, member 1	Mus musculus	78-83
23035563-4	2012	agonist 5-HT(1A) receptors 8-OH-DPAT, [(+)-8-Hydroxy-2-(dipropylamino)tetralin] in a dose of 0.1 mg/kg or antagonist WAY-100635, [N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleat salt] at a dose of 0.2 mg/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-15
22465320-0	2012	Elucidating the role of 5-HT(1A) and 5-HT(7) receptors on 8-OH-DPAT-induced behavioral recovery after experimental traumatic brain injury.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Homo sapiens	24-31
22465320-1	2012	8-OH-DPAT is a 5-HT(1A/7) receptor agonist that enhances behavioral recovery after traumatic brain injury (TBI).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	15-22
22465320-2	2012	This study is a first attempt to decipher whether the benefits induced by 8-OH-DPAT after TBI are mediated by 5-HT(1A) or 5-HT(7) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Homo sapiens	110-117
22465320-9	2012	Evaluation of a specific 5-HT(7) receptor agonist will further elucidate the contribution of 5-HT(1A) and 5-HT(7) receptors on behavioral recovery conferred by acute 8-OH-DPAT treatment after TBI.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-175	5-hydroxytryptamine receptor 1A	Homo sapiens	93-100
22414862-6	2012	These changes could be blocked by the 5-HT(1A) receptor agonist 8-OH-DPAT (0.5 mg/kg, i.p., 30 min before IFN-alpha administration), but not by the standard antidepressant imipramine (10 mg/kg, i.p., 30 min before IFN-alpha administration) although both of them could ameliorate the depressive-like behavior of mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	38-55
22414862-6	2012	These changes could be blocked by the 5-HT(1A) receptor agonist 8-OH-DPAT (0.5 mg/kg, i.p., 30 min before IFN-alpha administration), but not by the standard antidepressant imipramine (10 mg/kg, i.p., 30 min before IFN-alpha administration) although both of them could ameliorate the depressive-like behavior of mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	interferon alpha	Mus musculus	106-115
22414862-6	2012	These changes could be blocked by the 5-HT(1A) receptor agonist 8-OH-DPAT (0.5 mg/kg, i.p., 30 min before IFN-alpha administration), but not by the standard antidepressant imipramine (10 mg/kg, i.p., 30 min before IFN-alpha administration) although both of them could ameliorate the depressive-like behavior of mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	interferon alpha	Mus musculus	214-223
21827451-4	2012	In vitro studies evaluated the potential of CBD to directly target 5-HT(1A) receptors and to modify the ability of the 5-HT(1A) agonist, 8-OH-DPAT, to stimulate [(35) S]GTPgammaS binding in rat brainstem membranes.	8-Hydroxy-2-(di-n-propylamino)tetralin	137-146	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-126
21538661-2	2012	Application of either 5-HT or 8-OH DPAT, a mixed 5-HT(1A)/5-HT(7) receptor agonist, inhibited AMPA receptor-mediated excitatory post synaptic currents (EPSCs); this effect was mimicked by the 5-HT(1A) receptor agonist 8-OH PIPAT and blocked by the 5-HT(1A) antagonist NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	49-56
21538661-2	2012	Application of either 5-HT or 8-OH DPAT, a mixed 5-HT(1A)/5-HT(7) receptor agonist, inhibited AMPA receptor-mediated excitatory post synaptic currents (EPSCs); this effect was mimicked by the 5-HT(1A) receptor agonist 8-OH PIPAT and blocked by the 5-HT(1A) antagonist NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	192-209
21538661-2	2012	Application of either 5-HT or 8-OH DPAT, a mixed 5-HT(1A)/5-HT(7) receptor agonist, inhibited AMPA receptor-mediated excitatory post synaptic currents (EPSCs); this effect was mimicked by the 5-HT(1A) receptor agonist 8-OH PIPAT and blocked by the 5-HT(1A) antagonist NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	192-199
21538661-8	2012	8-OH DPAT also modulated the current evoked by exogenously applied AMPA, inducing either a reduction or an increase of amplitude in distinct neurons; these effects were respectively blocked by 5-HT(1A) and 5-HT(7) receptor antagonists, indicating that both receptors exert a postsynaptic action.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	193-200
22233732-2	2012	We hypothesized that chronic treatment with the 5-HT(1A) agonist 8-OH-DPAT would alter the glucose metabolism index in dorsal raphe (DR), medial prefrontal cortex (mPFC), medial preoptic area of hypothalamus (mPOA), ventromedial nucleus of hypothalamus (VMH), and field CA1 of hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	LOW QUALITY PROTEIN: carbonic anhydrase 1	Callithrix jacchus	270-273
21221824-3	2012	MATERIALS AND METHODS: Here, we performed central injections of 5-HT1A agonist (8-OHDPAT) or antagonist (WAY100635) in anesthetized rats and analyzed changes in the electromyographic activity of several UAM and other cardiorespiratory parameters.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	64-70
22690554-2	2012	Administration of 5-HT(1A)-receptors agonist 8-OH-DPAT at low dose (0.1 mg/kg) affecting upon presynaptic receptors resulted in immunostimulation in CBA mice and did not change the immune response level in mice of ASC strain.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	18-25
22690554-2	2012	Administration of 5-HT(1A)-receptors agonist 8-OH-DPAT at low dose (0.1 mg/kg) affecting upon presynaptic receptors resulted in immunostimulation in CBA mice and did not change the immune response level in mice of ASC strain.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	steroid sulfatase	Mus musculus	214-217
22690554-3	2012	Activation of postsynaptic 5-HT(1A)-receptors with higher dose of 8-OH-DPAT (1.0 mg/kg) caused immunosuppression in CBA and AKR strains while under the same conditions the immune response of ASC mice was increased.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	27-34
22690554-3	2012	Activation of postsynaptic 5-HT(1A)-receptors with higher dose of 8-OH-DPAT (1.0 mg/kg) caused immunosuppression in CBA and AKR strains while under the same conditions the immune response of ASC mice was increased.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	steroid sulfatase	Mus musculus	191-194
22690554-4	2012	Decrease the immune reactions in ASC mice was observed only after application of 8-OHDPAT at dose of 5 mg/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-89	steroid sulfatase	Mus musculus	33-36
22221104-4	2012	KEY FINDINGS: The results demonstrated that the 5-HT(1A) agonist 8-OH-DPAT (s.c.) induced reductions in duration of LORR at 0.1, 0.5 and 1.0 mg/kg (P < 0.01), and prolongation of LORR latency at 0.5 and 1.0 mg/kg (s.c., P < 0.01) in pentobarbital (45 mg/kg, i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	48-55
22221104-6	2012	This effect of 8-OH-DPAT was antagonized either by 5-HT(1A) antagonist p-MPPI (5 mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	51-58
22221104-12	2012	On the other hand, spinosin inhibited 8-OH-DPAT-induced hypothermia, which has been generally attributed to the activation of somatodendritic 5-HT(1A) autoreceptors in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	142-149
22221104-13	2012	CONCLUSIONS: Based on our previous results and the present data, it should be presumed that presynaptic 5-HT(1A) autoreceptor mechanisms may be involved in the inhibitory effect of spinosin on 8-OH-DPAT-induced hypothermia and also in the potentiating effect of spinosin on pentobarbital-induced LORR in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	193-202	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	104-111
22031471-8	2012	Fluoxetine attenuated hypothermia induced by the 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin, decreased DR 5-HT neuronal activity, and decreased 5-HT release in both vehicle- and corticosterone-pretreated mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-113	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	49-66
22074644-7	2012	Binding of [(3)H]-8-OH-DPAT was significantly higher in the frontal associated cortex (FrA), nucleus accumbens (NAc), and the cingulate cortex (CC) of TRPV1KO mice than WT mice, while the expression of 5-HT(1A) receptors was higher in the FrA, NAc, and cortex of TRPV1KO mice than WT mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	151-156
22074644-7	2012	Binding of [(3)H]-8-OH-DPAT was significantly higher in the frontal associated cortex (FrA), nucleus accumbens (NAc), and the cingulate cortex (CC) of TRPV1KO mice than WT mice, while the expression of 5-HT(1A) receptors was higher in the FrA, NAc, and cortex of TRPV1KO mice than WT mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	202-209
21221824-4	2012	We also compared the pattern of Fos expression induced after central injection of a control solution or 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-112	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	32-35
21221824-10	2012	This restricted pattern of Fos expression likely identified the neural substrate responsible for the enhancement of UAM respiratory activity observed after 8-OHDPAT injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-164	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	27-30
21982918-11	2011	The stress response was abolished following 8-OH-DPAT or muscimol microinjection suggesting the cardiovascular responses to stress are mediated by the NRP and likely involve the 5HT(1A) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	Nrp	Rattus norvegicus	151-154
22849969-5	2012	The effects of 8-OH-DPAT and d-fenfluramine were blocked by pretreatment with the selective 5-HT(1A) receptor antagonist WAY-100635 (0.01 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	92-109
21946431-5	2012	The results showed that activation of 5-HT1A receptors by 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) increased phosphorylation of the N-terminal serine of both GSK3alpha and GSK3beta in several areas of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-96	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	38-44
21946431-5	2012	The results showed that activation of 5-HT1A receptors by 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) increased phosphorylation of the N-terminal serine of both GSK3alpha and GSK3beta in several areas of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-96	glycogen synthase kinase 3 alpha	Mus musculus	168-177
21946431-5	2012	The results showed that activation of 5-HT1A receptors by 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) increased phosphorylation of the N-terminal serine of both GSK3alpha and GSK3beta in several areas of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-96	glycogen synthase kinase 3 beta	Mus musculus	182-190
21946431-5	2012	The results showed that activation of 5-HT1A receptors by 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) increased phosphorylation of the N-terminal serine of both GSK3alpha and GSK3beta in several areas of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	38-44
21946431-5	2012	The results showed that activation of 5-HT1A receptors by 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) increased phosphorylation of the N-terminal serine of both GSK3alpha and GSK3beta in several areas of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	glycogen synthase kinase 3 alpha	Mus musculus	168-177
21946431-5	2012	The results showed that activation of 5-HT1A receptors by 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) increased phosphorylation of the N-terminal serine of both GSK3alpha and GSK3beta in several areas of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	glycogen synthase kinase 3 beta	Mus musculus	182-190
21946431-6	2012	The effect of 8-OH-DPAT was accompanied by an increase in the active phosphorylation of Akt, and was blocked by LY294002, an inhibitor of phosphoinositide 3-kinases (PI3K).	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	thymoma viral proto-oncogene 1	Mus musculus	88-91
21946431-6	2012	The effect of 8-OH-DPAT was accompanied by an increase in the active phosphorylation of Akt, and was blocked by LY294002, an inhibitor of phosphoinositide 3-kinases (PI3K).	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	138-164
21780177-2	2012	The selective 5-HT1A receptor agonist, 8-OH-DPAT((R)-(+)-8-hydroxy-2-(di-n-propylamino) tetralin), reversed detrusor-sphincter dyssynergia (DSD) in the spinal cord injury (SCI) rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
22509307-0	2012	The 5HT1a receptor agonist 8-Oh DPAT induces protection from lipofuscin accumulation and oxidative stress in the retinal pigment epithelium.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-18
22509307-7	2012	8-OH DPAT reduced superoxide generation and increased mitochondrial superoxide dismutase (MnSOD) levels and the ratio of reduced glutathione to the oxidized form of glutathione in H(2)O(2)-treated cells compared to controls and protected against H(2)O(2)-initiated lipid peroxidation, nitrotyrosine levels and mitochondrial damage.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	superoxide dismutase 2, mitochondrial	Mus musculus	90-95
22509307-9	2012	Systemic administration of 8-OH DPAT improved the electroretinogram response in SOD2 knockdown eyes of mice compared to knockdown eyes receiving vehicle control.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	superoxide dismutase 2, mitochondrial	Mus musculus	80-84
22509307-10	2012	There was a significant increase in the ONL thickness in mice treated with 8-OH DPAT at 4 months past the time of MnSOD knockdown compared to untreated controls together with a 60% reduction in RPE lipofuscin.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	superoxide dismutase 2, mitochondrial	Mus musculus	114-119
21982809-4	2011	Bilateral intra-MPFC administration of 5HT(1A) receptor agonist, 8-OH-DPAT (5, 10, and 50 ng/rat) decreased the percentages of open arm time (OAT%) and open arm entries (OAE%), indicating an anxiogenic response.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
21817925-4	2011	Further, eating elicited by dorsal and median raphe injections of the 5-HT1A agonist 8-OH-DPAT (0.8 nmol) was attenuated by L-NAME or 7-NI pretreatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-76
21964386-2	2011	produced stronger hypothermic effect in mice than activation of 5-HT(1A) receptors by their agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propilamino)tetralin) injected by the same route at an equimolar dose.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	64-71
21964386-6	2011	5-HT(1A) receptor agonist 8-OH-DPAT (40 nM i.c.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-17
21471397-6	2011	5-HT(1A) receptor stimulation with 8-hydroxy-2-(di-propylamino)tetralin (8-OH-DPAT) postponed HSD by up to 40%, mediating genotype-independent protection.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-71	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-17
21899601-2	2011	Application of the 5-HT(1A)  receptor (5-HT(1A) R) agonist 8-OH-DPAT was shown (i) to depress cellular cAMP, leading to dephosphorylation of Glyalpha(3) R and augmentation of postsynaptic inhibition of neurons expressing Glyalpha(3) R (Manzke et al., 2010) and (ii) to hyperpolarize respiratory neurons through 5-HT-activated potassium channels.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	19-26
21899601-2	2011	Application of the 5-HT(1A)  receptor (5-HT(1A) R) agonist 8-OH-DPAT was shown (i) to depress cellular cAMP, leading to dephosphorylation of Glyalpha(3) R and augmentation of postsynaptic inhibition of neurons expressing Glyalpha(3) R (Manzke et al., 2010) and (ii) to hyperpolarize respiratory neurons through 5-HT-activated potassium channels.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	39-46
21635907-2	2011	To better characterize this possible mechanism, c-fos immunohistochemistry was first used to determine the effects of systemic administration of the full 5-HT1AR agonist +-8-OH-DPAT on L-Dopa-induced immediate early gene expression within M1 and the prefrontal cortex (PFC) of rats with unilateral medial forebrain bundle (MFB) dopamine (DA) lesions.	8-Hydroxy-2-(di-n-propylamino)tetralin	172-181	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	48-53
21635907-5	2011	While no treatment effects were seen within the PFC, systemic +-8-OH-DPAT suppressed L-Dopa-induced c-fos within M1.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	100-105
21610139-6	2011	Inhibition of neurons in the dorsomedial hypothalamus (DMH) or rostral raphe pallidus nucleus (rRPa) with muscimol or activation of 5-HT1A receptors in the rRPa with 8-OH-DPAT eliminated the shivering, BAT thermogenic, tachycardic and pressor responses evoked by skin cooling or by nanoinjection of prostaglandin (PG) E2, a pyrogenic mediator, into the MPO.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-175	5-hydroxytryptamine receptor 1A	Rattus norvegicus	132-138
21471397-6	2011	5-HT(1A) receptor stimulation with 8-hydroxy-2-(di-propylamino)tetralin (8-OH-DPAT) postponed HSD by up to 40%, mediating genotype-independent protection.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-17
21412223-8	2011	Early adolescent pretreatment with the mixed autoreceptor/heteroceptor 5-HT1A receptor agonist, 8-OH-DPAT, but not the autoreceptor-selective agonist, S-15535, also enhanced quinpirole-induced locomotor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
20656461-4	2011	We show that administration of the 5-HT(1A) receptor agonist 8-OH-DPAT prompts a dose-dependent reduction in local cerebral blood volume (CBV) in brain areas rich in neurons expressing post-synaptic 5-HT(1A) receptor, including the prefrontal cortex, hippocampus and amygdalar nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	35-52
21316388-4	2011	Agonist of 5-HT(1A) receptor (8-OH-DPAT) or 5-HT(2A/2C) receptor (DOI) attenuated fur cleaning at a dose of 1 mg/kg but not of 0.2 mg/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	11-28
21301323-3	2011	A second objective was to explore the participation of 5-HT1A receptors in the effects of clomipramine and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
21301323-6	2011	Clomipramine and 8-OH-DPAT decreased the burying behavior in both strains of rats through a direct interaction with the 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	120-126
21445531-7	2011	SIN-1 increased the distance traveled (mean +- SEM) in the open-field test (4431 +- 306.1 cm; F(7,63) = 2.44, P = 0.028) and this effect was blocked by previous 8-OH-DPAT (2885 +- 490.4 cm) or AP7 (3335 +- 283.5 cm) administration (P < 0.05, Duncan test).	8-Hydroxy-2-(di-n-propylamino)tetralin	161-170	MAPK associated protein 1	Homo sapiens	0-5
20656461-4	2011	We show that administration of the 5-HT(1A) receptor agonist 8-OH-DPAT prompts a dose-dependent reduction in local cerebral blood volume (CBV) in brain areas rich in neurons expressing post-synaptic 5-HT(1A) receptor, including the prefrontal cortex, hippocampus and amygdalar nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	199-216
20656461-5	2011	Region-specific inhibition of the response by co-injection of 8-OH-DPAT with the selective 5-HT(1A) receptor antagonist WAY-100635, or in 5-HT(1A) knock-out mice, suggests that 5-HT(1A) receptors are the primary targets of the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	91-108
20656461-5	2011	Region-specific inhibition of the response by co-injection of 8-OH-DPAT with the selective 5-HT(1A) receptor antagonist WAY-100635, or in 5-HT(1A) knock-out mice, suggests that 5-HT(1A) receptors are the primary targets of the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	91-98
21886599-4	2011	PCP-induced abnormal behaviors were significantly attenuated by GE, and these effects were comparable to those of 8-OH-DPAT, a 5-HT(1A) receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	127-144
21070242-7	2011	However, 8-OH-DPAT-stimulated [(35) S] GTPgammaS binding in the BTBR hippocampal CA(1) region was 28% higher, indicating elevated 5-HT(1A) capacity to activate G-proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	130-137
20959966-1	2011	INTRODUCTION: In rats, activation of medial septum (MS) 5-HT(1A) receptors with the 5-HT(1A)/5-HT(7) receptor agonist 8-OH-DPAT disrupts encoding and consolidation, but not retrieval of a spatial memory in the water maze task.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-63
20959966-1	2011	INTRODUCTION: In rats, activation of medial septum (MS) 5-HT(1A) receptors with the 5-HT(1A)/5-HT(7) receptor agonist 8-OH-DPAT disrupts encoding and consolidation, but not retrieval of a spatial memory in the water maze task.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-91
20959966-2	2011	These findings might be explained by an action of 8-OH-DPAT on 5-HT(1A) receptors located on cholinergic neurons which the drug could transiently hyperpolarise.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-70
20980537-6	2011	Application of agonists selective to 5-HT(2B) and 5-HT(2C) receptors (including BW723C86) significantly increased the LLRs and associated Ca PICs, whereas application of agonists to 5-HT(1), 5-HT(2A), 5-HT(3), or 5-HT(4/5/6/7) receptors (e.g., 8-OH-DPAT) did not.	8-Hydroxy-2-(di-n-propylamino)tetralin	244-253	5-hydroxytryptamine receptor 2B	Rattus norvegicus	37-44
21107539-4	2011	OBJECTIVES: The objectives of this study are to assess the anti-aggressive effects of 5-HT(1A) (8-OH-DPAT) and 5-HT(1B) (CP-93,129) receptor agonists microinjected into DRN and VO PFC, respectively, and to study the aggressive behavior in postpartum female Wistar rats using the social instigation protocol to increase aggression.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-93
20971089-9	2011	The 5-HT-induced hyperpolarizing effects were mimicked by 8-OH-DPAT (5-HT(1A) receptor agonist) and alpha-methyl-5-HT (5-HT(2) receptor agonist) and blocked by WAY-100635 (5-HT(1A) receptor antagonist) and ketanserin (5-HT(2) receptor antagonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	69-86
20638418-5	2010	Injections of 8-OH-DPAT (a 5-HT(1A) agonist) blocked water intake and increased urinary excretion, while pMPPF or the OT antagonist injected bilaterally before 8-OH-DPAT blocked its inhibitory effect on water intake and its diuretic effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-34
21446059-1	2011	It has been shown that the agonist of 5HT1A-receptors 8-OH-DPAT induces contraction of aortic rings in the presence of angiotensin II.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	angiotensinogen	Rattus norvegicus	119-133
21446059-2	2011	This effect is not associated with activation of alpha1-adrenoceptors by 8-OH-DPAT as it is reproduced in the presence of prazosin which completely suppresses the nonspecific vasoconstrictive effect of 8-OH-DPAT via alpha1-adrenoceptors on the aorta incubated without angiotensin II.	8-Hydroxy-2-(di-n-propylamino)tetralin	202-211	angiotensinogen	Rattus norvegicus	268-282
20451559-5	2010	The results showed that DRN administration of the 5-HT(1A) receptor agonist 8-OH-DPAT which inhibits the activity of 5-HT neurons favored the expression of escape induced by SIN-1.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	MAPK associated protein 1	Homo sapiens	174-179
20457184-6	2010	The involvement of 5HT-1A receptors in behavioural response was assessed by measuring mRNA expression in cell bodies (raphe nuclei) and projection regions (frontal cortex, hippocampus) by use of RT-PCR and in situ hybridization, and by measuring functionality of cortical 5HT-1A receptors by use of [(3)H]8-OH-DPAT radioligand binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	305-314	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
20939929-10	2010	Control intravenous injections of the 5-HT1A agonist 8-OH-DPAT evoked a small bradycardia and potentiated baroreflex bradycardia.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
20838806-7	2010	Agonists of 5-HT receptor subtypes 5-HT(1A) (8-OH-DPAT) and 5-HT(2A) (DOI) mimicked the effect of 5-HT; also, the effect of 8-OH-DPAT and DOI was blocked in the presence of specific blockers of 5-HT(1A) (WAY 100135) and 5-HT(2A) (MDL 11,939) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	35-42
20838806-7	2010	Agonists of 5-HT receptor subtypes 5-HT(1A) (8-OH-DPAT) and 5-HT(2A) (DOI) mimicked the effect of 5-HT; also, the effect of 8-OH-DPAT and DOI was blocked in the presence of specific blockers of 5-HT(1A) (WAY 100135) and 5-HT(2A) (MDL 11,939) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	35-42
20838806-7	2010	Agonists of 5-HT receptor subtypes 5-HT(1A) (8-OH-DPAT) and 5-HT(2A) (DOI) mimicked the effect of 5-HT; also, the effect of 8-OH-DPAT and DOI was blocked in the presence of specific blockers of 5-HT(1A) (WAY 100135) and 5-HT(2A) (MDL 11,939) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	194-201
20709144-4	2010	A concentration-related inhibition of withdrawal was observed when methamphetamine-exposed planarians were placed into a solution containing either methamphetamine and 5-HT (0.1-100 muM) or methamphetamine and the 5-HT(1A) receptor agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) (10, 20 muM).	8-Hydroxy-2-(di-n-propylamino)tetralin	240-278	5-hydroxytryptamine receptor 1A	Homo sapiens	214-231
20802053-2	2010	Opioid-induced ventilatory depression was shown to be counteracted in anesthetized rats by serotonin(1A)-receptor (5-HT(1A)-R)-agonist 8-OH-DPAT, which cannot be applied to humans.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Homo sapiens	115-122
20488186-6	2010	Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	5-hydroxytryptamine receptor 1A	Homo sapiens	39-56
20488186-6	2010	Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	5-hydroxytryptamine receptor 1A	Homo sapiens	151-168
20488186-6	2010	Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	5-hydroxytryptamine receptor 1A	Homo sapiens	151-168
20616303-8	2010	The inhibitory effect of 8-hydroxy-2-dipropylaminotetralin hydrobromide, a 5-HT(1A) agonist, after oral administration on small intestinal transit was blocked by raclopride or saclofen.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-71	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	75-82
20450907-0	2010	Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43
20450907-0	2010	Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43
20450907-0	2010	Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43
20450907-1	2010	8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is the prototypical agonist at serotonin 5-HT1A receptors; however, activity at other targets contributes to the functional effects of the compound as well.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98
20450907-1	2010	8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is the prototypical agonist at serotonin 5-HT1A receptors; however, activity at other targets contributes to the functional effects of the compound as well.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-49	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98
20398719-2	2010	Here, we conducted an intracerebral microinjection study of (+/-)-8-hydroxy-2-(di-n-propylamino)-tetralin ((+/-)8-OH-DPAT) to determine the action site of the 5-HT(1A) agonist in alleviating EPS.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	159-166
20423722-0	2010	Receptor-genes cross-talk: effect of chronic 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin treatment on the expression of key genes in brain serotonin system and on behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-101	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	45-52
20423722-5	2010	Chronic treatment with selective agonist of 5-HT(1A) receptor 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) produced considerable decrease in hypothermic response to acute administration of 8-OH-DPAT in CBA/Lac mice indicating desensitization of 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-100	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-61
20423722-5	2010	Chronic treatment with selective agonist of 5-HT(1A) receptor 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) produced considerable decrease in hypothermic response to acute administration of 8-OH-DPAT in CBA/Lac mice indicating desensitization of 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-100	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-51
20423722-5	2010	Chronic treatment with selective agonist of 5-HT(1A) receptor 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) produced considerable decrease in hypothermic response to acute administration of 8-OH-DPAT in CBA/Lac mice indicating desensitization of 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-61
20423722-5	2010	Chronic treatment with selective agonist of 5-HT(1A) receptor 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) produced considerable decrease in hypothermic response to acute administration of 8-OH-DPAT in CBA/Lac mice indicating desensitization of 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-51
20423722-5	2010	Chronic treatment with selective agonist of 5-HT(1A) receptor 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) produced considerable decrease in hypothermic response to acute administration of 8-OH-DPAT in CBA/Lac mice indicating desensitization of 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	221-230	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-61
20423722-5	2010	Chronic treatment with selective agonist of 5-HT(1A) receptor 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1.0 mg/kg i.p., 14 days) produced considerable decrease in hypothermic response to acute administration of 8-OH-DPAT in CBA/Lac mice indicating desensitization of 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	221-230	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-51
20423722-9	2010	The obtained data on the effect of 8-OH-DPAT-induced desensitization of 5-HT(1A) receptors on 5-HT(1A), 5-HT(2A) and TPH-2 gene expression demonstrated the role of 5-HT(1A) receptor as indirect regulator of gene expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	72-79
20423722-9	2010	The obtained data on the effect of 8-OH-DPAT-induced desensitization of 5-HT(1A) receptors on 5-HT(1A), 5-HT(2A) and TPH-2 gene expression demonstrated the role of 5-HT(1A) receptor as indirect regulator of gene expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	94-101
20423722-9	2010	The obtained data on the effect of 8-OH-DPAT-induced desensitization of 5-HT(1A) receptors on 5-HT(1A), 5-HT(2A) and TPH-2 gene expression demonstrated the role of 5-HT(1A) receptor as indirect regulator of gene expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	104-111
20423722-9	2010	The obtained data on the effect of 8-OH-DPAT-induced desensitization of 5-HT(1A) receptors on 5-HT(1A), 5-HT(2A) and TPH-2 gene expression demonstrated the role of 5-HT(1A) receptor as indirect regulator of gene expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	tryptophan hydroxylase 2	Mus musculus	117-122
20423722-9	2010	The obtained data on the effect of 8-OH-DPAT-induced desensitization of 5-HT(1A) receptors on 5-HT(1A), 5-HT(2A) and TPH-2 gene expression demonstrated the role of 5-HT(1A) receptor as indirect regulator of gene expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	72-89
19895724-4	2010	A significant increase (32%, p<0.05) in (+)8-OH-DPAT-induced [35S]GTPgammaS labelling of immunoprecipitates was obtained with anti-Galphai3 antibodies but not with anti-Galphao, anti-Galphai1, anti-Galphai2, anti-Galphaz or anti-Galphas antibodies.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	G protein subunit alpha i2	Rattus norvegicus	201-209
20412834-4	2010	In neuropathic rats, subtype 5-HT1A agonist 8-OH-DPAT (100 nM) was found to potently depress evoked field potentials, as opposed to 5-HT2A or 5-HT2B subtype agonists TCB-2 (100 nM) or BW 723C86 (1 microM), respectively, which consistently enhanced evoked potentials.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
20223238-7	2010	In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-182	5-hydroxytryptamine receptor 1A	Homo sapiens	114-131
20223238-7	2010	In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-193	5-hydroxytryptamine receptor 1A	Homo sapiens	114-131
20176013-8	2010	The anti-immobility effect of the selective 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetaralin (8-OH-DPAT) was also antagonized by WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-59
20456632-10	2010	The dose-effect curve after +/-8-OH-DPAT for these activities was clearly shifted to the right in SERT-/- animals compared to other genotypes.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	solute carrier family 6 member 4	Rattus norvegicus	98-102
20456632-11	2010	WAY-100635 alone had no effect on sexual behavior in any genotype, but was able to antagonize the +/-8-OH-DPAT-induced decrease in sexual activities indicating the involvement of the 5-HT(1A) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	183-190
20144658-6	2010	Pretreatment of the LSA with the 5-HT(1A) antagonist pMPPF partially reduced the inhibitory effect of 5-HT and totally reversed the effects of 8-OH-DPAT on 1.8% NaCl intake induced by sodium depletion.	8-Hydroxy-2-(di-n-propylamino)tetralin	143-152	5-hydroxytryptamine receptor 1A	Rattus norvegicus	33-40
20534514-7	2010	RGS-insensitive mice were also 5-10 times more responsive to the antidepressant-like effects of the SSRI fluvoxamine and 5-HT1A-selective agonist 8-hydroxy-2-dipropylaminotetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-179	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	121-127
20381465-0	2010	Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
20520769-9	2010	Concordantly, the administration of 5-HT, 8-OH-DPAT (a specific 5-HT1A receptor agonist), or fluoxetine (a 5-HT reuptake inhibitor) increased tubulin acetylation.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Homo sapiens	64-79
20171860-7	2010	significantly antagonized 5-HT(1A) agonist 8-OH-DPAT (0.1mg/kg, i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-33
20171860-9	2010	These results suggest that spinosin may be an antagonist at postsynaptic 5-HT(1A) receptors because these effects of 8-OH-DPAT were considered to be mediated via postsynaptic 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	73-80
20171860-9	2010	These results suggest that spinosin may be an antagonist at postsynaptic 5-HT(1A) receptors because these effects of 8-OH-DPAT were considered to be mediated via postsynaptic 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	175-182
19766402-2	2010	5-HT(1A) receptor function was determined by measuring [(35)S]GTPgammaS binding stimulated by the 5-HT(1A) receptor agonist 8-OH-DPAT (1 microM), an indication of the capacity of the receptor to activate G proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-17
19766402-2	2010	5-HT(1A) receptor function was determined by measuring [(35)S]GTPgammaS binding stimulated by the 5-HT(1A) receptor agonist 8-OH-DPAT (1 microM), an indication of the capacity of the receptor to activate G proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	98-115
19766402-5	2010	Corticosterone treatment (10mg/kg, sc once daily for 21 days) of wild-type mice resulted in a decrease in 5-HT(1A) receptor function in prefrontal cortex [8-OH-DPAT-stimulated [(35)S]GTPgammaS binding (% above basal), vehicle-treated: 39+/-4.9; corticosterone-treated: 17+/-2.8], but not in hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	155-164	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	106-123
19766402-7	2010	In contrast, corticosterone treatment of GR+/- mice resulted in an increase in 5-HT(1A) receptor function in hippocampus which reached statistical significance in CA2/3 region [8-OH-DPAT-stimulated [(35)S]GTPgammaS binding (% above basal), vehicle-treated: 41+/-9.7; corticosterone-treated: 94+/-23].	8-Hydroxy-2-(di-n-propylamino)tetralin	177-186	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	79-96
20508280-5	2010	In addition, intra-SNc injection of 8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT; 10 microg/rat), a 5-HT(1A) receptor agonist, decreased 6-OHDA-induced catalepsy.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-112
20042459-3	2010	8-Hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, decreased volume threshold (VT) for initiating voiding and increased contraction amplitude (CA) during TU-CMGs but decreased CA during TV-CMGs.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
20042459-3	2010	8-Hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, decreased volume threshold (VT) for initiating voiding and increased contraction amplitude (CA) during TU-CMGs but decreased CA during TV-CMGs.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
19789870-12	2010	In vitro binding of [(18)F]F15599 was blocked by WAY100635 and 8-OH-DPAT, respectively, prototypical 5-HT(1A) antagonist and agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	101-108
20508280-5	2010	In addition, intra-SNc injection of 8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT; 10 microg/rat), a 5-HT(1A) receptor agonist, decreased 6-OHDA-induced catalepsy.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-112
20508280-6	2010	The effects of buspirone (7.5 mg/kg, ip) and 8-OH-DPAT (10 microg/rat, intra-SNc) were abolished by 1-(2-methoxyphenyl)-4-[4-(2-phthalimido) butyl]piperazine hydrobromide (NAN-190; 10 microg/rat, intra-SNc), a 5-HT(1A) receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	210-217
20164327-3	2010	Here, we show that 5-HT(1A)R-selective agonist 8-OH-DPAT and selective serotonin reuptake inhibitor (SSRI) fluoxetine downregulated hippocampal neuronal nitric oxide synthase (nNOS) expression, whereas 5-HT(1A)R-selective antagonist NAN-190 upregulated hippocampal nNOS expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	19-26
20164327-3	2010	Here, we show that 5-HT(1A)R-selective agonist 8-OH-DPAT and selective serotonin reuptake inhibitor (SSRI) fluoxetine downregulated hippocampal neuronal nitric oxide synthase (nNOS) expression, whereas 5-HT(1A)R-selective antagonist NAN-190 upregulated hippocampal nNOS expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	nitric oxide synthase 1, neuronal	Mus musculus	144-174
20164327-3	2010	Here, we show that 5-HT(1A)R-selective agonist 8-OH-DPAT and selective serotonin reuptake inhibitor (SSRI) fluoxetine downregulated hippocampal neuronal nitric oxide synthase (nNOS) expression, whereas 5-HT(1A)R-selective antagonist NAN-190 upregulated hippocampal nNOS expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	nitric oxide synthase 1, neuronal	Mus musculus	176-180
20164327-3	2010	Here, we show that 5-HT(1A)R-selective agonist 8-OH-DPAT and selective serotonin reuptake inhibitor (SSRI) fluoxetine downregulated hippocampal neuronal nitric oxide synthase (nNOS) expression, whereas 5-HT(1A)R-selective antagonist NAN-190 upregulated hippocampal nNOS expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	202-209
20164327-3	2010	Here, we show that 5-HT(1A)R-selective agonist 8-OH-DPAT and selective serotonin reuptake inhibitor (SSRI) fluoxetine downregulated hippocampal neuronal nitric oxide synthase (nNOS) expression, whereas 5-HT(1A)R-selective antagonist NAN-190 upregulated hippocampal nNOS expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	nitric oxide synthase 1, neuronal	Mus musculus	265-269
20164327-9	2010	Additionally, NAN-190 decreased and 8-OH-DPAT increased phosphorylated cAMP response element-binding protein (CREB) levels in WT mice but not in KO mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	cAMP responsive element binding protein 1	Mus musculus	71-108
20164327-9	2010	Additionally, NAN-190 decreased and 8-OH-DPAT increased phosphorylated cAMP response element-binding protein (CREB) levels in WT mice but not in KO mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	cAMP responsive element binding protein 1	Mus musculus	110-114
19913081-8	2010	Only Uncaria hook (3.13-50 microg/ml), of the seven constituent herbal extracts, inhibited the [(3)H]8-OH-DPAT binding to 5-HT1A receptors in a concentration-dependent manner, and the IC(50) value was estimated to be 7.42 microg/ml.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Homo sapiens	122-128
20128812-8	2010	DOI-induced head twitches were decreased by the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in SERT +/+ and +/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-103	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	48-55
20128812-8	2010	DOI-induced head twitches were decreased by the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in SERT +/+ and +/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-103	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	119-123
20128812-8	2010	DOI-induced head twitches were decreased by the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in SERT +/+ and +/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	48-55
20128812-8	2010	DOI-induced head twitches were decreased by the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in SERT +/+ and +/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	119-123
19747494-12	2010	In contrast, the inhibitory response of DRN neurons to the 5HT(1A) agonist, 8OH-DPAT (1 microg/1 microl, intra-DRN) was not potentiated by swim stress, ruling out a non-specific enhanced permeability of GIRK channel.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
19944672-5	2010	The 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) restored the attenuated hypothermic response to ethanol in the mutants to similar levels in wild-type mice, with no effect in wild-types.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-68	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-21
19944672-5	2010	The 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) restored the attenuated hypothermic response to ethanol in the mutants to similar levels in wild-type mice, with no effect in wild-types.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-21
19540238-7	2010	The DOI-induced PRL increase did not occur when (+/-)-8-OH-DPAT (DPAT) was concurrently infused.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-63	prolactin	Meleagris gallopavo	16-19
20736508-4	2010	However, the incidence of SWD was markedly reduced either by the 5-HT(1A) agonist (+-)-8-hydroxy-2-(di-n-propylamino)-tetralin [(+-)8-OH-DPAT] or the 5-HT(2) agonist (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+-)DOI].	8-Hydroxy-2-(di-n-propylamino)tetralin	82-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-72
20235428-0	2010	[Agonist 5HT1A-receptors of serotonin 8-OH-DPAT increase the power of collapse of the aorta and mesenteric artery in rats in the presence of endothelin-1 or vasopressin and cause vessel relaxation precollapsing with noradrenaline].	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	9-14
20235428-0	2010	[Agonist 5HT1A-receptors of serotonin 8-OH-DPAT increase the power of collapse of the aorta and mesenteric artery in rats in the presence of endothelin-1 or vasopressin and cause vessel relaxation precollapsing with noradrenaline].	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	endothelin 1	Rattus norvegicus	141-153
20235428-0	2010	[Agonist 5HT1A-receptors of serotonin 8-OH-DPAT increase the power of collapse of the aorta and mesenteric artery in rats in the presence of endothelin-1 or vasopressin and cause vessel relaxation precollapsing with noradrenaline].	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	arginine vasopressin	Rattus norvegicus	157-168
20235428-1	2010	Agonist 5HT1A serotonin receptors 8-OH-DPAT at 70-80% in rats relax the isolated aorta and mesenteric artery, precollapsed with noradrenaline.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-13
20235428-3	2010	The addition of 8-OH-DPAT to the aorta in a state of rest or precollapsed with endothelin-1 or vasopressin causes an increase in power reduction.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	endothelin 1	Rattus norvegicus	79-91
20235428-3	2010	The addition of 8-OH-DPAT to the aorta in a state of rest or precollapsed with endothelin-1 or vasopressin causes an increase in power reduction.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	arginine vasopressin	Rattus norvegicus	95-106
20736508-6	2010	In addition, the inhibitory effects of (+-)8-OH-DPAT and (+-)DOI were reversed by WAY-100135 (5-HT(1A) antagonist) and ritanserin (5-HT(2) antagonist), respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-101
19309036-5	2009	Intraseptal infusion of the 5-HT(1A) receptor agonist (R)-8-OH-DPAT (1 or 4 microg/rat) did not affect spatial learning in the water maze task but impaired emotional memory in the passive avoidance task at the higher dose tested (4 microg/rat).	8-Hydroxy-2-(di-n-propylamino)tetralin	54-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-35
19400983-6	2009	Only treatment with the 5-HT1A receptor agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) showed a differential effect between genotypes, with a disruption of PPI occurring in Nrg1+/- mice compared to no effect in wild-type controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	24-39
19400983-6	2009	Only treatment with the 5-HT1A receptor agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) showed a differential effect between genotypes, with a disruption of PPI occurring in Nrg1+/- mice compared to no effect in wild-type controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	neuregulin 1	Mus musculus	178-182
19447286-3	2009	At 24-48 h acutely 8-OH-DPAT (0.062 mg/kg) administration enhanced memory and attenuated mRNA 5-HT(1A)<5-HT(7) receptors expression respect to saline group.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	94-101
19785653-7	2009	Similarly, the 5-HT(1A) agonist 8-OH-DPAT applied to 20 neurones had an excitatory (8), inhibitory (7) or no effect (5) on the 20 neurones tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-22
19410634-3	2009	The systemic administration of 8-OH-DPAT at doses in the range of 0.5-128 microg/kg showed an excitatory-inhibitory effect on the firing rate of pyramidal neurons in mPFC of sham-lesioned rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	complement factor properdin	Mus musculus	166-170
19410634-5	2009	In contrast to sham-lesioned rats, 8-OH-DPAT, at the same doses, showed no excitatory effect in the lesioned rats although the inhibitory phase of the effect of 8-OH-DPAT on the firing rate of pyramidal neurons in mPFC was still present.	8-Hydroxy-2-(di-n-propylamino)tetralin	161-170	complement factor properdin	Mus musculus	214-218
19410634-6	2009	Furthermore, the local application of 8-OH-DPAT, 5 microg, in mPFC inhibited the firing rate of pyramidal neurons in sham-lesioned rats, while having no effect on firing rate in the lesioned rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	complement factor properdin	Mus musculus	62-66
19447286-7	2009	Together these data revealed that, when both 5-HT(1A) and 5-HT(7) receptors were stimulated by 8-OHDPAT under memory consolidation, subtle changes emerged, not evident at behavioral level though detectable at genes expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-103	5-hydroxytryptamine receptor 1A	Homo sapiens	45-52
19538947-6	2009	Microinjection of a 5-HT(1A) receptor agonist (8-OH-DPAT, 0.01 and 0.1 microg) decreased TI behavior, an effect blocked by pretreatment with WAY-100635 (0.033 microg), a 5-HT(1A) antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Cavia porcellus	20-27
19538947-6	2009	Microinjection of a 5-HT(1A) receptor agonist (8-OH-DPAT, 0.01 and 0.1 microg) decreased TI behavior, an effect blocked by pretreatment with WAY-100635 (0.033 microg), a 5-HT(1A) antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Cavia porcellus	170-177
19470384-6	2009	In the 3wFS group, the 8-OH-DPAT-induced c-Fos expression in the medial prefrontal cortex was significantly attenuated compared to that in the non-FS control group.	8-Hydroxy-2-(di-n-propylamino)tetralin	23-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	41-46
19576144-1	2009	OBJECTIVE: To determine changes in response to a selective serotonin-1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) following long-term consumption of sugar as part of meal in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-80
19434397-7	2009	The 5-HT1A agonist 8-OH-DPAT and the 5-HT2 agonists mCPP and DOI decreased the duration of avoidance behaviour in LR rats, but increased it in HR rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
19576144-1	2009	OBJECTIVE: To determine changes in response to a selective serotonin-1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) following long-term consumption of sugar as part of meal in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-80
19361557-7	2009	Cotreatment with the 5-HT(1A) agonist 8-OH-DPAT significantly attenuated the amphetamine-induced axial and limb dyskinesias, whilst locomotor scores remained unchanged.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-28
19328786-2	2009	Acute systemic administration (76-1520 nmol/kg s.c.) of 8-OH-DPAT, a selective 5-HT(1A) somatodendritic autoreceptor agonist, induced a clear and dose-dependent preference for salt intake through free choice between water and 0.3 M NaCl simultaneously offered under basal conditions.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-86
19243449-5	2009	The mixed Htr (1a/7) agonist, 8-OH-DPAT, reduces impulsive behavior in adolescent rats and in naive adults, whose impulsivity is enhanced by the Htr7 antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 7	Rattus norvegicus	145-149
19111592-5	2009	Although the hypothermic response to the 5-HT(1A) receptor agonist 8-OH-DPAT was increased in adult deprived rats compared to non-deprived control group, no differences between groups were found in the effect of the systemic 8-OH-DPAT administration on serotoninergic cell firing in dorsal raphe nucleus and in the 5-HT release at the ventral hippocampus levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-48
19075042-3	2009	The 5-HT(1A) receptor agonist, 8-hydroxy-2-dipropylaminotetralin, produced an increase in contractions that was highly variable, of low potency, and was not significantly inhibited by the 5-HT(1A) antagonist WAY100635 [[O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide].	8-Hydroxy-2-(di-n-propylamino)tetralin	31-64	5-hydroxytryptamine receptor 1A	Homo sapiens	4-21
19270432-2	2009	Our previous study also showed that hyperactivity in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) was ameliorated by amphetamine in a serotonin (5-HT)(1A)-dependent manner and that amphetamine calmed wild-type mice given the 5-HT(1A) agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	269-278	adenylate cyclase activating polypeptide 1	Mus musculus	66-124
19095043-7	2009	Pretreatment with PTX to the PVN before peripheral injections of 17-beta-estradiol 3-benzoate completely prevented the reduction of the oxytocin response to the 5-HT(1A) receptor agonist, (+)-8-hydroxy-2-dipropylaminotetralin (DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	188-225	5-hydroxytryptamine receptor 1A	Rattus norvegicus	161-168
19095043-7	2009	Pretreatment with PTX to the PVN before peripheral injections of 17-beta-estradiol 3-benzoate completely prevented the reduction of the oxytocin response to the 5-HT(1A) receptor agonist, (+)-8-hydroxy-2-dipropylaminotetralin (DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	227-231	5-hydroxytryptamine receptor 1A	Rattus norvegicus	161-168
19179855-9	2009	Pretreatment with the 5-HT(1A) agonists 8-OH-DPAT or LY 293284 did not modify the WAY 100635 curve, but pretreatment with the selective dopamine D(4) antagonists sonepiprazole or A-381393 completely blocked the cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-29
18951909-1	2009	5-HT(1A) receptors were studied via [(3)H]WAY-100635 and [(3)H]8-OH-DPAT binding to rat brain cortical membranes.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-7
18801389-3	2009	Our results showed that intra-vlPAG injection of the endogenous agonist serotonin, the 5-HT1A/7 agonist 8-OH-DPAT or 5-HT2A/2C agonist DOI impaired the acquisition of inhibitory avoidance, without interfering with escape performance.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
18801389-5	2009	Moreover, as shown by the results of antagonism studies, 5-HT2A receptors are recruited for the anxiolysis caused by serotonin and DOI, while 5-HT1A receptors account for the effect of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	185-194	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-148
18930788-10	2008	These findings suggest that the 5-HT(1A) receptor plays an inhibitory role in behavioral phase shifts, a facilitatory role in light-induced gene expression, a necessary role in phase shifts to 8-OH-DPAT, and is not necessary for activity-induced phase advances that oppose photic phase shifts to long light pulses.	8-Hydroxy-2-(di-n-propylamino)tetralin	193-202	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-49
18611291-4	2008	Four weeks after MDMA administration (20 mg/kg b.i.d for 4 d), a 2-fold increase in the potency of the 5-HT1A receptor agonist ipsapirone to inhibit the discharge of DRN 5-HT neurons and a larger hypothermic response to 8-OH-DPAT were observed in MDMA- compared to saline-treated mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	220-229	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	103-118
19106465-4	2008	Bilateral injections of the 5-HT(1A) receptor agonist 8-OH-DPAT (1 and 4 microg/0.2 microl in each side) into the ventrolateral striatum partially but significantly reduced apomorphine-induced repetitive jaw movements.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-35
19106465-5	2008	The 5-HT(1A) receptor antagonist WAY-100635 (1 microg), which alone did not affect the effects of apomorphine, antagonized the inhibitory effects of 8-OH-DPAT (4 microg).	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
18688602-5	2008	OBJECTIVES: The objectives of the study are to assess the anti-aggressive effects of 5-HT1A and 5-HT1B agonist receptors [8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT) and CP-93,129] in the VO PFC of socially provoked male mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-174	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	85-102
18809415-3	2008	However, the net stimulation of [35S]GTPgammaS binding induced by the 5-HT1A agonist 8-OH-DPAT was significantly attenuated in dorsal raphe nucleus (DRN), but not in hippocampus, after chronic fluoxetine.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-76
18688602-5	2008	OBJECTIVES: The objectives of the study are to assess the anti-aggressive effects of 5-HT1A and 5-HT1B agonist receptors [8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT) and CP-93,129] in the VO PFC of socially provoked male mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	85-102
19014464-5	2008	The 5-HT1A, 5-HT1B and 5-HT1D receptor agonists 8-OH-DPAT (3 microM), CP93129 (3 microM) and L694247 (3 microM), but not the 5-HT1F receptor agonist LY344864 (1 - 3 microM) inhibited evoked IPSCs.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
18789911-5	2008	During a microdialysis study of anaesthetized rats, the 5-HT1A receptor agonist, R-(+)-8-OH-DPAT (0.1 mg/kg), decreased 5-HT release in the medial prefrontal cortex of control rats but this effect was significantly attenuated in DSP-4-treated animals (10-12 weeks old).	8-Hydroxy-2-(di-n-propylamino)tetralin	81-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
18667366-5	2008	In this study we showed that intracisternal injection of a low dose (1 microg/kg) of the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), significantly reduced the increases in heart rate and renal sympathetic nerve activity evoked by disinhibition of the DMH, but had no effect on these responses when injected intravenously.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-154	5-hydroxytryptamine receptor 1A	Homo sapiens	89-106
18667366-5	2008	In this study we showed that intracisternal injection of a low dose (1 microg/kg) of the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), significantly reduced the increases in heart rate and renal sympathetic nerve activity evoked by disinhibition of the DMH, but had no effect on these responses when injected intravenously.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Homo sapiens	89-106
18667366-6	2008	Subsequent intracisternal administration of the 5-HT(1A) receptor antagonist WAY-100635 restored the DMH-evoked cardiovascular responses to levels observed before 8-OH-DPAT administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	163-172	5-hydroxytryptamine receptor 1A	Homo sapiens	48-65
19014464-5	2008	The 5-HT1A, 5-HT1B and 5-HT1D receptor agonists 8-OH-DPAT (3 microM), CP93129 (3 microM) and L694247 (3 microM), but not the 5-HT1F receptor agonist LY344864 (1 - 3 microM) inhibited evoked IPSCs.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1B	Rattus norvegicus	12-18
19014464-5	2008	The 5-HT1A, 5-HT1B and 5-HT1D receptor agonists 8-OH-DPAT (3 microM), CP93129 (3 microM) and L694247 (3 microM), but not the 5-HT1F receptor agonist LY344864 (1 - 3 microM) inhibited evoked IPSCs.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1D	Rattus norvegicus	23-29
18853336-3	2008	A selective agonist of 5-HT 1A receptors 8-OH-DPAT (1 mg/kg) induces the immunosuppression, whereas 5-HT 1A blockade with WAY-100635 (1 mg/kg) resulted in immunostimulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	23-30
18789922-0	2008	5-HT7 receptor stimulation by 8-OH-DPAT counteracts the impairing effect of 5-HT(1A) receptor stimulation on contextual learning in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	76-93
18789922-1	2008	The principal 5-HT(1A) receptor agonist 8-Hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) impairs several different types of learning.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-75	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-31
18789922-1	2008	The principal 5-HT(1A) receptor agonist 8-Hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) impairs several different types of learning.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-31
18789922-6	2008	These findings indicate that 5-HT(7) receptor stimulation by 8-OH-DPAT counteracts 5-HT(1A) receptor-mediated impairments in hippocampal-dependent contextual learning.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	83-100
18579305-4	2008	Microinjection of the 5-HT 1A receptor agonist 8-OH-DPAT (1.0, 2.0, 5.0 microg) into VLO produced dose-dependent antinociception, which was reversed by the 5-HT 1A receptor antagonist (NAN-190, 20 mug).	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-29
18579305-4	2008	Microinjection of the 5-HT 1A receptor agonist 8-OH-DPAT (1.0, 2.0, 5.0 microg) into VLO produced dose-dependent antinociception, which was reversed by the 5-HT 1A receptor antagonist (NAN-190, 20 mug).	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	156-163
18607571-3	2008	Stimulation with the 5-HT(1A/7) receptor agonist, 8-OH-DPAT, reduced P-T(185)/Y(187)-ERK2.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	mitogen-activated protein kinase 1	Homo sapiens	85-89
18801415-1	2008	Systemic administration of selective 5-HT1A agonists, such as 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OHDPAT), stimulates the electrical activity of ventral tegmental area (VTA) dopamine neurons by a mechanism which remains unknown.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
18607571-5	2008	Pretreatment with the cholesterol sequestering agent, methyl-beta-cyclodextrin, before adding 8-OH-DPAT, significantly counteracted the inhibitory influence of 8-OH-DPAT on P-T(185)/Y(187)-ERK2 and P-S(133)-CREB.	8-Hydroxy-2-(di-n-propylamino)tetralin	160-169	mitogen-activated protein kinase 1	Homo sapiens	189-193
18801415-1	2008	Systemic administration of selective 5-HT1A agonists, such as 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OHDPAT), stimulates the electrical activity of ventral tegmental area (VTA) dopamine neurons by a mechanism which remains unknown.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
18607571-5	2008	Pretreatment with the cholesterol sequestering agent, methyl-beta-cyclodextrin, before adding 8-OH-DPAT, significantly counteracted the inhibitory influence of 8-OH-DPAT on P-T(185)/Y(187)-ERK2 and P-S(133)-CREB.	8-Hydroxy-2-(di-n-propylamino)tetralin	160-169	cAMP responsive element binding protein 1	Homo sapiens	207-211
18801415-5	2008	administration of the 5-HT1A agonist 8-OHDPAT induced a strong stimulation of burst and firing activity of dopamine neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
18801415-10	2008	Inactivation of the local 5-HT1A receptors by the microinfusion within the VTA of the selective 5-HT1A antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate (WAY 100,635), or of pertussis toxin, reduced the ability of 8-OHDPAT to stimulate the firing of dopamine neurons but not their burst activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	266-274	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
18801415-11	2008	On the other hand, burst activation elicited by 8-OHDPAT was strongly reduced following the inactivation of prefrontal 5-HT1A receptors achieved by the microinfusion of WAY 100,635 within the PFC.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
18581099-6	2008	Furthermore, SERT-/- rats displayed a reduced hypothermic response to the 5-HT1A receptor agonist 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-106	solute carrier family 6 member 4	Rattus norvegicus	13-17
18585397-0	2008	Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	FBJ osteosarcoma oncogene	Mus musculus	77-80
18585397-7	2008	Furthermore, the anticataleptic dose of 8-OH-DPAT showed a regionally specific reduction of haloperidol-induced Fos expression in the dorsolateral striatum (dlST) and the core region of the nucleus accumbens (AcC), without affecting that in the medial prefrontal cortex, the shell region of the nucleus accumbens or the lateral septal nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	FBJ osteosarcoma oncogene	Mus musculus	112-115
18585397-8	2008	These results suggest that 8-OH-DPAT alleviates antipsychotic-associated extrapyramidal motor disorders by stimulating the postsynaptic 5-HT(1A) receptors, which specifically counteracts the D(2) receptor blocking actions of antipsychotics in the dlST and AcC.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	dopamine receptor D2	Mus musculus	191-204
18581099-6	2008	Furthermore, SERT-/- rats displayed a reduced hypothermic response to the 5-HT1A receptor agonist 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
18581099-9	2008	We further found that both 8-OHDPAT and S-15535 pretreatment increased low-dose cocaine-induced locomotor activity in SERT-/- rats, but not SERT+/+ rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-35	solute carrier family 6 member 4	Rattus norvegicus	118-122
18581099-10	2008	At a high cocaine dose, only SERT+/+ animals responded to 8-OHDPAT and S-15535.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-66	solute carrier family 6 member 4	Rattus norvegicus	29-33
18690109-2	2008	We used automated startle boxes to compare the effect of the 5-HT1A receptor agonist, (+/-)-8-hydroxy-dipropyl-amino-tetralin (8-OH-DPAT), on PPI in three mouse strains.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	61-76
18690109-5	2008	In Balb/c mice, the effect of 8-OH-DPAT was blocked by the typical antipsychotic and dopamine D2 receptor antagonist, haloperidol and the third generation antipsychotic, aripiprazole, which has activity at both 5-HT1A and dopamine D2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	dopamine receptor D2	Mus musculus	85-105
18690109-5	2008	In Balb/c mice, the effect of 8-OH-DPAT was blocked by the typical antipsychotic and dopamine D2 receptor antagonist, haloperidol and the third generation antipsychotic, aripiprazole, which has activity at both 5-HT1A and dopamine D2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	211-217
18459133-5	2008	Stimulation with the 5-HT(1A) receptor agonist 8-OH-DPAT and pharmacological agonists of AC induced PKA and protein phosphatase 2A (PP2A) activity, which in turn inhibited: Akt activity, IkappaBalpha degradation, nuclear translocation of NF-kappaB, and expression of X-linked inhibitor of apoptosis protein (XIAP/BIRC4).	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	E3 ubiquitin-protein ligase XIAP	Cricetulus griseus	308-312
18498439-4	2008	Injections of the 5-HT(1A/7) agonist +8-OH-DPAT or dark pulses at CT-6 induced phase-advances of the wheel-running activity rhythm and down-regulated the expression of the clock genes Per1-2 and c-FOS in the SCN in a similar way.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	LOW QUALITY PROTEIN: period circadian protein homolog 1	Mesocricetus auratus	184-190
18498439-4	2008	Injections of the 5-HT(1A/7) agonist +8-OH-DPAT or dark pulses at CT-6 induced phase-advances of the wheel-running activity rhythm and down-regulated the expression of the clock genes Per1-2 and c-FOS in the SCN in a similar way.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	proto-oncogene c-Fos	Mesocricetus auratus	195-200
18622176-2	2008	This study explored the effects of food restriction and streptozotocin treatment on behavioral effects related to 5-HT1A (+)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT) and 5-HT2A [(+/-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI)] receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-173	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
18622176-2	2008	This study explored the effects of food restriction and streptozotocin treatment on behavioral effects related to 5-HT1A (+)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT) and 5-HT2A [(+/-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI)] receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	175-184	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
18622186-0	2008	Behavior selectively elicited by novel stimuli: modulation by the 5-HT1A agonist 8-OHDPAT and antagonist WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-89	5-hydroxytryptamine receptor 1A	Homo sapiens	66-72
18502317-2	2008	The present study was conducted to determine if this effect persists into adulthood following extended durations of abstinence and whether it could be modulated with the 5-HT(1A) agonist (+/-)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	187-241	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-177
18502317-2	2008	The present study was conducted to determine if this effect persists into adulthood following extended durations of abstinence and whether it could be modulated with the 5-HT(1A) agonist (+/-)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	243-252	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-177
18495311-3	2008	The selective 5-HT1A agonists, 8-hydroxydipropylaminotetraline (8-OH-DPAT) and tandospirone, significantly attenuated haloperidol-induced bradykinesia in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-20
18495311-4	2008	The alleviation of haloperidol-induced bradykinesia by 8-OH-DPAT was completely antagonized by WAY-100135 (a selective 5-HT1A antagonist), but was unaffected by cerebral 5-HT depletion with p-chlorophenylalanine (PCPA) treatment (300 mg/kg, i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	119-125
18513131-3	2008	In preclinical studies, it has been demonstrated that R (+)-8-hydroxy-dipropylaminotetralin (8-OHDPAT), a 5-HT1A agonist, has anxiolytic properties.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-101	5-hydroxytryptamine receptor 1A	Homo sapiens	106-112
18164909-5	2008	Furthermore, hypothermia by the 5-HT(1A) receptor agonist 8-OH DPAT (0.25 mg/kg) was significantly attenuated in mice treated with PCP.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-49
18455431-3	2008	In the presence of NMDA, a low concentration of the 5-HT(1A) agonist 8-OH-DPAT substantially reduced the number of spikes, and a low concentration of the 5-HT(2A/C) agonist alpha-Me-5HT significantly enhanced it, while both agonists were ineffective when applied alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	52-59
18607747-3	2008	The effects of microinjections of the serotonin 5-HT(1A) receptor agonist 8-hydroxydipropylaminotetraline (8-OH-DPAT) into these brain structures were analogous to the effects of neurotensin.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-65
18602835-8	2008	Paradoxically, sensitivity in sleep-deprived and control animals was reduced not only by a 5-HT(1A) receptor antagonist but also by a 5-HT(1A) receptor agonist (8-OHDPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	161-169	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-141
18367171-7	2008	The 5-HT-activated K+ current was mimicked by a 5-HT1A receptor agonist, (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide, and was reversibly blocked by a 5-HT1A receptor antagonist, 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine hydrobromide, but not by a 5-HT2 receptor antagonist, ketanserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	48-54
18430360-6	2008	Both the frequency inhibition and the amplitude inhibition of the GABAergic and the glycinergic sIPSC by 8-OH-DPAT had dose-dependent tendencies and could be reversed by WAY-100635, an antagonist of 5-HT1A/7 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	199-205
18469535-6	2008	The decrease in pLMV induced by the5-HT1A agonist (8-OH-DPAT), and the 5-HT1B/2C agonist (mCPP), was antagonized by pretreatment with the 5-HT1A antagonist (WAY-100635) at a dose that had no effect of its own on pLMV.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	35-41
18182050-3	2008	Using in vivo microdialysis, we found that the ability of the 5-HT(1A) receptor agonist 8-hydroxydipropylaminotetralin hydrobromide (8-OH-DPAT) (0.025 mg/kg, s.c.) to decrease extracellular 5-HT levels in striatum was attenuated following chronic treatment of rats with the SSRIs sertraline or fluoxetine.	8-Hydroxy-2-(di-n-propylamino)tetralin	133-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-69
18410179-3	2008	Subcutaneous injections of the selective 5-HT(1A) agonist 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a drug that reduces 5-HT release by acting on presynaptic autoreceptors, dose-dependently increased consumption of 0.45 M NaCl in a one-bottle test.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-95	5-hydroxytryptamine receptor 1A	Homo sapiens	41-48
18410179-3	2008	Subcutaneous injections of the selective 5-HT(1A) agonist 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a drug that reduces 5-HT release by acting on presynaptic autoreceptors, dose-dependently increased consumption of 0.45 M NaCl in a one-bottle test.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Homo sapiens	41-48
17728111-3	2008	The results showed that intra-DH injection of the 5-HT1A/7 agonist 8-OH-DPAT facilitated inhibitory avoidance, an anxiogenic effect, without affecting escape.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-56
18289523-1	2008	The effect of chronic citalopram or escitalopram administration on 5-HT1A receptor function in the dorsal raphe nucleus was determined by measuring [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (R)-(+)-8-OH-DPAT (1nM-10 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	215-232	5-hydroxytryptamine receptor 1A	Homo sapiens	67-82
18289523-1	2008	The effect of chronic citalopram or escitalopram administration on 5-HT1A receptor function in the dorsal raphe nucleus was determined by measuring [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (R)-(+)-8-OH-DPAT (1nM-10 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	215-232	5-hydroxytryptamine receptor 1A	Homo sapiens	191-206
18460773-6	2008	Activation of postsynaptic 5-HT1A receptors by 8-OH-DPAT in the 5-HT depleted rats or the 5-HT depleted stress rats significantly decreased the symptoms of anxiety and learned helplessness behaviors which were prevented by the treatment of WAY100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
18269931-4	2008	Pretreatment with 8-OH-DPAT (1 mg/kg) prevented the neuronal loss in CA1 subfield 72 h after ischemia and also the dramatic decrease in BDNF immunoreactivity observed in this area at an earlier time.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	carbonic anhydrase 1	Homo sapiens	69-72
18269931-4	2008	Pretreatment with 8-OH-DPAT (1 mg/kg) prevented the neuronal loss in CA1 subfield 72 h after ischemia and also the dramatic decrease in BDNF immunoreactivity observed in this area at an earlier time.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	brain derived neurotrophic factor	Homo sapiens	136-140
18269931-6	2008	The results indicate that both NR1 subunit phosphorylation and the neurotrophin BDNF account, at least in part, for the neuroprotective effect of 8-OH-DPAT on cell damage induced by global ischemia in the gerbil hippocampus and support the potential interest of 5-HT1A receptor activation in the search for neuroprotective strategies.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	31-34
18269931-6	2008	The results indicate that both NR1 subunit phosphorylation and the neurotrophin BDNF account, at least in part, for the neuroprotective effect of 8-OH-DPAT on cell damage induced by global ischemia in the gerbil hippocampus and support the potential interest of 5-HT1A receptor activation in the search for neuroprotective strategies.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	brain derived neurotrophic factor	Homo sapiens	80-84
18269931-6	2008	The results indicate that both NR1 subunit phosphorylation and the neurotrophin BDNF account, at least in part, for the neuroprotective effect of 8-OH-DPAT on cell damage induced by global ischemia in the gerbil hippocampus and support the potential interest of 5-HT1A receptor activation in the search for neuroprotective strategies.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Homo sapiens	262-277
18094064-3	2008	We previously showed in conscious piglets that activation of 5-HT1A receptors with (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) in the paragigantocellularis lateralis (PGCL), a medullary region lateral to the raphe that contains substantial numbers of 5-HT neurons, eliminates rapid eye movement (REM) sleep and decreases shivering in a cold environment, but does not attenuate peripheral vasoconstriction.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-125	5-hydroxytryptamine receptor 1A	Homo sapiens	61-67
18094064-3	2008	We previously showed in conscious piglets that activation of 5-HT1A receptors with (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) in the paragigantocellularis lateralis (PGCL), a medullary region lateral to the raphe that contains substantial numbers of 5-HT neurons, eliminates rapid eye movement (REM) sleep and decreases shivering in a cold environment, but does not attenuate peripheral vasoconstriction.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Homo sapiens	61-67
18094064-9	2008	The effects of 8-OH-DPAT were prevented after dialysis of the selective 5-HT1A receptor antagonist WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Homo sapiens	72-87
18441384-2	2008	The purpose of this study was to determine changes in respiratory motor pattern of phrenic nerve activity and respiratory rhythm after systemic application of specific 5-HT(1A) receptor agonist 8-hydroxy-2-di-npropylamino-tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	232-241	5-hydroxytryptamine receptor 1A	Rattus norvegicus	168-175
18441384-3	2008	We hypothesized that systemic application of specific 5-HT(1A) receptor agonist 8-OH-DPAT in spontaneously breathing anaesthetized rats will enhance phrenic motor output and phrenic respiratory rate.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-61
18441384-6	2008	Stimulating effect of 8-OH-DPAT on phrenic nerve activity was abolished by intravenous application of the selective 5-HT(1A) receptor antagonist WAY, N-(2-(4,2-methoxyphenyl)-1-piperazinyl)ethyl)-N-2-pyridinyl-cyclohexane-carboxamide maleate (WAY-100635).	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-123
18441384-7	2008	These results show that stimulation of 5-HT(1A) receptors by intravenous application of 8-OH-DPAT enhances phrenic nerve activity in spontaneously breathing rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-46
17721726-3	2008	Scatchard analysis using 8-OH-DPAT, a 5-HT1A specific agonist showed a decreased receptor during liver regeneration after PH and NDEA induced hepatocellular carcinoma.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
18076976-4	2008	The 5-HT1A function of the dPAG was evaluated by local injections of 8-OH-DPAT (4 and 8 nmol/0.2 microL) and WAY-100635 (10 nmol/0.2 microL), selective agonist and antagonist of 5-HT1A receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
18166275-2	2008	In previous immuno-electron microscopic studies, we have demonstrated an internalization of 5-HT(1A) autoreceptors in the nucleus raphe dorsalis (NRD) of rats, after the acute administration of a single dose of the specific agonist 8-hydroxy-2-(di-n-propylamine)tetralin (8-OH-DPAT) or of the selective 5-HT reuptake inhibitor, fluoxetine.	8-Hydroxy-2-(di-n-propylamino)tetralin	272-281	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-99
17959705-5	2008	Systemic administration of 8-OH-DPAT (10, 30, and 100 microg/kg) attenuated stress-induced tachycardia in a dose-dependent manner, and this effect was suppressed by the 5-HT(1A) antagonist WAY-100635 (100 microg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	169-176
17959705-8	2008	Activation of 5-HT(1A) receptors in the medullary raphe by microinjection of 8-OH-DPAT mimicked the antitachycardic effect of the systemically administered drug but did not affect basal HR.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-21
17891381-1	2008	RATIONALE AND OBJECTIVES: We previously found that the inhibition of median raphe nucleus (MRN) 5-HT transmission by local injections of a 5-HT1A agonist 8-OH-DPAT or corticotrophin-releasing factor (CRF) mimic the effect of foot shock stress to reinstate alcohol seeking.	8-Hydroxy-2-(di-n-propylamino)tetralin	154-163	5-hydroxytryptamine receptor 1A	Rattus norvegicus	139-145
17924524-3	2008	8-OH-DPAT (4 microg/0.5 microL) infused before each acquisition session prevented learning/retention of the platform location, an effect attenuated by pretreatment with the 5-HT1A receptor antagonist WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	173-179
17392733-6	2008	Serotonergic inhibition of mIPSC frequency was mimicked by (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide, a specific 5-HT(1A) receptor agonist, and blocked by 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine hydrobromide, a specific 5-HT(1A) receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	124-131
17936346-0	2008	The stimulus effects of 8-OH-DPAT: evidence for a 5-HT2A receptor-mediated component.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 2A	Rattus norvegicus	50-56
17936346-1	2008	A previous investigation in our laboratory found that the stimulus effects of the 5-HT2A agonist, LSD, are potentiated by 5-HT1A receptor agonists including the prototypic agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	181-190	5-hydroxytryptamine receptor 2A	Rattus norvegicus	82-88
17936346-1	2008	A previous investigation in our laboratory found that the stimulus effects of the 5-HT2A agonist, LSD, are potentiated by 5-HT1A receptor agonists including the prototypic agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	181-190	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
17936346-3	2008	These observations led us in the present investigation to test the hypothesis that stimulus control by 8-OH-DPAT [0.2 mg/kg; 15 min pretreatment time] is modulated by 5-HT2A ligands.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 2A	Rattus norvegicus	167-173
17936346-6	2008	As shown previously, stimulus control by 8-OH-DPAT and the generalization of 8-OH-DPAT to the 5-HT1A partial agonist, buspirone, was completely blocked by the selective 5-HT1A antagonist, WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	169-175
17936346-6	2008	As shown previously, stimulus control by 8-OH-DPAT and the generalization of 8-OH-DPAT to the 5-HT1A partial agonist, buspirone, was completely blocked by the selective 5-HT1A antagonist, WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
17936346-6	2008	As shown previously, stimulus control by 8-OH-DPAT and the generalization of 8-OH-DPAT to the 5-HT1A partial agonist, buspirone, was completely blocked by the selective 5-HT1A antagonist, WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	169-175
17936346-7	2008	In contrast, antagonism by the selective 5-HT2A antagonist, M100907 [0.1 mg/kg; 30 min pretreatment time], of 8-OH-DPAT and of the generalization of 8-OH-DPAT to buspirone was statistically significant but less than complete.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 2A	Rattus norvegicus	41-47
17936346-7	2008	In contrast, antagonism by the selective 5-HT2A antagonist, M100907 [0.1 mg/kg; 30 min pretreatment time], of 8-OH-DPAT and of the generalization of 8-OH-DPAT to buspirone was statistically significant but less than complete.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine receptor 2A	Rattus norvegicus	41-47
17675218-7	2008	The patients with cardiovascular disease showed a reduction (-50.40%) (p<0.01) of the 3H-8OH-DPAT bound to the platelet membranes 5-HT1A receptors (1.652+/-0.79 fmol/mg protein) with respect to the control group (3.331+/-0.16 fmol/mg protein).	8-Hydroxy-2-(di-n-propylamino)tetralin	92-100	5-hydroxytryptamine receptor 1A	Homo sapiens	133-139
17944876-6	2007	However, a significant decrease in the ability of both, the 5-HT(1A) receptor agonist (+/-)-8-OH-DPAT and the 5-HT(2A/C) receptor agonist (-)DOI, to stimulate [(35)S]GTPgammaS binding was detected in the hippocampal CA(1) area and fronto-parietal cortex of CB(1) receptor knockout mice, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-101	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	60-77
17976547-0	2007	5-HT1A receptors mediate (+)8-OH-DPAT-stimulation of extracellular signal-regulated kinase (MAP kinase) in vivo in rat hypothalamus: time dependence and regional differences.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
17976547-0	2007	5-HT1A receptors mediate (+)8-OH-DPAT-stimulation of extracellular signal-regulated kinase (MAP kinase) in vivo in rat hypothalamus: time dependence and regional differences.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	Eph receptor B1	Rattus norvegicus	53-90
17976547-3	2007	In contrast, decreased levels of phosphoERK (pERK) have been reported in hippocampus following in vivo administration of either azapirone or aminotetralin 5-HT1A agonists, such as 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	180-213	5-hydroxytryptamine receptor 1A	Rattus norvegicus	155-161
17976547-3	2007	In contrast, decreased levels of phosphoERK (pERK) have been reported in hippocampus following in vivo administration of either azapirone or aminotetralin 5-HT1A agonists, such as 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	215-224	5-hydroxytryptamine receptor 1A	Rattus norvegicus	155-161
17976547-9	2007	Pretreatment with the 5-HT1A receptor-specific antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide (WAY100635) completely blocked the (+)8-OH-DPAT-mediated changes in pERK levels in PVN, medial basal hypothalamus, and hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-190	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
17976547-11	2007	In conclusion, these results demonstrate that 8-OH-DPAT activation of MAP kinase signaling in vivo is a transient and region-specific phenomenon and in rat hypothalamus and hippocampus is mediated by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	200-206
17692935-3	2007	Thus, post-training administration of 8-OHDPAT (agonist for 5-HT(1A/7) receptors) only at 0.250 and 0.500 mg/kg impaired both STM and LTM.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-46	sulfotransferase family 1A member 3	Homo sapiens	126-129
17684732-6	2007	The 5-HT(1A) receptor agonist, 8-hydroxy-di-propylaminotetralin (8-OH-DPAT), had no effect on PPI in C57Bl/6 mice but markedly increased PPI in Balb/c mice, with the effect being attenuated in Galpha(z) knock-outs.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-21
17134528-9	2007	Using quantitative autoradiography, 5-HT1A receptor number and function were determined by the binding of [3H]WAY-100635, and by [35S]GTPgammaS binding stimulated by the 5-HT1A receptor agonist 8-OH-DPAT, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	194-203	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	170-185
17916336-4	2007	In the current study, the effects of iontophoretic application of the 5-HT 1A agonist 8-OH-DPAT on auditory responses were compared with the characteristic frequencies (CFs), recording depths, and control first-spike latencies of the same group of IC neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	70-77
17704821-4	2007	The potency of each compound at antagonizing the effect of the 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)-tetraline], was quantified using the Schild equation.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-70
17704821-6	2007	KEY RESULTS: Consistently with a 5-HT(1A) receptor antagonist profile, incubation of slices with an equimolar (10 nM) concentration of each compound markedly reduced the inhibitory effect of 8-OH-DPAT on the firing rate of DR neurones, causing a significant rightward shift in its concentration-response curve.	8-Hydroxy-2-(di-n-propylamino)tetralin	191-200	5-hydroxytryptamine receptor 1A	Rattus norvegicus	33-40
17702902-12	2007	These results demonstrate that although hypothermia mediated by both MDMA and DPAT shares a common dependence on the activation of 5-HT(1A) receptors, the location of these receptors is different for each drug.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	131-138
17965535-5	2007	Fenfluramine, a 5-HT releaser, and 8-OH-DPAT, a potent 5-HT1A-receptor agonist, also significantly decreased the duration of freezing.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	55-70
17852699-2	2007	Microinjections of 8-OH-DPAT (1 microg) into the right or left CA1 hippocampal area produced a significant decrease in the number of avoidances in a shuttle box.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	carbonic anhydrase 1	Rattus norvegicus	63-66
17852699-7	2007	The stronger memory-modulating effect after injection of 8-OH-DPAT or NAN190 into the right CA1 hippocampal area suggests a rightward bias in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	carbonic anhydrase 1	Rattus norvegicus	92-95
18195469-1	2007	The interaction between the selective sigma (sigma) receptor agonists and 8-OH-DPAT, a serotonin (5-HT)(1A) receptor agonist, was examined in the forced swimming test in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-116
18195469-4	2007	The effect of DTG and 8-OH-DPAT co-administration was partly counteracted by WAY 100635 (0.1 mg/kg) as well as by BD 1047 (3 mg/kg), a 5-HT(1A) and sigma(1) receptor antagonists, respectively, suggesting the involvement of both receptor types in the anti-immobility effect in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	135-142
18195469-4	2007	The effect of DTG and 8-OH-DPAT co-administration was partly counteracted by WAY 100635 (0.1 mg/kg) as well as by BD 1047 (3 mg/kg), a 5-HT(1A) and sigma(1) receptor antagonists, respectively, suggesting the involvement of both receptor types in the anti-immobility effect in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	sigma non-opioid intracellular receptor 1	Rattus norvegicus	148-165
18074789-1	2007	It is shown that a selective agonist of 5-HT1A receptors 8-OH-DPAT in a low dose (0.1 mg/kg), which is known to affect mainly the presynaptic 5-HT1A receptors increased the immune response at the peak of reactions (the forth or fifth day after immunization with sheep red blood cells - SRBC) in CBA mice and Wistar rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
18074789-1	2007	It is shown that a selective agonist of 5-HT1A receptors 8-OH-DPAT in a low dose (0.1 mg/kg), which is known to affect mainly the presynaptic 5-HT1A receptors increased the immune response at the peak of reactions (the forth or fifth day after immunization with sheep red blood cells - SRBC) in CBA mice and Wistar rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-148
17765930-7	2007	Subsequent experiments showed that the Htr1a agonist 8-OH-DPAT (1 or 2 mg/kg) elicited serotonin syndrome behaviors in a dose-dependent manner, blocked by WAY 100635 (1 mg/kg), in mice of all three genotypes, confirming the role of Htr1a receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	39-44
17765930-7	2007	Subsequent experiments showed that the Htr1a agonist 8-OH-DPAT (1 or 2 mg/kg) elicited serotonin syndrome behaviors in a dose-dependent manner, blocked by WAY 100635 (1 mg/kg), in mice of all three genotypes, confirming the role of Htr1a receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	232-237
18074789-3	2007	The preliminary blockade of 5-HT1A receptor with a selective antagonist of 5-HT1A receptors WAY-100635 (0.1 mg/kg) prevented the immunostimulating effect of 5-HT 1A receptors agonist 8-OH-DPAT, whereas WAY-100635 administration alone in the same dose didn"t change the immune response.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
18074789-3	2007	The preliminary blockade of 5-HT1A receptor with a selective antagonist of 5-HT1A receptors WAY-100635 (0.1 mg/kg) prevented the immunostimulating effect of 5-HT 1A receptors agonist 8-OH-DPAT, whereas WAY-100635 administration alone in the same dose didn"t change the immune response.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-81
18074789-3	2007	The preliminary blockade of 5-HT1A receptor with a selective antagonist of 5-HT1A receptors WAY-100635 (0.1 mg/kg) prevented the immunostimulating effect of 5-HT 1A receptors agonist 8-OH-DPAT, whereas WAY-100635 administration alone in the same dose didn"t change the immune response.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	157-164
17336942-2	2007	METHODS: 5-HT1A receptor function, at the level of receptor-G protein interaction, was assessed with quantitative autoradiography of [35S]GTPgammaS binding stimulated by the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	198-207	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	9-24
17853773-2	2007	8-OH DPAT, a 5-HT1A agonist and 5-CT, a 5-HT7 agonist inhibited the lordosis differently in non-receptive and receptive rats, however, the response was attenuated in a dose-dependent manner following 5-CT treatment in the first two tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
17853773-6	2007	This finding shows that WAY 100 135, a 5-HT1A antagonist has potency to attenuate inhibitory influence of 8-OH DPAT by enhancing lordosis behavior acutely in female rats with a low estrous state.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
17336942-2	2007	METHODS: 5-HT1A receptor function, at the level of receptor-G protein interaction, was assessed with quantitative autoradiography of [35S]GTPgammaS binding stimulated by the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	198-207	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	174-189
17663006-7	2007	NHE activity was significantly increased by 8-OH-DPAT and alpha-methyl-5-HT, agonists of, respectively, 5-HT(1A) and 5-HT(2) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	solute carrier family 9 member C1	Homo sapiens	0-3
17526557-2	2007	An intravenous bolus of the 5-HT(1A) receptor agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT, 10 microg kg(-1)) evoked increases in both breathing rate and tidal volume.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-35
18309776-3	2007	Pretreatment with 8-OH-DPAT (1 mg/kg) prevented the neuronal loss in CA1 subfield 72 h after ischemia.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	carbonic anhydrase 1	Homo sapiens	69-72
18309776-5	2007	The results suggest that NR1 subunit phosphorylation plays a role in the neuroprotective effect of 8-OH-DPAT on cell damage induced by global cerebral ischemia in the gerbil hippocampus and support the potential interest of 5-HT1A receptor activation in the search for neuroprotective strategies.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	25-28
17663006-7	2007	NHE activity was significantly increased by 8-OH-DPAT and alpha-methyl-5-HT, agonists of, respectively, 5-HT(1A) and 5-HT(2) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine receptor 1A	Homo sapiens	104-111
17551320-5	2007	Pretreatment with DPT blocked 8-OH-DPAT-elicited lower-lip retraction, suggesting antagonist activity of DPT at 5-HT1A receptors; however, in the presence of MDL100907 DPT produced not only flat body posture but also lower-lip retraction, suggesting that agonist activity of DPT at 5-HT2A receptors masked agonist activity at 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
17555728-8	2007	The selective 5-HT(1A) receptor antagonist WAY100135 (10 microM) blocked the inhibition produced by 1 microM 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-21
17459373-4	2007	8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT), a 5-HT1A receptors full agonist, caused a significant decrease in extracellular 5-HT concentrations.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
17459373-4	2007	8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT), a 5-HT1A receptors full agonist, caused a significant decrease in extracellular 5-HT concentrations.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
17627673-5	2007	SB-649915 behaved as an antagonist at both 5-HT1A and 5-HT1B receptors in vitro and in vivo, reversing 5-HT, (+)8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and SKF99101-induced functional/behavioral responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-151	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-60
17392335-2	2007	Activation of presynaptic 5-HT(1A) receptors inhibits serotonergic neurones in the ventral medulla and caudal raphe, and we tested the hypothesis that administration of 8-hydroxydipropylaminotetralin (8-OH-DPAT), a 5-HT(1A) agonist, within the rostroventral medulla and caudal raphe would enhance baroreceptor-mediated inhibition of respiratory activity in decerebrate, neonatal piglets.	8-Hydroxy-2-(di-n-propylamino)tetralin	201-210	5-hydroxytryptamine receptor 1A	Homo sapiens	26-33
17392335-9	2007	We conclude that activation of 5-HT(1A) receptors after systemic administration of 8-OH-DPAT enhanced baroreflex-mediated inhibition of ventilation, but this effect cannot be attributed to 5-HT(1A) receptor activation within the rostroventral medulla and caudal raphe.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	31-38
17392335-9	2007	We conclude that activation of 5-HT(1A) receptors after systemic administration of 8-OH-DPAT enhanced baroreflex-mediated inhibition of ventilation, but this effect cannot be attributed to 5-HT(1A) receptor activation within the rostroventral medulla and caudal raphe.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	31-48
17627673-5	2007	SB-649915 behaved as an antagonist at both 5-HT1A and 5-HT1B receptors in vitro and in vivo, reversing 5-HT, (+)8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and SKF99101-induced functional/behavioral responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	153-162	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-60
17493597-5	2007	(+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (a 5-HT1A receptor agonist, 1 and 2 mg/kg) markedly reduced paired-pulse inhibition in the CA1 region of SS adult gerbils only.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-44	5-hydroxytryptamine receptor 1A	Homo sapiens	48-63
17431134-5	2007	The preadministration of the 5-HT(1A) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 microg/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED(50) by 56 and 44%, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-88	5-hydroxytryptamine receptor 1A	Homo sapiens	29-46
17431134-5	2007	The preadministration of the 5-HT(1A) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 microg/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED(50) by 56 and 44%, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Homo sapiens	29-46
17592949-1	2007	The serotonin 1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) produces a drastic facilitation of ejaculation characterized by a significant reduction in the number of pre-ejaculatory intromissions and a shortening of ejaculation latency.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-25
17592949-1	2007	The serotonin 1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) produces a drastic facilitation of ejaculation characterized by a significant reduction in the number of pre-ejaculatory intromissions and a shortening of ejaculation latency.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-25
17368430-7	2007	The ketamine STM-induced deficit was blocked by 8-OHDPAT (5-HT(1A/7) agonist) and SB-399885 (a 5-HT(6) antagonist) but not by 5-HT(1B), 5-HT(2) and 5-HT(7) antagonists, thus implicating 5-HT(1A/7) and 5-HT(6) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-56	sulfotransferase family 1A member 3	Homo sapiens	13-16
17383105-10	2007	The 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)-tetraline) (8-OH-DPAT, 0.25 mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
17493597-5	2007	(+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (a 5-HT1A receptor agonist, 1 and 2 mg/kg) markedly reduced paired-pulse inhibition in the CA1 region of SS adult gerbils only.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-44	carbonic anhydrase 1	Homo sapiens	136-139
17218026-8	2007	pMPPF bilateral injections (5-HT(1A) antagonist) previously to 8-OH-DPAT injections have completely blocked the inhibitory effect over NaCl 1.8% intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-35
17609739-0	2007	8-Hydroxy-2-(di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
17609739-3	2007	The results of this study show that the acute dose-dependent depressant effect of 8-OH-DPAT on food intake in fasted rats is mediated by an action at 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	150-156
17416565-6	2007	The present study shows that responses to 8-hydroxy-2-(di-n-propylamino)tetraline (8-OH-DPAT), a selective 5-HT 1A agonist decreased following exposure to single stress and the decreases were normalized following adaptation to stress.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	107-114
17321680-1	2007	The 5-HT(1A) receptor agonist 8-OH-DPAT (0.5mg/kg) enhances behavioral recovery when administered 15min after experimental traumatic brain injury (TBI).	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	4-21
17229445-8	2007	The activity of the 5-HT(1A) receptors was assessed by means of the hypothermic response to the selective 5-HT(1A) agonists S-15535 (preferential autoreceptor agonist) and 8-OHDPAT (full pre- and postsynaptic receptor agonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	172-180	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	20-27
17300778-3	2007	The hyperphagic effect of 8-OH-DPAT (100 mg/kg, s.c.) was abolished by concurrent treatment with the 5HT1A receptor antagonist N-[2-(4-2-methoxyphenyl)-1-piperazinyl]-N-(2-pyridyl) cyclohexanecarboxamide (WAY100635; 0.3 mg/kg, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	101-115
17300778-4	2007	These data show that 8-OH-DPAT produces an increase in food consumption in non-deprived mice by a 5-HT1A receptor-mediated mechanism of action.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	98-113
17159160-0	2007	Single exposure to a serotonin 1A receptor agonist, (+)8-hydroxy-2-(di-n-propylamino)-tetralin, produces a prolonged heterologous desensitization of serotonin 2A receptors in neuroendocrine neurons in vivo.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-42
17167032-4	2007	Under these conditions, 5-HT and the prototypic selective 5-HT1A agonist (+)8-hydroxy-2-(di-n-propylamino)tetralin [(+)-8-OH-DPAT] both stimulated [35S]GTPgammaS binding to Galphao to a similar extent, raising binding to approximately 130% of basal with pEC50 values of 7.91 and 7.87, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
17167032-4	2007	Under these conditions, 5-HT and the prototypic selective 5-HT1A agonist (+)8-hydroxy-2-(di-n-propylamino)tetralin [(+)-8-OH-DPAT] both stimulated [35S]GTPgammaS binding to Galphao to a similar extent, raising binding to approximately 130% of basal with pEC50 values of 7.91 and 7.87, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
17141811-6	2007	Adaptive changes in 5-HT(1A) receptor function were studied by measuring 8-OH-DPAT-mediated hypothermia and lower lip retraction (LLR) in the animals 24h after LH test session.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	20-37
17313964-3	2007	In this test, chronic administration of the non-selective SRI imipramine enhances the inhibitory effect on escape caused by the intra-DPAG injection of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	sorcin	Rattus norvegicus	58-61
17313964-3	2007	In this test, chronic administration of the non-selective SRI imipramine enhances the inhibitory effect on escape caused by the intra-DPAG injection of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	5-hydroxytryptamine receptor 1A	Rattus norvegicus	156-162
20641465-11	2004	Selective agonists such as 8-hydroxy-N-N-dipropylaminotetralin (8-OH-DPAT) were initially studied, but because they bind to the relatively few 5-HT1A receptors in the high-affinity state, the higher affinity required in that situation was difficult to achieve (6).	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Homo sapiens	143-149
17250628-12	2007	However, following 8-OH-DPAT, hippocampal 5-HT(1A) receptor expression was higher in E than in PF females in CA1, with a trend toward higher expression in E than in C females in CA2, whereas following DOI, a prenatal group by subfield interaction suggests lower 5-HT(1A) mRNA levels in E and PF compared with C females in CA1 and the dentate gyrus.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-49
16679005-6	2007	R-(+)-8-OH-DPAT (0.1 mg/kg) induced hypothermia and "5-HT(1A) syndrome" in both control and DSP-4-lesioned animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-15	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-60
17202670-0	2007	The 5-HT1A receptor full agonist, 8-OH-DPAT inhibits ACTH-induced 5-HT2A receptor hyperfunction in rats: involvement of 5-HT1A receptors in the DOI-induced wet-dog shakes in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
17113046-0	2007	Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
17113046-2	2007	The purpose of this study was to investigate cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
17113046-14	2007	Co-administration of WAY-100635, a 5-HT1A receptor antagonist, with 8-OH-DPAT eliminated the effect of 8-OH-DPAT on motor complications indicating that the observed 8-OH-DPAT responses were probably mediated at the 5-HT1A autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
17113046-14	2007	Co-administration of WAY-100635, a 5-HT1A receptor antagonist, with 8-OH-DPAT eliminated the effect of 8-OH-DPAT on motor complications indicating that the observed 8-OH-DPAT responses were probably mediated at the 5-HT1A autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	215-221
17113046-14	2007	Co-administration of WAY-100635, a 5-HT1A receptor antagonist, with 8-OH-DPAT eliminated the effect of 8-OH-DPAT on motor complications indicating that the observed 8-OH-DPAT responses were probably mediated at the 5-HT1A autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
17113046-14	2007	Co-administration of WAY-100635, a 5-HT1A receptor antagonist, with 8-OH-DPAT eliminated the effect of 8-OH-DPAT on motor complications indicating that the observed 8-OH-DPAT responses were probably mediated at the 5-HT1A autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
17113046-15	2007	Moreover, 8-OH-DPAT plus levodopa significantly reduced hyperphosphorylation of GluR1 at serine 845, which was closely associated with levodopa-induced motor complications.	8-Hydroxy-2-(di-n-propylamino)tetralin	10-19	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	80-85
17202670-0	2007	The 5-HT1A receptor full agonist, 8-OH-DPAT inhibits ACTH-induced 5-HT2A receptor hyperfunction in rats: involvement of 5-HT1A receptors in the DOI-induced wet-dog shakes in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	proopiomelanocortin	Canis lupus familiaris	53-57
17202670-0	2007	The 5-HT1A receptor full agonist, 8-OH-DPAT inhibits ACTH-induced 5-HT2A receptor hyperfunction in rats: involvement of 5-HT1A receptors in the DOI-induced wet-dog shakes in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 2A	Canis lupus familiaris	66-81
17202670-0	2007	The 5-HT1A receptor full agonist, 8-OH-DPAT inhibits ACTH-induced 5-HT2A receptor hyperfunction in rats: involvement of 5-HT1A receptors in the DOI-induced wet-dog shakes in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	proopiomelanocortin	Canis lupus familiaris	174-178
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	proopiomelanocortin	Canis lupus familiaris	79-83
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	proopiomelanocortin	Canis lupus familiaris	189-193
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	proopiomelanocortin	Canis lupus familiaris	189-193
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	310-316
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	375-381
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 2A	Canis lupus familiaris	399-414
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	proopiomelanocortin	Canis lupus familiaris	189-193
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	proopiomelanocortin	Canis lupus familiaris	79-83
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	proopiomelanocortin	Canis lupus familiaris	189-193
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	proopiomelanocortin	Canis lupus familiaris	189-193
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	310-316
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	375-381
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 2A	Canis lupus familiaris	399-414
17202670-3	2007	The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	proopiomelanocortin	Canis lupus familiaris	189-193
17101120-3	2006	We examined whether neonatal exposure to a 5-HT(1A) (8OH-DPAT) or a 5-HT(1B) (CGS 12066B) receptor agonist can mimic the effect of neonatal exposure to citalopram on adult sexual behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-50
16736239-4	2006	In stressed mice, WAY-100635 prevented the anticonvulsant effect of 8-OH-DPAT, a 5-HT(1A) receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	81-98
17067296-4	2006	The 5-HT1B receptor agonist CP93129 mimicked the inhibitory effect of 5-HT, but the 5-HT1A agonist (R)-(+)-8-hydroxy-DPAT (8-OHDPAT) had no effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	123-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-90
16996750-1	2006	Immuno-electron microscopic and beta-microprobe studies have demonstrated that the internalization of serotonin 5-HT(1A) autoreceptors, after acute treatment with the selective 5-HT(1A) receptor agonist 8-OH-DPAT or with the specific serotonin reuptake inhibitor (SSRI) fluoxetine, is associated with a marked decrease in the in vivo binding of [(18)F]MPPF in the nucleus raphe dorsalis (NRD) of rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	203-212	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-119
16868646-0	2006	The 5-HT(1A) receptor active compounds (R)-8-OH-DPAT and (S)-UH-301 modulate auditory evoked EEG responses in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
16868646-6	2006	Also, the 5-HT(1A) agonist (R)-8-OH-DPAT caused a significant increase in the TC ratio at the highest dose studied (0.5 mg/kg s.c.), while the 5-HT(1A) antagonist (S)-UH-301 did not significantly affect the TC ratio at any dose studied (0.1-5 mg/kg s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	27-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-17
16884702-7	2006	Pretreatment with WAY-100635, a 5-HT1A receptor antagonist, almost completely blocked the contralateral turning behavior evoked by tandospirone and 8-OHDPAT, but not that by apomorphine.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-156	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
16841149-1	2006	Experiments performed on male CBA mice immunized with sheep erythrocytes at a dose of 5 x 10(8) cells showed that the selective agonist of serotonin 5-HT(1A) receptors 8-OH-DPAT (1 mg/kg) suppresses the immune response in aggressive animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	149-156
16841149-2	2006	In mice demonstrating the submissive type of behavior, formed during 10 days of experience of defeats, activation of 5-HT(1A) receptors with 8-OH-DPAT had no effect on the immune response.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	117-124
16896955-3	2006	RESULTS AND DISCUSSION: Treatment of male ArKO mice with the 5-HT1A receptor agonist, 8-hydroxy-dipropyl-aminotetralin (8-OH-DPAT), caused an increase in PPI that was significantly greater than in male wild-type controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	61-76
16839691-2	2006	Therefore, the aim of the present study was to examine the role of endogenous and exogenous ovarian steroids in the induction of perseverative responses in a T-maze by the 5-HT1A agonist 8-OH-DPAT (1.0 and 2.0 mg/kg, SC) and in the preventive action of the selective serotonin reuptake inhibitor, fluoxetine (10.0 mg/kg, three times, SC).	8-Hydroxy-2-(di-n-propylamino)tetralin	187-196	5-hydroxytryptamine receptor 1A	Homo sapiens	172-178
16951575-3	2006	Intravenous administration of the specific 5-HT1A agonist (2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT) (0.1 mg/kg) decreased the Renshaw cell burst response by 20-45%.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
16951575-5	2006	These results suggest that 8-OH-DPAT-induced decrease in Renshaw cell burst firing was mediated by 5-HT1A receptors located either presynaptically or postsynaptically.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
16814751-2	2006	We analysed [3H]8-OH-DPAT-specific binding to 5-HT1A receptors in male and female mice after group or isolation housing by in vitro autoradiography (n = 6 per group).	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	46-52
16796994-0	2006	Stereoselectivity of 8-OH-DPAT toward the serotonin 5-HT1A receptor: biochemical and molecular modeling study.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-67
16796994-1	2006	The great majority of pharmacological investigations of 5-HT1A receptors" reactivity has been performed using racemic 8-OH-DPAT, therefore the biochemical as well as behavioral profiles of both 8-OH-DPAT enantiomers are not circumstantiated.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
16796994-1	2006	The great majority of pharmacological investigations of 5-HT1A receptors" reactivity has been performed using racemic 8-OH-DPAT, therefore the biochemical as well as behavioral profiles of both 8-OH-DPAT enantiomers are not circumstantiated.	8-Hydroxy-2-(di-n-propylamino)tetralin	194-203	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
16292325-6	2006	In contrast, H and NH mice were equally responsive to the REM sleep inhibitory effect of 5-HT1A receptor stimulation (by 8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	89-104
16469836-10	2006	The serotonin (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (1 mg/kg iv) enhanced spontaneous EUS activity and the pelvic-EUS reflex.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
16035959-2	2006	We evaluated, using quantitative autoradiography, the effect of these antidepressant treatments on [35S]GTPgammaS binding stimulated by the 5-HT1A receptor agonist 8-OH-DPAT, a measure of the capacity of 5-HT1A receptors to activate G proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	164-173	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-146
16035959-2	2006	We evaluated, using quantitative autoradiography, the effect of these antidepressant treatments on [35S]GTPgammaS binding stimulated by the 5-HT1A receptor agonist 8-OH-DPAT, a measure of the capacity of 5-HT1A receptors to activate G proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	164-173	5-hydroxytryptamine receptor 1A	Rattus norvegicus	204-210
16469836-11	2006	WAY-100635 (0.1-1 mg/kg iv), a 5-HT1A antagonist, reversed the effect of 8-hydroxy-2-(di-n-propylamino)-tetralin and suppressed EUS activity and the pelvic-EUS reflex.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
16380238-6	2006	While repeated corticosterone attenuated the inhibitory effect of 5-HT1A receptor activation by 8-OH-DPAT and enhanced the excitatory effect of 5-HT4 receptor activation by zacopride, imipramine treatment of naive rats resulted in opposite changes.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
16836640-0	2006	Contribution of spinal 5-HT1A and 5-HT7 receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord-transected mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	23-29
16730359-6	2006	The inhibition of the synthesis of 5-HT by p-chlorophenylalanine and the pre-administration of the 5-HT(1A) receptor agonist, 8-OH-DPAT at 40microg/kg, caused a significant potentiation of the tramadol effect decreasing the ED(50) by 53% and 67% respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Homo sapiens	99-116
16643965-2	2006	Acute injection of 5-HT(1A) agonists 8-OH-DPAT and buspirone dose-dependently counteracted the tacrine-induced oral movements (ED(50)=0.04 and 1.0mg/kg, respectively), an effect reversed by the selective 5-HT(1A) antagonist WAY 100,635.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-26
16643965-2	2006	Acute injection of 5-HT(1A) agonists 8-OH-DPAT and buspirone dose-dependently counteracted the tacrine-induced oral movements (ED(50)=0.04 and 1.0mg/kg, respectively), an effect reversed by the selective 5-HT(1A) antagonist WAY 100,635.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	204-211
17025199-4	2006	Agonist of 5-HT(1A)-receptor 8-OH-DPAT (0.5 mg/kg for rats and 2.0 mg/kg for mice, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	11-28
16878502-0	2006	[8-OH-DPAT modulates expression of 5-HT(1A)/5-HT(2A), 17beta-estradiol receptor mRNAs in ovariectomized rats in Porsolt test].	8-Hydroxy-2-(di-n-propylamino)tetralin	1-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-42
16708025-0	2006	Hypothermic responses to 8-OH-DPAT in the Ts65Dn mouse model of Down syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	42-48
16708025-1	2006	Recently, we have demonstrated that potassium channels containing G-protein-activated potassium channel 2 (GIRK2) subunits play a significant role in hypothermia induced by several neurotransmitter receptor agonists, including the serotonin (5-HT)1A/5-HT7 receptor agonist 8-OH-DPAT [R-(+)-8-hydroxy-2-(di-n-propylamino) tetralin].	8-Hydroxy-2-(di-n-propylamino)tetralin	273-282	potassium inwardly-rectifying channel, subfamily J, member 6	Mus musculus	107-112
16708025-4	2006	Here, we used quantitative radiotelemetry to investigatehypothermic responses to 8-OH-DPAT in the Down syndrome mouse model Ts65Dn (which carries an extra chromosomal 16 segment containing Girk2).	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	124-130
16708025-5	2006	Our results indicate that, in relation to euploid controls, Ts65Dn mice display significantly increased hypothermic responses to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	60-66
16687500-6	2006	Additionally, amphetamine produced an antihyperkinetic effect in wild-type mice that received the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-153	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	98-105
16878502-0	2006	[8-OH-DPAT modulates expression of 5-HT(1A)/5-HT(2A), 17beta-estradiol receptor mRNAs in ovariectomized rats in Porsolt test].	8-Hydroxy-2-(di-n-propylamino)tetralin	1-10	5-hydroxytryptamine receptor 2A	Rattus norvegicus	44-51
16878502-9	2006	Simultaneously, 8-OH-DPAT induced significant increase of 5-HT(1A)-, 5-HT(2A)-receptors mRNAs expression and decrease of 17beta-estradiol receptor mRNA expression in hippocampus in OVX rats as compared to the control.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-65
16878502-9	2006	Simultaneously, 8-OH-DPAT induced significant increase of 5-HT(1A)-, 5-HT(2A)-receptors mRNAs expression and decrease of 17beta-estradiol receptor mRNA expression in hippocampus in OVX rats as compared to the control.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	5-hydroxytryptamine receptor 2A	Rattus norvegicus	69-76
16675002-2	2006	These catecholamines can be modulated by the 5-HT(1A) serotonin receptor agonist 8-hydroxy-2-(N,N-di-n-propylamino)tetralin (8-OH DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-52
16434566-5	2006	One week later on PD 67, animals were challenged with either multiple doses of MDMA (four 5 or 10 mg/kg doses) or a single dose of the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (0.1 or 0.5 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	152-190	5-hydroxytryptamine receptor 1A	Rattus norvegicus	135-142
16730785-6	2006	However, treatment with 8-OH-DPAT (5-HT1A receptor agonist, 100 microg, i.pl.)	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
16447179-4	2006	The purpose of this work is to determine the specific binding sites using [(3)H]8-hydroxy-2(di-n-propylamino)tetralin ([(3)H]8-OH-DPAT), a specific agonist of the 5-HT(1A) receptor, and to characterize the diurnal rhythm in the binding by an autoradiography procedure in the crayfish ES.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-134	5-hydroxytryptamine receptor 1A	Homo sapiens	163-180
16406667-6	2006	In addition, WAY-100635 administration reduced the effect of 8-OH-DPAT injection, suggesting a selective 5-HT1A receptor role.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
16533661-10	2006	Results indicate that a similar dendritic spine density can be found in morphologically different populations of MePD neurons and, 8-OH-DPAT can facilitate male sexual behavior by acting on postsynaptic 5-HT1A receptors in this brain area.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-140	5-hydroxytryptamine receptor 1A	Rattus norvegicus	203-209
16293365-6	2006	Injection of the 5-HT1A agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin, 0.5 mg/kg, s.c.) reversed the increase in iBAT thermogenesis (-1.5 +/- 0.4 degrees C, P<0.01, n = 6), and decreased core temperature (-1.5 +/- 0.4 degrees C, P<0.01, n = 6).	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
16293365-6	2006	Injection of the 5-HT1A agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin, 0.5 mg/kg, s.c.) reversed the increase in iBAT thermogenesis (-1.5 +/- 0.4 degrees C, P<0.01, n = 6), and decreased core temperature (-1.5 +/- 0.4 degrees C, P<0.01, n = 6).	8-Hydroxy-2-(di-n-propylamino)tetralin	44-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
16435395-1	2006	Systemic administration of the 5-HT1A receptor agonist 8-OH-DPAT modifies 5-HT neuronal transmission via stimulation of presynaptic and postsynaptic receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
16435395-8	2006	The selective 5-HT1A antagonist WAY-100635 (3 mg/kg) prevented the increased NADH fluorescence after 8-OH-DPAT, but had no own effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
16435395-9	2006	The results show that systemic administration of the 5-HT1A agonist 8-OH-DPAT dose-dependently affects neuronal activity in the ventral hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
16256213-0	2006	Mice over-expressing the 5-HT(1A) receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	25-42
16223872-4	2006	1) Pretraining administration of the 5-HT(1A) receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide] facilitated PA retention at low doses (0.01 and 0.03 mg/kg) but impaired PA retention at higher doses (0.1-1.0 mg/kg), consistent with previous findings in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	37-54
16223872-4	2006	1) Pretraining administration of the 5-HT(1A) receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide] facilitated PA retention at low doses (0.01 and 0.03 mg/kg) but impaired PA retention at higher doses (0.1-1.0 mg/kg), consistent with previous findings in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-125	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	37-54
16289351-7	2006	Thus, 5HT1A autoreceptor activation must be involved in this effect of S 15535 which contrasts with the opposite, inhibitory influence upon phase shifts of the "full" agonist, 8-OH-DPAT, which acts by stimulation of postsynaptic 5HT1A receptors [Rea et al., J Neurosci 14 (1994) 3635].	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine receptor 1A	Rattus norvegicus	229-234
16516955-3	2006	Chronic injection of 5-HT(1A) receptor agonist 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) (2, 4 and 8 mug/rat/day) to dorsal raphe nucleus (DRN) delayed tolerance to morphine analgesia, whereas injection of the same doses of 8-OH-DPAT to the median raphe nucleus (MRN) did not alter tolerance to morphine.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-28
16516955-3	2006	Chronic injection of 5-HT(1A) receptor agonist 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) (2, 4 and 8 mug/rat/day) to dorsal raphe nucleus (DRN) delayed tolerance to morphine analgesia, whereas injection of the same doses of 8-OH-DPAT to the median raphe nucleus (MRN) did not alter tolerance to morphine.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-28
16386718-0	2006	Investigation of mechanisms mediating 8-OH-DPAT-induced impairment of spatial memory: involvement of 5-HT1A receptors in the dorsal hippocampus in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	101-107
16386718-1	2006	The purpose of this study was to identify mechanisms that mediate the impairment of spatial memory induced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A/5-HT7 receptor agonist, in the eight-arm radial maze in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-148	5-hydroxytryptamine receptor 1A	Rattus norvegicus	164-170
16386718-2	2006	WAY-100635 and NAN-190, 5-HT1A receptor antagonists, reversed the impairment of spatial memory induced by systemic injection of 8-OH-DPAT (1 mg/kg, i.p.).	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
16386718-7	2006	These findings suggest that 5-HT1A receptors in the DH play an important role in the mechanisms underlying the 8-OH-DPAT-induced impairment of spatial memory in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
16453979-7	2006	However, sleep deprivation decreased the potency of the 5-HT1A agonist 8-OH-DPAT to inhibit 5-HT neuronal firing in wild-type mice, whereas it had no effect in GR-i animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	56-62
16139268-9	2005	Intrathecal application of serotonin (5-HT) or a 5-HT 1A/7 agonist (8-OH DPAT) in transected rats had a protective effect that blocked the adverse effect of uncontrollable stimulation (Experiment 3).	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-56
16452654-7	2006	Paradoxically, systemic administration of the 5-HT1a agonist 8-OH-DPAT also attenuated LTP.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	46-52
15964603-4	2005	The relative order of efficacy for activation of GIRK current was 5-HT approximately F 13714 approximately L 694,247 approximately LY 228,729>flesinoxan approximately (+/-)8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	175-184	potassium inwardly rectifying channel subfamily J member 3 L homeolog	Xenopus laevis	49-53
16359722-1	2005	This study utilized a novelty-induced suppression of feeding task to examine anxiety-like behaviour and the anxiolytic effects of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), in rats prenatally exposed to ethanol.	8-Hydroxy-2-(di-n-propylamino)tetralin	150-188	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-140
16081165-4	2005	Apoptotic and non-apoptotic fetal rhombencephalic neurons were quantitated in primary cultures that were treated with 50 mM ethanol and with 100 nM of a 5-HT1A agonist such as 8-OH-DPAT [8-hydroxy 2-(di-n-propylamino)tetralin], ipsapirone, or buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine receptor 1A	Homo sapiens	153-159
16148240-5	2005	We analyzed sleep before and after unilaterally dialyzing the 5-HT1A agonist (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) into the juxtafacial PGCL in conscious newborn piglets.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Homo sapiens	62-68
16148240-8	2005	The effects of 8-OH-DPAT were blocked by local pretreatment with N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexane-carboxamide, a selective 5-HT1A antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Homo sapiens	162-168
16359722-1	2005	This study utilized a novelty-induced suppression of feeding task to examine anxiety-like behaviour and the anxiolytic effects of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), in rats prenatally exposed to ethanol.	8-Hydroxy-2-(di-n-propylamino)tetralin	190-199	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-140
16026684-1	2005	We investigated the influence of prolonged administration of the 5-HT1A receptor agonists (8-OH-DPAT or buspirone) or its antagonist, NAN-190 to rat pups on development of their cortical barrel field.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
15972834-8	2005	HVA calcium current inhibition was mimicked by 5-CT, a 5-HT1 receptor agonist, and by R(+)-8-hydroxydipropylaminotetralin hydrobromide (8-OH-DPAT), a specific 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine receptor 1A	Rattus norvegicus	159-165
16053268-2	2005	Such type of behavioural syndrome is induced by 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT) by directly stimulating the central postsynaptic 5-hydroxytryptamine (5-HT, serotonin) receptors of the 5-HT1A type.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	205-211
16053268-2	2005	Such type of behavioural syndrome is induced by 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT) by directly stimulating the central postsynaptic 5-hydroxytryptamine (5-HT, serotonin) receptors of the 5-HT1A type.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	205-211
15955549-2	2005	In rats, administration of the serotonin-1A (5-HT1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), causes a disruption of PPI.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
16049570-10	2005	In contrast, the inhibitory effect of the 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propilamino)-tetralin (8-OH-DPAT) was attenuated in the OFC after both 3 and 8 weeks of paroxetine administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-49
15955549-0	2005	8-OH-DPAT-induced effects on prepulse inhibition: pre- vs. post-synaptic 5-HT1A receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	73-79
16217972-1	2005	Selective agonist of 5-HT1A receptors--8-OH-DPAT (1 mg/kg) induced a suppression of the immune reaction in aggressive male CBA mice immunized with SRBC (5 x 10(8)).	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	21-27
16217972-1	2005	Selective agonist of 5-HT1A receptors--8-OH-DPAT (1 mg/kg) induced a suppression of the immune reaction in aggressive male CBA mice immunized with SRBC (5 x 10(8)).	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	caveolae associated 3	Mus musculus	147-151
16217972-2	2005	In submissive mice with 10-day defeat experience in confrontation tests, the activation of 5-HT1A receptors with 8-OH-DPAT did not alter the immune response, whereas the application of selective antagonist of 5-HT1A receptors WAY-100635 increased the immune reaction only in submissive mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	91-97
15955549-2	2005	In rats, administration of the serotonin-1A (5-HT1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), causes a disruption of PPI.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
15955549-12	2005	Taken together, these data suggest that the disruption of PPI observed in rats with systemic 8-OH-DPAT treatment is predominantly due to an activation of post-synaptic, rather than pre-synaptic, 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	195-201
15743927-5	2005	administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 274 +/- 53 versus 70 +/- 20 pg/ml, P < 0.01 for ACTH and 10.7 +/- 3.4 versus 4.6 +/- 0.7 pg/ml, P < 0.05 for oxytocin after saline or WAY pretreatment, respectively).	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
15619113-4	2005	METHODS: The current study examined behavioral responses to a pleasurable stimulus (sucrose), estrous cycle length (in female rats), and plasma hormone levels following systemic administration of a selective 5-HT(1A) receptor agonist [(+)8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT); 40 mug/kg, s.c.; administered 15 min prior to sacrifice], in male and female rats exposed to 4 weeks of CMS.	8-Hydroxy-2-(di-n-propylamino)tetralin	238-289	5-hydroxytryptamine receptor 1A	Rattus norvegicus	208-215
15872102-6	2005	Treatment with the 5-HT1A agonist 8-hydroxy-2-(di-n-propylmino)tetralin (8-OH DPAT) (250 microg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
15829255-2	2005	Pre-training administration of the 5-HT1A receptor agonist 8-OH-DPAT impaired WM performance and facilitated PA retention at low doses (0.01 and 0.03 mg/kg) and impaired PA retention at higher doses (0.1-1.0 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	35-50
15894080-5	2005	Following behavioral evaluation, the binding of [3H]8-hyroxy-2-(di-n-propylamino) tertalin ([3H]8-OH-DPAT) to 5-HT1A receptors in rat brain was investigated.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	110-116
15894080-6	2005	[3H]8-OH-DPAT binding after AEAJ (200 mg/kg) treatment showed a marked increase in the frontal cortex, hippocampus (CA2 and CA3 regions) and in the lateral septum versus vehicle-treated controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	carbonic anhydrase 2	Rattus norvegicus	116-119
15565434-8	2005	MK 212 and 8-OH-DPAT had irregular effects among rats and only reduced %NLR to below 50% levels at doses markedly suppressing responding.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-20	C-X-C motif chemokine receptor 5	Rattus norvegicus	72-75
15719219-3	2005	OBJECTIVES: This study was conducted to examine the effects of chronic pretreatment with the SSRIs fluvoxamine and paroxetine on the facilitation of ejaculation induced by the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	200-209	5-hydroxytryptamine receptor 1A	Rattus norvegicus	176-182
15817184-7	2005	Forebrain 5-HT1A binding was assessed post-mortem using in vitro receptor autoradiography with the agonist [3H]8-OH-DPAT (3H-8-hydroxy-2-[di-n-propylamino]tetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	107-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
15765530-2	2005	5-HT1A receptor density, the receptor mRNA expression in brain structures, and functional correlates for 5-HT1A receptors identified as 8-OH-DPAT-induced hypothermia and lower lip retraction (LLR) were studied in Norway rats bred for 59 generations for the lack of aggressiveness and for high affective aggressiveness with respect to man.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
15765530-5	2005	5-HT1A receptor agonist 8-OH-DPAT (0.5 mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
15834109-5	2005	Coapplication of 8-OH-DPAT with WAY-100,635 (10 microM), a highly selective 5-HT(1A) antagonist, significantly reduced the phase advance, both in experiments with WT and KO mice, suggesting the greater importance of this serotonin sub-type independent of genetic modification.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	76-83
15777775-2	2005	We have previously demonstrated that pindolol, a beta-adrenoceptor blocker/5-hydroxytryptamine(1A/1B) receptor antagonist, enhanced tramadol antinociception and that the selective 5-HT1A agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reduced it.	8-Hydroxy-2-(di-n-propylamino)tetralin	195-233	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	180-186
15798786-7	2005	Specific binding to 5-HT1A receptors was assessed by autoradiography of brain sections using the 5-HT1A agonist [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
15798786-7	2005	Specific binding to 5-HT1A receptors was assessed by autoradiography of brain sections using the 5-HT1A agonist [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
15798786-8	2005	5-HT1A receptor stimulation was measured using R-(+)-8-OH-DPAT-stimulated [35S]GTPgammaS-binding autoradiography.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
15721170-4	2005	The 5-HT(1A) agonists 8-OH-DPAT and buspirone mimic the effect of 5-HT, whereas the selective 5-HT(1A) receptor antagonist WAY-100635 (1 microM) significantly prevents the effect of 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11
15661577-5	2005	In addition, 8-OH-DPAT inhibited the H(2)O(2)-induced elevation of glutamate release into the medium and cytosolic Ca(2+) concentration ([Ca(2+)](c)), generation of reactive oxygen species (ROS), and caspase-3 activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-22	caspase 3	Rattus norvegicus	200-209
15733547-7	2005	The 5-HT1A receptor selective antagonist (S)-N-tert-butyl-3-(4-(2-methoxyphenyl)piperazine-1-yl)-2-phenylpropanamide hydrochloride and the 5-HT2A receptor selective antagonist ketanserin tartrate inhibited the 8-OH-DPAT and the m5-HT induced acetylcholine release.	8-Hydroxy-2-(di-n-propylamino)tetralin	210-219	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
15661450-7	2005	Increases in vocalization thresholds produced by nPf-administered 8-OH-DPAT were mediated by both 5-HT1A and 5-HT7 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
15722055-1	2005	This study examined the distribution of 5-HT-immunoreactive perikarya (5-HT-IRp) and the effects of local injections of 8-OH-DPAT into 5-HT-IRp-containing pontine and mesencephalic regions on feeding and drinking behaviors in free-feeding pigeons.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	Wnt family member 2	Homo sapiens	140-143
15722055-2	2005	When infused into the midline 5-HT-IRp-containing areas, 8-OH-DPAT (6.1 nmol) reliably elicited drinking and, to a lesser extent, feeding responses during the first hour after injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	Wnt family member 2	Homo sapiens	35-38
15722055-6	2005	Pretreatment with local injections of p-MPPI (an antagonist of 5-HT1A receptors) attenuated the ingestive responses evoked by 8-OH-DPAT injections.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69
15722055-7	2005	Injections of 8-OH-DPAT into lateral 5-HT-IRp-containing sites evoked only inconsistent and weak ingestive responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	Wnt family member 2	Homo sapiens	42-45
15844666-6	2005	The 5-HT(1A) receptor agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) mimicked 5-HT evoked inhibitions in all the nuclei tested and induced weak inhibitory responses also in neurons excited by 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
15844666-6	2005	The 5-HT(1A) receptor agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) mimicked 5-HT evoked inhibitions in all the nuclei tested and induced weak inhibitory responses also in neurons excited by 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
15680266-3	2005	Only the 8-OH-DPAT-induced decrease of such an effect could be blocked by the postsynaptic antagonist of the 5-HT1A receptor 1-(2-methoxyphenyl)-4-[(4-succinimido)butyl]-piperazine (MM-77).	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	109-124
15786964-1	2005	5-HT1A type serotonin receptors influence the immunomodulating action of the selective preparations 8-OH-DPAT (5-HT1A receptor agonist) and WAY-100635 (5-HT1A receptor antagonist) in CBA mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-6
15786964-1	2005	5-HT1A type serotonin receptors influence the immunomodulating action of the selective preparations 8-OH-DPAT (5-HT1A receptor agonist) and WAY-100635 (5-HT1A receptor antagonist) in CBA mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	111-126
15786964-2	2005	The activation of 5HT1A receptors with 8-OH-DPAT (1 mg/kg) decreased, while their blocking with WAY-100635 (1 mg/kg) increased the reaction intensity at the peak of response to immunization with ram erythrocytes.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	18-23
15786964-3	2005	Preliminary blocking of the 5-HT1A receptors with WAY-100635 prevented the inhibiting action of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	28-34
16019152-0	2005	Effects of chronic paroxetine pretreatment on (+/-)-8-hydroxy-2-(di-n-propyl-amino)tetralin induced c-fos expression following sexual behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-91	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	100-105
16019152-10	2005	Chronic treatment with paroxetine reduced Fos-immunoreactivity in the locus coeruleus, and prevented the increase in Fos-immunoreactive neurons induced by 8-OH-DPAT in the oxytocinergic magnocellular part of the paraventricular nucleus as well as in the locus coeruleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	155-164	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	117-120
16019152-12	2005	Chronic paroxetine treatment and 8-OH-DPAT changed c-fos expression in a number of other brain areas, indicating that Fos-immunohistochemistry is a useful tool to find locations where selective serotonin reuptake inhibitors and 8-OH-DPAT exert their effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-56
16019152-12	2005	Chronic paroxetine treatment and 8-OH-DPAT changed c-fos expression in a number of other brain areas, indicating that Fos-immunohistochemistry is a useful tool to find locations where selective serotonin reuptake inhibitors and 8-OH-DPAT exert their effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	118-121
16019152-12	2005	Chronic paroxetine treatment and 8-OH-DPAT changed c-fos expression in a number of other brain areas, indicating that Fos-immunohistochemistry is a useful tool to find locations where selective serotonin reuptake inhibitors and 8-OH-DPAT exert their effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	228-237	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-56
16019152-12	2005	Chronic paroxetine treatment and 8-OH-DPAT changed c-fos expression in a number of other brain areas, indicating that Fos-immunohistochemistry is a useful tool to find locations where selective serotonin reuptake inhibitors and 8-OH-DPAT exert their effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	228-237	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	118-121
16129565-2	2005	Depleting 5-HT with p-chlorophenylalanine (300 mg/kg initially followed by 100 mg/kg/day) or stimulating 5-HT1A receptors with 8-OH-DPAT (1 mg/kg or 2 mg/kg, s.c. injections twice daily) for 14 days had no effect on cell proliferation as measured by Ki-67 or BrdU (5-bromo-3-deoxyuridine) immunocytochemistry in the dentate gyrus.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
15708488-0	2005	Effects of injections of 8-hydroxy-2-(di-n-propylamino)tetralin or muscimol in the median raphe nucleus on c-fos mRNA in the rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-63	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	107-112
15708488-2	2005	Using an animal model of relapse, we have shown that intra-MRN injection of the 5-HT(1A) autoreceptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reinstates alcohol seeking in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-148	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-87
15708488-2	2005	Using an animal model of relapse, we have shown that intra-MRN injection of the 5-HT(1A) autoreceptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reinstates alcohol seeking in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	150-159	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-87
15708488-10	2005	In the ventral hippocampus, only 8-OH-DPAT increased c-fos, while in the basolateral nucleus of the amygdala and locus coeruleus, it was increased only by muscimol.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	53-58
15571670-0	2004	The 5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-9
15571670-14	2004	The level of serum S100B was increased in 8-OH-DPAT-treated animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	S100 calcium binding protein B	Rattus norvegicus	19-24
15571670-15	2004	Increased damage observed in WAY-100635-treated animals supports the hypothesis that the protective 8-OH-DPAT action may be mediated by specific 5HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-150
15598153-3	2004	Presession treatment with the 5-HT1A agonist 8-OH-DPAT (subcutaneous injections at a dose of 0.15 mg/kg) retarded acquisition of the CR, but only when the localized CS was used.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
15589343-4	2004	Fluoxetine alone induced a trend towards desensitization of 5-HT1A autoreceptors as shown by a reduction in the effect of 8-OH-DPAT to lower 5-HT levels in frontal cortex, and desensitized 5-HT1B autoreceptors in frontal cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
15521063-4	2004	Subsequent activation of 5-HT1A receptors by 8-OH-DPAT always produced an inhibition of the SK current, showing the existence of a specific pathway between the receptor and the ion channel.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled L homeolog	Xenopus laevis	25-31
15364487-4	2004	or s.c.) after training, significantly decreased the improvement of performance produced by the 5-HT(1A/7) agonist 8-OH-DPAT to levels lower than controls".	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Homo sapiens	96-103
15140278-5	2004	The 5-HT1A receptor agonist 8-OH-DPAT decreased both immobility in the forced swim test and the body core temperature.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
15589388-0	2004	5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
15589388-1	2004	Fluoxetine, a selective serotonin reuptake inhibitor, shows moderate efficacy and potency in the rat forced swimming depression test and the shock-induced ultrasonic vocalization anxiety test, whereas the 5-HT(1A) receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is highly efficient and potent in both models.	8-Hydroxy-2-(di-n-propylamino)tetralin	231-275	5-hydroxytryptamine receptor 1A	Rattus norvegicus	205-212
15589388-2	2004	Whereas the 5-HT(1A) receptor antagonist WAY 100,635 abolishes the effect of 8-OH-DPAT in both models, it only attenuates the antidepressant-like effect of fluoxetine.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-19
15589388-4	2004	This suggests that the antidepressant-like effect of fluoxetine and 8-OH-DPAT results from indirect (via increased synaptic availability of 5-HT) and direct stimulation of postsynaptic 5-HT(1A) receptors, respectively; whereas the anxiolytic-like effect of fluoxetine is not mediated by 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	185-192
15589388-4	2004	This suggests that the antidepressant-like effect of fluoxetine and 8-OH-DPAT results from indirect (via increased synaptic availability of 5-HT) and direct stimulation of postsynaptic 5-HT(1A) receptors, respectively; whereas the anxiolytic-like effect of fluoxetine is not mediated by 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	287-294
15589388-5	2004	The data support the hypothesis that the antidepressant- and anxiolytic-like effect of 8-OH-DPAT is predominantly mediated by post- and presynaptic 5-HT(1A) receptors, respectively, and that 5-HT(1A) receptors are only partially involved in the antidepressant-like effect of fluoxetine.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	148-155
15469667-5	2004	5-HT1A receptor binding was assayed in post-mortem prefrontal cortex using [3H]8-OH-DPAT, and specific binding determined by 1 microM 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15
15167982-2	2004	OBJECTIVES: To use a low dose range of +/-8-hydroxy-2-(di- n-propylamino)tetralin (8-OHDPAT) to preferentially stimulate 5-HT(1A) autoreceptors and a medium 8-OHDPAT dose range to stimulate both 5-HT(1A) autoreceptors and postsynaptic receptors as pretreatments prior to either saline or cocaine.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-128
15199370-1	2004	The serotonin 5-HT(1A) receptor agonist, 8-OH-DPAT (8-hydroxy-2-di-n-propylamino-tetralin), impairs retention performance in a passive avoidance learning task in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-31
15199370-1	2004	The serotonin 5-HT(1A) receptor agonist, 8-OH-DPAT (8-hydroxy-2-di-n-propylamino-tetralin), impairs retention performance in a passive avoidance learning task in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-31
15167982-2	2004	OBJECTIVES: To use a low dose range of +/-8-hydroxy-2-(di- n-propylamino)tetralin (8-OHDPAT) to preferentially stimulate 5-HT(1A) autoreceptors and a medium 8-OHDPAT dose range to stimulate both 5-HT(1A) autoreceptors and postsynaptic receptors as pretreatments prior to either saline or cocaine.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	195-202
15167982-2	2004	OBJECTIVES: To use a low dose range of +/-8-hydroxy-2-(di- n-propylamino)tetralin (8-OHDPAT) to preferentially stimulate 5-HT(1A) autoreceptors and a medium 8-OHDPAT dose range to stimulate both 5-HT(1A) autoreceptors and postsynaptic receptors as pretreatments prior to either saline or cocaine.	8-Hydroxy-2-(di-n-propylamino)tetralin	157-165	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-128
15167982-11	2004	CONCLUSIONS: It is suggested that the facilitatory effect of 8-OHDPAT on cocaine-induced locomotor stimulation is mediated by inhibition of 5-HT(1A) somato-dendritic autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-147
27518390-4	2004	Using a 5-HT1A receptor binding assay, with a specific 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino) tetralin), the mechanism of the anti-depression effect ofN.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
15554266-5	2004	Using a 5-HT1A receptor binding assay, with a specific 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino) tetralin), the mechanism of the anti-depression effect of N.s.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
15554266-5	2004	Using a 5-HT1A receptor binding assay, with a specific 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino) tetralin), the mechanism of the anti-depression effect of N.s.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
27518390-4	2004	Using a 5-HT1A receptor binding assay, with a specific 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino) tetralin), the mechanism of the anti-depression effect ofN.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
27518390-4	2004	Using a 5-HT1A receptor binding assay, with a specific 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino) tetralin), the mechanism of the anti-depression effect ofN.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
27518390-4	2004	Using a 5-HT1A receptor binding assay, with a specific 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino) tetralin), the mechanism of the anti-depression effect ofN.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
15219641-4	2004	T3 administered daily at 20 microg/kg s.c. for 2 weeks reduced the sensitivity of 5-HT(1A) autoreceptors which control 5-HT release, as measured by the effect of 8-OH-DPAT to decrease 5-HT in the hypothalamus, and also the sensitivity of hypothalamic 5-HT(1B) receptors as measured by the effect of the 5-HT(1B) receptor agonist CP 93129 to decrease 5-HT release.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-89
15353231-6	2004	Initial experiments conducted with noninfected rats showed that acute administration of 8-OH-DPAT (0.01-0.3 mg/kg, subcutaneous [s.c.]) dose dependently decreased striatal levels of 5-HT, an effect postulated to result from activation of somatodendritic 5-HT(1A) autoreceptors in the DRN.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	254-261
15353231-8	2004	Conversely, rats infected with HSV-RGS4 in the DRN showed a blunted neurochemical response to 8-OH-DPAT (0.03 mg/kg, s.c.); however, increasing the dose to 0.3 mg/kg reversed this effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	regulator of G-protein signaling 4	Rattus norvegicus	35-39
15482641-1	2004	Twenty agonists and nine antagonists were evaluated for their ability to compete for [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) binding to the cloned human serotonin-1A (ch-5-HT1A) receptor expressed in Chinese hamster ovary cells and for their ability to alter adenylyl cyclase activity in the same cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-128	5-hydroxytryptamine receptor 1A	Homo sapiens	191-207
15482641-1	2004	Twenty agonists and nine antagonists were evaluated for their ability to compete for [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) binding to the cloned human serotonin-1A (ch-5-HT1A) receptor expressed in Chinese hamster ovary cells and for their ability to alter adenylyl cyclase activity in the same cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Homo sapiens	191-207
15234111-4	2004	Moreover, the 5-HT(1A) receptor agonist 8-OH-DPAT (1 microM) mimicked the 5-HT effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Homo sapiens	14-31
15306247-1	2004	We used the D(2) receptor agonist, apomorphine (APO) and the 5-HT(1A) receptor agonist, 8-OHDPAT (8OH) in a low dose range to stimulate autoreceptors and in this way assess the separate and combined effects of reduced DA and 5-HT activity upon spontaneous and cocaine induced locomotor behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-68
15306247-1	2004	We used the D(2) receptor agonist, apomorphine (APO) and the 5-HT(1A) receptor agonist, 8-OHDPAT (8OH) in a low dose range to stimulate autoreceptors and in this way assess the separate and combined effects of reduced DA and 5-HT activity upon spontaneous and cocaine induced locomotor behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-68
15306247-9	2004	When the combined APO/8OH group also received the 5-HT(1A) antagonist, WAY 100635 (0.05 mg/kg), the effect on activity was equivalent to 0.05 mg/kg APO alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-25	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-57
15225681-1	2004	The somatodendritic 5-HT1A agonist 8-OH-DPAT reduces serotonergic activity and stimulates feeding in freely feeding rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
15152026-1	2004	The serotonin (5-hydroxytryptamine1A) 5-HT1A receptor agonist 8-OH-DPAT [(R)- (+)-8-hydroxy-2-(di-n-propylamino)tetralin] inhibits bladder activity under nociceptive but not innocuous conditions in cats with an intact spinal cord, suggestive of an effect on primary afferent C fibers or their targets.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44
15342106-9	2004	Intra-DPAG injection of the 5-HT1A agonist 8-OH-DPAT and of DOI, a preferential 5-HT2A agonist, also inhibited escape, an effect antagonized by WAY-100635 and ketanserin, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
15314215-6	2004	Importantly, treatment with a 5-HT-1A agonist, (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide, abolished the aggressive behavior in Y1-knockout mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-104	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	30-37
15380839-7	2004	The selective 5HT(1A) agonist, 8OH-DPAT, dose-dependently blocked vocalization in both genotypes and also increased locomotion.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-20
15014926-0	2004	Intraseptal injection of the 5-HT1A/5-HT7 agonist 8-OH-DPAT and working memory in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
15064330-3	2004	The sensitivity of the hypothalamic 5-HT1A receptors was measured as oxytocin and adrenocorticotropic hormone (ACTH) responses to the 5-HT1A receptor agonist (+)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide [(+)8-OH-DPAT] (40 microg/kg s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	158-214	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
15064330-3	2004	The sensitivity of the hypothalamic 5-HT1A receptors was measured as oxytocin and adrenocorticotropic hormone (ACTH) responses to the 5-HT1A receptor agonist (+)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide [(+)8-OH-DPAT] (40 microg/kg s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	158-214	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-140
15064330-3	2004	The sensitivity of the hypothalamic 5-HT1A receptors was measured as oxytocin and adrenocorticotropic hormone (ACTH) responses to the 5-HT1A receptor agonist (+)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide [(+)8-OH-DPAT] (40 microg/kg s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	217-228	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
15225681-8	2004	The effect of 8-OH-DPAT on brain glucose was antagonized by pre-treatment with the 5-HT1A antagonist WAY 100635 (3 mg/kg i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
15225681-10	2004	The data indicate, therefore, that the effect of 8-OH-DPAT on hypothalamic glucose is mediated by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
15225681-15	2004	The data demonstrate furthermore 8-OH-DPAT-induced changes of hypothalamic glucose level, implicating 5-HT1A receptors being involved not only in the control of hypothalamic 5-HT as shown before, but also in the control of hypothalamic glucose.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-108
15219613-7	2004	It was therefore concluded that the internalization of 5-HT1A autoreceptors accounted for the decreased binding in vivo of [18F]MPPF in the nucleus raphe dorsalis of rats treated with 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-193	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
15190115-2	2004	We have demonstrated previously, using immunoelectron microscopy with specific 5-HT1A antibodies, that an internalization of 5-HT1A autoreceptors is associated with their desensitization in rats given a single dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	246-284	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
15190115-2	2004	We have demonstrated previously, using immunoelectron microscopy with specific 5-HT1A antibodies, that an internalization of 5-HT1A autoreceptors is associated with their desensitization in rats given a single dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	246-284	5-hydroxytryptamine receptor 1A	Homo sapiens	125-131
15240353-5	2004	DOI and 8-OH-DPAT also produced a marked induction of c-Fos in the paraventricular nucleus (PVN), but the induction was not different if the two compounds were given together.	8-Hydroxy-2-(di-n-propylamino)tetralin	8-17	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	54-59
15109976-3	2004	injection of the 5-HT(1A) receptor agonist 8-hydroxy-2-[di-n-propylamino] tetralin (8-OH-DPAT) (1-10 microg) induced analgesic effects in the formalin model of tonic pain whereas in the paw pressure test, it decreased the vocalization threshold.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-24
15109976-3	2004	injection of the 5-HT(1A) receptor agonist 8-hydroxy-2-[di-n-propylamino] tetralin (8-OH-DPAT) (1-10 microg) induced analgesic effects in the formalin model of tonic pain whereas in the paw pressure test, it decreased the vocalization threshold.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-24
15109976-6	2004	At 10 microg, 8-OH-DPAT totally abolished the effect of 5 mg/kg of morphine; this inhibitory effect was antagonized by pre-treatment with 0.63 mg/kg of the 5-HT(1A) antagonist WAY-100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2-pyridinyl)-cyclohexanecarboxamide-trihydrochloride).	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	156-163
15213359-5	2004	The application of 2-3 microM 8-OH-DPAT, acting through 5-HT(1A) receptors, resulted in a reversible decrease of bursting frequency.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-63
15291246-7	2004	In addition, a 5-HT1A receptor agonist 8-OH-DPAT reduced the duration of immobility in non-diabetic mice, but not in diabetic mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	15-30
15120594-8	2004	Our results also showed that microinjection of a 5-HT(1A) agonist (0.003, 0.01 and 0.1 microg of 8-hydroxy-dipropylaminotretalin (8-OH-DPAT)) into the PAG increased the duration of TI episodes.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Cavia porcellus	49-56
15628665-4	2004	We report here the pharmacological characterization of one of the first isolated clones of CHO cells stably expressing the human 5-HT1A receptor using the selective agonist 8-OH-DPAT and antagonist p-MPPF.	8-Hydroxy-2-(di-n-propylamino)tetralin	173-182	5-hydroxytryptamine receptor 1A	Homo sapiens	129-144
14722325-0	2004	Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor agonist 8-hydroxy-2-dipropylaminotetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-96
14604841-8	2004	Treatment with fluoxetine produced a dose-dependent desensitization of hormone responses to injection of the 5-HT1A receptor agonist (+/-)8-hydroxy-2-(di-n-propylamino)tetralin ((+/-)8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	133-176	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
14996544-5	2004	A combination of the 5-HT1B receptor agonist CP-94,253 (20 mg/kg) and the 5-HT1A receptor agonist 8-OH-DPAT (0.5 mg/kg) induced marked hyperactivity in WT but not in 5-HT2C KO mice, nor in mice treated with the selective 5-HT2C receptor antagonist, SB 242084 (1.5 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	74-89
14996544-5	2004	A combination of the 5-HT1B receptor agonist CP-94,253 (20 mg/kg) and the 5-HT1A receptor agonist 8-OH-DPAT (0.5 mg/kg) induced marked hyperactivity in WT but not in 5-HT2C KO mice, nor in mice treated with the selective 5-HT2C receptor antagonist, SB 242084 (1.5 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	221-236
15033384-0	2004	8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	23-29
15009637-4	2004	(R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT, 0.5 mg/kg) reduced 5-HT levels to 30% of basal values in 5-HT1A+/+ mice, but not in 5-HT1A-/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	129-135
15009637-4	2004	(R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT, 0.5 mg/kg) reduced 5-HT levels to 30% of basal values in 5-HT1A+/+ mice, but not in 5-HT1A-/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	156-162
15037812-4	2004	The amplitude of the P1-N1 component was also reduced by the 5-HT1A agonist 8-OH-DPAT and 5-HT1B agonist anpirtoline.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
14604841-8	2004	Treatment with fluoxetine produced a dose-dependent desensitization of hormone responses to injection of the 5-HT1A receptor agonist (+/-)8-hydroxy-2-(di-n-propylamino)tetralin ((+/-)8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	178-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
14979803-0	2004	Memory reactivation in rats treated with the 5-HT1A agonist 8-OH-DPAT: a case of gone, but not forgotten.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
16438111-7	2004	Thus, the 5-HT1A receptor antagonist NAN-190 induced anxiolytic effect in intact female rats, while 5-HT1A receptor agonist 8-OH-DPAT produced an anxiolytic profile on OVX rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-106
14684260-13	2004	In support of a role in receptor specificity, pretreatment with the 5-HT1A receptor agonist 8-OH-DPAT (1.25 mg/kg, i.p., two times) or with the 5-HT(1A/B) receptor antagonist pindolol (30 mg/kg, i.p., two times), enhanced or blocked, respectively, the hyperlocomotion induced by CPA.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	68-74
16438112-4	2004	Administration of 5-HT1A receptor agonist 8-OH-DPAT alone or in combination with 17beta-estradiol significantly (p<0.05) improved PAR in OVX rats and failed to normalize PAR in intact rats with proestrus and estrus.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
15183519-7	2004	IS potentiation of morphine-induced DA efflux in the NAc was also dependent upon activation of 5-HT neurons in the DRN because it was blocked by intra-DRN microinjection of the 5-HT1A autoreceptor agonist 8-hydroxy-2-di-n-(propylamino)-tetralin (1 microg).	8-Hydroxy-2-(di-n-propylamino)tetralin	205-244	5-hydroxytryptamine receptor 1A	Rattus norvegicus	177-183
14555716-8	2003	5-HT reduced these EPSCs to 50.0 +/- 13 % of control (P < 0.001), as did the 5-HT1A agonist, 8-OH-DPAT (52.5 +/- 17 %, P < 0.001) and the 5-HT1B agonist, CP 93129 (40.6 +/- 29 %, P < 0.01).	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
14654097-4	2004	Activation of 5-HT7 receptors was thought to be responsible for the shift, despite the clear preference of 8-OH-DPAT for 5-HT1A sites in terms of receptor binding affinity.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-127
14654097-9	2004	By aiding in the identification of the 5-HT receptor subtype responsible for the observed phase shifts and cAMP changes, 8-OH-DPAT represents an important pharmacological tool for 5-HT7 receptor activation, essentially broadening its role as the prototypical 5-HT1A agonist to one combining these two receptor activities.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	259-265
13680080-5	2004	In experiment 2, subjects received an intra-DRN microinjection of the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 1.0 microg/0.5 microl) either before IS or before morphine (3.0 mg/kg, SC) injections during CPP testing.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-77
13680080-5	2004	In experiment 2, subjects received an intra-DRN microinjection of the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 1.0 microg/0.5 microl) either before IS or before morphine (3.0 mg/kg, SC) injections during CPP testing.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-77
14556235-5	2003	In CHO-K1 cells expressing 5-HT1A receptors, 5-HT and DA inhibited the specific binding of selective antagonist [3H]-8-OH-DPAT with IC50 values of 10.2 nM and 1.4 microM, and both 5-HT and DA inhibited the forskolin-induced accumulation of cAMP.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Homo sapiens	27-33
14656287-9	2003	8-OH-DPAT, a 5-HT1A receptor agonist, also inhibited Ca(2+) currents in dissociated neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28
14653308-5	2003	5-HTT null mutants on the 129S6 background showed reduced 5-HT(1A) receptor binding (as measured by quantitative autoradiography) and reduced 5-HT(1A) receptor function (as measured by 8-OH-DPAT-induced hypothermia).	8-Hydroxy-2-(di-n-propylamino)tetralin	185-194	huntingtin	Mus musculus	2-5
14614949-0	2003	Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Homo sapiens	30-36
14727506-3	2003	In the present study, behavioral responses to centrally acting drugs (amphetamine, haloperidol, risperidone, fluoxetine, and 8-OH-DPAT) were examined in PACAP-KO.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	adenylate cyclase activating polypeptide 1	Mus musculus	153-161
14727506-9	2003	A 5-HT1A receptor agonist, 8-OH-DPAT, significantly lowered rectal temperature in wild-type mice, while it had only a small effect in PACAP-KO.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	2-17
14622181-4	2003	The inhibitory response of DRN neurons to intravenous injection of the 5-HT1A agonist 8-OH-DPAT was dramatically reduced in knockout 5-HTT compared with wild-type mice, especially in females.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	71-77
14622228-5	2003	Motor performances and locomotor parameters were analysed in spinal animals receiving daily, for 1 month, a dose of the 5-HT1A agonist 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-143	5-hydroxytryptamine receptor 1A	Rattus norvegicus	120-126
12909675-5	2003	The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.1 mg kg-1 I.V.)	8-Hydroxy-2-(di-n-propylamino)tetralin	19-57	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	4-10
14614948-2	2003	Oral MKC-242 and 8-OH-DPAT, selective 5-HT1A receptor agonists, decreased cortical 5-HT release at low and high doses, while the receptor agonists increased cortical DA release only at a high dose.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	38-53
12923612-5	2003	The selective antagonists p-MPPI and WAY100,635 abolished stimulation of binding by (+)8-OH-DPAT, clozapine and S16924 (p-MPPI), indicating that these actions were mediated specifically by 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-96	5-hydroxytryptamine receptor 1A	Homo sapiens	189-196
12885442-6	2003	Microinjections of the 5-HT(1A) receptor agonist 8-OHDPAT (0.1, 1.0 and 3.0 nmol) into the medial hypothalamus suppressed PAG-elicited hissing in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-57	5-hydroxytryptamine receptor 1A	Homo sapiens	23-40
12885442-7	2003	Administration of the 5-HT(1A) antagonist p-MPPI (3.0 nmol) blocked the suppressive effects of 8-OHDPAT upon hissing.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-103	5-hydroxytryptamine receptor 1A	Homo sapiens	22-29
12892833-7	2003	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) impaired this response, suggesting an anxiolytic effect, and the preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) was ineffective.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-67	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
12892833-7	2003	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) impaired this response, suggesting an anxiolytic effect, and the preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) was ineffective.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
12892833-7	2003	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) impaired this response, suggesting an anxiolytic effect, and the preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) was ineffective.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 2A	Homo sapiens	158-173
12763605-0	2003	Effects of autoshaping procedures on 3H-8-OH-DPAT-labeled 5-HT1a binding and 125I-LSD-labeled 5-HT2a binding in rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
12818723-4	2003	Thus, after stimulation with forskolin, the agonists dopamine (at D(2A) and D(3)), noradrenaline (at alpha(2C)), or 8-OH-DPAT (at 5-HT(1A)) induced a reduction in cAMP accumulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	130-137
12753073-5	2003	In the brains of alcohol-naive mice, we measured [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-dipropyl-aminotetralin hydrobromide (8-OH-DPAT; 1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	116-169	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	92-107
12814524-1	2003	OBJECTIVE: To monitor pre and postsynaptic receptor responsiveness and consumption of ethanol following the repeated administration of a selective serotonin-1A receptor agonist, 8-hydroxy-2-di-n-propylaminotetralin (8-OH-DPAT), to ethanol treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-214	5-hydroxytryptamine receptor 1A	Rattus norvegicus	147-168
12814524-11	2003	Pre and postsynaptic serotonin-1A receptor dependent responses monitored on the 6th day were higher in 5-day saline than 5-day 8-OH-DPAT injected animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-42
12763095-3	2003	Using conventional whole-cell patch recording, we confirmed that the 5-HT(1A) agonist, 8-hydroxy-2-dipropylaminotetralin, presynaptically decreased electrically evoked GABA release while the 5-HT(3) agonist, m-chlorophenylbiguanide (mCPBG), presynaptically facilitated release.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-120	5-hydroxytryptamine receptor 1A	Homo sapiens	69-76
12787852-2	2003	In view of a role of 5-hydroxytryptamine (5-HT; serotonin)-1A receptors in the elicitation of EPS, the present study concerns pre- and postsynaptic responses to a selective 5-HT-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) following acute and chronic administration of haloperidol in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	199-238	5-hydroxytryptamine receptor 1A	Homo sapiens	173-189
12793521-4	2003	Sensitivity of the somatodendritic 5-HT1A autoreceptors was assessed by measuring the reduction in extracellular 5-HT induced by systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-di-n-(propylamino)-tetralin (8-OH-DPAT), while sensitivity of nerve terminal 5-HT1B autoreceptors was measured by observing the increase in 5-HT release after systemic injection of the 5-HT1B receptor antagonist GR 127935.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-223	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
12793521-4	2003	Sensitivity of the somatodendritic 5-HT1A autoreceptors was assessed by measuring the reduction in extracellular 5-HT induced by systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-di-n-(propylamino)-tetralin (8-OH-DPAT), while sensitivity of nerve terminal 5-HT1B autoreceptors was measured by observing the increase in 5-HT release after systemic injection of the 5-HT1B receptor antagonist GR 127935.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-223	5-hydroxytryptamine receptor 1A	Rattus norvegicus	160-166
12793521-4	2003	Sensitivity of the somatodendritic 5-HT1A autoreceptors was assessed by measuring the reduction in extracellular 5-HT induced by systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-di-n-(propylamino)-tetralin (8-OH-DPAT), while sensitivity of nerve terminal 5-HT1B autoreceptors was measured by observing the increase in 5-HT release after systemic injection of the 5-HT1B receptor antagonist GR 127935.	8-Hydroxy-2-(di-n-propylamino)tetralin	225-234	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
12764106-7	2003	Treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylmino)tetralin (8-OH-DPAT; 250 microg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
12729947-0	2003	Effects of 8-OH-DPAT on open field performance of young and aged rats prenatally exposed to diazepam: a tool to reveal 5-HT1A receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-20	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
12770951-6	2003	The 5-HT(1A) receptor agonist (+/-)-8-hydroxy-2-(di-n-propyl-amino)-tetralin (R(+)-8-OH-DPAT) reproduced these effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-76	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-21
12770951-6	2003	The 5-HT(1A) receptor agonist (+/-)-8-hydroxy-2-(di-n-propyl-amino)-tetralin (R(+)-8-OH-DPAT) reproduced these effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-92	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-21
12770951-7	2003	Serotonin- or R(+)-8-OH-DPAT-induced increases in phagocytosis were blocked by the 5-HT(1A) receptor antagonist WAY100635 and the NF-kappaB inhibitor pyrrolidinedithiocarbamate.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-28	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	83-100
12658527-2	2003	OBJECTIVE: This study compares Long-Evans rats and squirrel monkeys to examine the hypothesis that low doses of the 5-HT(1A) selective agonists, 8-OH-DPAT and alnespirone, will preferentially increase, and at higher doses decrease alcohol drinking, and whether these effects can be antagonized by WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-123
12677356-9	2003	The effects of 8-OH-DPAT were blocked by the 5-HT(1A) antagonist WAY 100635, at a dose that itself had no significant effects on behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-52
12626670-2	2003	In current-clamp mode, activation of 5-HT1A receptors by 8-OH-DPAT led to depolarization and an increase in input resistance in most motoneurons but caused hyperpolarization and a decrease in input resistance in the remaining smaller fraction of cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Homo sapiens	37-43
12649391-7	2003	All thermic responses to 8-OH-DPAT, including the lethality, were effectively blocked by pretreatment with the 5-HT(1A) receptor antagonist WAY100635, suggesting line differences in thermoregulatory circuits that are influenced by 5-HT(1A) receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	111-128
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-60	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-60	caspase 3	Homo sapiens	94-103
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-60	mitogen-activated protein kinase 3	Homo sapiens	166-172
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	caspase 3	Homo sapiens	94-103
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	mitogen-activated protein kinase 3	Homo sapiens	166-172
12676358-2	2003	Two 5-HT(1A) agonists, Repinotan hydrochloride (BAY x 3702) and 8-OH-DPAT, block caspase-3 activation and apoptosis caused by anoxia/reoxygenation and H(2)O(2) treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11
12676358-2	2003	Two 5-HT(1A) agonists, Repinotan hydrochloride (BAY x 3702) and 8-OH-DPAT, block caspase-3 activation and apoptosis caused by anoxia/reoxygenation and H(2)O(2) treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	caspase 3	Homo sapiens	81-90
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	protein kinase C alpha	Homo sapiens	49-57
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	caspase 3	Homo sapiens	122-131
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	protein kinase C alpha	Homo sapiens	158-166
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	mitogen-activated protein kinase 1	Homo sapiens	185-188
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	caspase 3	Homo sapiens	193-202
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	204-211
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	mitogen-activated protein kinase 3	Homo sapiens	229-235
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	protein kinase C alpha	Homo sapiens	158-166
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	caspase 3	Homo sapiens	193-202
12649391-7	2003	All thermic responses to 8-OH-DPAT, including the lethality, were effectively blocked by pretreatment with the 5-HT(1A) receptor antagonist WAY100635, suggesting line differences in thermoregulatory circuits that are influenced by 5-HT(1A) receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	231-248
12803776-5	2003	Like WAY 100635, MP349 antagonized the hypothermia induced by the 5-HT(1A)-receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin(8-OH-DPAT) in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-130	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	66-83
12803776-5	2003	Like WAY 100635, MP349 antagonized the hypothermia induced by the 5-HT(1A)-receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin(8-OH-DPAT) in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-140	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	66-83
12675132-6	2003	Systemic injection of 8-OH-DPAT (0.5 mg/kg, SC), an agonist of 5-HT1A receptors, caused a smaller ACh release than citalopram.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
12606921-8	2003	Conversely, 8-OH-DPAT (0.25-1 mg/kg; 5-HT1A agonist) decreased the antinociceptive effect of acetaminophen.	8-Hydroxy-2-(di-n-propylamino)tetralin	12-21	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	37-43
12684269-4	2003	Ligand binding studies were used to determine dissociation constants for agonist binding to the 5-HT(1A) receptor: (a) K(i) values for agonists were determined in competition versus the binding of the agonist [(3)H]-8-OH DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	216-225	5-hydroxytryptamine receptor 1A	Homo sapiens	96-113
12588512-4	2003	The 5-HT(1A) agonist 8-OH-DPAT, which had no effect on vasopressin secretion, stimulated oxytocin secretion.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11
12611395-0	2003	5-HT1A receptor agonist 8-OH-DPAT acts in the hindbrain to reverse the sympatholytic response to severe hemorrhage.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
12604665-4	2003	NMDA-induced caspase-3 activity and DNA fragmentation were almost completely blocked by the 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and (R)-5-fluoro-8 hydroxy-2-(dipropylamino)-tetralin (R-UH-301).	8-Hydroxy-2-(di-n-propylamino)tetralin	108-147	caspase 3	Rattus norvegicus	13-22
12604665-4	2003	NMDA-induced caspase-3 activity and DNA fragmentation were almost completely blocked by the 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and (R)-5-fluoro-8 hydroxy-2-(dipropylamino)-tetralin (R-UH-301).	8-Hydroxy-2-(di-n-propylamino)tetralin	108-147	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
12604665-4	2003	NMDA-induced caspase-3 activity and DNA fragmentation were almost completely blocked by the 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and (R)-5-fluoro-8 hydroxy-2-(dipropylamino)-tetralin (R-UH-301).	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	caspase 3	Rattus norvegicus	13-22
12604665-4	2003	NMDA-induced caspase-3 activity and DNA fragmentation were almost completely blocked by the 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and (R)-5-fluoro-8 hydroxy-2-(dipropylamino)-tetralin (R-UH-301).	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
12604665-5	2003	Additionally, the protective effects of 8-OH-DPAT and R-UH-301 on NMDA-induced caspase-3 activation and apoptosis were reversed by pretreatment with the 5-HT1A antagonists N-[2-[4-(2-methoxyphenyl)-1-piperazinyl] ethyl]-N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) and S-UH-301, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	caspase 3	Rattus norvegicus	79-88
12604665-5	2003	Additionally, the protective effects of 8-OH-DPAT and R-UH-301 on NMDA-induced caspase-3 activation and apoptosis were reversed by pretreatment with the 5-HT1A antagonists N-[2-[4-(2-methoxyphenyl)-1-piperazinyl] ethyl]-N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) and S-UH-301, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-159
12604665-7	2003	Caspase-3 activation and DNA fragmentation in primary mesencephalic neurons were almost completely inhibited by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	caspase 3	Rattus norvegicus	0-9
12588512-4	2003	The 5-HT(1A) agonist 8-OH-DPAT, which had no effect on vasopressin secretion, stimulated oxytocin secretion.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	oxytocin/neurophysin I prepropeptide	Homo sapiens	89-97
12588512-10	2003	WAY 100635 inhibited 8-OH-DPAT-induced oxytocin secretion.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	oxytocin/neurophysin I prepropeptide	Homo sapiens	39-47
12604090-3	2003	The benzodiazepine receptor agonist, diazepam, the serotonin synthesis inhibitor, para-chlorophenylalanine (p-CPA), and the 5-HT(1A) receptor agonist, 8-OH-DPAT, were all found to attenuate morphine and U50,488 analgesia.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	124-141
12667918-4	2003	IP 8-OH-DPAT attenuated ICV IL-1 beta-induced anorexia (P<.01).	8-Hydroxy-2-(di-n-propylamino)tetralin	3-12	interleukin 1 beta	Rattus norvegicus	28-37
12667918-7	2003	Median raphe injections of 8-OH-DPAT significantly attenuated both IL-1 beta- and LPS-induced anorexia (both P<.01).	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	interleukin 1 beta	Rattus norvegicus	67-76
12589380-4	2003	an acute serotonin (5-HT) inhibition induced by the specific stimulation of 5-HT1A autoreceptors (8-OHDPAT 5-100 microg/kg), on naloxone-induced conditioned place aversion in morphine-dependent rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
12589517-5	2003	The 5-HT(1A) agonist, 8-OH-DPAT (0.031, 0.125, 0.5 and 2.0 mg/kg, -15 min) produced perseveration in young and adult rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
12589517-11	2003	This result indicated that the 5-HT(1A) receptor is involved in the deficits on spontaneous alternation produced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-38
12496947-7	2003	Corticosterone treatment was found to induce a significant attenuation in the response to 8-OHDPAT, indicating functional desensitization of somatodendritic 5-HT(1A) autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	157-164
12623219-9	2003	Furthermore, the findings indicate that a down-regulation of the somato-dendritic 5-HT(1A) autoreceptors, following their stimulation with 8-OH-DPAT and possibly also indirectly with 5-HT reuptake inhibitors, may be compensated by a subsequent "sensitization" of the inhibitory galanin receptors in the DRN.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-89
12478210-9	2002	The results confirm that 8-OH-DPAT disrupts temporal differentiation in a free-operant psychophysical schedule, reducing T50, and indicate that this effect of 8-OH-DPAT is mediated by postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	197-203
12467878-4	2002	In subsets of neurons, 8-OH-DPAT (1 microM), a specific 5-HT1A agonist, continuously inhibited mIPSC frequency without effects on mIPSC amplitude.	8-Hydroxy-2-(di-n-propylamino)tetralin	23-32	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
12466249-6	2002	8-OH-DPAT treatment of OK cells led to PKC(beta)-dependent phosphorylation of the alpha-subunit Ser-11 and Ser-18 residues, and determination of enzyme activity with the S11A and S18A mutants indicated that both residues are essential for the agonist-dependent stimulation of Na(+),K(+)-ATPase activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	protein kinase C beta	Homo sapiens	39-48
12478210-9	2002	The results confirm that 8-OH-DPAT disrupts temporal differentiation in a free-operant psychophysical schedule, reducing T50, and indicate that this effect of 8-OH-DPAT is mediated by postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	159-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	197-203
12419413-5	2002	Similarly, removal of PSA from the Syrian hamster SCN in vivo potentiated the daytime phase-advancing effects of behavioral arousal (sleep deprivation) and of systemic application of 8-OH-DPAT (61% and 220% greater, respectively, than inactivated enzyme controls; both P<.05).	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	aminopeptidase puromycin sensitive	Rattus norvegicus	22-25
12414103-4	2002	8-OH-DPAT-induced suppression of the mAHP and enhancement of the ADP were also antagonized by a protein kinase A (PKA) inhibitor H89, whereas 8-OH-DPAT could inhibit the mAHP and enhance the ADP in the presence of a protein kinase C (PKC) inhibitor chelerythrine.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	96-112
12414103-4	2002	8-OH-DPAT-induced suppression of the mAHP and enhancement of the ADP were also antagonized by a protein kinase A (PKA) inhibitor H89, whereas 8-OH-DPAT could inhibit the mAHP and enhance the ADP in the presence of a protein kinase C (PKC) inhibitor chelerythrine.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	114-117
12354565-3	2002	In contrast to the effect in cells, the 5-HT(1A) receptor agonist 8-hydroxy-N,N-diproylaminotetralin (8-OH-DPAT) dose- and time-dependently decreased basal levels of phosphorylated Erk1/2 (phospho-Erk1/2) in rat hippocampus (ED(50) approximately 0.1 mg/kg, maximum approximately 90%) without altering total Erk1/2.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-47
12354565-3	2002	In contrast to the effect in cells, the 5-HT(1A) receptor agonist 8-hydroxy-N,N-diproylaminotetralin (8-OH-DPAT) dose- and time-dependently decreased basal levels of phosphorylated Erk1/2 (phospho-Erk1/2) in rat hippocampus (ED(50) approximately 0.1 mg/kg, maximum approximately 90%) without altering total Erk1/2.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	mitogen activated protein kinase 3	Rattus norvegicus	181-187
12354565-3	2002	In contrast to the effect in cells, the 5-HT(1A) receptor agonist 8-hydroxy-N,N-diproylaminotetralin (8-OH-DPAT) dose- and time-dependently decreased basal levels of phosphorylated Erk1/2 (phospho-Erk1/2) in rat hippocampus (ED(50) approximately 0.1 mg/kg, maximum approximately 90%) without altering total Erk1/2.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	mitogen activated protein kinase 3	Rattus norvegicus	197-203
12354565-3	2002	In contrast to the effect in cells, the 5-HT(1A) receptor agonist 8-hydroxy-N,N-diproylaminotetralin (8-OH-DPAT) dose- and time-dependently decreased basal levels of phosphorylated Erk1/2 (phospho-Erk1/2) in rat hippocampus (ED(50) approximately 0.1 mg/kg, maximum approximately 90%) without altering total Erk1/2.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	mitogen activated protein kinase 3	Rattus norvegicus	197-203
12354565-8	2002	8-OH-DPAT also reduced the levels of the upstream activator of Erk1/2, phosphorylated extracellular signal-regulated kinase kinase (phospho-MEK1/2), and at least one potential downstream target, the nuclear transcription factor phospho-Elk-1.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	mitogen activated protein kinase 3	Rattus norvegicus	63-69
12354565-8	2002	8-OH-DPAT also reduced the levels of the upstream activator of Erk1/2, phosphorylated extracellular signal-regulated kinase kinase (phospho-MEK1/2), and at least one potential downstream target, the nuclear transcription factor phospho-Elk-1.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	mitogen activated protein kinase kinase 1	Rattus norvegicus	140-146
12354565-8	2002	8-OH-DPAT also reduced the levels of the upstream activator of Erk1/2, phosphorylated extracellular signal-regulated kinase kinase (phospho-MEK1/2), and at least one potential downstream target, the nuclear transcription factor phospho-Elk-1.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	ETS transcription factor ELK1	Rattus norvegicus	236-241
12237254-6	2002	5 The proportion of 5-HT(1A) receptor binding sites detected by [(3)H]-MPPF that displayed high affinity for 8-OH-DPAT was significantly greater when the interacting G protein contained isoleucine rather than glycine at residue(351).	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Homo sapiens	20-37
12237254-8	2002	7 These results indicate that a higher avidity ternary complex is formed between 8-OH-DPAT, the 5-HT(1A) receptor and G proteins when isoleucine rather than glycine is located at residue(351) of the interacting G protein.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	96-113
12423245-5	2002	The effect of the other 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin on cortical DA release was also less in isolation-reared mice than in group-reared mice, and that of the drug on cortical 5-HT release did not differ between both groups.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-86	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	24-39
12237750-0	2002	Prolonged corticosterone treatment alters the responsiveness of 5-HT1A receptors to 8-OH-DPAT in rat CA1 hippocampal neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	64-70
12237750-0	2002	Prolonged corticosterone treatment alters the responsiveness of 5-HT1A receptors to 8-OH-DPAT in rat CA1 hippocampal neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	carbonic anhydrase 1	Rattus norvegicus	101-104
12237750-4	2002	Prolonged, but not acute treatment with corticosterone attenuated (+/-)-8-hydroxy-2-di- N-propylamino)tetralin hydrobromide (8-OH-DPAT)-induced inhibition of population spikes, and 8-OH-DPAT-induced hyperpolarization in rat CA1 hippocampal neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	carbonic anhydrase 1	Rattus norvegicus	224-227
12223536-4	2002	Intra-MRN infusions of 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] (a 5-HT1A agonist that decreases 5-HT cell firing and release) reinstated alcohol seeking.	8-Hydroxy-2-(di-n-propylamino)tetralin	23-32	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
12223536-4	2002	Intra-MRN infusions of 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] (a 5-HT1A agonist that decreases 5-HT cell firing and release) reinstated alcohol seeking.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
12236633-2	2002	8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produces a hypothermia in mice that serves as an in-vivo model of somatodendritic 5-HT1A autoreceptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	134-140
12363404-3	2002	Chronic ECS reduced the ability of the 5-HT(1A) receptor agonist 8-hydroxy-2(di-n-propylamino)tetraline (8-OH-DPAT) (0.2 mg/kg s.c.) to decrease 5-HT levels in hypothalamus as shown by in vivo microdialysis, indicative of a reduction in sensitivity of presynaptic 5-HT(1A) autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-46
12363404-3	2002	Chronic ECS reduced the ability of the 5-HT(1A) receptor agonist 8-hydroxy-2(di-n-propylamino)tetraline (8-OH-DPAT) (0.2 mg/kg s.c.) to decrease 5-HT levels in hypothalamus as shown by in vivo microdialysis, indicative of a reduction in sensitivity of presynaptic 5-HT(1A) autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	264-271
12185404-8	2002	The 5-HT(1A) antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-cyclohexanecarboxamide maleate (WAY 100635; 0.2 mg/kg) blocked the R-(+)-8-OHDPAT (0.03 mg/kg)-mediated increase in locomotion.	8-Hydroxy-2-(di-n-propylamino)tetralin	152-166	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
12185404-10	2002	CONCLUSIONS: The present data indicate that R-(+)-8-OHDPAT can increase motor activity in monoamine-depleted rats through postsynaptic 5-HT(1A) receptors and not necessarily through 5-HT(1A) autoreceptor-mediated alterations in 5-HT synthesis and release.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	135-142
12065723-6	2002	In contrast to the low densities of [(3)H]5-CT binding sites, high-to-moderate densities of [(3)H]8-OH-DPAT binding sites (10 nM) were found throughout the brain of 5-HT(1A) and 5-HT(1A/1B) knockout mice (olfactory system, septum, thalamus, hypothalamus, amygdala, CA3 field of the hippocampus, cortical mantle, and central gray).	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	165-172
12236633-2	2002	8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produces a hypothermia in mice that serves as an in-vivo model of somatodendritic 5-HT1A autoreceptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	134-140
12236633-8	2002	However, administration of an additional dose of CORT 2 h prior to the 8-OH-DPAT challenge occluded this CORT-mediated attenuation in a dose-dependent fashion.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	cortistatin	Mus musculus	49-53
12236633-8	2002	However, administration of an additional dose of CORT 2 h prior to the 8-OH-DPAT challenge occluded this CORT-mediated attenuation in a dose-dependent fashion.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	cortistatin	Mus musculus	105-109
11965359-2	2002	Treatment with the selective 5-HT(1A) serotonin receptor agonist 8-OH-DPAT (0.1, 0.25, 0.5 and 2.0 mg/kg) induced a dose-dependent decrease in the amount of time spent by the males near the partition, or "partition time", which is considered the main pattern of sexual motivation.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	29-36
11965359-4	2002	The 5-HT(1A) antagonist p-MPPI (0.1, 0.2 and 0.4 mg/kg) itself did not affect behavior or alter plasma testosterone, but attenuated the inhibiting effect of 8-OH-DPAT on behavior and totally antagonised the effect of the 5-HT(1A) agonist on testosterone response.	8-Hydroxy-2-(di-n-propylamino)tetralin	157-166	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-11
12166089-4	2002	The 5-HT and other 5-HT1A receptor agonists, flesinoxan and 8-hydroxy-2- (di-n-propylamino)tetralon (8-OH-DPAT), significantly decreased the population excitatory postsynaptic potential (EPSP) in the CA3-CA1 excitatory synapse in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34
12523493-3	2002	The silent antagonist of 5-HT1A receptors, WAY 100635, which abolished the hypothermic effect of 8-OH-DPAT, inhibited the hypothermia induced by NAN-190 administered at a dose of 1 mg/kg (but not 2 mg/kg) and by MP245 (0.5 and 1 mg/kg), but failed to change the MM77 (1 and 4 mg/kg)-induced decrease in body temperature in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	25-31
12069904-7	2002	A similar result was obtained in the amygdala of 5-HT(1B) KOs after activation by the selective 5-HT(1A) receptor agonist R-(+)8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	49-56
12069904-7	2002	A similar result was obtained in the amygdala of 5-HT(1B) KOs after activation by the selective 5-HT(1A) receptor agonist R-(+)8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	96-113
12166089-4	2002	The 5-HT and other 5-HT1A receptor agonists, flesinoxan and 8-hydroxy-2- (di-n-propylamino)tetralon (8-OH-DPAT), significantly decreased the population excitatory postsynaptic potential (EPSP) in the CA3-CA1 excitatory synapse in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	carbonic anhydrase 3	Homo sapiens	200-207
12020863-10	2002	E(2)-induced enhancement was also observed when the selective 5-HT(1A) agonist, 8-hydroxy-2-(di-n-propylamino) tetralin, but not the 5-HT(2A/2C) agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, was administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-69
12004193-3	2002	In addition, the finding that 8-OH-DPAT, CGS-12066A and SC53116 also inhibited AVP-induced flank marking suggests that 5-HT could also inhibit flank marking by acting through 5-HT1A, 5-HT7, 5-HT1B and/or 5-HT4 receptor subtypes.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	175-181
12067006-9	2002	However, 8-hydroxy-DPAT (selective 5-HT1A agonist) produced antinociception assessed by electric current but not tail flick.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
11959427-4	2002	Finally, pretreatment with the selective 5-HT(1A) agonist, 8-hydroxy-2-(di-N-propylamino) tetralin (1 mg/kg, intraperitoneally), attenuated the KCl-evoked 5-HT release.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-48
11900785-1	2002	The effects of the 5-HT1A agonist, (+/-)-8-hydroxy-dipropylaminotetralin (8-OHDPAT) upon the unconditioned and conditioned behavior induced by cocaine were assessed in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
12031873-6	2002	However, addition of the specific 5-HT(1A) receptor agonist 8-OH-DPAT as well as the alpha1-adrenoceptor antagonist prazosin could not substantially block this tracer accumulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Homo sapiens	34-51
11900812-3	2002	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 100 microg/kg) stimulated food intake in 3-month-old lean control rats but inhibited feeding in obese Zucker rats (300 microg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
11900812-3	2002	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 100 microg/kg) stimulated food intake in 3-month-old lean control rats but inhibited feeding in obese Zucker rats (300 microg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
11930983-6	2002	In the DPAT paradigm, intraperitoneal injections of the 5-HT1A agonist were given prior to acute restraint and a 40 min session of nutrient self-selection.	8-Hydroxy-2-(di-n-propylamino)tetralin	7-11	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
11888554-6	2002	HAL-induced catalepsy, while reduced by the systemic administration of the 5-HT(1A) agonist 8-OH-DPAT (0.1 mg/kg sc), was insensitive to GR 125487, systemically (1, 3, 10 mg/kg ip) or locally (20 and 40 nmol/20 microl) administered into the third ventricle.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-82
11897085-4	2002	5-HT1A binding sites, as labeled with [3H]8-hydroxy-dipropylaminotetralin (8-OH-DPAT), were highest in the superficial, retinorecipient layers of the tectum, intermediate in layers 6 and 7 and low in the remaining layers.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6
11906526-7	2002	The potency of the 5-HT1A agonist 8-OH-DPAT to produce hypothermia and to reduce the firing of DRN serotoninergic neurons was significantly less in the mutants, indicating a desensitization of 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	19-25
11906526-7	2002	The potency of the 5-HT1A agonist 8-OH-DPAT to produce hypothermia and to reduce the firing of DRN serotoninergic neurons was significantly less in the mutants, indicating a desensitization of 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	193-199
11850148-1	2002	The 5-HT(1A) agonist 8-OH-DPAT has been reported to disrupt prepulse inhibition (PPI) of the acoustic startle reflex after local administration into the raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
11877317-7	2002	5-HT(1A) receptor binding and coupling to G proteins were assessed using [(3)H]-8-OH-DPAT and [(35)S]-GTP gamma S autoradiography, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-17
12022444-11	2002	Selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) decreased the height of twitches and this effect was significantly attenuated in the presence of 5-HT antagonist metergoline (1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	25-64	5-hydroxytryptamine receptor 1A	Cavia porcellus	10-16
11882917-7	2002	Moreover, the effect of 8-OH-DPAT was antagonized by WAY 100135, a selective 5-HT1A antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
11889759-3	2002	Based on our previous experimental studies that 8-OH-DPAT, a potent 5-HT1A agonist, attenuates an increase in L-DOPA-induced extracellular DA in the striatum of the rat model of Parkinson"s disease, we hypothesized that L-DOPA-induced dyskinesia in patients with Parkinson"s disease is alleviated by a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	68-74
11889759-3	2002	Based on our previous experimental studies that 8-OH-DPAT, a potent 5-HT1A agonist, attenuates an increase in L-DOPA-induced extracellular DA in the striatum of the rat model of Parkinson"s disease, we hypothesized that L-DOPA-induced dyskinesia in patients with Parkinson"s disease is alleviated by a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Homo sapiens	302-308
11817498-0	2002	Role of 5-HT1A receptors in the mediation of acute citalopram effects: a 8-OH-DPAT challenge study.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
12959153-11	2002	In a second experiment, neurotoxic lesions of the MRN with local injections of N-methyl-D-aspartate or the activation of 5-HT1A somatodendritic auto-receptors of the MRN by microinjections of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) before the training sessions also reduced the amount of freezing and the fear-potentiated startle.	8-Hydroxy-2-(di-n-propylamino)tetralin	220-258	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-127
12959153-11	2002	In a second experiment, neurotoxic lesions of the MRN with local injections of N-methyl-D-aspartate or the activation of 5-HT1A somatodendritic auto-receptors of the MRN by microinjections of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) before the training sessions also reduced the amount of freezing and the fear-potentiated startle.	8-Hydroxy-2-(di-n-propylamino)tetralin	220-258	5-hydroxytryptamine receptor 1A	Rattus norvegicus	196-202
12959153-11	2002	In a second experiment, neurotoxic lesions of the MRN with local injections of N-methyl-D-aspartate or the activation of 5-HT1A somatodendritic auto-receptors of the MRN by microinjections of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) before the training sessions also reduced the amount of freezing and the fear-potentiated startle.	8-Hydroxy-2-(di-n-propylamino)tetralin	260-269	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-127
12959153-11	2002	In a second experiment, neurotoxic lesions of the MRN with local injections of N-methyl-D-aspartate or the activation of 5-HT1A somatodendritic auto-receptors of the MRN by microinjections of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) before the training sessions also reduced the amount of freezing and the fear-potentiated startle.	8-Hydroxy-2-(di-n-propylamino)tetralin	260-269	5-hydroxytryptamine receptor 1A	Rattus norvegicus	196-202
11746719-1	2001	It was previously shown that the excitatory effect of the 5-HT(1A) agonist 8-OH-DPAT on firing activity of locus coeruleus (LC) norepinephrine (NE) neurons and the inhibitory action of the 5-HT(1A) antagonist WAY 100,635 are dependent on the presence of 5-HT neurons, whereas the inhibitory action of the 5-HT(2) agonist DOI is not.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-65
11746722-6	2001	When the 5-HT(1A) receptor agonist 8-OH-DPAT was administered intravenously at a dose of 0.1, 0.3, or 1 mg/kg 30 min after tracer injection, binding of [carbonyl-(11)C]WAY-100635 was displaced in both age groups in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	9-26
11746722-9	2001	In addition, these observations suggested that the age-related impairment of 5-HT(1A) receptor responses to 8-OH-DPAT might be related to the reduced efficacy of antidepressant therapy in elderly patients with depression.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Homo sapiens	77-94
12022444-11	2002	Selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) decreased the height of twitches and this effect was significantly attenuated in the presence of 5-HT antagonist metergoline (1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Cavia porcellus	10-16
11705793-6	2001	The model was successfully applied to characterize the complex hypothermic response profiles after administration of the reference 5-HT(1A) agonists R-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) and S-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	191-202	5-hydroxytryptamine receptor 1A	Rattus norvegicus	131-138
11705793-6	2001	The model was successfully applied to characterize the complex hypothermic response profiles after administration of the reference 5-HT(1A) agonists R-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) and S-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	208-219	5-hydroxytryptamine receptor 1A	Rattus norvegicus	131-138
11704258-4	2001	Pretreatment with the 5-HT(1A) agonist, 8-OHDPAT (0.2 mg/kg) enhanced and pretreatment with the 5-HT(1A) antagonist, WAY 100635 (0.4 mg/kg) eliminated the locomotor stimulant effect of cocaine.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-29
11742145-1	2001	HDS and LDS rats are the result of selective breeding for differences in the hypothermic effects of the 5-hydroxytryptamine-1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); HDS (high DPAT sensitivity) rats exhibit a much greater hypothermic response than do LDS (low DPAT sensitivity) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	144-182	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-126
11742145-1	2001	HDS and LDS rats are the result of selective breeding for differences in the hypothermic effects of the 5-hydroxytryptamine-1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); HDS (high DPAT sensitivity) rats exhibit a much greater hypothermic response than do LDS (low DPAT sensitivity) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	144-182	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
11742145-1	2001	HDS and LDS rats are the result of selective breeding for differences in the hypothermic effects of the 5-hydroxytryptamine-1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); HDS (high DPAT sensitivity) rats exhibit a much greater hypothermic response than do LDS (low DPAT sensitivity) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-193	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-126
11742145-1	2001	HDS and LDS rats are the result of selective breeding for differences in the hypothermic effects of the 5-hydroxytryptamine-1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); HDS (high DPAT sensitivity) rats exhibit a much greater hypothermic response than do LDS (low DPAT sensitivity) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-193	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
11742145-14	2001	These findings suggest that the selective breeding for differences in 8-OH-DPAT-induced hypothermia has resulted in changes in other behaviours and also changes in the response to 5-HT1A agonist treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
11742145-15	2001	Moreover, these findings are consistent with the hypotheses that: (a) 5-HT1A agonist actions underlie the buspirone-induced and 8-OH-DPAT-induced increases in Noise Alone startle amplitude; whereas (b) the buspirone-induced reduction in potentiated startle is not the result of 5-HT1A agonist actions of this compound.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-76
11742145-15	2001	Moreover, these findings are consistent with the hypotheses that: (a) 5-HT1A agonist actions underlie the buspirone-induced and 8-OH-DPAT-induced increases in Noise Alone startle amplitude; whereas (b) the buspirone-induced reduction in potentiated startle is not the result of 5-HT1A agonist actions of this compound.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	278-284
11606626-2	2001	In nucleus raphe dorsalis (NRD) and hippocampus (CA3), the selective 5-HT(1A) agonist (+)-8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) reduces the firing activity of serotoninergic (5-HT) and pyramidal neurons, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-129	carbonic anhydrase 3	Homo sapiens	49-52
11606626-2	2001	In nucleus raphe dorsalis (NRD) and hippocampus (CA3), the selective 5-HT(1A) agonist (+)-8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) reduces the firing activity of serotoninergic (5-HT) and pyramidal neurons, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-129	5-hydroxytryptamine receptor 1A	Homo sapiens	69-76
11606626-2	2001	In nucleus raphe dorsalis (NRD) and hippocampus (CA3), the selective 5-HT(1A) agonist (+)-8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) reduces the firing activity of serotoninergic (5-HT) and pyramidal neurons, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-140	5-hydroxytryptamine receptor 1A	Homo sapiens	69-76
11595206-0	2001	Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	81-87
11588191-4	2001	Furthermore, a approximately 10-fold decrease in the potency of the 5-HT(1A) receptor agonist ipsapirone to inhibit the discharge of serotoninergic neurons in the dorsal raphe nucleus within brainstem slices, and reduced hypothermic response to 8-OH-DPAT, were noted in NK1-/- versus NK1+/+ mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	245-254	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	68-85
11595206-3	2001	Diazepam (0.1 mg/kg) and the 5-HT(1A) receptor agonist 8-OH-DPAT (0.003 and 0.01 mg/kg) also increased social interaction, whereas an acute dose of the selective serotonin re-uptake inhibitor fluoxetine (10 mg/kg) decreased the time spent in social interaction.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Homo sapiens	29-46
11779040-9	2001	Acute treatment with 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, dose-dependently (0.05, 0.1 and 0.2 mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	21-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
11679057-9	2001	Finally, using Fos as a marker for neural activity, we showed attenuation of 8-OH-DPAT-stimulated activity in the paraventricular nucleus following 21 days of citalopram treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-18
11769569-0	2001	Selective 5-HT1A receptor agonist, 8-OH-DPAT, locally administered into the dorsal raphe nucleus increased extracellular acetylcholine concentrations in the medial prefrontal cortex of conscious rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
11779040-9	2001	Acute treatment with 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, dose-dependently (0.05, 0.1 and 0.2 mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
11549378-2	2001	Administration of the 5-HT(1A) agonist 8-OH-DPAT resulted in decreases in fractional brain blood volumes.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-29
11549378-3	2001	Administration of the 5-HT(1A) antagonist WAY-100635 following a dose of 8-OH-DPAT resulted in increases in fractional blood volumes greatest in hippocampus and cortex and smallest in thalamus and caudate-putamen.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-29
11494406-3	2001	The inhibition was mimicked by the selective 5-HT1A agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) and was reduced by the 5-HT1A antagonist NAN-190, indicating its mediation by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
11494406-11	2001	On the other hand, application of 8-OH-DPAT inhibited I(Ca) and blocked Iso- and Sp-cAMPS-induced enhancement.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	calmodulin 2, pseudogene 1	Rattus norvegicus	84-89
11557264-3	2001	We examined whether 5-HT(1D) and 5-HT(7) receptors are involved in (R)-8-OH-DPAT-induced inhibition of the monosynaptic reflex in spinalized rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-80	5-hydroxytryptamine receptor 1D	Rattus norvegicus	20-27
11524149-1	2001	The cellular location of 5-HT1A and 5-HT1B binding sites in the hippocampus was investigated using a stereotaxic unilateral lesion of the CA1 field by ibotenic acid, followed by autoradiography on brain sections with the specific ligands [3H]8-OH-DPAT and S-CM-G[125I]TNH2, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	242-251	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
11504806-6	2001	In 5-HT(1B) receptor knockout mice, R-8-OH-DPAT evoked a significantly diminished response in the ventral hippocampus, but not the striatum, suggesting the potential desensitization of 5-HT(1A) receptors in the median raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-47	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	3-10
11504806-6	2001	In 5-HT(1B) receptor knockout mice, R-8-OH-DPAT evoked a significantly diminished response in the ventral hippocampus, but not the striatum, suggesting the potential desensitization of 5-HT(1A) receptors in the median raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-47	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	185-192
11565620-10	2001	The selective 5-HT1A agonist 8-OH-DPAT reduced 5-HT efflux in both DRN and MRN.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
11528218-15	2001	We administered 8-hydroxy-2-(di-n-propylamino)tetralin (DPAT), a 5HT(1A) agonist, either alone or in conjunction with stress and examined the effects of these pretreatments on the magnitude of facilitation.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
11566145-1	2001	Previous reports indicate that the behavioural effects (including anxiolytic-like actions, hypothermia, "serotonergic syndrome," maternal behaviour and aggression and reduction in ambulation) of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), are completely blocked in lactating rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	255-264	5-hydroxytryptamine receptor 1A	Rattus norvegicus	199-205
11990069-5	2001	It was also demonstrated that the few selected compounds (4d, 5a-c and 5e) with the highest affinity (Ki up to 50 nM) for 5-HT1A receptors, administered at doses of 10-20 mg/kg, behaved like antagonists of postsynaptic 5-HT1A receptors, as they reduced the 8-OH-DPAT (5-HT1A agonist)-induced lower lip retraction and behavioral syndrome in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	257-266	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
11569620-0	2001	Effects of histidine on working memory deficits induced by the 5-HT1A-receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Homo sapiens	63-78
11569620-1	2001	We investigated the effects of histidine on spatial memory deficits induced by the 5-HT1A-receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	108-146	5-hydroxytryptamine receptor 1A	Homo sapiens	83-98
11489454-6	2001	I5-HT was mimicked by a 5-HT1A receptor selective agonist, 8-OH-DPAT, and was reversibly blocked by a 5-HT1A receptor antagonist, piperazine maleate, but not by a 5-HT2 receptor antagonist, ketanserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
11472307-0	2001	Additive hypothermic effects of the 5-HT1A receptor agonist 8-OH-DPAT and the dopamine D2/3 receptor agonist 7-OH-DPAT in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
11275281-9	2001	The present results suggest that the enhancing effect produced by 8-OH-DPAT on learning consolidation involves activation of 5-HT(1A) receptors and an additional mechanism, probably related to the 5-HT(7) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Homo sapiens	125-132
11448518-7	2001	8-Hydroxy-di-n-propylamino tetralin (8-OH-DPAT), a selective 5-HT(1A) agonist, mimicked the facilitation of 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Homo sapiens	61-68
16414856-2	2001	The serotonin (5HT1A) receptor agonist 8-OH-DPAT has been reported to attenuate extrapyramidal side effects of haloperidol.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-20
11516433-3	2001	We found a higher efficacy of 8-OH-DPAT-induced hypothermia in 5-HT(1B) -/- KO compared to wild-type mice suggesting that an adaptive thermoregulatory process involving the functional activity of somatodendritic 5-HT(1A) receptors is altered in mutant mice lacking 5-HT(1B) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	63-70
11516433-3	2001	We found a higher efficacy of 8-OH-DPAT-induced hypothermia in 5-HT(1B) -/- KO compared to wild-type mice suggesting that an adaptive thermoregulatory process involving the functional activity of somatodendritic 5-HT(1A) receptors is altered in mutant mice lacking 5-HT(1B) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	212-219
11516433-3	2001	We found a higher efficacy of 8-OH-DPAT-induced hypothermia in 5-HT(1B) -/- KO compared to wild-type mice suggesting that an adaptive thermoregulatory process involving the functional activity of somatodendritic 5-HT(1A) receptors is altered in mutant mice lacking 5-HT(1B) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	265-272
11275281-0	2001	Role of 5-HT(1A) and 5-HT(7) receptors in the facilitatory response induced by 8-OH-DPAT on learning consolidation.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	8-15
11422448-9	2001	The enhancement of NA firing activity by the 5-HT1A agonist 8-OH-DPAT was abolished in long-term reboxetine-treated rats, whereas, the inhibitory effect of the 5-HT2 agonist DOI was attenuated by about three-fold.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
11290379-1	2001	Vigilance and parallel occurrence of epileptic activity after administration of the 5-HT(1A) agonist 8-OH-DPAT and the NMDA receptor antagonist MK-801 were studied in the genetic absence epilepsy model WAG/Rij rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-91
11334797-3	2001	Microdialysis of a 5-HT(1A) receptor agonist, 8-OH-DPAT (10 mM), into the RVLM for 30 min attenuated cardiovascular responses to muscle contraction and had no effect on glutamate levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-26
11334797-4	2001	A subsequent administration of 10 mM WAY100635, a 5-HT(1A) antagonist, into the RVLM antagonized the attenuating effects of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-57
11294742-2	2001	Microinjection of the selective 5-HT1A agonist 8-hydroxy-di-n-propylamino tetralin (8-OH-DPAT) decreased arterial blood pressure and splanchnic sympathetic nerve activity (SNA).	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
11294742-6	2001	Preinjection of the selective 5-HT1A antagonist NAN-190 in the RVLM blocked the sympathoinhibitory effect of 8-OH-DPAT and attenuated the inhibitory effect on the somatosympathetic reflex.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
11550043-1	2001	Serotonin 5-HT(1A)receptor agonist 8-OH DPAT suppressed drinking behavior in Brattleboro and Wistar rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-26
11323141-9	2001	Intrathecal injection of the 5-hydroxytryptamine(1A) (5-HT1A) receptor agonist 8-hydroxy-DPAT hydroxybromide (8-OH-DPAT) (0.305, 1.525, 3.05, and 15.25 mM) dose-dependently increased Adelta- and C-responses and post-discharge in most of the WDR neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-60
11173084-9	2001	The results obtained indicate that 8-OHDPAT acting on the pre-synaptic 5-HT1A receptors decreases fear behavior and acting on 5-HT1A post-synaptic receptors increases fear behavior in the light-dark transitions test.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
11173084-9	2001	The results obtained indicate that 8-OHDPAT acting on the pre-synaptic 5-HT1A receptors decreases fear behavior and acting on 5-HT1A post-synaptic receptors increases fear behavior in the light-dark transitions test.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	126-132
11259559-2	2001	Systemic administration of the 5-HT(1A) receptor agonist 8-OH-DPAT had a biphasic effect on brain reward thresholds, without affecting the latency to respond, a measure of performance.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-38
11259559-4	2001	The 5-HT(1A) receptor antagonist p-MPPI had no effect on brain stimulation behavior, but reversed both the 8-OH-DPAT-induced lowering and elevation of thresholds, indicating that both of these effects of 8-OH-DPAT are mediated through the 5-HT(1A) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
11259559-4	2001	The 5-HT(1A) receptor antagonist p-MPPI had no effect on brain stimulation behavior, but reversed both the 8-OH-DPAT-induced lowering and elevation of thresholds, indicating that both of these effects of 8-OH-DPAT are mediated through the 5-HT(1A) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	239-246
11259559-4	2001	The 5-HT(1A) receptor antagonist p-MPPI had no effect on brain stimulation behavior, but reversed both the 8-OH-DPAT-induced lowering and elevation of thresholds, indicating that both of these effects of 8-OH-DPAT are mediated through the 5-HT(1A) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	204-213	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
11259559-4	2001	The 5-HT(1A) receptor antagonist p-MPPI had no effect on brain stimulation behavior, but reversed both the 8-OH-DPAT-induced lowering and elevation of thresholds, indicating that both of these effects of 8-OH-DPAT are mediated through the 5-HT(1A) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	204-213	5-hydroxytryptamine receptor 1A	Rattus norvegicus	239-246
11259559-8	2001	Thus, it is suggested here that the reward-potentiating effects of systemically administered low doses of 8-OH-DPAT may be the result of reduced serotonergic neurotransmission, mediated by activation of 5-HT(1A) somatodendritic autoreceptors in the median, but not the dorsal, raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	203-210
11182534-2	2001	The 5-HT(1A) agonist 8-OH-DPAT decreased immobility in the forced swim test in mice as previously described.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-11
11330332-4	2001	Both 8-OH-DPAT (1 microM) and 5-HT (10 microM) elicited a pronounced increase in [35S]GTPyS binding in the dorsal raphe nucleus, which contains serotonergic cell bodies bearing 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	5-14	5-hydroxytryptamine receptor 1A	Homo sapiens	177-183
11330332-6	2001	In the dentate gyrus, lateral septum and entorhinal cortex, structures enriched in postsynaptic 5-HT1A receptors, 8-OH-DPAT (1 microM) and 5-HT (10 microM) also elicited a marked increase in [35S]GTPgammaS binding which was likewise blocked by pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Homo sapiens	96-102
11275295-0	2001	The selective 5-HT(1A) receptor antagonist p-MPPI antagonizes sleep--waking and behavioural effects of 8-OH-DPAT in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-21
11275295-1	2001	Systemic administration of the selective 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) increases waking and reduces slow wave sleep (SWS) and rapid eye movement (REM) sleep in the freely moving rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-48
11386160-1	2001	The 5-HT1A agonist 8-OH-DPAT was shown to diminish the water and 1.8% NaCl solution consumption, whereas its antagonist pMPPI--to enhance the water intake in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
11343623-1	2001	The 5-HT1A agonist 8-OH-DPAT produces a hypothermia in mice mediated by somatodendritic 5-HT1A receptors, that is attenuated by antidepressants and corticosterone.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-10
11343623-1	2001	The 5-HT1A agonist 8-OH-DPAT produces a hypothermia in mice mediated by somatodendritic 5-HT1A receptors, that is attenuated by antidepressants and corticosterone.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	88-94
11238719-6	2001	These 8-OH-DPAT-induced changes in L-DOPA-derived extracellular DA were antagonized by further pretreatment with WAY-100635, a selective 5-HT(1A) antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	6-15	5-hydroxytryptamine receptor 1A	Rattus norvegicus	137-144
11230515-6	2001	Such TRH-induced 5-HT responses were prevented by the 5-HT1A antagonist NAN-190 (1 microM) and mimicked by the 5-HT1A agonist 8-OH-DPAT (1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	thyrotropin releasing hormone	Rattus norvegicus	5-8
11230515-6	2001	Such TRH-induced 5-HT responses were prevented by the 5-HT1A antagonist NAN-190 (1 microM) and mimicked by the 5-HT1A agonist 8-OH-DPAT (1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
11249960-3	2001	In both DRN and MRN, 5-HT release on short trains was reduced by the selective 5-HT(1A) agonist 8-OH-DPAT (1 microM), an effect blocked by the selective 5-HT(1A) antagonist WAY 100635 (0.1 microM) but not by SB 216641 (0.05 and 0.2 microM) or BRL 15572 (0.5 microM), selective antagonists at the 5-HT(1B) and 5-HT(1D) receptors respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-86
11249960-3	2001	In both DRN and MRN, 5-HT release on short trains was reduced by the selective 5-HT(1A) agonist 8-OH-DPAT (1 microM), an effect blocked by the selective 5-HT(1A) antagonist WAY 100635 (0.1 microM) but not by SB 216641 (0.05 and 0.2 microM) or BRL 15572 (0.5 microM), selective antagonists at the 5-HT(1B) and 5-HT(1D) receptors respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-160
11249960-3	2001	In both DRN and MRN, 5-HT release on short trains was reduced by the selective 5-HT(1A) agonist 8-OH-DPAT (1 microM), an effect blocked by the selective 5-HT(1A) antagonist WAY 100635 (0.1 microM) but not by SB 216641 (0.05 and 0.2 microM) or BRL 15572 (0.5 microM), selective antagonists at the 5-HT(1B) and 5-HT(1D) receptors respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1B	Rattus norvegicus	296-303
11220775-8	2001	The mixed 5-HT(1A/7) receptor agonist, R(+)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT), reduced the evoked EPSC amplitude in both wild-type and 5-HT1B receptor knockout mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	166-181
11220775-9	2001	This effect of 8-OH-DPAT was minimally attenuated by the selective 5-HT1A receptor antagonist WAY 100635 but was reversibly and significantly reduced in the presence of ritanserin, a mixed 5-HT(2/7) receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	67-82
11478737-3	2001	significantly inactivated 5-HT1A receptors, as measured by [3H]8-hydroxy-2-[di-n-propylamino]-tetralin ([3H]8-OH-DPAT), in cortex (64%, p < 0.0001) and hippocampus (48%, p < 0.0001).	8-Hydroxy-2-(di-n-propylamino)tetralin	104-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
11462981-7	2001	The most efficacious compounds (12f, 23gE, 28a, and 28b) were further explored for their ability to antagonize 8-OH-DPAT-induced inhibition of forskolin-stimulated cAMP formation in a cell line expressing the 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	209-215
11478737-5	2001	A dose dependent protection of cortical 5-HT1A receptors from EEDQ inactivation with pre-treatment of different doses of 8-OH-DPAT (4-20 mg/kg) was observed, along with recovery of affinity of [3H]8-OH-DPAT for 5-HT1A receptors in both regions.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
11478737-5	2001	A dose dependent protection of cortical 5-HT1A receptors from EEDQ inactivation with pre-treatment of different doses of 8-OH-DPAT (4-20 mg/kg) was observed, along with recovery of affinity of [3H]8-OH-DPAT for 5-HT1A receptors in both regions.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	211-217
11478737-5	2001	A dose dependent protection of cortical 5-HT1A receptors from EEDQ inactivation with pre-treatment of different doses of 8-OH-DPAT (4-20 mg/kg) was observed, along with recovery of affinity of [3H]8-OH-DPAT for 5-HT1A receptors in both regions.	8-Hydroxy-2-(di-n-propylamino)tetralin	197-206	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
11478737-9	2001	The results of this study suggest that 8-OH-DPAT inhibited EEDQ inactivation of cortical and hippocampal 5-HT1A receptors in a concentration dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
11137865-4	2001	Presynaptic 5-HT(1A) receptor activity, as measured by the effect of a challenge dose (0.2 mg/kg s.c.) of the 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) to reduce 5-HT levels in the hypothalamus, was not affected by corticosterone administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-166	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-19
11267626-1	2001	Previous studies showed that repeated estrogen treatment reduces the ability of the 5-HT(1A) receptor agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT), to inhibit lordosis behavior of female rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-149	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-91
11267626-1	2001	Previous studies showed that repeated estrogen treatment reduces the ability of the 5-HT(1A) receptor agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT), to inhibit lordosis behavior of female rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-91
11164513-3	2001	The present study was aimed to describe the features of coital reflex exhaustion and to determine if the 5-HT1A agonist 8-OH-DPAT was able to reverse exhaustion of this ejaculatory-like response.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
11164513-4	2001	Additionally, the effect of pre-treatment with the 5-HT1A antagonist WAY 100635 on the 8-OH-DPAT induced motor response was evaluated.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	51-57
11164513-9	2001	Notwithstanding, pre-treatment with WAY 100635 was able to block the 8-OH-DPAT-induced motor response implying that its effect was exerted upon 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	144-150
11164517-6	2001	The administration of the selective 5-HT1A agonist, 8-OH-DPAT, counteracted the CTAs produced by MB and 7-NI.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Homo sapiens	36-42
11137865-4	2001	Presynaptic 5-HT(1A) receptor activity, as measured by the effect of a challenge dose (0.2 mg/kg s.c.) of the 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) to reduce 5-HT levels in the hypothalamus, was not affected by corticosterone administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-166	5-hydroxytryptamine receptor 1A	Rattus norvegicus	110-117
11137865-6	2001	Postsynaptic 5-HT(1A) receptor activity, as measured by the effect of 8-OH-DPAT to increase cyclic AMP levels in the hippocampus, was not affected by corticosterone administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-20
11135008-2	2001	We found that 8-hydroxy-2-(n-dipropylamino)tetralin hydrobromide (8-OH-DPAT), a selective 5-HT1A receptor agonist, induced a dose-dependent increase in wakefulness (W) and decrease in deep slow-wave sleep (SWS), but had no significant effect on the generation of paradoxical sleep (PS) at concentrations of 5-500 microM.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Homo sapiens	90-105
11161597-6	2001	The application of 8-hydroxy-2(di-n-propylamino)tetralin, a specific 5-HT(1A) receptor agonist, enhanced GABA responses, whereas alpha-methyl-5-hydroxytryptamine, a 5-HT(2A) receptor agonist, depressed them.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-76
11173221-10	2001	Furthermore, cFos activation by 8-OH-DPAT was blocked by pimozide--a 5-HT(7) antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	13-17
11077069-8	2001	Both the degree of 5-HT(1A) receptor activation by 8-OH-DPAT and (-)-pindolol, and its inhibition by spiperone, strongly correlate (r(2): 0.78-0.81) with the octanol/water partition coefficients of the mutated amino acid at position 351 of the G(alphai3) protein.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	19-36
11077070-2	2001	Chronic T3 administration prior to treatment with the 5-HT(1A) agonist, 8-OH-DPAT, significantly decreased BDNF mRNA in the dentate gyrus region of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-61
11077070-2	2001	Chronic T3 administration prior to treatment with the 5-HT(1A) agonist, 8-OH-DPAT, significantly decreased BDNF mRNA in the dentate gyrus region of the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	brain-derived neurotrophic factor	Rattus norvegicus	107-111
11077070-4	2001	Pretreatment with the 5-HT(1A) antagonist, WAY 100635, completely blocked the 8-OH-DPAT-induced down-regulation of BDNF mRNA in chronic T3-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-29
11077070-4	2001	Pretreatment with the 5-HT(1A) antagonist, WAY 100635, completely blocked the 8-OH-DPAT-induced down-regulation of BDNF mRNA in chronic T3-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	brain-derived neurotrophic factor	Rattus norvegicus	115-119
11287817-6	2001	), a 5-HT reuptake inhibitor, and 8-hydroxy-2-(di-n-propylamino)tetralin, a 5-HT(1A) receptor agonist, also suppressed the HTR induced by BZ-RAs.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-72	5-hydroxytryptamine receptor 1A	Homo sapiens	76-93
11347816-14	2001	The 5HT1A/5HT7 agonist 8-hydroxy DPAT inhibited both the nicotine and GABA-evoked release of dopamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	23-37	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	4-9
11202614-3	2000	Pretreatment with the 5-HT1A-receptor agonists 8-OH-DPAT ((+/-)-8-hydroxy-dipropylaminotetralin) and 5-CT (5-carboxamidotryptamine) dose-dependently prevented the amnesia induced by 5-HT1A antagonists, scopolamine, dicyclomine and exposure to an hypoxic environment.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-37
11104831-8	2000	Taken together, the results are evidence that buspirone, S 14506 and 8-OH-DPAT, administered in cumulative doses, decreased 5-HT release by activating similar 5-HT1A receptors, because a common apparent pA2 value was obtained for WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	159-165
11202614-3	2000	Pretreatment with the 5-HT1A-receptor agonists 8-OH-DPAT ((+/-)-8-hydroxy-dipropylaminotetralin) and 5-CT (5-carboxamidotryptamine) dose-dependently prevented the amnesia induced by 5-HT1A antagonists, scopolamine, dicyclomine and exposure to an hypoxic environment.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-28
11101361-6	2000	One of the tryptamines, 4-fluoro-5-methoxy-DMT (6), displayed high 5-HT(1A) agonist activity, with potency greater than that of the 5-HT(1A) agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine receptor 1A	Rattus norvegicus	132-139
11068021-5	2000	The similar inhibition of miniature IPSC frequency was mimicked by a specific 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 1 microM), and the effects of tandospirone were prevented in the presence of a specific 5-HT1A receptor antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine hydrobromide (NAN-190, 1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	102-141	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
11069935-7	2000	Both nifedipine, an L-type Ca(2+) channel antagonist, and omega-conotoxin GVIA, a selective N-type channel blocker, abolished the induction of associative LTD. 8-hydroxy-2-dipropylaminotetralin (OH-DPAT), a 5-HT(1A) receptor agonist, inhibited postsynaptic Ca(2+) influx through N-type Ca(2+) channels, without affecting presynaptic transmitter release.	8-Hydroxy-2-(di-n-propylamino)tetralin	160-193	5-hydroxytryptamine receptor 1A	Homo sapiens	207-224
11069959-7	2000	When injected both subcutaneously and intrahippocampally, 8-OH-DPAT induced the 5-HT syndrome, indicative of postsynaptic 5-HT(1A) receptor activation at the dose ranges that impaired fear conditioning.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	122-139
11069959-12	2000	It is concluded that the deficits in fear conditioning induced by 8-OH-DPAT are a result of postsynaptic 5-HT(1A) receptor activation that interferes with learning processes operating at acquisition but not consolidation.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	105-122
11068021-6	2000	Activation of 5-HT1A receptors by 8-OH-DPAT (1 microM) evoked no direct postsynaptic effects in enzyme-treated isolated basolateral amygdala neurons, suggesting that tandospirone acts at presynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
11049861-7	2000	LV injection of the 5-HT(1A) agonist (+)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) also delayed the hypotensive (10 microg: 8.6 +/- 0.3, P < 0.01; 20 microg: 9.2 +/- 0.3 ml, P < 0.01), bradycardic, and sympathoinhibitory responses to hemorrhage.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-27
11049861-7	2000	LV injection of the 5-HT(1A) agonist (+)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) also delayed the hypotensive (10 microg: 8.6 +/- 0.3, P < 0.01; 20 microg: 9.2 +/- 0.3 ml, P < 0.01), bradycardic, and sympathoinhibitory responses to hemorrhage.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-27
11198126-6	2000	Administration of the 5-HT1A antagonists WAY-100635 and NAN-190 alone produced dose-dependent rate-decreasing effects, but the effects on accuracy of responding in the acquisition components differed from those of the 5-HT1A agonists (8-OH-DPAT and LY228729), in that they did not produce an increase in the percentage of errors.	8-Hydroxy-2-(di-n-propylamino)tetralin	235-244	5-hydroxytryptamine receptor 1A	Homo sapiens	22-28
11050108-4	2000	8-OH-DPAT-induced hypothermia was absent in female 5-HTT -/- and markedly attenuated in 5-HTT +/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	51-56
11050108-4	2000	8-OH-DPAT-induced hypothermia was absent in female 5-HTT -/- and markedly attenuated in 5-HTT +/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	88-93
11071365-9	2000	The 5-HT1A receptor agonist 8-OH-DPAT (0.01 to 1 microM) and the 5-HT1B receptor agonist CGS-12066A (0.01 to 1 microM) inhibited the electrically stimulated [3H]serotonin and [3H]GABA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
11071365-10	2000	The 5-HT1A antagonist WAY-100135 (1 microM) was without effect on [3H]serotonin and [3H]GABA efflux by itself but it reversed the 8-OH-DPAT-induced transmitter release inhibition.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
11124584-4	2000	This effect was mimicked by 2 microg/side 8-OH-DPAT, a 5-HT1A agonist, but not by DOI, a 5-HT2 agonist, BMY7378, a presynaptic 5-HT1A agonist or MCPP, a 2B & 2C agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
11050366-5	2000	Moreover, (+/-)8-OH-DPAT (0.125-1 mg/kg, s.c.), a selective 5-HT(1A) agonist, reduces the analgesic effect of tramadol in the same tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-67
11029650-2	2000	Bilateral infusion of (-)-nicotine (4 and 8 microg) and of the 5-HT1A receptor agonist 8-OH-DPAT (200 and 500 ng) into the lateral septum decreased the time spent in social interaction, indicating anxiogenic effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
11029650-3	2000	The anxiogenic effect of 8-OH-DPAT (500 ng) was completely reversed by coadministration of a behaviourally inactive dose of the 5-HT1A receptor antagonist, WAY 100635 (200 ng).	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
11029650-7	2000	The effects of 8-OH-DPAT demonstrate that stimulation of 5-HT1A receptors in the lateral septum has anxiogenic effects in two animal tests and that the anxiogenic effects of nicotine are mediated at least in part by these 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
10991934-2	2000	We studied the effects of low doses of 8-OH-DPAT, a 5-HT(1A) receptor agonist, on the impairment of spatial learning caused by scopolamine injected into the CA1 region of the dorsal hippocampus of rats performing a two-platform spatial discrimination task.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Homo sapiens	52-69
10991934-2	2000	We studied the effects of low doses of 8-OH-DPAT, a 5-HT(1A) receptor agonist, on the impairment of spatial learning caused by scopolamine injected into the CA1 region of the dorsal hippocampus of rats performing a two-platform spatial discrimination task.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	carbonic anhydrase 1	Rattus norvegicus	157-160
10998110-3	2000	In analogy to the serotonin1A (5-HT1A) agonist, 8-OH-DPAT (-100%), pindolol dose-dependently (0.063- 1.0 mg/kg) decreased (-70%) the firing rate of serotonergic neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
10936212-2	2000	Serotonin, (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT], and buspirone inhibited cyclic AMP production in cells expressing native and mutant 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-48	5-hydroxytryptamine receptor 1A	Homo sapiens	150-157
11070178-7	2000	In the hypothalamic paraventricular nucleus, both clozapine and DOI/8-OH-DPAT induced a remarkably high number of Fos-positive nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	114-117
10936212-2	2000	Serotonin, (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT], and buspirone inhibited cyclic AMP production in cells expressing native and mutant 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-63	5-hydroxytryptamine receptor 1A	Homo sapiens	150-157
10997729-8	2000	A significant, non-parallel shift in the dose-response curve of serotonergic neurons to the serotonin-1A (5-HT1A) agonist 8-OH-DPAT occurred over the 21 days of treatment with fluoxetine, indicating a desensitization of the 5-HT1A receptor during this period.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
10997729-8	2000	A significant, non-parallel shift in the dose-response curve of serotonergic neurons to the serotonin-1A (5-HT1A) agonist 8-OH-DPAT occurred over the 21 days of treatment with fluoxetine, indicating a desensitization of the 5-HT1A receptor during this period.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	224-230
11026743-2	2000	Because others have shown that systemic administration of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) reduces 5-HT levels throughout the brain, we tested the effects of 8-OH-DPAT on the enhancement of the acoustic startle reflex by the dopamine D1 receptor agonist SKF 82958.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
10974314-7	2000	Postsynaptic 5-HT(1A) receptor sensitivity in the hippocampus, measured by the effect of 8-OH-DPAT to increase cAMP levels in the dialysate, was increased after chronic clomipramine.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-20
11026743-2	2000	Because others have shown that systemic administration of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) reduces 5-HT levels throughout the brain, we tested the effects of 8-OH-DPAT on the enhancement of the acoustic startle reflex by the dopamine D1 receptor agonist SKF 82958.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
11026743-5	2000	Furthermore, SKF 82958 produced a dramatic induction of c-Fos in the DR, an effect that was blocked by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	56-61
10924666-8	2000	The 5-HT(1A) agonist 8-OHDPAT produced a robust increase in cortical dopamine (DA) release without affecting striatal DA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
10934282-3	2000	Hyperalgesia could be attributed to the elimination of presynaptic inhibition by 5-HT of glutamatergic primary C-afferent terminals and an associated decrease in the density of [(3)H]8-OH-DPAT binding sites whose receptors are neither 5-HT(1A)- nor 5-HT(7)-subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	235-242
10952674-6	2000	Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-69	5'-nucleotidase, cytosolic II	Homo sapiens	125-128
10952674-6	2000	Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-69	5-hydroxytryptamine receptor 1A	Homo sapiens	174-191
10952674-6	2000	Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5'-nucleotidase, cytosolic II	Homo sapiens	125-128
10952674-6	2000	Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Homo sapiens	174-191
10908630-5	2000	Therefore, we examined whether phase advances elicited by 8-OH DPAT were associated with a change of Period mRNA levels in the SCN.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	period	Drosophila melanogaster	101-107
10900249-5	2000	and s.c. administration, LY426965 blocked the lower lip retraction, flat body posture, hypothermia, and increase in rat serum corticosterone induced by the 5-HT(1A) agonist 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	173-182	5-hydroxytryptamine receptor 1A	Homo sapiens	156-163
10900249-5	2000	and s.c. administration, LY426965 blocked the lower lip retraction, flat body posture, hypothermia, and increase in rat serum corticosterone induced by the 5-HT(1A) agonist 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	184-217	5-hydroxytryptamine receptor 1A	Homo sapiens	156-163
10973527-13	2000	The 8-OH DPAT treatment, however, selectively blocked this behavioral effect of cocaine suggesting a qualitative influence of 5-HT(1A) receptors upon cocaine, independent of locomotion activation by cocaine.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	126-133
11006720-1	2000	The 5-hydroxytryptamine1a (5-HT1a) receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 0.15 mg/kg) impaired rats" rapid visual learning on a computerized maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
11006720-1	2000	The 5-hydroxytryptamine1a (5-HT1a) receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 0.15 mg/kg) impaired rats" rapid visual learning on a computerized maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
11006720-3	2000	The selective 5-HT1a receptor antagonist WAY-100635 (0.3 mg/kg) was itself without effect on accuracy, but was effective in reversing effects of 8-OH-DPAT (on both accuracy and DT).	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
10884564-3	2000	Microiontophoretic ejection of either the selective serotonin(1A) (5-HT(1A)) agonist (+)8-OH-DPAT or the 5-HT(1B/1D) agonist alniditan resulted in the reversible suppression of the response to superior sagittal sinus stimulation of 29/46 and 18/20 trigeminal neurones, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	67-74
10884564-5	2000	Microiontophoretic ejection of the selective 5-HT(1A) receptor antagonist WAY-100635 significantly antagonised the effect of (+)8-OH-DPAT (effect reduced by 30%, P<0.05).	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Homo sapiens	45-62
10924015-7	2000	In contrast, [3H]8-OH-DPAT binding in the hippocampal CA1 and CA3 regions was decreased by -9% and -20% from the level of chronic ethanol-treated FH rat (p < 0.05) and returned to the control level seen in FH (naive) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	carbonic anhydrase 1	Rattus norvegicus	54-57
10924015-7	2000	In contrast, [3H]8-OH-DPAT binding in the hippocampal CA1 and CA3 regions was decreased by -9% and -20% from the level of chronic ethanol-treated FH rat (p < 0.05) and returned to the control level seen in FH (naive) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	carbonic anhydrase 3	Rattus norvegicus	62-65
10882396-5	2000	Saturation studies using [(3)H]-8-OH-DPAT and [(3)H]-MPPF revealed a single, high affinity site (K(D)approximately 1 nM) in HEK293 cells expressing human 5-HT(1A) receptors and rat cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Homo sapiens	154-161
10899359-0	2000	MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2- (di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-102	5-hydroxytryptamine receptor 1A	Homo sapiens	36-43
10903975-2	2000	The 5-HT(1A) agonist 8-OH-DPAT has been shown to have additional 5-HT uptake inhibiting properties.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
10903975-3	2000	The present work was undertaken to examine further the binding of [(3)H]-8-OH-DPAT in the raphe area of the rat brain, a region rich in 5-HT(1A) receptors and 5-HT uptake sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-143
10903975-13	2000	Whereas the affinities of R(+) and S(-) enantiomers of 8-OH-DPAT for the 5-HT uptake site are similar, R(+)8-OH-DPAT has 10 times higher affinity for the non-5-HT(1A) site than S(-)8-OH-DPAT and was considered as an outlier in the correlation.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	158-165
10903975-13	2000	Whereas the affinities of R(+) and S(-) enantiomers of 8-OH-DPAT for the 5-HT uptake site are similar, R(+)8-OH-DPAT has 10 times higher affinity for the non-5-HT(1A) site than S(-)8-OH-DPAT and was considered as an outlier in the correlation.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	158-165
10860641-4	2000	m CPP (2.5 mg kg(-1)), DOI (2.5 mg kg(-1)) and 8-OH-DPAT (1 mg kg(-1)) increased the serum PRL levels to a similar value, without affecting FSH and LH concentrations.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	prolactin	Rattus norvegicus	91-94
10788764-4	2000	The 5-HT(1A/1B) agonist RU24969 reduced PPI and habituation in WT and 1AKO, but not 1BKO mice, whereas the 5-HT(1A) agonist 8-OH-DPAT increased PPI in WT and 1BKO, but not in 1AKO mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	107-114
10958110-6	2000	MR mRNA expression was induced in hippocampal CA1/CA2 subregions (27-37%) by all antidepressants, while moclobemide and 8-OH-DPAT significantly increased GR gene expression mainly in the CA1 region (31-44%).	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	carbonic anhydrase 1	Rattus norvegicus	187-190
11103884-0	2000	Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
11103884-2	2000	We investigated whether tolerance occurs to these effects after repeated administration of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	110-148	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-101
11103884-3	2000	For comparison, we also assessed the ability of 8-OH-DPAT to produce elements of the 5-HT1A behavioural syndrome (i.e. forepaw treading, flat body posture and lower lip retraction), some of which readily demonstrate tolerance.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-91
11103884-6	2000	In contrast, the ability of 8-OH-DPAT to produce the 5-HT1A behavioural syndrome was significantly attenuated by the repeated treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
10864885-3	2000	Alternatively, a significant (P<0.05) decrease in extracellular 5-HT was observed in control animals upon challenge with the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.03 and 0.1 mg kg(-1)).	8-Hydroxy-2-(di-n-propylamino)tetralin	145-183	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-135
10923758-10	2000	The 5-HT(1A) receptor agonist 8-OH-DPAT (0.05-1 mg/kg, s.c.) had biphasic effects on OAIA, antagonising the response at the lowest dose and intensifying it at the highest dose.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-21
10841434-4	2000	Changes in acetylcholine (ACh) release induced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, in the rat hippocampus were measured using a microdialysis technique and a radioimmunoassay for ACh.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-110
10841434-4	2000	Changes in acetylcholine (ACh) release induced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, in the rat hippocampus were measured using a microdialysis technique and a radioimmunoassay for ACh.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-110
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	butyrylcholinesterase	Rattus norvegicus	162-176
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	butyrylcholinesterase	Rattus norvegicus	178-181
10867965-5	2000	RESULTS: In the absence of EEDQ, each 5-HT1A agonist produced full effects, the rank order of potency being: S 14506 > 8-OH-DPAT > buspirone > ipsapirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
10794819-3	2000	The vehicle-treated ischemic rats had a median number of dorsal CA1 neurons of 49,900 whereas the 8-OH-DPAT-treated ischemic rats had a significant lower median number of dorsal CA1 neurons 105,200 (P=0.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	carbonic anhydrase 1	Rattus norvegicus	178-181
11343573-3	2000	The enhancement of the firing rate of LC neurons produced by the 5-HT1A agonist 8-OH-DPAT (10-50 &mgr;g/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
10823340-6	2000	Systemic administration of the selective 5-HT1A receptor agonist 8-OHDPAT induces dose-dependent effects; i.e. low doses increase slow wave sleep and reduce waking, whereas large doses increase waking and reduce slow wave sleep and REM sleep.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-73	5-hydroxytryptamine receptor 1A	Homo sapiens	41-56
10676857-1	2000	The stereoselectivity of the serotonin1A (5-HT1A) receptor compound 8-hydroxy-2(di-N-propylamino)tetralin (8-OH-DPAT) on forskolin-stimulated adenylyl cyclase activity was investigated in membranes from human 5-HT pre-synaptic (raphe nuclei) and post-synaptic (hippocampus and prefrontal cortex) regions of autopsy brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-105	5-hydroxytryptamine receptor 1A	Homo sapiens	29-58
10676857-1	2000	The stereoselectivity of the serotonin1A (5-HT1A) receptor compound 8-hydroxy-2(di-N-propylamino)tetralin (8-OH-DPAT) on forskolin-stimulated adenylyl cyclase activity was investigated in membranes from human 5-HT pre-synaptic (raphe nuclei) and post-synaptic (hippocampus and prefrontal cortex) regions of autopsy brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	29-58
10665824-4	2000	Electrophysiological recordings in brain slices showed that chronic fluoxetine treatment reduced the potency of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin to inhibit neuronal activity in the dorsal raphe nucleus, but did not affect 5-HT1A-evoked responses of CA1 pyramidal cells in the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-169	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-122
10823407-15	2000	CONCLUSIONS: The results suggest that stimulation of presynaptic 5-HT1A receptors is involved in the ability of 8-OH-DPAT to cause attentional dysfunction and enhance impulsivity while slowing of responding and increase in errors of omission mainly depend on stimulation of post-synaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
10823407-15	2000	CONCLUSIONS: The results suggest that stimulation of presynaptic 5-HT1A receptors is involved in the ability of 8-OH-DPAT to cause attentional dysfunction and enhance impulsivity while slowing of responding and increase in errors of omission mainly depend on stimulation of post-synaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	288-294
10823409-6	2000	RESULTS: The 5-HT1A agonists (+)8-OH-DPAT (0.01-0.1 mg/kg) and flesinoxan (0.3-1.0 mg/kg), the selective 5-HT1B agonist CP-94,253 (0.03-30.0 mg/kg), and the mixed 5-HT1B/2C receptor agonist TFMPP (0.1-10.0 mg/kg) dose-dependently reduced USVs.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	13-19
10823409-6	2000	RESULTS: The 5-HT1A agonists (+)8-OH-DPAT (0.01-0.1 mg/kg) and flesinoxan (0.3-1.0 mg/kg), the selective 5-HT1B agonist CP-94,253 (0.03-30.0 mg/kg), and the mixed 5-HT1B/2C receptor agonist TFMPP (0.1-10.0 mg/kg) dose-dependently reduced USVs.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	105-111
10649830-5	2000	The crucial involvement of the postsynaptic 5-HT1A receptors in the action of 8-OH-DPAT was confirmed.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
10649830-6	2000	Thus, the 5-HT1A receptor antagonists WAY 100635 and (-)-pindolol blocked the PA deficit by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
10617146-7	2000	Exposure of raphe cells to 5-HT, (+/-)-8 hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; a 5-HT1A agonist), or citalopram induced a significant decrease in number of GR binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
10617146-7	2000	Exposure of raphe cells to 5-HT, (+/-)-8 hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; a 5-HT1A agonist), or citalopram induced a significant decrease in number of GR binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-77	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	167-169
10617146-8	2000	The effect of 8-OH-DPAT was reversed by WAY 100135 [N-tert-butyl-3-[1-[1-(2-methoxy)phenyl]piperazinyl]-1-phenylpropiona mide; a 5-HT1A antagonist].	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	129-135
10665824-4	2000	Electrophysiological recordings in brain slices showed that chronic fluoxetine treatment reduced the potency of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin to inhibit neuronal activity in the dorsal raphe nucleus, but did not affect 5-HT1A-evoked responses of CA1 pyramidal cells in the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-169	carbonic anhydrase 1	Rattus norvegicus	274-277
10624814-4	1999	Hippocampal 5-HT1A receptor mRNA was decreased in CA4 and increased in dentate gyrus by single or repeated ECS, with parallel alterations in [3H]8-OH-DPAT binding site densities.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-18
10529722-9	1999	The results showed that YM992 attenuated the inhibitory effect of intravenous administration of LSD and the 5-HT(1A) agonist 8-OH-DPAT on the firing activity of 5-HT neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-115
10588924-0	1999	Facilitation by 8-OH-DPAT of passive avoidance performance in rats after inactivation of 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-96
10588924-3	1999	The effect of 8-OH-DPAT was prevented by the 5-HT(1A) receptor antagonists, NAN-190 and WAY-100635, at doses without any intrinsic effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-52
10565817-5	1999	8-OH-DPAT-induced hypothermia was blocked by the 5-HT(1A) antagonist WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	49-56
10565817-11	1999	The results indicate that lack of the 5-HTT is associated with a functional desensitization of 5-HT(1A) receptor responses to 8-OH-DPAT, which may be a consequence, at least in part, of the decrease in density of 5-HT(1A) receptors in the hypothalamus and dorsal raphe of 5-HTT-/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	95-112
10565817-11	1999	The results indicate that lack of the 5-HTT is associated with a functional desensitization of 5-HT(1A) receptor responses to 8-OH-DPAT, which may be a consequence, at least in part, of the decrease in density of 5-HT(1A) receptors in the hypothalamus and dorsal raphe of 5-HTT-/- mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	95-102
10565846-0	1999	R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-14	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-40
10724448-2	2000	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A agonist, dose-dependently reduced the expression of AMPH (2.5 mg/kg)-induced sensitization.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-60
10724448-2	2000	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A agonist, dose-dependently reduced the expression of AMPH (2.5 mg/kg)-induced sensitization.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-60
10724448-3	2000	The latter inhibitory effect of 8-OH-DPAT was reversed by (S)-N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenyl propamine (WAY 100135), a 5-HT1A antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	148-154
10633476-4	1999	The present study examines the effects of microinjection of a 5-HT1A agonist (8-OH-DPAT) and a 5-HT1A antagonist (spiperone) into the dorsal raphe nucleus (DRN) on AEP recorded epidurally from the primary and secondary auditory cortex in behaving cats.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	legumain	Homo sapiens	164-167
10633476-5	1999	We found a stronger intensity dependence only of AEP from the primary auditory cortex after 8-OH-DPAT, which inhibits the firing rate of serotonergic DRN neurons, and a weaker intensity dependence after spiperone, which increases serotonergic cell firing, as compared to baseline measurements.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-101	legumain	Homo sapiens	49-52
10938574-3	1999	In view of a role of 5-hydroxytryptamine (5-HT) in adaptation to stress the present study concerns effects of a 5-HT-1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) on the synthesis of 5-HT in brain regions of rats adapted to a repeated restraint stress schedule of 2h/day for 5 days.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-119
10564740-4	1999	In diet-induced obese (DiO) rats, specific binding to 5-HT(1A) receptors ([3H]8-OH-DPAT) was significantly increased in the dorsal and median raphe by 90% (P<0.01) and 132% (P<0.05), respectively, compared with chow-fed controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-61
10502313-2	1999	Administration of 8-OH-DPAT (0.1 and 1 mg/kg) induced a marked and dose-related increase in the number of cells positive for Fos-LI in the locus coeruleus (LC), the main source of noradrenergic projections to the forebrain.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	125-128
10502313-4	1999	The effect of both 8-OH-DPAT (0.1 mg/kg) and buspirone (10 mg/kg) on Fos-LI in the LC was blocked by pretreatment with the selective 5-HT(1A) receptor antagonist WAY 100635 (1 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	69-72
10502313-6	1999	In addition to the LC, 8-OH-DPAT (0.1 mg/kg) also induced a marked increase in Fos-LI in various forebrain areas including the medial prefrontal cortex (infralimbic and cingulate cortical areas).	8-Hydroxy-2-(di-n-propylamino)tetralin	23-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	79-82
10502313-7	1999	More detailed analysis of the Fos response to 8-OH-DPAT in the medial prefrontal cortex revealed that the effect was attenuated by pretreatment with a combination of the beta(1)- and beta(2)-adrenoceptor antagonists ICI 118551 (4 mg/kg) and metoprolol (4 mg/kg), but not the alpha(1)-adrenoceptor antagonist prazosin (5 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	30-33
10541727-7	1999	The prototypical 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-(2-di-n-propylamino)tetralin] substituted for LY233708.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	17-24
10536192-4	1999	The 5-HT(1A) agonist (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT) diminished calcitonin analgesia, this effect being antagonised by the 5-HT(1A) antagonist (WAY 100, 135).	8-Hydroxy-2-(di-n-propylamino)tetralin	21-73	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-11
10536192-4	1999	The 5-HT(1A) agonist (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT) diminished calcitonin analgesia, this effect being antagonised by the 5-HT(1A) antagonist (WAY 100, 135).	8-Hydroxy-2-(di-n-propylamino)tetralin	21-73	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	156-163
10536192-4	1999	The 5-HT(1A) agonist (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT) diminished calcitonin analgesia, this effect being antagonised by the 5-HT(1A) antagonist (WAY 100, 135).	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-11
10536192-4	1999	The 5-HT(1A) agonist (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT) diminished calcitonin analgesia, this effect being antagonised by the 5-HT(1A) antagonist (WAY 100, 135).	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	156-163
10536192-5	1999	As the stimulation of 5-HT(1A) autoreceptors reduces the turnover of 5-HT, the effect of 8-OH-DPAT on calcitonin analgesia may be attributed to this decrease.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-29
10515324-4	1999	Tests for generalization and antagonism showed that 5-HT1A receptor agonists, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (66.7%), flesinoxan (72.7%), buspirone (58.3%), and ipsapirone (36.4%) only partially substituted for the eltoprazine cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	52-67
10550491-7	1999	In contrast, the 5-HT(1A) agonist, 8-OH-DPAT (0.3 mg/kg) reduced preference for the large reinforcer at the start of the session, and reduced preference for the small reinforcer at the end of the session, i.e. produced a regression to indifference.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-24
10541727-7	1999	The prototypical 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-(2-di-n-propylamino)tetralin] substituted for LY233708.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-84	5-hydroxytryptamine receptor 1A	Homo sapiens	17-24
10440734-3	1999	Anxiety-like behavior was reduced in both NCAM+/+ and NCAM-/- mice by systemic administration of the benzodiazepine agonist diazepam and the 5-HT1A receptor agonists buspirone and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	neural cell adhesion molecule 1	Mus musculus	42-46
10440734-3	1999	Anxiety-like behavior was reduced in both NCAM+/+ and NCAM-/- mice by systemic administration of the benzodiazepine agonist diazepam and the 5-HT1A receptor agonists buspirone and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	neural cell adhesion molecule 1	Mus musculus	54-58
10440734-3	1999	Anxiety-like behavior was reduced in both NCAM+/+ and NCAM-/- mice by systemic administration of the benzodiazepine agonist diazepam and the 5-HT1A receptor agonists buspirone and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	141-156
10440734-4	1999	However, NCAM-/- mice showed anxiolytic-like effects at lower doses of buspirone and 8-OH-DPAT than NCAM+/+ mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	neural cell adhesion molecule 1	Mus musculus	9-13
10454495-5	1999	Likewise, WAY 100635 (10(-6) M) inhibited contraction to the 5-HT(1A) receptor agonists (+/-)-8-hydroxydipropylaminotetralin hydrobromide (8-OH-DPAT) and LY238729, without altering contraction to norepinephrine or sumatriptan.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	61-68
10817541-3	1999	In behavioral studies both compounds behaved like postsynaptic 5-HT1A receptor antagonists as they reduced lower lip retraction and behavioral syndrome induced by 8-OH-DPAT (5-HT1A receptor agonist) in rats, but 6 was more effective in these tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	163-172	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
10494579-3	1999	In addition, the effect of chronic metyrapone and desipramine treatments on the hypothermic response to a challenge with the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) was assessed.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-180	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
10494579-10	1999	attenuated the hypothermic response to an acute challenge with 8-OH-DPAT (0.05 mg/kg s.c.), indicating a change to the sensitivity of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-140
10621953-3	1999	In this respect, we have carried out two series of experiments: the first series examined the effects of systemic injections of 8-OH-DPAT, a 5-HT1A receptor agonist, successively on a model of anxiety and on a learning task; secondly the effects of selective infusions into the medial septum were studied in the same experimental design.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	141-156
10381597-7	1999	The serotonergic effect was mimicked by the 5-HT1A specific agonist 8-OH DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) and blocked by the 5-HT1A antagonist spiperone.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
10381597-7	1999	The serotonergic effect was mimicked by the 5-HT1A specific agonist 8-OH DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) and blocked by the 5-HT1A antagonist spiperone.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
10366740-6	1999	In the hippocampus, 5-HT1A-m3i labeling revealed a characteristic laminar pattern that coincided with that seen by autoradiographic binding of the 5-HT1A agonist [3H]-8-OH-DPAT in all strata of the hippocampal formation.	8-Hydroxy-2-(di-n-propylamino)tetralin	167-176	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
10440082-0	1999	A neuronal nitric oxide synthase inhibitor 7-nitroindazole reduces the 5-HT1A receptor against 8-OH-DPAT-elicited hyperphagia in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-104	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
10440082-1	1999	The effects of the neuronal nitric oxide (NO) synthase inhibitor 7-nitroindazole on 8-hydroxy-2-di-n-(propylamino)tetralin (8-OH-DPAT)-induced hyperphagia, which is mediated by the 5-HT1A autoreceptor, were investigated in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	181-187
10422888-4	1999	The inhibitory actions of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the 5-HT2A/5-HT2C.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
10422896-2	1999	The conditioned taste aversion induced by 8-OH-DPAT (0.22 mg/kg) and Org 13011 (0.5 mg/kg) was readily blocked by the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride (WAY-100635) (0.1 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	118-133
10422896-4	1999	It is concluded that the conditioned taste aversion induced by 8-OH-DPAT or Org 13011 is mediated via 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	102-108
10431755-9	1999	8-OH-PIPAT and 8-OH-DPAT, two selective 5-HT1A agonists, produced a small but significant increase in cyclic AMP formation at concentrations above 0.04 microM and 10 microM, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
10465692-2	1999	The following effects of activating postsynaptic 5-HT1A receptors by the agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were significantly increased: tail-flick, reciprocal forepaw treading, flat body posture.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
10465692-2	1999	The following effects of activating postsynaptic 5-HT1A receptors by the agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were significantly increased: tail-flick, reciprocal forepaw treading, flat body posture.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
10465692-3	1999	The hyperphagic effect of activating presynaptic 5-HT1A receptors by 8-OH-DPAT tended to increase and hypothermia on activating postsynaptic 5-HT1A sites tended to decrease.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
10371664-0	1999	Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
10371664-5	1999	Further to the OB study, we simultaneously studied adaptive changes in 5-HT1A receptor function, utilizing alterations in the hypothermic response to the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	5-hydroxytryptamine receptor 1A	Rattus norvegicus	154-160
10371664-11	1999	The ability of the combination group to attenuate the hypothermic effects of 8-OH-DPAT faster than paroxetine alone, further emphasizes the role of the 5-HT1A receptor in the mechanism of action of antidepressants, and as a target for the development of faster acting antidepressants.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	152-158
10412836-0	1999	Modulation of sympathetic nerve activity by microinjection of the 5-HT1A receptor agonist 8-OH-DPAT into the rostroventrolateral medulla.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Homo sapiens	66-81
10412836-6	1999	This study demonstrates that differential inhibition of regional sympathetic outflows can be elicited by microinjection of the 5-HT1A receptor agonist 8-OH-DPAT into the RVLM.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Homo sapiens	127-142
10380960-2	1999	Using in vivo microdialysis in unanesthetized rats, we show that the local application of the selective 5-HT1A receptor agonist 8-OH-DPAT decreased the 5-HT output to approximately 50% of controls in medial prefrontal cortex (mPFC) but not in dorsal hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-110
10320714-2	1999	In the present study, the selective 5-HT1A receptor agonist 8-hydroxy-2-(N,N-dipropylamino)tetralin (8-OH-DPAT) significantly reduced N-methyl-d-aspartate (NMDA) receptor-mediated synaptic responses recorded in Mg2+-free medium in rat visual cortical slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
10215901-8	1999	Further results indicated that post-training intra-amygdala infusion of buspirone or the 5-HT1A agonist 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) caused a time-dependent and dose-dependent retention deficit.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
10344593-3	1999	A concentration-dependent increase in enzyme activity was observed with the 5-HT1A agonist R (+)-2-dipropylamino-8-hydroxy-1,2,3, 4-tetrahydronaphthalene hydrobromide (8-OH-DPAT) in homogenates or in glial membrane enriched fractions from cerebral cortex and in hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
10344593-4	1999	Spiperone, a 5-HT1A antagonist, completely inhibited the response to 8-OH-DPAT but had no effect on Na+/K+-ATPase activity in cerebellum where LSD, a 5-HT6 agonist, elicited a dose-dependent response similar to that of 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
10498288-11	1999	Microinjection of the 5-HT1A receptor agonist (+/-)-8-hydroxy-dipropylaminotetralin (8-OH-DPAT; 7.5 nmol, 50 nl) into the DRN led to a long-lasting reduction of the release rate of serotonin in the locus coeruleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
10379620-4	1999	RESULTS: Firstly, the 5-HT1A agonists 8-OH-DPAT and ipsapirone attenuated the extrapyramidal-like effects of haloperidol and risperidone more than their therapeutic-like effects; this was not observed for tropapride, where all of its effects were markedly attenuated.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Homo sapiens	22-28
10379620-6	1999	Thirdly, neuroleptics apparently differed in their sensitivity to interactions with 5-HT1A agonists inasmuch as 8-OH-DPAT and ipsapirone attenuated the effects of tropapride on hindlimb retraction times more than those of haloperidol or risperidone.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Homo sapiens	84-90
10191333-9	1999	Finally, the 5-HT1A agonist 8-OH-DPAT (0.2-1.2 mg/kg, s.c.) induced in both strains a reduction in the amount of paradoxical sleep.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	13-19
10366740-6	1999	In the hippocampus, 5-HT1A-m3i labeling revealed a characteristic laminar pattern that coincided with that seen by autoradiographic binding of the 5-HT1A agonist [3H]-8-OH-DPAT in all strata of the hippocampal formation.	8-Hydroxy-2-(di-n-propylamino)tetralin	167-176	5-hydroxytryptamine receptor 1A	Rattus norvegicus	147-153
10366740-8	1999	The detailed matching of the anti-5-HT1A-m3i antibody with [3H]-8-OH-DPAT binding suggests that the antibody recognizes a functionally active form of the 5-HT1A receptor protein capable of binding 5-HT1A agonist ligands.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
10366740-8	1999	The detailed matching of the anti-5-HT1A-m3i antibody with [3H]-8-OH-DPAT binding suggests that the antibody recognizes a functionally active form of the 5-HT1A receptor protein capable of binding 5-HT1A agonist ligands.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	154-160
10366740-8	1999	The detailed matching of the anti-5-HT1A-m3i antibody with [3H]-8-OH-DPAT binding suggests that the antibody recognizes a functionally active form of the 5-HT1A receptor protein capable of binding 5-HT1A agonist ligands.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	154-160
10188639-5	1999	Similarly, quantitative autoradiography using the radiolabeled 5-HT(1A) receptor agonist 8-hydroxy-2-(di-N-propylamino) tetralin demonstrated a significant decline in receptor density in 3- and 13-month MC and HC groups as compared to age-matched LC groups in the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-128	5-hydroxytryptamine receptor 1A	Homo sapiens	63-80
10086229-6	1999	We conclude that 8-OH-DPAT is effective as early as 3 days of age in the quieting of isolation-induced USV and that the regional age-dependent development of 5-HT1A receptors and projections are important factors in the observed differential sensitivity to 8-OH-DPAT administration during development.	8-Hydroxy-2-(di-n-propylamino)tetralin	257-266	5-hydroxytryptamine receptor 1A	Rattus norvegicus	158-164
10027850-8	1999	Furthermore, the data provide evidence for a major involvement of these 5-HT1A receptors in the modulation of aggressive behavior by 8-OH-DPAT, ipsapirone, buspirone, and eltoprazine.	8-Hydroxy-2-(di-n-propylamino)tetralin	133-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
10215509-5	1999	Scatchard analysis of [3H]8-hydroxy-dipropylaminotetraline (8-OH-DPAT) binding to 5-HT1A receptors demonstrated the presence of high- and low-affinity binding sites in both treatment and control groups.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
10215509-6	1999	IFN significantly increased both Kd and Bmax measures of [3H]8-OH-DPAT binding at low-affinity binding sites, but not at the high-affinity sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	interferon alpha 1	Homo sapiens	0-3
10023030-2	1999	While 8-OH-DPAT has been characterized as an agonist at the 5-HT1A receptor, it also acts at other receptor sites including the dopamine D2 receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	6-15	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
10023030-3	1999	The current experiments investigated whether 8-OH-DPAT injected into the MPOA facilitates male sexual behavior through stimulation of the 5-HT1A receptor or the dopamine D2 receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	138-144
9918559-4	1999	for 14 days and were challenged with a 5-HT1A agonist, [8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) 50 microg/kg, s.c.] 2, 4, 7, 14, 28, or 60 days post-treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
10100214-9	1999	[11C]NAD-299 binding was inhibited by addition of the 5-HT1A receptor ligands WAY-100635, pindolol, (+/-)-8-OH-DPAT, 5-HT, and buspirone, leaving a low background of nonspecific binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-115	5-hydroxytryptamine receptor 1A	Homo sapiens	54-69
9988099-4	1999	In contrast, in vitro electrophysiological recordings performed 24 h after the last injection of alnespirone showed that the potency of the 5-HT1A receptor agonist, 8-OH-DPAT, to depress the firing of serotoninergic neurons in the dorsal raphe nucleus, was significantly reduced after a 21-day treatment with alnespirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	165-174	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-146
9878719-4	1999	5-HT and the 5-HT1A receptor agonist, (+)8-hydroxy-2(di-N-propylamino)tetraline (8-OH-DPAT), were able to inhibit forskolin-stimulated adenylyl cyclase activity in a dose-dependent manner for 48 h after death in rat and human brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28
9878719-11	1999	The (+)8-OH-DPAT dose-response curve was completely reversed by 5-HT1A receptor antagonists in rat cortex and all human brain areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	7-16	5-hydroxytryptamine receptor 1A	Homo sapiens	64-79
10025590-2	1999	In vivo ICV injections of modified antisense oligodesoxynucleotides yielded at most an 18% specific decrease in 5-HT1A receptor expression in the hippocampus only, as measured by [3H]8-OH-DPAT autoradiographic labeling.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
9878840-3	1999	To determine the specific 5-HT1A receptor binding, [3H]8-OH-DPAT was used as radioligand.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-64	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	26-41
9878840-6	1999	The 5-HT1A agonist 8-OH-DPAT was found to increase DNA synthesis and accelerated cell growth.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-10
10721047-2	1999	The non-selective NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) and neuronal NOS (nNOS) inhibitor 7-nitroindazole (7-NI) clearly suppressed increases in food intake by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	nitric oxide synthase 1	Rattus norvegicus	78-90
10721047-2	1999	The non-selective NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) and neuronal NOS (nNOS) inhibitor 7-nitroindazole (7-NI) clearly suppressed increases in food intake by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	nitric oxide synthase 1	Rattus norvegicus	92-96
10449982-2	1999	When these cells were grown in serum-free medium and treated with 10(-8) M agonist selective for either the 5-HT(1A) or 5-HT(4) receptor subtype (8-OH-DPAT and SC53116, respectively), this significantly stimulated cAMP synthesis and increased insulin-like growth factor I (IGF-I), but not IGF-II, protein levels compared to vehicle-treated controls, as measured by semi-quantitative immunobinding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	108-115
10449982-2	1999	When these cells were grown in serum-free medium and treated with 10(-8) M agonist selective for either the 5-HT(1A) or 5-HT(4) receptor subtype (8-OH-DPAT and SC53116, respectively), this significantly stimulated cAMP synthesis and increased insulin-like growth factor I (IGF-I), but not IGF-II, protein levels compared to vehicle-treated controls, as measured by semi-quantitative immunobinding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	insulin-like growth factor 1	Mus musculus	243-271
10449982-2	1999	When these cells were grown in serum-free medium and treated with 10(-8) M agonist selective for either the 5-HT(1A) or 5-HT(4) receptor subtype (8-OH-DPAT and SC53116, respectively), this significantly stimulated cAMP synthesis and increased insulin-like growth factor I (IGF-I), but not IGF-II, protein levels compared to vehicle-treated controls, as measured by semi-quantitative immunobinding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	insulin-like growth factor 1	Mus musculus	273-278
10449982-2	1999	When these cells were grown in serum-free medium and treated with 10(-8) M agonist selective for either the 5-HT(1A) or 5-HT(4) receptor subtype (8-OH-DPAT and SC53116, respectively), this significantly stimulated cAMP synthesis and increased insulin-like growth factor I (IGF-I), but not IGF-II, protein levels compared to vehicle-treated controls, as measured by semi-quantitative immunobinding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	insulin-like growth factor 1	Mus musculus	289-295
10195336-9	1999	Binding of [3H]8-OH-DPAT following clozapine was decreased in frontal, parietal, temporal and entorhinal cortices but increased in the CA3 division of Ammon"s horn.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-24	carbonic anhydrase 3	Rattus norvegicus	135-138
10208375-1	1999	Selective breeding for high and low sensitivity to the hypothermic response induced by the 5-HT1A receptor agonist 8- OH-DPAT has established two lines of rat (HDS and LDS, respectively) whose behavior differs in a model of depression and in the social interaction test of anxiety.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97
9886078-0	1999	Differential regulation of somatodendritic serotonin 5-HT1A receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(Di-n-propylamino)tetralin: microdialysis and autoradiographic studies in rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-183	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
9886078-1	1999	Single treatment with the serotonin (5-hydroxytryptamine) 5-HT1A receptor agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and alnespirone (S-20499) reduces the extracellular 5-HT concentration (5-HText) in the rat midbrain and forebrain.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
9862756-8	1999	Subcutaneous injection of the 5-HT-1a receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (0.2 mg/kg) resulted in a decrease in 5-HT levels in both cortex and hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-37
9862759-0	1999	Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-91
9862759-5	1999	Fluoxetine produced a dose-dependent reduction in the oxytocin, ACTH, and corticosterone responses to the 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT, 50 micrograms/kg, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	121-156	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
9862759-5	1999	Fluoxetine produced a dose-dependent reduction in the oxytocin, ACTH, and corticosterone responses to the 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT, 50 micrograms/kg, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	158-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
10221360-0	1999	Effect of a long-term low tryptophan diet on the prolactin responses to the 5-HT1A and 5-HT2C agonists, 8-OH-DPAT and mCPP in the male rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	prolactin	Rattus norvegicus	49-58
10025679-3	1999	Pretreatment of rats with the selective 5-HT1A receptor antagonist WAY 100635 for a period of 7 days using subcutaneously implanted osmotic minipumps (1 mg/kg/day) was sufficient to block the inhibition of 5-HT synthesis following the 5-HT 1A receptor agonist 8-OH-DPAT (0.3 mg/kg s.c.), but failed to inhibit the decrease of hippocampal 5-HT synthesis by fluoxetine (10 mg/kg i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	260-269	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
9928242-6	1998	As the direct 5-HT1A agonist 8-OH-DPAT increases PPI in mice, the unmasking of these effects may also contribute to the PPI-increasing effects of 5-HT releasers in 5-HT1B knockout mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-20
9928242-6	1998	As the direct 5-HT1A agonist 8-OH-DPAT increases PPI in mice, the unmasking of these effects may also contribute to the PPI-increasing effects of 5-HT releasers in 5-HT1B knockout mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	164-170
9836617-1	1998	A series of four racemic ring-substituted trans-2-(indol-3-yl)cyclopropylamine derivatives was synthesized and tested for affinity at the 5-HT1A receptor, by competition with [3H]-8-OH-DPAT in rat hippocampal homogenates, and for affinity at the agonist-labeled cloned human 5-HT2A, 5-HT2B, and 5-HT2C receptor subtypes.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	5-hydroxytryptamine receptor 1A	Homo sapiens	138-153
9843894-8	1998	Serotonin-inhibited cells were also inhibited by the 5-HT1A-receptor agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT; 1-10 microM; n = 7).	8-Hydroxy-2-(di-n-propylamino)tetralin	77-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
9843894-8	1998	Serotonin-inhibited cells were also inhibited by the 5-HT1A-receptor agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT; 1-10 microM; n = 7).	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
9886765-0	1998	Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-97
10065902-4	1998	5-HT1A and 5-HT2A receptors were characterised by saturation studies using [3H] 8-OH-DPAT and [3H] Ketanserin respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-12
9877012-7	1998	The 5-HT1A agonist, 8-OH-DPAT (0.03-0.3 mg/kg), increased chain lengths within a narrow dose range, whereas the 5-HT1A antagonist, WAY 100 635 (0.03-0.3 mg/kg), reduced chain lengths.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9813368-2	1998	We investigated the effects of chronic systemic injections of salmon calcitonin on the [3H]-8-OHDPAT binding to 5-HT1A receptors in the frontal cortex and hippocampus in adrenalectomized and intact (non adrenalectomized) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-100	calcitonin-related polypeptide alpha	Rattus norvegicus	69-79
9813368-2	1998	We investigated the effects of chronic systemic injections of salmon calcitonin on the [3H]-8-OHDPAT binding to 5-HT1A receptors in the frontal cortex and hippocampus in adrenalectomized and intact (non adrenalectomized) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
9855483-2	1998	The purpose of the present study was to determine whether activation of 5-HT1A receptors by its selective agonist, 8-OH DPAT, can induce the serotonin syndrome (SS) in this species.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
9855483-11	1998	Overall, these data suggest that the SS produced by 8-OH DPAT in the least shrew is mediated via the activation of serotonergic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
9818982-3	1998	Administration of 8-OH-DPAT, a serotonin1A autoreceptor agonist, reduces the ability of CCK to inhibit feeding.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	cholecystokinin	Rattus norvegicus	88-91
9818982-4	1998	We determined if CCK"s alcohol satiation effect also depends on activity of serotonergic neurons by administering 8-OH-DPAT (120-240 microg/kg) to 23-h water-deprived female and male rats, followed 1 h later by i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	cholecystokinin	Rattus norvegicus	17-20
9818982-6	1998	8-OH-DPAT significantly (p < 0.05) interacted with CCK, and reduced CCK"s ethanol satiation effect when given i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	cholecystokinin	Rattus norvegicus	54-57
9818982-6	1998	8-OH-DPAT significantly (p < 0.05) interacted with CCK, and reduced CCK"s ethanol satiation effect when given i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	cholecystokinin	Rattus norvegicus	71-74
9818982-8	1998	Female rats showed this interaction of 8-OH-DPAT with CCK at a higher dose than males when given i.p., but females were more sensitive to s.c. 8-OH-DPAT"s ability to reduce ethanol intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	cholecystokinin	Rattus norvegicus	54-57
9817696-2	1998	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A and 5-HT7 agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Homo sapiens	56-62
9817696-2	1998	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A and 5-HT7 agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Homo sapiens	56-62
9863668-6	1998	The perfusion of 1-100 microM of 8-OH-DPAT or the novel 5-HT1A agonist BAY x 3702 decreased the efflux of 5-HT, whereas the perfusion of the 5-HT1A antagonist WAY-100635 failed to alter 5-HT release.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	141-147
9824467-7	1998	Prior administration of 8-OH-DPAT significantly reduced haloperidol-induced Fos-LI in all four striatal quadrants while DOI and 8-OHDPAT + DOI significantly reduced Fos-LI only in dorso- and ventrolateral quadrants.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-79
9824467-7	1998	Prior administration of 8-OH-DPAT significantly reduced haloperidol-induced Fos-LI in all four striatal quadrants while DOI and 8-OHDPAT + DOI significantly reduced Fos-LI only in dorso- and ventrolateral quadrants.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-136	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	165-168
9824467-9	1998	Pretreatment with 8-OHDPAT in haloperidol treated rats reduced Fos-LI in the core region yielding to a c-fos pattern similar to that induced by clozapine.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-26	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	63-66
9824467-9	1998	Pretreatment with 8-OHDPAT in haloperidol treated rats reduced Fos-LI in the core region yielding to a c-fos pattern similar to that induced by clozapine.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-26	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	103-108
9787882-4	1998	In a second study, specific responses induced by 8-OH-DPAT, namely inhibition of brain 5-HT synthesis and stimulation of feeding, were examined as correlates of 5-HT1A autoreceptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	161-167
9757054-0	1998	The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9786223-2	1998	In dissociated cholinergic basal forebrain neurons using whole-cell recordings, it is shown that a selective serotonin 5-HT1A agonist (8-OH-DPAT) predominantly blocks N-type HVA calcium current, although a minor reduction of P-type current was also observed.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Cavia porcellus	119-125
9806333-6	1998	Both NDO 008 and the two enantiomers of 8-OH-DPAT induced the serotonin syndrome at the dose range that produced inhibition of the PA response, thus, indicating activation of postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	188-194
9826061-0	1998	Dimerization of 8-OH-DPAT increases activity at serotonin 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	5-hydroxytryptamine receptor 1A	Homo sapiens	58-64
9826061-6	1998	Hence, the 8-OH-DPAT dimer shows increased efficacy at 5-HT1A receptors compared to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-20	5-hydroxytryptamine receptor 1A	Homo sapiens	55-61
9845002-4	1998	The main response to serotonin application (2-20 microM) was an inhibition that could be mimicked by 8-OH-DPAT (a 5-HT1A receptor agonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Homo sapiens	114-129
9753272-5	1998	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), administered intraperitoneally (0.5 mg/kg) increased gastric pain threshold and gastric tone.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9753272-5	1998	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), administered intraperitoneally (0.5 mg/kg) increased gastric pain threshold and gastric tone.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9753272-7	1998	Flesinoxan (4 mg/kg, intraperitoneally), another 5-HT1A agonist reproduced the effects of 8-OH-DPAT on pain threshold and gastric tone and the alpha2-receptor antagonist yohimbine did not modify the action of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
9744919-6	1998	The 5-HT1A receptor agonist (+/-)-8-hydroxy-dipropylamino-tetralin (8-OH-DPAT; 5-50 microM) hyperpolarized RVLM neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9744926-7	1998	Although the serotonin agonists for the 5-HT1B,2C,3 receptors were ineffective, the effects were mimicked by the 5-HT1A-receptor agonists (8-OH-DPAT, 5-CT) and prevented by the 5-HT1A-receptor antagonist NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	5-hydroxytryptamine receptor 1A	Homo sapiens	113-128
12580024-13	1998	The selective 5-HT1A agonist (+)-8-OH-DPAT (10(-8)-10(-5) M) had no significant effect, but at concentration of 10(-4) M, inhibited evoked 3H-Ach.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-42	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20
9721928-3	1998	We constructed cumulative concentration response curves to the selective 5-HT1A agonist (+)-8-OH-DPAT on both extracellular recordings of 5-HT neurones and electrically stimulated 5-HT release in dorsal raphe brain slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-101	5-hydroxytryptamine receptor 1A	Homo sapiens	73-79
9721928-4	1998	Chronic paroxetine desensitized the 5-HT1A receptors controlling firing, with an increase in EC50 from 10.7 nM to 46.2 nM 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Homo sapiens	36-42
9671650-7	1998	Application of 5-HT or its agonists 5-carboxamidotryptamine maleate and (+/-)-8-hydroxy-2-(di-n-propyl-amino) tetralin hydrobromide on cells transformed with 5-HTap1 produced a dose-dependent inhibition of forskolin-stimulated cAMP accumulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-131	G-protein-coupled 5-hydroxytryptamine receptor	Aplysia californica	158-165
9685586-2	1998	In contrast drugs that inhibit serotonergic neurotransmission such as the 5-HT1A agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) stimulate food intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
9685586-2	1998	In contrast drugs that inhibit serotonergic neurotransmission such as the 5-HT1A agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) stimulate food intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
9685586-12	1998	These findings suggest that the reversal of FEN and FLU anorexia by 8-OH-DPAT is partially dependent on the integrity of brain 5-HT systems since their disruption compromises the ability of this 5-HT1A agonist to antagonize the feeding suppressant action of either FEN or FLU.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	195-201
9651229-5	1998	Discharge activity of REM-on neurons was almost completely suppressed by local microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), although this agonist had minimal or no effect on the Wake/REM-on neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-174	5-hydroxytryptamine receptor 1A	Homo sapiens	120-126
9651229-5	1998	Discharge activity of REM-on neurons was almost completely suppressed by local microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), although this agonist had minimal or no effect on the Wake/REM-on neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine receptor 1A	Homo sapiens	120-126
9697927-6	1998	WAY 100635 (0.5 mg/kg, s.c.), a selective antagonist of 5-HT1A receptors, affecting neither the basal nor the ethanol-induced ascorbic acid release per se, antagonized the suppressing effect of 8-OH-DPAT on ethanol-induced ascorbic acid release in striatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	194-203	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
9806333-11	1998	The impairment of PA retention induced by both NDO 008 and R(+)-8-OH-DPAT was fully blocked by the active S(+)- enantiomer of the selective 5-HT1A antagonist WAY 100135 and the mixed 5-HT1A/beta-adrenoceptor antagonist L(-)-alprenolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-146
9806333-11	1998	The impairment of PA retention induced by both NDO 008 and R(+)-8-OH-DPAT was fully blocked by the active S(+)- enantiomer of the selective 5-HT1A antagonist WAY 100135 and the mixed 5-HT1A/beta-adrenoceptor antagonist L(-)-alprenolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	183-189
9655867-10	1998	Although 8-OH-DPAT did not increase plasma levels of renin or vasopressin in rats treated with vehicle, 8-OH-DPAT produced an elevation (75%) in plasma renin concentration but not in vasopressin levels in rats that received i.c.v.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	renin	Rattus norvegicus	152-157
9716353-13	1998	Finally, increasing doses of alnespirone or 8-OH-DPAT weakly increased sniffing induced by apomorphine (0.75 mg/kg, s.c.) in mice and decreased grooming induced by the dopamine D1 receptor agonist SK&F 39393 ((+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol, 1.87 mg/kg, s.c.), whereas buspirone decreased both apomorphine-induced sniffing and SK&F 39393-induced grooming.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	dopamine receptor D1	Mus musculus	168-188
9716353-15	1998	The results also suggest that the stimulation of 5-HT1A receptors by either alnespirone or 8-OH-DPAT modulates the availability of striatal [3H]SCH 23390 and [3H]raclopride binding sites and possibly the functioning of striatal dopamine D1 and D2 receptors in opposite directions.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	49-55
10065919-7	1998	Further, the effects of 8-OH-DPAT were inhibited by pretreatment with the 5-HT1A antagonist, (-)-alprenolol (3.0 and 30.0 mg/kg i.p.).	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
9692774-8	1998	The TDS-induced K+ currents (I(TDS)) were mimicked by 8-OH-DPAT, a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
9920534-5	1998	The selective 5-HT1A receptor antagonist WAY100635 produced a potent (IC50, 2.3 nM) and complete block of the 8-OH-DPAT-stimulated response.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Homo sapiens	14-29
9717768-3	1998	The increase was attenuated by putative 5-HT1A-receptor agonists, MKC-242 and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	78-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
9717768-3	1998	The increase was attenuated by putative 5-HT1A-receptor agonists, MKC-242 and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
9733164-6	1998	The 5-HT1a agonist 8-OH-DPAT potentiated PSs in the dentate gyrus, while not affecting paired-pulse inhibition.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9776386-5	1998	The suppressant effect of 5-HT and of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) on the firing rate of 5-HT neurons was also unaltered after milnacipran (60 mg/kg/day x 14 days, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
9776386-5	1998	The suppressant effect of 5-HT and of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) on the firing rate of 5-HT neurons was also unaltered after milnacipran (60 mg/kg/day x 14 days, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	68-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
9678654-5	1998	Furthermore, KA 672 generalized to the selective 5-HT1A agonist, 8-hydroxy-dipropylaminotetralin [8-OH-DPAT], and this generalization was blocked by WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
9699220-2	1998	[3H]SCH 23390, [3H]spiperone, and [3H]-8-OH-DPAT were employed as specific radioligands for the D1, D2 and 5-HT1A receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Bos taurus	107-113
9638960-5	1998	That these groups of dense Fos-IR appeared as a result of the ejaculation per se, was assessed by administrating the 5-HT1A agonist 8-OH-DPAT to the males, whereupon they ejaculated within a few seconds, without the usual amount of preceding behavioral elements.	8-Hydroxy-2-(di-n-propylamino)tetralin	132-141	5-hydroxytryptamine receptor 1A	Rattus norvegicus	117-123
9871775-4	1998	Surprisingly enough, the dimer of 8-OH-DPAT 6 binds to 5HT1A, 5HT1B and 5HT1D receptors with similar high affinity.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1A	Homo sapiens	55-60
9871775-4	1998	Surprisingly enough, the dimer of 8-OH-DPAT 6 binds to 5HT1A, 5HT1B and 5HT1D receptors with similar high affinity.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1B	Homo sapiens	62-67
9871775-4	1998	Surprisingly enough, the dimer of 8-OH-DPAT 6 binds to 5HT1A, 5HT1B and 5HT1D receptors with similar high affinity.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1D	Homo sapiens	72-77
9753102-6	1998	The effect of 5-HT was mimicked by the selective 5-HT1A agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) and was blocked by the selective 5-HT1A antagonist 1-(2-methoxyphenyl)-4[4-(2-phthalimido)butyl]piperazine oxadiazol-3-yl]methyl]phenyl]-methanesulphonamide.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
9618425-5	1998	Phenylbiguanide (PBG) and m-chlorophenylbiguanide, two selective 5-HT3 agonists, mimicked the 5-HT responses, but 8-hydroxy-2-(di-n-propylamino)tetralin, a selective 5-HT1A agonist, was without effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-152	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
9676898-5	1998	The selective 5-HT1A receptor antagonist WAY-100635 (0.15 mg/kg s.c.) enhanced the inhibitory actions of 5-HTP on the male rat ejaculatory behavior, and this dose of WAY-100635 fully antagonized 8-OH-DPAT-induced facilitation (0.25 mg/kg s.c.) of the ejaculatory behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	195-204	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
9650801-9	1998	5-HT1A receptor agonists, e.g. 8-OH-DPAT and flesinoxan and partial agonists, e.g. pindolol, buspirone and ipsapirone had low potency in this in vivo assay.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-15
9539213-8	1998	The selective serotonin-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), reduced serotonin levels (-65%) and increased those of dopamine and noradrenaline by +100%), and +175%, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-35
9536454-3	1998	The data indicate that the reversal of haloperidol-induced EPS by (+/-)-8-OH-DPAT and its enantiomers is mediated via effects at 5-HT1A receptors, not dopamine D2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-81	5-hydroxytryptamine receptor 1A	Homo sapiens	129-135
9539213-8	1998	The selective serotonin-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), reduced serotonin levels (-65%) and increased those of dopamine and noradrenaline by +100%), and +175%, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-35
9704975-0	1998	Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	90-110
9704975-1	1998	The mechanisms involved in the enhancement of acetylcholine (ACh) release in the rat hippocampus by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a serotonin (5-HT)1A receptor agonist, were investigated using in vivo microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	154-181
9704975-6	1998	), a selective 5-HT1A receptor antagonist, completely eliminated the enhancement of ACh release induced by locally applied 8-OH-DPAT, but only partially reduced the effects induced by systemically administered 8-OH-DPAT, in both groups of rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	123-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
9631950-7	1998	Microinjection of the 5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin (DPAT; 0.1-10 microg/0.5 microl/side) or the 5-HT1A antagonist WAY 100635 (0.01-1.0 microg/0.5 microl/side) into the VTA or SNR did not substitute for the systemic cocaine cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
9593901-2	1998	However, the 5-HT1A agonist 8-hydroxy-di-propylaminotetralin (8-OH-DPAT), injected either systemically or into the medial preoptic area (MPOA), facilitates ejaculation.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
9601697-4	1998	The effects of RU24969 could not be antagonized by the selective 5HT1A antagonist p-MPPI and little or no striatal Fos expression could be observed after injections of the selective 5HT1A agonist 8-OHDPAT or the selective 5HT3 antagonist MDL-72222.	8-Hydroxy-2-(di-n-propylamino)tetralin	196-204	5-hydroxytryptamine receptor 1A	Rattus norvegicus	182-187
9650846-1	1998	The neurochemical profile at both post and presynaptic 5-HT1A receptors of a novel 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) analog, 5-methyl-8-hydroxy-2-(di-n-propylamino)tetralin ?(+/-)-5-Me-8-OH-DPAT?	8-Hydroxy-2-(di-n-propylamino)tetralin	83-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
9650846-1	1998	The neurochemical profile at both post and presynaptic 5-HT1A receptors of a novel 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) analog, 5-methyl-8-hydroxy-2-(di-n-propylamino)tetralin ?(+/-)-5-Me-8-OH-DPAT?	8-Hydroxy-2-(di-n-propylamino)tetralin	123-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
9652362-0	1998	Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	93-99
9652368-1	1998	Previous studies suggest that the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) increases the secretion of oxytocin, adrenocorticotropic hormone (ACTH), corticosterone and prolactin but not renin.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
9652368-1	1998	Previous studies suggest that the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) increases the secretion of oxytocin, adrenocorticotropic hormone (ACTH), corticosterone and prolactin but not renin.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	renin	Rattus norvegicus	220-225
9652368-1	1998	Previous studies suggest that the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) increases the secretion of oxytocin, adrenocorticotropic hormone (ACTH), corticosterone and prolactin but not renin.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
9652368-1	1998	Previous studies suggest that the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) increases the secretion of oxytocin, adrenocorticotropic hormone (ACTH), corticosterone and prolactin but not renin.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	renin	Rattus norvegicus	220-225
9652368-2	1998	However, the lack of selective 5-HT1A receptor antagonists made it difficult to confirm that 5-HT1A receptors mediate the neuroendocrine responses to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	150-159	5-hydroxytryptamine receptor 1A	Rattus norvegicus	93-99
9652368-4	1998	8-OH-DPAT, 500 microg/kg s.c., increased plasma levels of oxytocin (to 970% above basal levels); ACTH (to 1622% above basal levels), corticosterone (to 458% above basal levels) and prolactin (to 313% above basal levels), but not renin.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	renin	Rattus norvegicus	229-234
9652368-8	1998	At the highest dose of WAY-100635 (10 mg/kg, s.c.), basal prolactin levels were markedly elevated (1550%) and administration of 8-OH-DPAT significantly elevated plasma renin concentration.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	renin	Rattus norvegicus	168-173
9652368-9	1998	Taken together, these data indicate that: (1) 8-OH-DPAT stimulates oxytocin, ACTH, and corticosterone but not prolactin secretion via activation of 5-HT1A receptors and (2) blockade of 5-HT1A receptors may unmask 8-OH-DPAT simulation of renin secretion via non-5-HT1A receptor mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	148-154
9652368-9	1998	Taken together, these data indicate that: (1) 8-OH-DPAT stimulates oxytocin, ACTH, and corticosterone but not prolactin secretion via activation of 5-HT1A receptors and (2) blockade of 5-HT1A receptors may unmask 8-OH-DPAT simulation of renin secretion via non-5-HT1A receptor mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	185-191
9652368-9	1998	Taken together, these data indicate that: (1) 8-OH-DPAT stimulates oxytocin, ACTH, and corticosterone but not prolactin secretion via activation of 5-HT1A receptors and (2) blockade of 5-HT1A receptors may unmask 8-OH-DPAT simulation of renin secretion via non-5-HT1A receptor mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	renin	Rattus norvegicus	237-242
9652368-9	1998	Taken together, these data indicate that: (1) 8-OH-DPAT stimulates oxytocin, ACTH, and corticosterone but not prolactin secretion via activation of 5-HT1A receptors and (2) blockade of 5-HT1A receptors may unmask 8-OH-DPAT simulation of renin secretion via non-5-HT1A receptor mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	185-191
9553162-18	1998	Receptor-specific binding was eliminated in the presence of the selective 5-HT1A receptor agonist, 8-OH-DPAT [(+/-)-8-hydroxy-2-dipropylaminotetralin].	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	74-89
9553162-18	1998	Receptor-specific binding was eliminated in the presence of the selective 5-HT1A receptor agonist, 8-OH-DPAT [(+/-)-8-hydroxy-2-dipropylaminotetralin].	8-Hydroxy-2-(di-n-propylamino)tetralin	110-149	5-hydroxytryptamine receptor 1A	Homo sapiens	74-89
9749777-3	1998	to modify the impairment of passive avoidance retention induced by the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propyloamino)tetralin (8-OH-DPAT) when injected prior to training.	8-Hydroxy-2-(di-n-propylamino)tetralin	137-146	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
9749777-6	1998	This 8-OH-DPAT dose produced signs of the 5-HT syndrome indicating a postsynaptic 5-HT1A receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	5-14	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
9749777-9	1998	8-OH-DPAT given at a low dose 0.03 mg/kg, which presumably stimulates somatodendritic 5-HT1A autoreceptors in vivo, did not alter passive avoidance retention or induce any visually detectable signs of the 5-HT syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
9586831-3	1998	Similar exaggerated responses are seen in a line of rats recently selected for increased sensitivity to the 5-HT1A agonist, 8-OH-DPAT (High DPAT Sensitive--HDS), relative to lines selectively bred for either low (Low DPAT Sensitive--LDS) or random (Random DPAT Sensitive--RDS) sensitivity to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
9586832-1	1998	Selective breeding for high and low sensitivity to the hypothermic response of the 5-HT1A receptor agonist 8-OH-DPAT has established two lines (HDS and LDS, respectively) whose behavior differs in a model of depression, but not in the elevated plus-maze test of anxiety.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
9566815-7	1998	The 5-HT1A partial agonist buspirone was also active in the dose range of 0.25-0.5 mg/kg, while the 5-HT1A full agonist 8-OH-DPAT was the only drug with presumed anxiolytic activity that clearly lacked any effect in this model.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-106
10065929-1	1998	Infusing the 5-HT1A receptor agonist R(+)-8-OH-DPAT into the septum or hippocampus reduced the fear responses of rats differentially in the elevated plus-maze and shock-probe burying tests, two rat models of anxiety.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
9446695-12	1998	Perfusion with a 5-HT1A agonist, 8-hydroxy-dipropylaminotetralin hydrobromide (8-OH-DPAT, 20-100 microM) induced an increase or a decrease in the respiratory rate.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
9512079-1	1998	We have previously reported that the serotonin 5-HT1A agonist 8-OH-DPAT and the 5-HT2c agonist TFMPP impair performance on a water maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
9512079-6	1998	At doses that did not affect performance in a previously learned maze, the 5-HT1A agonists 8-OH-DPAT (0.1 mg/kg) and buspirone (1 mg/kg) slowed acquisition of a new maze configuration as measured by both swim time to the exit platform and errors committed.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-81
9617994-5	1998	In Experiment 1, rats received an injection of 8-OH-DPAT (a 5HT1A agonist) or saline and were then allowed to select from two diets: low protein/high carbohydrate or high protein/low carbohydrate.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-65
9798263-2	1998	The 5-HT1A agonist-8-OH-DPAT (0.25, 0.5, 1 mg/kg) and dihydropyridine calcium channel antagonist-nifedipine (10 mg/kg) produced decreases in immobility time.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-10
9798263-10	1998	These results suggest that 5-HT1A agonists and dihydropyridine calcium channel blockers may have antidepressant efficacy in the forced swimming test, but the effects of buspirone and 8-OH-DPAT may be mediated via different mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	27-33
9570480-3	1998	At 10 microM, the 5-HT1A receptor agonist R(+)-8-hydroxy-2-(di-n-propylamino)tetralin [R(+)-8-OH-DPAT] stimulated GTPgammaS binding from 27.1 +/- 2.5 to 45.7 +/- 4.2 fmol/mg protein.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
9498732-5	1998	Co-treatment with the 5-HT1A receptor agonist 8-OH-DPAT (0.1 mg/kg) also augmented the effect of haloperidol.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-37
9519243-0	1998	Brain 5-HT1A receptor autoradiography and hypothermic responses in rats bred for differences in 8-OH-DPAT sensitivity.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	6-12
9519243-1	1998	Three rat lines were selectively bred for high (HDS), random (RDS), or low (LDS) hypothermic responses to the specific 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	143-152	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
9519243-3	1998	To investigate the relationship of body temperature of 5-HT1A receptor binding sites, autoradiographic analyses of [3H]8-OH-DPAT binding to 5-HT1A receptors in brains of these rats were conducted.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-146
9519243-8	1998	These data suggest that differences in 5-HT1A receptor number may contribute to the exaggerated hypothermic response to 8-OH-DPAT in HDS rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
9473697-4	1998	This was associated with significantly higher [3H]8-OH-DPAT binding in the inferior part of CA1.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	carbonic anhydrase 1	Rattus norvegicus	92-95
9550290-7	1998	For both h5-HT1A and rat 5-HT1A receptors, the Ki values for competition binding of 15 serotonergic ligands with [3H]-S 15535 was highly correlated with that of [3H]-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-175	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-31
9435153-5	1998	In contrast to sigma ligands and other reference compounds, the 5-HT1A agonists buspirone, 8-OH-DPAT and spiroxatrine dose-dependently produced BMY 14802-like discriminative stimulus effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Homo sapiens	64-70
9435184-6	1998	Further, 5-HT1A antagonists, NAN-190, penbutolol, (-)-pindolol, tertatolol and WAY-100635, produced dose-related decreases in 8-OH-DPAT-appropriate selection, and their potencies for antagonism in rats and pigeons were highly correlated (r = 0.96, P < .01).	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	9-15
9694030-4	1998	Ethanol consumption was significantly and selectively reduced by the 5-hydroxytryptamine-1A (5-HT1A) full agonist 8-OH-DPAT (0.3-1.0 mg/kg) and the 5-HT3 antagonist granisetron (0.1-1.0 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-91
9694030-4	1998	Ethanol consumption was significantly and selectively reduced by the 5-hydroxytryptamine-1A (5-HT1A) full agonist 8-OH-DPAT (0.3-1.0 mg/kg) and the 5-HT3 antagonist granisetron (0.1-1.0 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	93-99
9694031-0	1998	5-HT1A receptor agonist (8-OH-DPAT) and 5-HT2 receptor agonist (DOI) disrupt the non-cognitive performance of rats in a working memory task.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
9694031-9	1998	These results suggest that the combination of 5-HT1A receptor stimulation by 8-OH-DPAT and 5-HT2 receptor stimulation by DOI can interfere with the non-cognitive performance of rats in the DNMTP task.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-52
9694031-10	1998	The results further indicate that the effect of 8-OH-DPAT may be mediated through post-synaptic rather than pre-synaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	121-127
9914716-4	1998	8-Hydroxy-di-n-propylamino tetralin (8-OH-DPAT; 3 microM), a selective agonist for the 5-HT1A receptor, mimicked 5-HT in producing the hyperpolarization.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
9808064-3	1998	The binding of the radiotracer in target tissues is blocked by pre-injection of the 5-HT1A receptor selective ligand 8-OH-DPAT (1 mg/kg, s.c.), suggesting that the binding is specific to 5-HT1A receptor sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	84-99
9808064-3	1998	The binding of the radiotracer in target tissues is blocked by pre-injection of the 5-HT1A receptor selective ligand 8-OH-DPAT (1 mg/kg, s.c.), suggesting that the binding is specific to 5-HT1A receptor sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	187-202
9808064-6	1998	The distribution of the radiotracer agrees well with the distribution of 5-HT1A receptors revealed by in vitro autoradiography with [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	73-79
9884118-8	1998	Data suggest that 8-OH-DPAT acting on 5-HT1A somatodendritic autoreceptors decreases anxiety.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
9884126-6	1998	They demonstrated: (1) that the androgenic and estrogenic metabolites of testosterone differentially modulate the ability of systemically administered 8-OH-DPAT (a 5HT1A agonist) and CGS12066B (a 5HT1B agonist) to decrease offensive aggression; and (2) when microinjected into the lateral septum (LS) or medial preoptic area (MPO), the aggression-attenuating effects of 1A and 1B agonists differ regionally and vary with the steroidal milieu.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Homo sapiens	164-169
9435630-7	1997	Microdialysis of a 5-HT1A agonist, 8-OH-DPAT (10 mM), into the rVLM for 30 min (n = 6) blunted the MAP change and reduced 5-HT release during contraction.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
9475626-4	1997	In contrast, the serotonin (5-HT1A) agonist 8-OHDPAT (5 microg) produced only a small effect on locomotor activity but reduced hippocampal serotonin output by 51%.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
9430444-10	1997	The 5-HT1A agonist 8-OHDPAT exerted an inhibitory effect in the VMN.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9832955-2	1997	The increased locomotor activity induced by the indirect DA agonist amphetamine (0.5 mg/kg) or cocaine (5 mg/kg) was dose-dependently inhibited by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.125-0.5 mg/kg), a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	147-185	5-hydroxytryptamine receptor 1A	Rattus norvegicus	218-224
9832955-6	1997	The obtained results indicate that 8-OH-DPAT inhibits the amphetamine- or cocaine-induced increases in the locomotor activity in rats via stimulation of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-159
9401677-2	1997	Autoradiographic studies were undertaken to measure the densities of (a) 5-HT1A sites labelled with 2 nM [3H]8-OH DPAT, (b) 5-HT2A sites labelled with 2 nM [3H] ketanserin, (c) D1 sites labelled with 1 nM [3H]SCH23390, and (d) D2 sites labelled with 20 nM [3H]sulpiride.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	73-79
9347319-2	1997	The binding characteristics of tritium labeled 8-hydroxy-dipropyl-aminotetralin, or [3H]8-OH-DPAT, to the serotonin1A (5-HT1A) receptor in the stably transfected HeLa cell clone HA6 and in human cortical tissue were examined and compared.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	106-135
9427327-2	1997	8-OH-DPAT increased the hybridization signal of the 5-HT1A receptor by 105% in the dorsal raphe nucleus (B7) 30 min after the injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	52-67
9427327-5	1997	At 8 h following 8-OH-DPAT injection, the effect had shifted to an increase in 5-HT1A receptor labeling by 68% in the B8 area.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Homo sapiens	79-94
9347319-4	1997	A series of kinetic studies of [3H]8-OH-DPAT binding to the transfected HA6 cell line demonstrated two components in both the association and the dissociation reactions.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	keratin 36	Homo sapiens	72-75
9517444-0	1997	A single pretreatment with 8-OH-DPAT reduces behavioral indices of serotonin 1A receptor activation in ovariectomized rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-88
9351653-6	1997	This inhibition was mimicked by N-(3-trifluoromethylphenyl)piperazine (TFMPP), a general serotonin receptor agonist, by 8-hydroxy-dipropylaminotetralin (8-OH-DPAT), a selective 5-HT1A receptor agonist, but not by phenylbiguanide, a 5-HT3 receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	153-162	5-hydroxytryptamine receptor 3A	Rattus norvegicus	232-246
9430429-2	1997	The pharmacological properties of [3H]alnespirone specific binding sites matched exactly (r = 0.95) those of 5-HT1A receptors identified with [3H]8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) as radioligand.	8-Hydroxy-2-(di-n-propylamino)tetralin	186-195	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
9430429-3	1997	Furthermore, membrane binding experiments and autoradiographic labeling of tissue sections showed that the regional distribution of [3H]alnespirone specific binding sites in the rat brain and spinal cord superimposed over that of 5-HT1A receptors specifically labeled by [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	275-284	5-hydroxytryptamine receptor 1A	Rattus norvegicus	230-236
9430429-4	1997	However, the differential sensitivity of [3H]alnespirone and [3H]8-OH-DPAT specific binding to various physicochemical effectors (temperature, pH, Mn2+, N-ethyl-maleimide) supports the idea that these two agonist radioligands did not recognize 5-HT1A receptors exactly in the same way.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	244-250
9375958-22	1997	It appears that the enhancement of reflexes by 8-OH-DPAT arises from a combined action at 5-HT1A-receptors and other, ritanserin-sensitive, sites which could be 5-HT1D- or 5-HT7-receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	90-96
9517442-2	1997	In the bicuculline model, both serotonin (20 microM) and its 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 10 microM) completely blocked the epileptiform discharge and caused membrane hyperpolarization and reduction in input resistance.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
9375958-22	1997	It appears that the enhancement of reflexes by 8-OH-DPAT arises from a combined action at 5-HT1A-receptors and other, ritanserin-sensitive, sites which could be 5-HT1D- or 5-HT7-receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	161-167
9361334-3	1997	Mirtazapine induced lower lip retraction in rats, as did the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	85-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
9549053-5	1997	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A/7 receptor agonist, stimulated LHRH release from GT1-1 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-60
9549053-5	1997	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A/7 receptor agonist, stimulated LHRH release from GT1-1 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	gonadotropin releasing hormone 1	Mus musculus	92-96
9549053-5	1997	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A/7 receptor agonist, stimulated LHRH release from GT1-1 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-60
9549053-5	1997	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A/7 receptor agonist, stimulated LHRH release from GT1-1 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	gonadotropin releasing hormone 1	Mus musculus	92-96
9380025-6	1997	The distribution of [3H]8-OH-DPAT binding sites was identical to that of the [35S]GTPgammaS labeling stimulated by the 5-HT1A agonist (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT)].	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Cavia porcellus	119-125
9380025-6	1997	The distribution of [3H]8-OH-DPAT binding sites was identical to that of the [35S]GTPgammaS labeling stimulated by the 5-HT1A agonist (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT)].	8-Hydroxy-2-(di-n-propylamino)tetralin	134-171	5-hydroxytryptamine receptor 1A	Cavia porcellus	119-125
9361334-3	1997	Mirtazapine induced lower lip retraction in rats, as did the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	132-141	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
9361334-5	1997	Blockade of the 5-HT1A receptors with pindolol (10 mg/kg) caused a strong reduction of the lower lip retraction induced both with mirtazapine and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Rattus norvegicus	16-22
9372532-0	1997	Nicotine withdrawal leads to increased sensitivity of serotonergic neurons to the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
9266775-6	1997	Pretreatment with the 5-HT-1A agonists (+)8-OH-DPAT (0.001-0.1 mg/kg) and LY274600 (0.3-3.0 mg/kg) either had no affect or exacerbated the nicotine-withdrawal-enhanced startle response.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-29
9374282-1	1997	The present study examined the distribution of [3H]8-OH-DPAT-labeled 5-HT1A receptors and their degree of coupling to G proteins in the hypothalamus and several other brain regions.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
9284512-0	1997	Demonstration of ejaculation-induced neural activity in the male rat brain using 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
9284512-4	1997	In the present study, the facilitative effect of the 5-HT1A receptor agonist 8-OH-DPAT on ejaculatory behavior was used to analyze the pattern of Fos immunoreactivity ejaculation preceded by minimal sexual activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
9284512-4	1997	In the present study, the facilitative effect of the 5-HT1A receptor agonist 8-OH-DPAT on ejaculatory behavior was used to analyze the pattern of Fos immunoreactivity ejaculation preceded by minimal sexual activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	146-149
9284512-7	1997	Males that ejaculated with the first intromission and were treated with a higher dose of 8-OH-DPAT (0.8 mg/kg) exhibited similar clusters of Fos-positive neurons in all areas except the posterodorsal preoptic nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	141-144
9374282-4	1997	5-HT1A receptors were labeled by 2 nM [3H]8-hydroxy-2-(dipropylamino)tetralin ([3H]8-OH-DPAT) in the absence or presence of guanylylimidodiphosphate (Gpp(NH)p, 10[-5] M) to determine the percentage of 5-HT1A receptors coupled to G proteins.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
9367249-5	1997	8-OHDPAT induced a rapid and transient increase in cortical blood flow (+34%) that was prevented totally by WAY100135 (5-HT1A antagonist) pre-treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-8	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
9300583-0	1997	Interactions between darodipine or isradipine and the 5-HT1A receptor agonist 8-OHDPAT in rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-60
9300583-2	1997	To investigate the mechanisms of these effects, the selective 5-HT1A receptor agonist 8-OHDPAT was injected S.C. to rats pretreated I.P.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
9300583-4	1997	By stimulating presynaptic 5-HT1A autoreceptor, 8-OHDPAT induced signs of inhibition of the serotonergic neutransmission (i.e., decrease of the 5-HIIA/5-HT ratio), but it also produced behavioral effects by stimulating postsynaptic 5-HT1A receptors (i.e., forepaw treadings).	8-Hydroxy-2-(di-n-propylamino)tetralin	48-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
9300583-4	1997	By stimulating presynaptic 5-HT1A autoreceptor, 8-OHDPAT induced signs of inhibition of the serotonergic neutransmission (i.e., decrease of the 5-HIIA/5-HT ratio), but it also produced behavioral effects by stimulating postsynaptic 5-HT1A receptors (i.e., forepaw treadings).	8-Hydroxy-2-(di-n-propylamino)tetralin	48-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	232-238
9278519-4	1997	The modulation of the T-type and the HVA currents was mimicked by selective 5-HT1A and 5-HT1D agonists: 8-OH-DPAT and L-694,247.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled L homeolog	Xenopus laevis	76-82
9369342-8	1997	Bromerguride decreased neither forskolin-stimulated cAMP accumulation nor extracellular 5-HT; instead, it antagonized the decrease of cAMP accumulation produced by 5-HT and the decrease of extracellular 5-HT produced by the 5-HT1A agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	239-283	5-hydroxytryptamine receptor 1A	Homo sapiens	224-230
9369342-8	1997	Bromerguride decreased neither forskolin-stimulated cAMP accumulation nor extracellular 5-HT; instead, it antagonized the decrease of cAMP accumulation produced by 5-HT and the decrease of extracellular 5-HT produced by the 5-HT1A agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	285-294	5-hydroxytryptamine receptor 1A	Homo sapiens	224-230
9378249-8	1997	Nimodipine antagonized the effects on 5-HT metabolism induced by 8-hydroxy-2-(di-N-propyl-amino)-tetralin through stimulation of 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	129-135
9316875-3	1997	Paroxetine reduced the oxytocin, adrenal corticotropic hormone and corticosterone responses to a challenge with the 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-166	5-hydroxytryptamine receptor 1A	Homo sapiens	116-122
9335080-3	1997	The 5-HT1A agonist 8-OH-DPAT counteracted lithium-induced CTA.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9342784-0	1997	The reduction in alcohol intake by the 5-HT1A agonist 8-OH DPAT and its attenuation by the alpha 2 adrenergic antagonist idazoxan correlates with blood glucose levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
9342784-1	1997	Serotonergic agents in general and the 5-HT1A agonist 8-OH DPAT in particular, reduce alcohol intake in rats and primates but the mechanism of this effect is not known.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
9314024-2	1997	Binding of [3H]8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) to 5-HT1A receptors in the hippocampus decreased 24 h after both acute and chronic (14 day) administration of CORT (50 mg/kg, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-76
9314024-5	1997	Flat body posture and hypothermia induced by 8-OH-DPAT, a 5-HT1A receptor agonist, were attenuated following chronic, but not acute, CORT administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	58-73
9314029-1	1997	Using in vivo extracellular recordings, we have examined the effect of the application of the prototypical 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), on the firing rate of locus coeruleus neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-170	5-hydroxytryptamine receptor 1A	Homo sapiens	107-122
9314029-1	1997	Using in vivo extracellular recordings, we have examined the effect of the application of the prototypical 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), on the firing rate of locus coeruleus neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	172-181	5-hydroxytryptamine receptor 1A	Homo sapiens	107-122
9313892-7	1997	Administration of the selective 5-HT1A antagonist, 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl] ethyl]-N-2-pyridinyl-benzamide hydrochloride (p-MPPI) (1.5 and 3.0 nmol), blocked the suppressive effects of 8-OHDPAT upon hissing.	8-Hydroxy-2-(di-n-propylamino)tetralin	206-214	5-hydroxytryptamine receptor 1A	Homo sapiens	32-38
9213074-1	1997	Racemic 8-OH-DPAT, (R,S)-8-hydroxy-2-(di-n-propylamino)tetralin, has become the prototype 5-HT1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	8-17	5-hydroxytryptamine receptor 1A	Rattus norvegicus	90-96
9213074-2	1997	The enantiomers of 8-OH-DPAT have similar affinities to the 5-HT1A receptor, but the (R)-enantiomer is a full agonist, whereas the (S)-enantiomer is a partial agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
9262338-8	1997	In vivo 5-HT1A agonist effects were demonstrated by the finding that relatively selective- and mixed-5-HT1A agonists produced one or more elements of the "serotonin syndrome," i.e., flat-body posture, forepaw treading, or lower-lip retraction, and produced high levels of drug-lever selection in rats trained to discriminate 8-OH-DPAT (0.16 mg/kg) from saline.	8-Hydroxy-2-(di-n-propylamino)tetralin	325-334	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
9239763-1	1997	The aminotetralin 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), pharmacologically characterized as a 5-HT1A receptor agonist, produces a pronounced decrease in ejaculation latency in the male rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	107-113
9239763-4	1997	In this paper we review the evidence in support for stimulation of serotonergic autoreceptors of the 5-HT1A receptor subtype as a mechanism of action for effects by 8-OH-DPAT on male rat ejaculatory behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	165-174	5-hydroxytryptamine receptor 1A	Rattus norvegicus	101-107
9292625-6	1997	Coadministration of the selective 5HT1A agonist 8-OH-DPAT (0.03-1.25 mg/kg S.C.) with anpirtoline (2.5 mg/kg) induced a dramatic increase in locomotor activity and a behavioural syndrome identical to that produced by RU24969.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-39
9261814-0	1997	Desensitization of spinal 5-HT1A receptors to 8-OH-DPAT: an in vivo spinal reflex study.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
9261814-2	1997	Administration of a selective 5-HT1A agonist, 8-OH-DPAT (0.1 mg kg-1) significantly depressed the monosynaptic mass reflex (MMR) amplitude, which was prevented effectively by S(-)-propranolol, a 5-HT1A antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
9261814-2	1997	Administration of a selective 5-HT1A agonist, 8-OH-DPAT (0.1 mg kg-1) significantly depressed the monosynaptic mass reflex (MMR) amplitude, which was prevented effectively by S(-)-propranolol, a 5-HT1A antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	195-201
9261814-3	1997	The inhibitory effect of 8-OH-DPAT on MMR amplitude was significantly attenuated with a single dose of 8-OH-DPAT (1 mg kg-1, s.c.) administered 24 h before the experiments, indicating a marked desensitization of spinal 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	219-225
9261814-3	1997	The inhibitory effect of 8-OH-DPAT on MMR amplitude was significantly attenuated with a single dose of 8-OH-DPAT (1 mg kg-1, s.c.) administered 24 h before the experiments, indicating a marked desensitization of spinal 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	219-225
9261814-6	1997	These results demonstrate that 5-HT1A receptor functionally modulates the spinal motor output and confirms the ability of 8-OH-DPAT to desensitize presynaptic 5-HT1A receptors as observed for the first time in rat spinal cord.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
9261814-6	1997	These results demonstrate that 5-HT1A receptor functionally modulates the spinal motor output and confirms the ability of 8-OH-DPAT to desensitize presynaptic 5-HT1A receptors as observed for the first time in rat spinal cord.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	159-165
9204940-5	1997	The 5-HT1a receptor agonist 8-OH-DPAT, applied systemically, caused a marked reduction in population spike responses to PP stimulation, whereas an opposite effect was produced by local application of this drug.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9252022-4	1997	Systemic administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.5 mg/kg, s.c.), a 5-HT1A agonist, significantly enhanced ACh release both in the presence and absence of Phy.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
9252022-4	1997	Systemic administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.5 mg/kg, s.c.), a 5-HT1A agonist, significantly enhanced ACh release both in the presence and absence of Phy.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
9178873-8	1997	Further, to evaluate the functional status of the autoreceptors under control conditions and after withdrawal from chronic ethanol, the selective serotonin-1A receptor agonist 8-hydroxy-(2-di-n-propylamino)tetralin was administered intravenously in cumulative doses (1-16 microg/kg) and dose-response curves were generated for both groups.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-214	5-hydroxytryptamine receptor 1A	Rattus norvegicus	146-167
9266609-10	1997	8-OH-DPAT increased PPI in both wild-type and 5-HT1B knockout mice in every experiment.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	46-52
9272757-0	1997	On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	61-68
9272757-0	1997	On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	189-195
9272757-9	1997	These data suggest that the anxiolytic-like effects of 8-OH-DPAT, but not the anxiogenic-like effects of buspirone, on the elevated plus-maze are mediated via 5-HT(1A) receptors in the CNS.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Homo sapiens	159-166
9218690-1	1997	The present study was undertaken to compare the properties of the [3H]8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) binding site in the dorsal raphe nucleus with the hippocampal 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-79	5-hydroxytryptamine receptor 1A	Homo sapiens	183-198
9218690-3	1997	[3H]8-OH-DPAT appears to bind to a single population of binding sites in both the hippocampus and the dorsal raphe nucleus, although the K(d) for the radioligand at the dorsal raphe site was five times that observed at the hippocampal 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Homo sapiens	235-250
9218690-4	1997	Similarly, although 5-HT and selective 5-HT1A receptor ligands displayed high affinity for the [3H]8-OH-DPAT binding site in the dorsal raphe nucleus, the affinity at the dorsal raphe site was less than that observed at the hippocampal 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	39-54
9218690-8	1997	However, addition of another putative 5HT1A receptor selective ligand, buspirone, did not alter the generation of [3H]inositol phosphates, but blocked the inhibitory effect of 8-OH-DPAT on phosphoinositide hydrolysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine receptor 1A	Homo sapiens	38-52
9218690-9	1997	These studies demonstrate that the 8-OH-DPAT binding site in the dorsal raphe nucleus displays a binding profile which is similar to the hippocampal 5-HT1A receptor, but unlike this 5-HT1A receptor the binding site in the dorsal raphe nucleus is negatively coupled to phosphoinositide turnover.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	149-164
9218690-9	1997	These studies demonstrate that the 8-OH-DPAT binding site in the dorsal raphe nucleus displays a binding profile which is similar to the hippocampal 5-HT1A receptor, but unlike this 5-HT1A receptor the binding site in the dorsal raphe nucleus is negatively coupled to phosphoinositide turnover.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	182-197
9209103-4	1997	The "anxiolytic" 5-HT1A agonist 8-hydroxy-2-(di-n-propyl amino) tetralin (8-OH-DPAT; 0.3 mg/kg) reduced basal 5-HT and the increase in 5-HT release on the X-maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-72	5-hydroxytryptamine receptor 1A	Cavia porcellus	17-23
9209103-4	1997	The "anxiolytic" 5-HT1A agonist 8-hydroxy-2-(di-n-propyl amino) tetralin (8-OH-DPAT; 0.3 mg/kg) reduced basal 5-HT and the increase in 5-HT release on the X-maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Cavia porcellus	17-23
9209103-5	1997	8-OH-DPAT given simultaneously with CCK-4, blocked the effects of CCK-4.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	cholecystokinin	Cavia porcellus	66-69
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-43
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-103
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-103
9178651-4	1997	In addition, extracellular 5-HT levels were lowered by the 5-HT(1B/1D) receptor agonist, sumatriptan, and the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, while perfusion of the selective serotonin re-uptake inhibitor, paroxetine, increased 5-HT in a concentration-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-173	5-hydroxytryptamine receptor 1A	Cavia porcellus	110-116
9152998-7	1997	Using [3H]WAY-100635, we confirmed an increase of 5-HT1A receptor binding sites in the frontal cortex in schizophrenia, previously demonstrated with [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	153-162	5-hydroxytryptamine receptor 1A	Homo sapiens	50-65
9152998-10	1997	First, they indicate that the elevated [3H]8-OH-DPAT binding seen in the same cases is attributable to an increase of 5-HT1A receptors rather than any other binding site.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	118-124
9152998-11	1997	Second, the enhanced [3H]8-OH-DPAT binding in schizophrenia reflects an increased density of 5-HT1A receptors, not an increased percentage of 5-HT1A receptors which are G-protein-coupled.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99
9226733-5	1997	In contrast, long-term treatment with imipramine enhanced the 5-HT1A-mediated inhibition, as the decrement in the amplitude of the flight response produced by 8-OH-DPAT was 96% after this treatment compared to 41% in controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	159-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
9203529-1	1997	The effects of gender, aging and gender x age on the binding of the 5-HT1A receptor high-affinity agonist [3H]8-hydroxy-2(di-N-propylamino)tetralin ([3H]8-OH-DPAT), were evaluated and compared in tissues of human prefrontal, temporal, parietal, occipital cortex and hippocampus obtained from 21 autopsy subjects.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-162	5-hydroxytryptamine receptor 1A	Homo sapiens	68-83
9163558-6	1997	The anxiolytic effects of 8-OH-DPAT and flesinoxan could only be antagonized with a high dose (1.0 and 3.0 mg/kg respectively) of the 5-HT1A receptor antagonist WAY-100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride).	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-140
9187317-2	1997	The binding of [3H]8-OH-DPAT to 5-HT1A serotonin receptors was increased after MK-801 (0.4 mg/kg) as was shown by autoradiographic studies in the frontal, cingulate and part of enthorinal cortex, subregions of the hippocampus and raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
9187318-1	1997	In a recent study, we observed circadian rhythms in the response to subcutaneous (s.c.) administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a serotonin (5-HT)1A receptor agonist, in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	160-187
9163561-3	1997	Tests for generalization and antagonism showed that compounds with agonistic action at the 5-HT1A receptor, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), buspirone and ipsapirone all substituted for the flesinoxan cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106
9163561-3	1997	Tests for generalization and antagonism showed that compounds with agonistic action at the 5-HT1A receptor, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), buspirone and ipsapirone all substituted for the flesinoxan cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-165	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106
9169295-1	1997	Administration of the 5-HT1A receptor agonist 8-OH-DPAT produced a biphasic pattern of effects on endurance performance of rats walking on top of a treadmill drum ([symbol: see text] = 166 mm, 16 rpm; approximately 8 m min-1), with enhanced performance at a low dose (0.1 mg kg-1 s.c.) followed by impairment (0.2-0.8 mg kg-1).	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
9164586-2	1997	Pretreatment with p-MPPI reduced or blocked the effect of the 5-HT1A receptor agonist 8-OH-DPAT on two responses mediated by postsynaptic 5-HT1A receptors, reduction of body temperature and the 5-HT behavioral syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77
9164586-2	1997	Pretreatment with p-MPPI reduced or blocked the effect of the 5-HT1A receptor agonist 8-OH-DPAT on two responses mediated by postsynaptic 5-HT1A receptors, reduction of body temperature and the 5-HT behavioral syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	62-68
9164586-4	1997	Pretreatment with p-MPPI also blocked the ability of 8-OH-DPAT to reduce extracellular 5-HT in the striatum, a response mediated by presynaptic 5-HT1A receptors in the dorsal raphe nucleus, but did not alter striatal 5-HT when administered alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Homo sapiens	144-150
9181636-0	1997	8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
9147028-2	1997	The behavioral responses, as well as the biogenic amines and metabolite contents in discrete brain areas were determined in male rats subcutaneously treated with a 5-HT1A (8-OHDPAT) or 5-HT2A (DOI) agonist at doses (0.5-2 mg/kg) sufficient to produce the typical effects of the stimulation of these brain receptor subtypes.	8-Hydroxy-2-(di-n-propylamino)tetralin	172-180	5-hydroxytryptamine receptor 1A	Rattus norvegicus	164-170
9225276-8	1997	Both cloned receptor subtypes displayed "5-HT1D receptor pharmacology" with the following rank order of binding affinities: 5-CT > 5-HT > sumatriptan > 8-OH-DPAT > (-)-pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	161-170	5-hydroxytryptamine receptor 1D	Cavia porcellus	41-56
9225281-8	1997	8-OH-DPAT in these and similar neurons produced the robust dose-dependent inhibitory response expected of a 5-HT1A agonist; increases in extracellular 5-HT resulting from re-uptake blockade by fluoxetine also suppressed unit activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Cavia porcellus	108-114
9225283-5	1997	Microiontophoretic ejection of the 5-HT1A/7 receptor agonist 8-OH-DPAT and of the 5-HT1A receptor antagonist WAY100635 both suppressed the spontaneous and QUIS-activated firing activity of orbitofrontal cortex neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Cavia porcellus	35-41
9225299-9	1997	Surprisingly, 8-hydroxy-2-(di-N-propylamino)-tetralin (8-OH DPAT), a 5-HT1A and 5-HT7 agonist was inactive on facial motoneurones unlike its reported agonist action on spinal motoneurones.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
9225301-0	1997	8-OH-DPAT-induced spontaneous tail-flicks in the rat are facilitated by the selective serotonin (5-HT)2C agonist, RO 60-0175: blockade of its actions by the novel 5-HT2C receptor antagonist SB 206,553.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	163-169
9105876-3	1997	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced temperature reduction, lower lip retraction and tail flick responses are widely used models of 5-HT1A receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Homo sapiens	154-169
9105876-3	1997	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced temperature reduction, lower lip retraction and tail flick responses are widely used models of 5-HT1A receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Homo sapiens	154-169
9079789-0	1997	Contrasting effects of systemic and intracerebral infusions of the 5-HT1A receptor agonist 8-OH-DPAT on spatial short-term working memory in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
9084602-13	1997	The 5-HT1A agonist 8-OH-DPAT mimicked, and the 5-HT1A antagonists (+)WAY 10,0135 and NAN 190 blocked, effects of 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9084603-8	1997	Current inhibition by 5-HT was mimicked by 8-OH-DPAT, a specific 5-HT1A agonist, and blocked by the 5-HT1a antagonists NAN 190 and (+) WAY 100135, but was unaffected by ketanserin, a 5-HT2A/C antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
9067310-1	1997	The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-58	iodothyronine deiodinase 3	Homo sapiens	152-154
9067310-1	1997	The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-58	immunoglobulin heavy diversity 2-15	Homo sapiens	159-161
9067310-1	1997	The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	iodothyronine deiodinase 3	Homo sapiens	152-154
9067310-1	1997	The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	immunoglobulin heavy diversity 2-15	Homo sapiens	159-161
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	immunoglobulin heavy diversity 2-15	Homo sapiens	82-85
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	iodothyronine deiodinase 3	Homo sapiens	90-93
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Homo sapiens	205-211
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	immunoglobulin heavy diversity 2-15	Homo sapiens	259-262
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	iodothyronine deiodinase 3	Homo sapiens	263-266
9067310-19	1997	Finally, VTA neurones are stimulated by (+)-8-OH-DPAT via 5-HT1A receptors and inhibited by (-)-8-OH-DPAT via hD3 and/or hD2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-53	5-hydroxytryptamine receptor 1A	Homo sapiens	58-64
9089665-4	1997	Systemic administration of the 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan dose-dependently decreased 5-HT levels in the CeA.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
9089665-4	1997	Systemic administration of the 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan dose-dependently decreased 5-HT levels in the CeA.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	carcinoembryonic antigen gene family 4	Rattus norvegicus	127-130
9131725-5	1997	The 8-OH-DPAT-induced hypothermia in mice (a 5-HT1A effect) was not inhibited by ROX.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	45-51
9105961-1	1997	5-HT1A receptor binding sites were measured, by saturation binding with [3H]8-OH-DPAT, in frontal and occipital cortex, hippocampus and amygdala obtained at post-mortem examination from suicide victims with a firm retrospective diagnosis of depression, and matched controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15
9017662-4	1997	The pharmacological profile of the [3H]8-OH-DPAT binding sites was consistent with the labelling of the 5-HT1A receptor in the hippocampus and cortex, whereas the striatal site shared strong similarity to the presynaptic serotonin transporter.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Homo sapiens	104-119
9017662-4	1997	The pharmacological profile of the [3H]8-OH-DPAT binding sites was consistent with the labelling of the 5-HT1A receptor in the hippocampus and cortex, whereas the striatal site shared strong similarity to the presynaptic serotonin transporter.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	solute carrier family 6 member 4	Homo sapiens	221-242
9084057-13	1997	Both 5-HT1 and 5-HT2 receptors are involved, and there was a functional interaction between 5-HT1A and 5-HT2A or 5-HT2C receptors, as ritanserin potentiated the antiaggressive effect of 1,5-HTP as well as that of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	213-222	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	92-104
9021891-0	1997	Chronic administration of the 5-HT1A receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
9021891-0	1997	Chronic administration of the 5-HT1A receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
9021891-1	1997	The present study investigated alterations of the regulation of serotonin (5-hydroxytryptamine; 5-HT) release by 5-HT1A autoreceptors following single and repeated treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	207-246	5-hydroxytryptamine receptor 1A	Rattus norvegicus	113-119
9021891-1	1997	The present study investigated alterations of the regulation of serotonin (5-hydroxytryptamine; 5-HT) release by 5-HT1A autoreceptors following single and repeated treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	207-246	5-hydroxytryptamine receptor 1A	Rattus norvegicus	183-189
9021891-1	1997	The present study investigated alterations of the regulation of serotonin (5-hydroxytryptamine; 5-HT) release by 5-HT1A autoreceptors following single and repeated treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	248-257	5-hydroxytryptamine receptor 1A	Rattus norvegicus	113-119
9021891-5	1997	The decrease of 5-HT release in the striatum produced by the challenge dose of the 5-HT1A receptor agonist was diminished following 7 and 14 days of pretreatment, but not after 1 day of pretreatment, with 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	205-214	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
9021891-7	1997	The results of the present study indicate that desensitization of 5-HT1A autoreceptors regulating 5-HT release in different brain regions by repeated treatment with 8-OH-DPAT occurs at different rates.	8-Hydroxy-2-(di-n-propylamino)tetralin	165-174	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
9167887-0	1997	Circadian rhythm in the hypothermic response to serotonin1A receptor agonist 8-OH-DPAT in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	48-68
9037397-5	1997	The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 1A	Homo sapiens	22-28
9037397-5	1997	The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 1A	Homo sapiens	22-37
9421130-11	1997	In 24FD pigeons, the 5-HT1a agonist 8-OH-DPAT (30.5 nmol) induced strong dipsogenic effects, as well as increase in food intake duration.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	5-hydroxytryptamine receptor 1A	Homo sapiens	21-27
9203078-3	1997	The 5-HT1A/5-HT2 antagonist, spiperone, alone, had no effect on basal 5-HT synthesis, however it attenuated the effect of 8-OH-DPAT by 56% and CGS 12066B by 39% but only barely that of citalopram by 17%.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9288830-3	1997	The present study was performed to examine 5-HT1A receptor activation of G-proteins using 8-OH-DPAT-stimulated [35S]GTPgammaS binding in membranes and brain sections.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
9048968-1	1997	The ligand binding characteristics of the recombinant human 5-HT1A receptor stably expressed in a Chinese Hamster Ovary (CHO) cell line are described using a selective agonist, [3H]8-OH-DPAT, and a novel antagonist radioligand, [3H]WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	181-190	5-hydroxytryptamine receptor 1A	Homo sapiens	60-75
9503254-3	1997	At high concentrations, the 5-HT1A agonist 8-OH-DPAT attenuated the carbachol-induced stimulation of inositol phosphates (InsPs) production, but this was not blocked by the presence of 5-HT1A antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	28-34
9048968-7	1997	Furthermore, [3H] 8-OH-DPAT labelled approximately 53-61% of total 5-HT1A sites recognised by [3H]WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	67-73
9048968-8	1997	The competition binding profiles of [3H]WAY-100635 and [3H]8-OH-DPAT were highly correlated and consistent with the recognition of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	131-137
9048968-10	1997	A significant correlation between the respective affinities of a range of agonists and antagonists at recombinant human and rodent hippocampal 5-HT1A binding sites (previously published) was also observed using [3H]WAY-100635 (r = 0.92; P < 0.0005) and [3H]8-OH-DPAT (r = 0.96; P < 0.0005).	8-Hydroxy-2-(di-n-propylamino)tetralin	260-269	5-hydroxytryptamine receptor 1A	Homo sapiens	143-149
8981617-1	1997	As previously shown, the 5-HT1A agonist 8-OH-DPAT is a potent facilitator of male rat copulatory behavior in both sexually experienced and sexually exhausted male rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
9016944-3	1996	Dose-effect curves obtained by simultaneously applying equipotent concentrations of the selective 5-HT1A agonist 8-OH-DPAT and the selective 5-HT1D receptor agonist sumatriptan are shifted to the right, although maximal effects are additive.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Homo sapiens	98-104
8997601-0	1996	Effects of galanin on 8-OH-DPAT induced decrease in body temperature and brain 5-hydroxytryptamine metabolism in the mouse.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	galanin and GMAP prepropeptide	Mus musculus	11-18
8997601-2	1996	= 1 nmol) blocked the hypothermia induced by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.5 mg/kg s.c.), in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-111	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	49-64
8997601-2	1996	= 1 nmol) blocked the hypothermia induced by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.5 mg/kg s.c.), in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	49-64
8997601-8	1996	8-OH-DPAT (0.5 mg/kg s.c.) also decreased cortical and hypothalamic 5-HT (5-hydroxytryptamine, serotonin) metabolism, an effect which was not blocked by pretreatment with galanin (0.3-3 nmol intracerebroventricular, i.c.v.).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	galanin and GMAP prepropeptide	Mus musculus	171-178
8997601-12	1996	These results suggest that the inhibition of 8-OH-DPAT induced hypothermia by galanin is probably not mediated by an interaction with 5-HT1A receptors but more likely by blocking the indirect activation by 8-OH-DPAT of central cholinergic pathways involved in temperature regulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	galanin and GMAP prepropeptide	Mus musculus	78-85
8997601-12	1996	These results suggest that the inhibition of 8-OH-DPAT induced hypothermia by galanin is probably not mediated by an interaction with 5-HT1A receptors but more likely by blocking the indirect activation by 8-OH-DPAT of central cholinergic pathways involved in temperature regulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	206-215	galanin and GMAP prepropeptide	Mus musculus	78-85
9017248-9	1996	The effects of the selective serotonin 5-HT1A receptor agonist, 8-OH-DPAT (20 microM) on GEPR-9 pyramidal CA1 neurons were similar to those of serotonin, except the magnitude of hyperpolarization and reduction of membrane input resistance were less than those produced by serotonin.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-54
9017248-9	1996	The effects of the selective serotonin 5-HT1A receptor agonist, 8-OH-DPAT (20 microM) on GEPR-9 pyramidal CA1 neurons were similar to those of serotonin, except the magnitude of hyperpolarization and reduction of membrane input resistance were less than those produced by serotonin.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	carbonic anhydrase 1	Rattus norvegicus	106-109
9017269-1	1996	Pretreatment with R(+)-8-OH-DPAT, a selective serotonin (5-HT)1A receptor agonist (50 micrograms/kg, s.c.), inhibited D-amphetamine sulfate (1.0 mg/kg, s.c.)-induced increases in extracellular levels of both 5-HT and dopamine (DA) in rat medial prefrontal cortex, as determined by in vivo microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-32	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-73
8982715-10	1996	These data argue that both central alpha 2-adrenoceptors and 5-HT1A receptors are involved in the mediation of mydriasis induced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	132-141	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	61-67
8982715-19	1996	Taken together these results show that 8-OH-DPAT initially stimulates 5-HT1A receptors, and it is likely that this is followed by release of noradrenaline onto postsynaptic alpha 2-adrenoceptors, the latter effect being responsible for the mydriatic response.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	70-76
11224473-2	1996	The high efficacy 5-HT(1A) receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetraline] was inactive, and the partial agonist buspirone showed an anxiolytic-like response that was weaker than the response to diazepam.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-25
9085496-5	1996	Both CGS-12066 and 8-OH-DPAT (5HT1B and 5HT1A receptor agonists, respectively) suppressed XII nerve activity in a dose-dependent manner by about 20%.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1B	Rattus norvegicus	30-35
9085496-5	1996	Both CGS-12066 and 8-OH-DPAT (5HT1B and 5HT1A receptor agonists, respectively) suppressed XII nerve activity in a dose-dependent manner by about 20%.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	40-54
8982661-2	1996	Forepaw treading in rats is mediated by postsynaptic 5-HT1A receptors, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamin)tetralin)-induced discriminative stimulus is predominantly mediated by postsynaptic, but presynaptic 5-HT1A receptors might also be involved, and footshock-induced ultrasonic vocalization involves predominantly presynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
11224475-1	1996	(=) 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) has been the most widely used pharmacological tool in research on 5-HT(1A) receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-42	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	121-138
11224475-1	1996	(=) 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) has been the most widely used pharmacological tool in research on 5-HT(1A) receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	121-138
11224475-5	1996	Findings are discussed in relation to differences in the intrinsic activity of 8-OH-DPAT isomers at 5-HT(1A) sites and the putative role of these receptors in anxiety-related processes.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	100-107
8982661-2	1996	Forepaw treading in rats is mediated by postsynaptic 5-HT1A receptors, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamin)tetralin)-induced discriminative stimulus is predominantly mediated by postsynaptic, but presynaptic 5-HT1A receptors might also be involved, and footshock-induced ultrasonic vocalization involves predominantly presynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	212-218
8982661-2	1996	Forepaw treading in rats is mediated by postsynaptic 5-HT1A receptors, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamin)tetralin)-induced discriminative stimulus is predominantly mediated by postsynaptic, but presynaptic 5-HT1A receptors might also be involved, and footshock-induced ultrasonic vocalization involves predominantly presynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	212-218
8922726-2	1996	We studied whether the stimulation of 5-HT1A receptors by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a specific 5-HT1A receptor agonist, reduced electroencephalographic (EEG) seizures induced by intrahippocampal injection of 0.04 microgram in 0.5 microliter of the glutamate analogue kainic acid in freely-moving rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
8945958-8	1996	The CRH antagonist alpha-helical CRH-(9-41) attenuated the increases in metabolic rate induced by DOI and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	corticotropin releasing hormone	Rattus norvegicus	4-7
8945958-8	1996	The CRH antagonist alpha-helical CRH-(9-41) attenuated the increases in metabolic rate induced by DOI and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	corticotropin releasing hormone	Rattus norvegicus	33-36
8933361-10	1996	The agonist 8-OH-DPAT enhanced the photically-induced increase of melatonin receptors by 10% and decreased the photically-induced increase in Fos by 18%.	8-Hydroxy-2-(di-n-propylamino)tetralin	12-21	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	142-145
8914117-3	1996	In schizophrenics, 5-HT1A binding site densities, determined autoradiographically by [3H]8-hydroxy-2,3-(dipropylamino)-tetralin ([3H]8-OH-DPAT), were significantly increased (+23%) in the dorsolateral prefrontal cortex, with a similar trend in anterior cingulate gyrus.	8-Hydroxy-2-(di-n-propylamino)tetralin	133-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
8939455-4	1996	Moreover, the stimulation of central 5HT1A receptors with the agonist 8-hydroxy-2-(di-n-propylamino)tetralin has been reported to produce an increase or decrease in the activity of adenylate cyclase.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-42
8939455-6	1996	8-Hydroxy-2-(di-n-propylamino)tetralin produced a significant and dose-dependent increase in cAMP concentration.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	cathelicidin antimicrobial peptide	Rattus norvegicus	93-97
8916191-4	1996	Our prediction was that the CCKA antagonist, devazepide, alone would potentiate the hyperphagic effect of the 5-HT1A agonist, 8-OH-DPAT, in free-feeding rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	110-116
9112695-1	1996	Effects of repeated treatment with antidepressant drugs on the reactivity of CA1 neurons to 5-hydroxytryptamine (5-HT), (+/-)-8-hydroxy-2-(dipropyl-amino)-tetralin (8-OH-DPAT)--the 5-HT1A receptor agonist, and the zacopride-5-HT4 receptor agonist were examined in the rat hippocampus ex vivo.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-163	carbonic anhydrase 1	Rattus norvegicus	77-80
9112695-1	1996	Effects of repeated treatment with antidepressant drugs on the reactivity of CA1 neurons to 5-hydroxytryptamine (5-HT), (+/-)-8-hydroxy-2-(dipropyl-amino)-tetralin (8-OH-DPAT)--the 5-HT1A receptor agonist, and the zacopride-5-HT4 receptor agonist were examined in the rat hippocampus ex vivo.	8-Hydroxy-2-(di-n-propylamino)tetralin	165-174	carbonic anhydrase 1	Rattus norvegicus	77-80
9112695-11	1996	It has been concluded that adaptive changes in the responsiveness of CA1 cells to 5-HT, 8-OH-DPAT and zacopride, induced by repeated administration of antidepressant drugs do not involve presynaptic effects on excitatory synaptic transmission.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	carbonic anhydrase 1	Rattus norvegicus	69-72
8956380-2	1996	The 5-HT1A agonist 8-OH-DPAT (0.16 mg/kg) significantly enhanced the inhibitory effects of both raclopride and haloperidol on the conditioned avoidance response and produced a small enhancement of the effects of haloperidol on escape failures.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8922726-2	1996	We studied whether the stimulation of 5-HT1A receptors by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a specific 5-HT1A receptor agonist, reduced electroencephalographic (EEG) seizures induced by intrahippocampal injection of 0.04 microgram in 0.5 microliter of the glutamate analogue kainic acid in freely-moving rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
8922726-2	1996	We studied whether the stimulation of 5-HT1A receptors by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a specific 5-HT1A receptor agonist, reduced electroencephalographic (EEG) seizures induced by intrahippocampal injection of 0.04 microgram in 0.5 microliter of the glutamate analogue kainic acid in freely-moving rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
8922726-2	1996	We studied whether the stimulation of 5-HT1A receptors by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a specific 5-HT1A receptor agonist, reduced electroencephalographic (EEG) seizures induced by intrahippocampal injection of 0.04 microgram in 0.5 microliter of the glutamate analogue kainic acid in freely-moving rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
8922726-11	1996	The anticonvulsant action of 8-OH-DPAT given intrahippocampally or systemically was significantly blocked by 5 micrograms, but not 1 microgram WAY 100635, a selective 5-HT1A receptor antagonist, administered in the hippocampus before the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	167-173
8922726-13	1996	These results indicate that postsynaptic 5-HT1A receptors in the hippocampus mediate the anticonvulsant action of 8-OH-DPAT and that their stimulation has an inhibitory role in the generation of limbic seizures.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
8957248-0	1996	8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
8899594-15	1996	A5+ and A5- cells differed regarding the inhibition of high-threshold Ca2+ currents by maximal concentrations of 5HT1A agonists (10 microM 5HT or 1 microM 8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	155-164	5-hydroxytryptamine receptor 1A	Rattus norvegicus	113-118
8912226-2	1996	Initially, the Ki value for 5-hydroxytryptamine (5-HT) binding to a site labeled by the 5-HT1A-selective ligand [3H]8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was 20-fold higher than the KD for [3H]5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
8923668-5	1996	The specific binding of the radioligand in the hippocampal region, an area rich in 5-HT1A receptor density, was blocked by a chasing dose of (+/-) 8-OH-DPAT (2 mg/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	147-156	5-hydroxytryptamine receptor 1A	Homo sapiens	83-98
8902886-1	1996	It was previously reported that selection for differences in the hypothermic effects to the selective 5-HT-1A agonist, 8-OH-DPAT, occurred rapidly, with very substantial differences present by the fourth generation.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-109
8902886-11	1996	The pattern of binding results suggests that these behavioral correlates of 8-OH-DPAT selection may be related to changes in cortical 5-HT-1A receptors rather than raphe autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-141
8831769-3	1996	The novel compounds have been evaluated for affinity to rat brain 5-HT1A receptors in competition experiments with [3H]-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
8891585-3	1996	Affinity constants were measured by saturation experiments for the selective 5-HT1A receptor agonist [3H]8-hydroxy-N,N-dipropyl-2-aminotetralin ([3H]8-OH-DPAT) and by inhibition assays of [3H]8-OH-DPAT binding for the other compounds.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-158	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
8798386-3	1996	Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-111	mitogen-activated protein kinase 1	Homo sapiens	14-18
8798386-3	1996	Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-111	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41
8798386-3	1996	Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	mitogen-activated protein kinase 1	Homo sapiens	14-18
8798386-3	1996	Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41
8912226-3	1996	In addition, a number of putative 5-HT1A selective ligands displayed poor affinity for the [3H]8-OH-DPAT site.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-104	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
8912226-7	1996	In addition, when clorgyline was used, 5-HT1A-selective compounds displayed high affinity for the DRN binding site consistent with [3H]8-OH-DPAT labeling a 5-HT1A receptor in this tissue.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
8912226-7	1996	In addition, when clorgyline was used, 5-HT1A-selective compounds displayed high affinity for the DRN binding site consistent with [3H]8-OH-DPAT labeling a 5-HT1A receptor in this tissue.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	156-162
8888935-0	1996	The 5-HT1A receptor agonist 8-OH-DPAT reduces ethanol intake and maintained behavior in female Sprague-Dawley rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8888935-8	1996	These results demonstrate that, under the present experimental conditions, the 5-HT1A receptor agonist 8-OH-DPAT reduced ethanol self-administration in the rat, and support a role for 5-HT1A receptors in the mediation of ethanol reinforcement.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-85
8888935-8	1996	These results demonstrate that, under the present experimental conditions, the 5-HT1A receptor agonist 8-OH-DPAT reduced ethanol self-administration in the rat, and support a role for 5-HT1A receptors in the mediation of ethanol reinforcement.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	184-190
9162203-0	1996	Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	56-63
8891278-5	1996	Evidence that the anxiogenic effect of 8-OH-DPAT (50 ng) was due to activation of 5-HT1A receptors came from the finding that (-)-tertatolol, a 5-HT1A receptor antagonist, reversed this effect at a dose (1.5 micrograms) which was silent when given alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
8891278-5	1996	Evidence that the anxiogenic effect of 8-OH-DPAT (50 ng) was due to activation of 5-HT1A receptors came from the finding that (-)-tertatolol, a 5-HT1A receptor antagonist, reversed this effect at a dose (1.5 micrograms) which was silent when given alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	144-150
8884615-6	1996	8-OH-DPAT (250 micrograms/kg sc) reduced it to 64% for about 1 h and this effect was completely prevented by the 5HT1A antagonist WAY 100635 (1 mg/kg sc).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	113-118
8819496-7	1996	Pretreatment of P11-5HT1A cells with the phorbol ester, phorbol 12-myristate 13-acetate (PMA), also resulted in desensitization of the 5-HT1A receptor, as indicated by a marked decrease in the potency and intrinsic activity of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	227-236	5-hydroxytryptamine receptor 1A	Homo sapiens	135-150
8865198-4	1996	The current (dose)-dependent inhibition produced by the serotonin agonists did not differ significantly from the inhibition produced by MDMA except for the 5-HT1A agonist 8-hydroxy-(2-di-n-propylamino) tetralin, which inhibited glutamate-evoked firing significantly more than MDMA or any of the other serotonin agonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-210	5-hydroxytryptamine receptor 1A	Homo sapiens	156-162
8873105-11	1996	Intravenous injection or iontophoretic application of 1192U90 or the 5-HT1A agonist (+/-)8-OH-DPAT inhibited the firing rates of dorsal raphe nucleus (DRN) neurons in rats, and the effects of both compounds were blocked by iontophoretically applied S(-) propranolol, a 5-HT1A antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
8870031-9	1996	At low doses (0.06-0.25 mg/kg), the 5-HT2A selective agonist, 8-OH DPAT, significantly but partially inhibited 5-HTP-induced HTR.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	36-42
8880946-3	1996	Repeated paroxetine antagonized the 8-OH-DPAT-induced behavioural syndrome (a 5-HT1A effect); imipramine showed similar, yet weaker, activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
8880946-5	1996	Repeated (or acute) paroxetine decreased the density of and increased the affinity for 5-HT1A receptors ([3H]-8-OH-DPAT used as ligand) in the hippocampus, while imipramine induced opposite effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
8874152-10	1996	Second, a direct action of 8-OH-DPAT on hypothalamic 5HT1A receptors is assumed, independent of peripheral adrenaline release.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-58
11224433-6	1996	We also found that three doses of the 5-HT(1A) agonist, 8-OH-DPAT, caused a biphasic dose effect on impulsivity.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Homo sapiens	38-45
8764667-2	1996	Direct administration of the 5-HT1A receptor agonist (+/-)-8-hydroxy-dipropylaminotetralin (8-OH-DPAT, 200 ng) into the MRN had significant anxiolytic effects in all three test situations examined (social interaction, plus-maze trails 1 and 2).	8-Hydroxy-2-(di-n-propylamino)tetralin	92-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
8840120-5	1996	The (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced lower lip retraction mediated by presynaptic 5-HT1A receptors was unchanged, whereas the open field activity induced by 8-OH-DPAT was enhanced in corticosterone pretreated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
8840120-5	1996	The (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced lower lip retraction mediated by presynaptic 5-HT1A receptors was unchanged, whereas the open field activity induced by 8-OH-DPAT was enhanced in corticosterone pretreated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
8841890-2	1996	A high density of 5-HT1A receptors, labeled by [3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT), was found in the superficial layers of the dorsal horn, with a significant enrichment ( approximately 20%) in the lumbar vs. the thoracic and cervical segments.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-104	5-hydroxytryptamine receptor 1A	Homo sapiens	18-24
8857590-11	1996	The 8-OH-DPAT effect also is likely mediated by 5-HT1D receptors; stereoselectivity was found with its enantiomers at this receptor site and the effect was blocked by ketanserin (1 microM) but not by spiperone (1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1D	Homo sapiens	48-54
8832223-4	1996	WAY 100135 (N-tertiobutyl-3-[4-(2-methoxyphenyl)-piperazinyl]-2-phenylpropana mide), the putative 5-HT1A receptor antagonist blocked the 8-OH-DPAT effect but not the responses to DOI.	8-Hydroxy-2-(di-n-propylamino)tetralin	137-146	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
8832223-8	1996	In addition, the robust genomic responses to 8-OH-DPAT as well as Northern hybridization with a cDNA probe for 5-HT1A mRNA in the cerebellum clearly implicate the functional expression of 5-HT1A receptors in this brain region.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	188-194
9162203-2	1996	In view of the evidence that one serotonin (5-HT) receptor, the 5-HT(1A) subtype, is associated with cortical glutamatergic neurons, we have used quantitative receptor autoradiography to measure the specific binding of the 5-HT(1A) receptor ligand [3H]8-OH-DPAT (2 nM) in sections of orbital frontal cortex taken from 18 control and 12 schizophrenic postmortem brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	252-261	5-hydroxytryptamine receptor 1A	Homo sapiens	64-71
9162203-2	1996	In view of the evidence that one serotonin (5-HT) receptor, the 5-HT(1A) subtype, is associated with cortical glutamatergic neurons, we have used quantitative receptor autoradiography to measure the specific binding of the 5-HT(1A) receptor ligand [3H]8-OH-DPAT (2 nM) in sections of orbital frontal cortex taken from 18 control and 12 schizophrenic postmortem brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	252-261	5-hydroxytryptamine receptor 1A	Homo sapiens	223-240
8853311-6	1996	These results suggest that [3H]-8OH-DPAT binding can be resolved as complex isotherms and we provided evidence that [3H]-8OH-DPAT labels 2 high-affinity GTP gamma S-sensitive and one low-affinity GTP gamma S-sensitive state of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	227-233
8797023-0	1996	Prior treatment with estrogen attenuates the effects of the 5-HT1A agonist, 8-OH-DPAT, on lordosis behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
8797023-1	1996	The effects of repeated treatment with estradiol benzoate to ovariectomized rats on the lordosis-inhibiting action of the 5-HT1A agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT), were examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	138-176	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
8797023-10	1996	These data are interpreted as evidence that (1) estradiol benzoate"s attenuation of the effects of 8-OH-DPAT on lordosis behavior is both dose and time dependent; (2) 5-HT1A receptor action in the VMN is attenuated by the hormone treatment; and (3) female gonadal hormones reduce the potency of the 5-HT1A agonist, 8-OH-DPAT, in inhibiting lordosis behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	167-173
8797023-10	1996	These data are interpreted as evidence that (1) estradiol benzoate"s attenuation of the effects of 8-OH-DPAT on lordosis behavior is both dose and time dependent; (2) 5-HT1A receptor action in the VMN is attenuated by the hormone treatment; and (3) female gonadal hormones reduce the potency of the 5-HT1A agonist, 8-OH-DPAT, in inhibiting lordosis behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	299-305
8797023-10	1996	These data are interpreted as evidence that (1) estradiol benzoate"s attenuation of the effects of 8-OH-DPAT on lordosis behavior is both dose and time dependent; (2) 5-HT1A receptor action in the VMN is attenuated by the hormone treatment; and (3) female gonadal hormones reduce the potency of the 5-HT1A agonist, 8-OH-DPAT, in inhibiting lordosis behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	315-324	5-hydroxytryptamine receptor 1A	Rattus norvegicus	167-173
8795088-0	1996	The oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin inhibits effects of the 5-HT1A receptor agonist 8-OH-DPAT on plasma levels of insulin, cholecystokinin and somatostatin.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	somatostatin	Rattus norvegicus	185-197
8795088-4	1996	8-OH-DPAT also increased insulin and decreased CCK and somatostatin levels, effects that were blocked by pretreatment with the oxytocin antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	cholecystokinin	Rattus norvegicus	47-50
8795088-4	1996	8-OH-DPAT also increased insulin and decreased CCK and somatostatin levels, effects that were blocked by pretreatment with the oxytocin antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	somatostatin	Rattus norvegicus	55-67
8795088-5	1996	Taken together, these data suggest that the effect of 8-OH-DPAT on plasma levels of insulin, somatostatin and CCK may be mediated by oxytocin.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	somatostatin	Rattus norvegicus	93-105
8795088-5	1996	Taken together, these data suggest that the effect of 8-OH-DPAT on plasma levels of insulin, somatostatin and CCK may be mediated by oxytocin.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	cholecystokinin	Rattus norvegicus	110-113
8795088-9	1996	Since oxytocinergic fibers which originate in the PVN project to the DMX, we suggest that the effect on the release of insulin, CCK and somatostatin induced by the 5 HT1A receptor agonist 8-OH-DPAT may be mediated by an oxytocinergic activation of a vagal mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	188-197	cholecystokinin	Rattus norvegicus	128-131
8795088-9	1996	Since oxytocinergic fibers which originate in the PVN project to the DMX, we suggest that the effect on the release of insulin, CCK and somatostatin induced by the 5 HT1A receptor agonist 8-OH-DPAT may be mediated by an oxytocinergic activation of a vagal mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	188-197	somatostatin	Rattus norvegicus	136-148
8728549-3	1996	However, in rats experienced with the plus-maze, 8-OH-DPAT (100 and 200 ng) had significant anxiolytic effects when administered to the dorsal raphe nucleus, which were antagonised by tertatolol (3 micrograms); this suggests they were mediated by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	247-253
8724452-1	1996	These experiments assessed whether reported increases in food consumption and food-reinforced instrumental performance in undeprived rats by the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) are due to an increment in the incentive value of foods.	8-Hydroxy-2-(di-n-propylamino)tetralin	160-197	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-151
8724452-1	1996	These experiments assessed whether reported increases in food consumption and food-reinforced instrumental performance in undeprived rats by the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) are due to an increment in the incentive value of foods.	8-Hydroxy-2-(di-n-propylamino)tetralin	199-208	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-151
8724453-0	1996	Somatodendritic 5-HT1A receptors are critically involved in the anxiolytic effects of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	16-22
8724453-3	1996	Therefore, it is concluded that the anxiolytic effects of 8-OH-DPAT are mediated by activation of somatodendritic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
8728551-9	1996	At this same interval 25 micrograms/kg s.c. 8-OH-DPAT, a 5-HT1A receptor agonist, significantly reduced extracellular 5-HT only in the frontal cortex of rats treated chronically with the vehicle.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
8728557-9	1996	In the case of defence, the effects of the antagonist were reinforced by the action of the agonist (8-OH-DPAT) in both males and females, indicating an inhibitory role of 5-HT1A perinatal activity on defence in the presence of malelike levels of circulating T and a facilitatory role when levels of T are low or negligible.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	171-177
8738244-1	1996	Studies determined if estradiol modulates cardiovascular responses evoked by administration of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, into the lateral cerebral ventricle.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	150-156
8738244-5	1996	In summary, estradiol selectively enhanced the bradycardia elicited by 8-OH-DPAT suggesting that estrogen modulates the function of central 5-HT1A receptors regulating heart rate.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-146
8741179-1	1996	The cAMP responses of (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and its enantiomers were measured at cloned human 5-HT1D alpha and 5-HT1D beta receptors in transfected C6-glial cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-66	5-hydroxytryptamine receptor 1B	Homo sapiens	146-157
8741179-2	1996	R(+)-8-OH-DPAT demonstrated potent intrinsic activity (EC50 value: 30 nM) at 5-HT1D alpha receptor sites, its maximal effect being comparable to that of sumatriptan.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-14	5-hydroxytryptamine receptor 1D	Homo sapiens	77-89
8793911-2	1996	The selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and 5-hydroxytryptamine (5-HT) caused concentration-dependent inhibitions of the electrically evoked release of [3H]acetylcholine from myenteric plexus preparations that had been preincubated with [3H]choline.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-77	5-hydroxytryptamine receptor 1A	Cavia porcellus	14-20
8793911-2	1996	The selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and 5-hydroxytryptamine (5-HT) caused concentration-dependent inhibitions of the electrically evoked release of [3H]acetylcholine from myenteric plexus preparations that had been preincubated with [3H]choline.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Cavia porcellus	14-20
8793912-2	1996	In the present report, the lordosis-inhibiting effects of the 5-HT1A agonist [(+/-) 8-hydroxy-2- (di-n-propylamino) tetralin) (8-OH-DPAT] were shown to be attenuated with 5-HT1A receptor antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
8793912-2	1996	In the present report, the lordosis-inhibiting effects of the 5-HT1A agonist [(+/-) 8-hydroxy-2- (di-n-propylamino) tetralin) (8-OH-DPAT] were shown to be attenuated with 5-HT1A receptor antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	171-177
8793912-2	1996	In the present report, the lordosis-inhibiting effects of the 5-HT1A agonist [(+/-) 8-hydroxy-2- (di-n-propylamino) tetralin) (8-OH-DPAT] were shown to be attenuated with 5-HT1A receptor antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
8793912-2	1996	In the present report, the lordosis-inhibiting effects of the 5-HT1A agonist [(+/-) 8-hydroxy-2- (di-n-propylamino) tetralin) (8-OH-DPAT] were shown to be attenuated with 5-HT1A receptor antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Rattus norvegicus	171-177
8801608-4	1996	With 5-HT agonists, 8-OH-DPAT (5-HT1A) suppressed the two oral stereotypies and increased standing (all 1.0 mg/kg) and preening (0.2 mg/kg), alpha-methylserotonin (5-HT2) suppressed the oral stereotypies and increased sitting (all 1.0 mg/kg), and m-CPBG (5-HT3) suppressed drinker-directed activity (1.0 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Homo sapiens	31-37
8882616-7	1996	The 5-HT1A receptor agonist, (+/-)-8-hydroxy-2-(di-n-propylamino) tetraline (8-OH-DPAT) (10 to 3000 nM) induced a concentration-dependent increase (P < 0.05) in Na+, K(+)-ATPase activity with an EC50 value of 355 nM (95% confidence limits: 178, 708).	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
8882616-8	1996	Maximal stimulation elicited by 3000 nM of 8-OH-DPAT was antagonized by the selective 5-HT1A receptor antagonist, (+)-WAY 100135 10 to 1000 nM) with an IC50 value of 20 nM (14, 29); 0.3 microM (+)-WAY 100135 completely abolished (P < 0.01) the stimulatory effect of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	86-101
8882616-8	1996	Maximal stimulation elicited by 3000 nM of 8-OH-DPAT was antagonized by the selective 5-HT1A receptor antagonist, (+)-WAY 100135 10 to 1000 nM) with an IC50 value of 20 nM (14, 29); 0.3 microM (+)-WAY 100135 completely abolished (P < 0.01) the stimulatory effect of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	269-278	5-hydroxytryptamine receptor 1A	Homo sapiens	86-101
8786576-3	1996	Intraspinal administration of 8-hydroxy-dipropylaminotetralin hydrobromide (8-OH-DPAT), a selective 5-HT(1A) agonist, by microdialysis produced a dose-dependent antinociception in the radiant-heat paw withdrawal test.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-107
8786576-5	1996	The inhibitory effects elicited by 8-OH-DPAT could be selectively blocked by perfusion of the spinal cord with S-(--)-propranolol, a selective 5-HT(1A) antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	143-150
8820175-0	1996	Partial agonistic activity of R- and S-enantiomers of 8-OH-DPAT at 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
8820175-1	1996	In this study, the 5-HT1A agonistic activity of R- and S-enantiomers of the prototypical 5-HT1A agonist 8-OH-DPAT was investigated using in vivo microiontophoresis and the hypothermic response in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
8820175-1	1996	In this study, the 5-HT1A agonistic activity of R- and S-enantiomers of the prototypical 5-HT1A agonist 8-OH-DPAT was investigated using in vivo microiontophoresis and the hypothermic response in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
8820175-5	1996	Racemic 8-OH-DPAT produced a dose-dependent hypothermia which was attenuated by the 5-HT1A antagonist pindolol, but not by the nonselective 5-HT antagonist methysergide.	8-Hydroxy-2-(di-n-propylamino)tetralin	8-17	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-90
8677015-5	1996	The 5-HT1A receptor agonist 8-OH-DPAT produced a statistically significant decrease in plasma insulin levels and an increase in glucose, whereas glucagon levels were unaffected.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8677015-10	1996	In support of a separate mediation of glucose secretion by 5-HT1A and DA D3 receptors, the effects of 8-OH-DPAT on glucose levels were antagonized by (-)pindolol pretreatment, and the 7-OH-DPAT-induced effects on glucose levels were antagonized by raclopride pretreatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
8851159-5	1996	The antiaggressive effect of a submaximal dose of 8-OH-DPAT was markedly potentiated by beta-adrenoceptor antagonists without 5-HT1A receptor affinity, whereas (-)-penbutolol was effective at only one dose (4.5 mumol/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	126-141
8820177-2	1996	The 5-HT1A receptors were labelled in total cortex membrane homogenates with [3H]8-OH-DPAT, and the monoamines measured in cingulate cortex by high-performance liquid chromatography.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8611634-3	1996	A strong passage dependence of 5-HT1A-R expression, as measured by mRNA levels as well as membrane binding to the selective agonist [3H]8-OH-DPAT, was observed only in the HN2 (hippocampal) and NCB-20 (CNS) cells which are derived from tissues of natural occurrence of the 5-HT1A-R. A paradigm of stress was obtained by carrying out continuous culture of cells without feeding.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	MT-RNR2 like 2 (pseudogene)	Homo sapiens	172-175
8720866-1	1996	Extracellular single-unit recording techniques were used to examine the firing characteristics of neurons in the medial septum/diagnol band of Broca complex (MS/DB) following injections of the 5-HT1A agonist, 8-OH-DPAT, into the median raphe nucleus (MRN) of urethane-anesthetized rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	209-218	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
8646424-4	1996	WAY100135 (10 mg kg-1, s.c.) and WAY100635 (1 mg kg-1, s.c.) significantly reduced the behaviours induced by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OHDPAT) (1 mg kg-1, s.c.) indicative of post-synaptic 5-HT1A receptor antagonism.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-148	5-hydroxytryptamine receptor 1A	Cavia porcellus	206-212
8646424-9	1996	but did not affect the maximum inhibition induced by 8-OHDPAT indicating competitive antagonism between 8-OHDPAT and WAY100635 at the 5-HT1A somato-dendritic autoreceptor in the dorsal raphe nucleus of the guinea-pig.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-112	5-hydroxytryptamine receptor 1A	Cavia porcellus	134-140
8632301-3	1996	The 5-HT1A agonists, buspirone and 8-OH-DPAT, which lack affinity for 5-HT2A/2C receptors, produced dose-related increases in punished responding.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
8632301-3	1996	The 5-HT1A agonists, buspirone and 8-OH-DPAT, which lack affinity for 5-HT2A/2C receptors, produced dose-related increases in punished responding.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 2A	Homo sapiens	70-76
8632339-8	1996	5-HT1D receptors, similarly to 5-HT1A autoreceptors, desensitize after long-term treatment with a selective 5-HT reuptake inhibitor or a reversible type A monoamine oxidase inhibitor because the efficacy of sumatriptan and of 8-OH-DPAT to inhibit the electrically evoked overflow of [3H]5-HT was reduced after the administration of either drug.	8-Hydroxy-2-(di-n-propylamino)tetralin	226-235	5-hydroxytryptamine receptor 1D	Rattus norvegicus	0-6
8734491-7	1996	Although the antagonism of the 8-OH-DPAT-induced decrease of 5-HT levels by (-)-pindolol and (+/-)-tertatolol is likely to be related to their 5-HT1A antagonist properties, their ability to increase extracellular 5-HT levels when given alone may involve interactions with 5-HT1B receptors at hippocampal 5-HT terminals.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	143-149
8734491-7	1996	Although the antagonism of the 8-OH-DPAT-induced decrease of 5-HT levels by (-)-pindolol and (+/-)-tertatolol is likely to be related to their 5-HT1A antagonist properties, their ability to increase extracellular 5-HT levels when given alone may involve interactions with 5-HT1B receptors at hippocampal 5-HT terminals.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine receptor 1B	Rattus norvegicus	272-278
9005436-1	1996	A three-dimensional model of the human 5-HT(1a) receptor was constructed by molecular modelling, and the molecular and electronic structures of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin (UH-301) and of (R)- and (S)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) were examined by molecular mechanics and quantum mechanics calculations and molecular dynamics simulations.	8-Hydroxy-2-(di-n-propylamino)tetralin	268-277	5-hydroxytryptamine receptor 1A	Homo sapiens	39-56
9005436-3	1996	Interactions of UH-301 and 8-OH-DPAT with the 5-HT(1a) receptor were examined by molecular dynamics simulations and energy minimization of receptor-ligand complexes.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Homo sapiens	46-63
9005436-5	1996	The simulations indicated that the 5-HT(1a) receptor agonists, (R)- and (S)-8-OH-DPAT and (R)-UH-301, interacted with the receptor at a site closer to Asp82 in TMH2 than did (S)-UH-301, which is a 5-HT1a receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-85	5-hydroxytryptamine receptor 1A	Homo sapiens	35-52
9005436-5	1996	The simulations indicated that the 5-HT(1a) receptor agonists, (R)- and (S)-8-OH-DPAT and (R)-UH-301, interacted with the receptor at a site closer to Asp82 in TMH2 than did (S)-UH-301, which is a 5-HT1a receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-85	5-hydroxytryptamine receptor 1A	Homo sapiens	197-212
8919313-2	1996	The maximal effect of 8-OH-DPAT (0.5 mg/kg, s.c.) was prevented by the 5-HT1A antagonist WAY 100635 (1 mg/kg, s.c.) and by the D1 antagonists SCH 23390 or SCH 39166 (both 0.3 mg/kg, s.c.) but not seven days after chemical lesion of the raphe serotoninergic neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
8808139-8	1996	Binding of [3H]8-OH-DPAT to 5-HT1A receptors revealed few receptor sites in PPT, and a low to moderate number of receptors in LDT compared to binding in DRN.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
8551355-7	1996	After abolishing the crossed IPSPs by spinal transection, systemic administration of the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT; 0.1-1.3 mg/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	113-170	5-hydroxytryptamine receptor 1A	Homo sapiens	89-104
8919313-3	1996	It is postulated that the 8-OH-DPAT activation of postsynaptic 5-HT1A receptors enhances the release of dopamine which, by acting at D1 receptors, stimulates the release of ACh in the frontal cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
8720579-3	1996	In support of receptor specificity, the effects of 8-OH-DPAT and DOI could be antagonised by pretreatment with the 5-HT1A/B and the 5-HT2A/C receptor antagonists (-)-pindolol (2 mg kg-1 s.c.) and ritanserin (2 mg kg-1 s.c.), respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	115-121
8720579-3	1996	In support of receptor specificity, the effects of 8-OH-DPAT and DOI could be antagonised by pretreatment with the 5-HT1A/B and the 5-HT2A/C receptor antagonists (-)-pindolol (2 mg kg-1 s.c.) and ritanserin (2 mg kg-1 s.c.), respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 2A	Rattus norvegicus	132-138
8720582-2	1996	All the 5-HT1A receptor agonists tested induced dose-dependent antinociception, the order of potency being (+/-)-8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) > buspirone > or = lesopitron > or = tandospirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-152	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	8-23
8720582-2	1996	All the 5-HT1A receptor agonists tested induced dose-dependent antinociception, the order of potency being (+/-)-8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) > buspirone > or = lesopitron > or = tandospirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	154-163	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	8-23
8742037-3	1996	The properties of the hippocampal 5-HT1A sites labelled by [3H]8-OH-DPAT were not affected by these stressful conditions.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
8742037-4	1996	Moreover, while the sensitivity of 5-HT1A receptors to 8-OH-DPAT in young rats returned to control values after 5 days of cold exposure, old rats still exhibited a significant desensitization of 5-HT1A receptors as compared to naive animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
9219632-1	1996	The effect of repeated treatment with antidepressant drugs imipramine, (+)oxaprotiline and paroxetine on neuronal responsiveness to 5-HT and the 5-HT1A receptor agonist 8-OH-DPAT was examined in the hippocampal slice preparation from the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	169-178	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-151
9219632-2	1996	5-HT and 8-OH-DPAT decreased the amplitude of population spikes evoked in the CA1 cell layer by electrical stimulation of the stratum radiatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	carbonic anhydrase 1	Rattus norvegicus	78-81
9328612-3	1996	In the second study we have compared the effectiveness of intracerebroventricular and intravenous administration of 8-OH-DPAT in frequently used behavioural models of 5-HT1A receptor activation, namely lower lip retraction, body temperature and tail flick responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	167-182
9328615-2	1996	WAY 100635 selectively blocked 5-HT1A receptor-mediated responses of 5-HT, 8-OH-DPAT, lesopitron and 5-CT.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Homo sapiens	31-46
8788480-1	1996	In mice injected with formalin into the hindpaw, the 5-HT1A receptor agonists, 8-OH-DPAT and flesinoxan, equipotently inhibited the early phase (EP) and late phase (LP) of licking.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	53-68
8788510-5	1996	An interesting finding was that blockade [3H]5-CT binding to 5-HT1A receptors by 8-OH-DPAT could only be achieved at very high concentrations of the displacer.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	61-67
8788529-3	1996	By comparison, 8-OH-DPAT, a 5-HT1A receptor selective agonist, has been previously shown to be more potent with an EC50 value of 7.0 microM.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
9025111-7	1996	When tested on pseudo-one-pulse stimulations (5 pulses, 100 Hz), the selective 5-HT1A agonist 8-OHDPAT (1.0 microM) had no effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-85
8788529-6	1996	The potencies of 8-OH-DPAT, BUS, IPSAP and GEP were correlated with their reported affinities for the 5-HT1A receptor (P < 0.01) but not the dopamine D2 receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-108
8788530-4	1996	WAY-100635 had an IC50 (displacement of specific [3H]8-OH-DPAT binding to 5-HT1A receptors in the rat hippocampus) of 1.35 nM and was > 100-fold selective for the 5-HT1A site relative to a range of other CNS receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
9138747-0	1996	Sleep/waking effects following intrathecal administration of the 5-HT(1A) Agonist 8-OH-DPAT alone and in combination with the putative 5-HT(1A) antagonist NAN-190 in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-72
9138747-2	1996	Total slow wave sleep (TSWS) was increased and waking was decreased over the 8-h recording period after the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (38 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	125-163	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-115
9138747-2	1996	Total slow wave sleep (TSWS) was increased and waking was decreased over the 8-h recording period after the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (38 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	165-174	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-115
8522955-5	1996	The 5-HT1A receptor antagonist (S)-(+)N-tert-butyl-3-[4-(2- methoxyphenyl)piperazin-1-yl]-2-phenylpropionamide dihydrochloride [(+)-WAY 100135] did not prevent the inhibition of glutamate release by 5-HT but blocked the inhibition by 8-OH-DPAT of the NMDA/AMPA-evoked cGMP responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	234-243	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8722493-1	1996	The present communication reports on the efficacy of (R)-8-OH-DPAT ((R)-8-hydroxy-2-(di-n-propylamino)tetralin) and (S)-LY-41 ((S)-8-acetyl-2-(di-n-propylamino)tetralin) in displaying the 5-HT1A syndrome and decreasing body temperature after administration of the compound subcutaneously into the gastric ventricle or into the oral cavity in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	188-194
8614270-0	1996	Central administration of 8-OH-DPAT and mCPP stimulates prolactin secretion in ovariectomized, estrogen-treated rats: lack of an effect on tuberoinfundibular dopaminergic neuron activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	prolactin	Rattus norvegicus	56-65
8614270-2	1996	8-OH-DPAT dose-dependently (0.1-10 microgram/rat, icv) stimulated serum PRL levels, and depressed serotonergic neuron activity in 30 min.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	prolactin	Rattus norvegicus	72-75
9025112-6	1996	In addition, 8-OH-DPAT and DOI caused a decrease in plasma CCK levels, whereas the 5-HT1B receptor agonist TFMPP gave rise to an increase in plasma CCK levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-22	cholecystokinin	Rattus norvegicus	59-62
8878215-4	1996	Topical application of the 5-HT1A agonist, 8-hydroxydipropylaminotetralin (8-OH-DPAT) reduces intraocular pressure (IOP).	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	27-33
8684602-4	1996	The 5-HT1A and 5-HT3 agonists, 8-OH-DPAT and 2-methyl-5-HT, respectively, produced only transient responses by themselves and did not interact with PGE2 or NA.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8848492-6	1996	In Experiment 2, the 5-HT1a autoreceptor agonist 8-OH-DPAT (0.25 mg/kg, SC) was used to suppress presynaptic release of 5-HT prior to systemic injection of either fenfluramine (5 mg/kg, IP) or PPA (5, 10, 20, and 30 mg/kg, IP).	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-27
8979820-3	1996	Autoradiography of tissue sections exposed to [3H]-8-OH-DPAT (8-hydroxy-dipropylaminotetraline) or to [125I]cyanopindolol plus isoproterenol showed that 5-HT1A and 5-HT1B receptors, respectively, were present in the superficial SC layers.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	153-159
8741953-0	1996	Circadian rhythm in the response of central 5-HT1A receptors to 8-OH-DPAT in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
8741953-1	1996	Circadian rhythm in the behavioral responsiveness to the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was studied in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
8741953-1	1996	Circadian rhythm in the behavioral responsiveness to the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was studied in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-140	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
7472476-2	1995	The effects were partially mimicked by the 5-HT1A receptor agonist, 8-OH-DPAT, and prevented by the 5-HT1A receptor antagonist, NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
8742464-0	1995	Effect of the CCKA antagonist devazepide on eating stimulated by raphe injection of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	cholecystokinin A receptor	Homo sapiens	14-18
8742464-2	1995	In the present study the CCKA receptor antagonist devazepide (50-200 micrograms kg-1, s.c.) was found reliably to potentiate the feeding response elicited by dorsal or median raphe injection of the 5-HT1A agonist 8-OH-DPAT (0.2-0.8 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	213-222	cholecystokinin A receptor	Homo sapiens	25-29
8742464-2	1995	In the present study the CCKA receptor antagonist devazepide (50-200 micrograms kg-1, s.c.) was found reliably to potentiate the feeding response elicited by dorsal or median raphe injection of the 5-HT1A agonist 8-OH-DPAT (0.2-0.8 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	213-222	5-hydroxytryptamine receptor 1A	Homo sapiens	198-204
8925288-0	1995	Serotonin and 8-OH-DPAT reduce excitatory transmission in rat hippocampal area CA1 via reduction in presumed presynaptic Ca2+ entry.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	carbonic anhydrase 1	Rattus norvegicus	79-82
8925288-0	1995	Serotonin and 8-OH-DPAT reduce excitatory transmission in rat hippocampal area CA1 via reduction in presumed presynaptic Ca2+ entry.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	carbonic anhydrase 2	Rattus norvegicus	121-124
8925288-1	1995	The effect of 5-HT and its 1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on excitatory transmission in CA1 pyramidal cells was studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-85	carbonic anhydrase 1	Rattus norvegicus	128-131
8925288-1	1995	The effect of 5-HT and its 1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on excitatory transmission in CA1 pyramidal cells was studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	carbonic anhydrase 1	Rattus norvegicus	128-131
8925288-5	1995	Both 5-HT and 8-OH-DPAT reduced this Ca2+ entry.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	carbonic anhydrase 2	Rattus norvegicus	37-40
8786639-6	1995	The comparative studies on the in vivo responses induced by MKC-242 and the 5-HT1A-receptor full agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) showed that MKC-242 and 8-OH-DPAT had similar efficacy at presynaptic 5-HT1A receptors, whereas the former had less efficacy than the latter at postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
8786639-6	1995	The comparative studies on the in vivo responses induced by MKC-242 and the 5-HT1A-receptor full agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) showed that MKC-242 and 8-OH-DPAT had similar efficacy at presynaptic 5-HT1A receptors, whereas the former had less efficacy than the latter at postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
8786639-6	1995	The comparative studies on the in vivo responses induced by MKC-242 and the 5-HT1A-receptor full agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) showed that MKC-242 and 8-OH-DPAT had similar efficacy at presynaptic 5-HT1A receptors, whereas the former had less efficacy than the latter at postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Rattus norvegicus	227-233
8786639-6	1995	The comparative studies on the in vivo responses induced by MKC-242 and the 5-HT1A-receptor full agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT) showed that MKC-242 and 8-OH-DPAT had similar efficacy at presynaptic 5-HT1A receptors, whereas the former had less efficacy than the latter at postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Rattus norvegicus	227-233
8657830-0	1995	Discriminative stimulus effects of the 5HT1A agonist 8-OH-DPAT: attenuation by mu but not by kappa opioids.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-44
7473172-0	1995	A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-75
7473172-5	1995	The potency of agonists in generalizing to 8-OH-DPAT correlated significantly (P < .05) with their affinity at rat hippocampal 5-HT1A receptors in vitro (r = .78), and with their potency to induce hypothermia in the rat (r = .96).	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	130-136
8602897-4	1995	The intravenous administration of the selective 5-HT1A agonist 8-OH-DPAT (30 micrograms/kg) and the 5-HT1 agonist TFMPP (0.5 mg/kg) reduced the 5-hydroxyindole signal by 23% and 18%, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	48-54
8602897-5	1995	Pretreatment with the 5-HT1A antagonist (+)WAY100135 (0.5 mg/kg IV) 30 minutes before the injection of the agonists, blocked the effect of 8-OH-DPAT but not that of TFMPP.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
8577395-2	1995	Further, this 8-OH-DPAT-induced inhibition of forskolin-stimulated activity was significantly attenuated after pre-exposure to 5-HT (10 microM) for 12 h. Spiperone (10 microM), a 5-HT1A and 5-HT2A antagonist, prevented 5-HT-induced desensitization of 5-HT1A receptor, but a selective 5-HT2A receptor antagonist, ketanserin, did not.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	179-191
8574685-3	1995	A dose of 100 micrograms/kg 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), an agonist at 5-HT1A receptors, reduced hippocampal extracellular 5-HT concentrations to the same extent in rats repeatedly given saline or citalopram.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
8574685-3	1995	A dose of 100 micrograms/kg 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), an agonist at 5-HT1A receptors, reduced hippocampal extracellular 5-HT concentrations to the same extent in rats repeatedly given saline or citalopram.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
8566173-2	1995	We now report that the 5-HT1A receptor agonist R(+)-8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT) is also capable of stimulating [3H]thymidine incorporation into SCLC GLC-8 cells, although with lower efficacy than 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Homo sapiens	23-38
8566173-4	1995	The 5-HT1A receptor antagonists spiperone and SDZ 216-525 completely abolished the effect of 8-OH-DPAT (IC50 30 nM for both drugs) behaving as pure antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
8564262-9	1995	Ionophoresis of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (5-30 nA) increased the firing rate of 19 and decreased that of 67 of the 104 vagal neurones tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
8564262-9	1995	Ionophoresis of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (5-30 nA) increased the firing rate of 19 and decreased that of 67 of the 104 vagal neurones tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
7671319-5	1995	Spiperone and NAN-190, antagonists to 5-HT1A receptor subtype, abolished the serotonin effects on calcium signaling, whereas an agonist to 5-HT1A receptor, 8OHDPAT, mimicked the serotonin-like action on the diminution of the intracellular calcium contents.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-163	5-hydroxytryptamine receptor 1A	Homo sapiens	139-154
7558717-9	1995	Inhibition studies with [3H] 5-HT plus 100 nM 8-OH-DPAT (which inhibits binding to 5-HT1A receptors only) representing total binding, indicated that no further displacement occurred when ligands preferentially selective for 5-HT1B, 5-HT1D alpha,1D beta, or 5-HT2C were tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	83-89
7562940-4	1995	All compounds showed high affinity at 5-HT1A sites (8.10 < or = pKis < or = 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses.	8-Hydroxy-2-(di-n-propylamino)tetralin	195-204	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44
8748396-9	1995	However, the data question the specificity of putative cognitive impairments reported in many previous studies with the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	120-126
8548311-0	1995	Sleep effects following intrathecal administration of the 5-HT1A agonist 8-OH-DPAT and the NMDA antagonist AP-5 in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
8548311-3	1995	The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (38 nmol) increased total slow wave sleep (TSWS) and decreased waking over the 8 h recording period.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8548311-3	1995	The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (38 nmol) increased total slow wave sleep (TSWS) and decreased waking over the 8 h recording period.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8549624-8	1995	Thus, the data suggest that the selective 5-HT1A receptor agonist 8-OH-DPAT may augment gastric secretory function via an adrenal-dependent mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
7545820-0	1995	Gender and estrous cycle effects of the 5-HT1A agonist, 8-OH-DPAT, on hypothalamic serotonin.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
7498319-5	1995	In the hippocampus and lateral septum, the very dense [3H]5-CT binding was displaced with high affinity by the 5-HT1A receptor selective agonist 8-hydroxy-dipropylaminotetralin ((+/-)-8-OH-DPAT), dihydroergotamine and 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-193	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
7498319-7	1995	The affinity of agonists, taken together with the fact that the distribution of these [3H]5-CT sites overlaps that of [3H]8-OH-DPAT binding sites in serial sections, suggest that these sites correspond to 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	205-211
8570018-3	1995	In hippocampal slices from developing rats and in hippocampal neurons, carbachol enhanced the accumulation of IP3 and this response was partially inhibited by 8-OH-DPAT with a potency compatible with the affinity of this agonist for 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	159-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	233-239
8532191-4	1995	The spontaneous firing rate of serotoninergic neurons recorded in brain stem slices and its inhibition due to 5-HT1A autoreceptor stimulation by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were similar in adrenalectomized rats and sham-operated animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-184	5-hydroxytryptamine receptor 1A	Rattus norvegicus	110-116
8532191-4	1995	The spontaneous firing rate of serotoninergic neurons recorded in brain stem slices and its inhibition due to 5-HT1A autoreceptor stimulation by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were similar in adrenalectomized rats and sham-operated animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	186-195	5-hydroxytryptamine receptor 1A	Rattus norvegicus	110-116
8532191-8	1995	Complementary autoradiographic experiments showed that [3H]8-OH-DPAT specific binding to 5-HT1A sites in the dorsal raphe nucleus (and the hippocampus) was not significantly altered following adrenalectomy and exposure of brain stem slices to corticosterone.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
7501649-2	1995	The 5-HT1A agonists 8-OH-DPAT (4-16 nmol) and BAY-R-1531 (4-16 nmol) raised the threshold of aversive electrical stimulation in a dose-dependent way.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7501649-4	1995	Previous intra-DPAG administration of the 5-HT1A receptor blocker NAN-190 (40 nmol) antagonized the antiaversive effect of 8-OH-DPAT (8 nmol), whereas pretreatment with the 5-HT2A receptor blocker spiperone (10 nmol) antagonized the effect of DOI (16 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	123-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
7501680-1	1995	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reduces the activity of brain 5-HT neurons via somatodendritic autoreceptors located in the midbrain raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
7501680-1	1995	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reduces the activity of brain 5-HT neurons via somatodendritic autoreceptors located in the midbrain raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-67	POU class 6 homeobox 1	Rattus norvegicus	104-111
7501680-1	1995	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reduces the activity of brain 5-HT neurons via somatodendritic autoreceptors located in the midbrain raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
7501680-1	1995	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reduces the activity of brain 5-HT neurons via somatodendritic autoreceptors located in the midbrain raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	POU class 6 homeobox 1	Rattus norvegicus	104-111
8539333-2	1995	5-HT1A receptors have been cloned and a variety of selective agonists, such as the aminotetraline 8-OH-DPAT and the pyrimidinylpiperazine ipsapirone, have become available.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6
8539429-8	1995	The sensitivity of the 5-HT1A receptors involved in the 8-OH-DPAT induced hypothermia was diminished.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	23-29
8521904-8	1995	Taken together, these results indicate that chronic ethanol exposure differentially alters sensitivity to several pharmacological effects of the 5-HT1A receptor ligand 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-151
7636750-6	1995	Repeated fluoxetine treatment attenuated the ability of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to decrease 5-HT release in both the striatum and hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
7636750-6	1995	Repeated fluoxetine treatment attenuated the ability of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to decrease 5-HT release in both the striatum and hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
7545820-2	1995	Consistent with its action at the somatodendritic 5-HT1A autoreceptor, 8-OH-DPAT decreased the 5-HIAA/5-HT ratio, but the decrease was least evident in proestrous females and in males.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-56
8524978-6	1995	The 5HT1A agonist 8-OH-DPAT produced drug-appropriate responding at higher doses (0.3-1.0 mg/kg), whereas much lower doses (0.003-1.0 mg/kg) antagonized the methamphetamine stimulus.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	4-9
8566108-2	1995	[3H]8-Hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) was used to label 5-HT1A receptors in the brain stem region containing the dorsal raphe nucleus and in the frontal cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
8566121-2	1995	WAY-100635 displaced specific binding of the 5-HT1A radioligand, [3H]8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), to rat hippocampal membranes with a pIC50 of 8.87.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
8566121-2	1995	WAY-100635 displaced specific binding of the 5-HT1A radioligand, [3H]8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), to rat hippocampal membranes with a pIC50 of 8.87.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
7540664-5	1995	Preincubation of transfected HeLa cell membranes with Ab-2 antibodies revealed two affinity binding sites of the 5-HT1A receptor (KDH = 0.54 +/- 0.09 nM and KDL = 13.74 +/- 4.9 nM) for the agonist 8-hydroxy-2-(di-n-[3H]propylamino) tetralin ([3H]8-OH-DPAT) binding, but Ab-1 and Ab-12 revealed only one site (KD of approximately 2.5 nM).	8-Hydroxy-2-(di-n-propylamino)tetralin	242-255	5-hydroxytryptamine receptor 1A	Homo sapiens	113-128
7566671-1	1995	The prolactin and behavioral responses elicited by the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) were examined in male rats previously exposed to chronic cocaine (15 mg/kg, i.p., b.i.d., 7 days) or saline.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
7566671-1	1995	The prolactin and behavioral responses elicited by the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) were examined in male rats previously exposed to chronic cocaine (15 mg/kg, i.p., b.i.d., 7 days) or saline.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
7562606-20	1995	Under current clamp, both 5-HT and 8-OH-DPAT decreased the amplitude of the after-hyperpolarization (AHP) that followed action potentials, indicating involvement of a 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	167-173
7662151-2	1995	The 5-HT1A agonist 8-OH-DPAT was microinjected into the region of the DRN either before exposure to IS or before testing for fear conditioning and escape learning conducted 24 hr later.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
7477436-4	1995	Electrophysiological recordings performed 24 h after the last injection showed that the potency of the 5-HT1A receptor agonist, 8-OH-DPAT, to depress the firing of serotoninergic neurons in the dorsal raphe nucleus within brain stem slices was significantly reduced as early as after a 3-day treatment with either drug.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	103-109
7582494-9	1995	The effects of MKC-242 and 8-OH-DPAT in the hypothalamus were antagonized by pretreatment with WAY100135 (10 mg kg-1), a silent 5-HT1A receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
7758118-5	1995	These effects were reproduced by the selective 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	47-62
7758118-6	1995	Serotonin- or 8-OH-DPAT-induced increase in proliferation could be blocked by the 5-HT1A receptor antagonists (+)WAY 100135 and propranolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	82-97
7760052-7	1995	The pharmacological binding profile of [3H]WAY-100635 was closely correlated with that of [3H]8-OH-DPAT, which is consistent with the labelling of 5-hydroxytryptamine1A (5-HT1A) sites in rat hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	147-168
7760052-7	1995	The pharmacological binding profile of [3H]WAY-100635 was closely correlated with that of [3H]8-OH-DPAT, which is consistent with the labelling of 5-hydroxytryptamine1A (5-HT1A) sites in rat hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-176
7791116-3	1995	In contrast, the prototypical 5-HT1A agonist 8-OH-DPAT displayed low affinity at each of these sites (pKi < 5.5).	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
7791116-10	1995	This difference probably reflects its D2 antagonist properties because the induction of STFs by 8-OH-DPAT was, in contrast to its induction of hypothermia and corticosterone secretion, blocked by the preferential D2 antagonist haloperidol.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	solute carrier family 3 member 1	Rattus norvegicus	38-40
7791133-9	1995	8-OH-DPAT (5-HT1A agonist) administered i.c.v.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	11-17
7566497-4	1995	The BMY7378- and 8-OH-DPAT-induced inhibition of 5-HT release were reversed by a 40 min pre-treatment with either (+/-)pindolol (8 mg/kg, s.c.) or WAY-100635 (0.3 mg/kg, s.c.), to block 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Homo sapiens	186-192
7675121-11	1995	The selective 5-HT1A receptor agonist 8-OH-DPAT also inhibited the firing of MRN (n = 5) and DRN (n = 12) neurones and with equal potency (MRN ED50, 1.32 +/- 0.40 microgram/kg i.v.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
7667330-6	1995	Further, a correlation analysis across each of the above agonists, as well as 8-OH-DPAT, buspirone, and (+)-flesinoxan, revealed a significant correlation for their relative potency in augmenting punished responding and their affinity for 5-HT1A receptors in vitro (r = +0.95, p < 0.001).	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Homo sapiens	239-245
7667347-5	1995	The 8-OH-DPAT, a classical 5-HT1A agonist, and alpha-methyl-5-hydroxytryptamine, a highly selective 5-HT2 agonist, injected directly into th e inferior colliculus also produced clear antiaversive effects in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
7619321-4	1995	In a subsequent experiment, this preference was attenuated by coadministration of the 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2(di-n-propylamino)tetralin during reexposure, suggesting that CCK interacts with 5-HT to modify incentive value.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-162	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-107
7783126-1	1995	In order to explore the structural requirements for high 5-HT1A affinity, a series of aryl-substituted N1-phenylpiperazines were synthesized and evaluated for their ability to displace [3H]-8-OH-DPAT from its specific binding sites in rat frontal cortex homogenates.	8-Hydroxy-2-(di-n-propylamino)tetralin	190-199	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
7647978-4	1995	5-HT</compound-id>, 8-OH-DPAT, buspirone and SR 57746A, a new selective 5-HT1A receptor agonist, displaced [3H]-8-OH-DPAT from specific binding sites in rat hippocampus membranes (Ki, nM; 1.8, 1.2, 15, 3.1 respectively) and stimulated rat defaecation dose-dependently.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
7647978-10	1995	The putative 5-HT1A receptor antagonist, pindolol, injected s.c. or i.c.v., significantly reduced the defaecation induced by systemically administered 8-OH-DPAT, buspirone or SR 57746A, but not 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
7608342-2	1995	The 5-HT1A receptor has been shown to mediate motoneuron responses in spinal reflex pathways using the highly selective 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	144-153	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
7608342-2	1995	The 5-HT1A receptor has been shown to mediate motoneuron responses in spinal reflex pathways using the highly selective 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	144-153	5-hydroxytryptamine receptor 1A	Homo sapiens	120-135
7675949-2	1995	The 5-HT1A receptor agonists 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and buspirone decreased immobility in the FST.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7675949-2	1995	The 5-HT1A receptor agonists 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and buspirone decreased immobility in the FST.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7675949-3	1995	The effect of 8-OH-DPAT was blocked by the 5-HT1A receptor antagonists NAN 190, BMY 7378 and pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
7675952-5	1995	Treatment with the 5-HT1A receptor agonist, 8-OH-DPAT (0.5 mg/kg, SC), did not affect PPI in either group but caused a marked increase in ASR magnitude in sham-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
7624830-4	1995	The firing activity of dorsal raphe 5-HT neurons was also reduced by 5-HT, 2-methyl-5-HT and the 5-HT1A agonist 8-OH-DPAT applied by microiontophoresis.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
7624830-6	1995	did not antagonize the inhibitory effect of the three 5-HT agonists on 5-HT neuronal firing activity, only that of 8-OH-DPAT was attenuated by the 5-HT1A antagonist (+) WAY 100135.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	147-153
7552245-7	1995	These were the only rCMRglc effects buspirone had in common with the potent 5-HT1A agonist DPAT and suggest that low dose buspirone activates preferentially 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
7619321-4	1995	In a subsequent experiment, this preference was attenuated by coadministration of the 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2(di-n-propylamino)tetralin during reexposure, suggesting that CCK interacts with 5-HT to modify incentive value.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-162	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
7619321-4	1995	In a subsequent experiment, this preference was attenuated by coadministration of the 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2(di-n-propylamino)tetralin during reexposure, suggesting that CCK interacts with 5-HT to modify incentive value.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-162	cholecystokinin	Rattus norvegicus	198-201
7714755-9	1995	The action of 8-hydroxy-2-(di-n-propylamino)tetralin was blocked by (-)-tertatolol (ID50 = 4.5 mg/kg), a novel 5-HT1A receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
7650876-4	1995	The 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino) tetralin (10-100 microM) and buspirone (50 microM) attenuated the anoxia-induced decrease in protein synthesis in the slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8540763-3	1995	In a similar manner, the 5-HT1A agonists, gepirone and 8-OH-DPAT, were found to facilitate the downregulation of beta-adrenoceptors induced by sertraline.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
7620698-3	1995	The selective 5-HT1A receptor agonist, (+)-8-OH-DPAT (1.0 microM) decreased stimulated 5-HT release to 31 +/- 3% of controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
7781583-9	1995	Furthermore, comparison of the specific binding of [3H]8-OH-DPAT to 5-HT1A receptors functionally coupled to G proteins with that of [3H]WAY 100635 to all 5-HT1A receptor binding sites (i.e. coupled and uncoupled with regard to G proteins) revealed no significant change in rats treated with either SSRI.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	68-74
7552245-10	1995	The topographic distribution and direction of rCMRglc changes by high doses of buspirone differ from those produced by the 5-HT1A agonist DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	138-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
7753891-1	1995	In the present experiments, the ability of the 5-HT1A agonist, 8-OH-DPAT, to inhibit lordosis was determined in ovariectomized hamsters and rats under various hormonal conditions.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
7753891-4	1995	Results indicate that the 5-HT1A agonist, 8-OH-DPAT, effectively inhibited lordosis in female hamsters, as well as female rats, under varied hormonal conditions.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
7748502-0	1995	8-OH-DPAT impairs spatial but not visual learning in a water maze by stimulating 5-HT1A receptors in the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
7748502-1	1995	The effect of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, on spatial and non-spatial learning in a water maze was studied using two tasks of equal difficulty, with the same motor, motivational and reinforcement demands.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
7853210-9	1995	Interestingly, the injection of 8-OH-DPAT into the striatum, where 5-HT1A receptors are hardly detectable, or a lateral ventricle, also yielded dose-dependent reduction in both the firing rate of serotonergic DRN neurons and the USV response.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
7853210-12	1995	As shown by the autoradiographic labeling by [3H]8-OH-DPAT at distance from its injection site in the dorsal hippocampus, the diffusion of 5-HT1A receptor agonists (from injected areas in the forebrain to the DRN where they directly inhibit the electrical activity of serotonergic neurons) more likely accounted for their anxiolytic-like effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	139-145
7781583-12	1995	Thus, the potency of the 5-HT1A autoreceptor agonist, 8-OH-DPAT, to depress the firing of serotonergic neurons in brain stem slices was significantly reduced as soon as after a 3-day treatment with either SSRI.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
7753334-0	1995	Differential sites of action of 8OHDPAT, a 5HT1A agonist, on ACTH and PRL secretion in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-48
7753334-0	1995	Differential sites of action of 8OHDPAT, a 5HT1A agonist, on ACTH and PRL secretion in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-39	prolactin	Rattus norvegicus	70-73
7753334-2	1995	In order to explore the possible neuroanatomical structures involved in this interaction, we examined ACTH and PRL responses to intracerebral infusions of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8OHDPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	182-221	prolactin	Rattus norvegicus	111-114
7753334-2	1995	In order to explore the possible neuroanatomical structures involved in this interaction, we examined ACTH and PRL responses to intracerebral infusions of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8OHDPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	182-221	5-hydroxytryptamine receptor 1A	Rattus norvegicus	159-164
7753334-6	1995	Infusion of 8OHDPAT (1 microgram/microliter/15 min) into the dorsal raphe nucleus induced a slow elevation of ACTH release but was ineffective on PRL secretion while infusion of 8OHDPAT into the PVN induced a moderate elevation of both ACTH and PRL.	8-Hydroxy-2-(di-n-propylamino)tetralin	12-19	prolactin	Rattus norvegicus	245-248
7753334-6	1995	Infusion of 8OHDPAT (1 microgram/microliter/15 min) into the dorsal raphe nucleus induced a slow elevation of ACTH release but was ineffective on PRL secretion while infusion of 8OHDPAT into the PVN induced a moderate elevation of both ACTH and PRL.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-185	prolactin	Rattus norvegicus	245-248
7753334-7	1995	After bilateral destruction of the PVN, PRL response to 8OHDPAT (0.1 and 0.25 mg/kg) was markedly potentiated.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-63	prolactin	Rattus norvegicus	40-43
7746801-11	1995	It is concluded that effects by 8-OH-DPAT on spontaneous motor activity in the reserpine treated rat primarily are due to stimulation of postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	150-156
7596027-5	1995	In both the pulmonary artery and aorta, 8-OH-DPAT, a 5-HT1A selective agonist, produced a concentration-dependent contraction.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
7712172-8	1995	Inhibition of epileptiform bursts was also achieved with the selective 5-HT1A agonist 8-hydroxydipropyl-amino-tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
7606493-0	1995	Anxiolytic effect of the 5-HT1A compounds 8-hydroxy-2-(di-n-propylamino) tetralin and ipsapirone in the social interaction paradigm: evidence of a presynaptic action.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
7606493-1	1995	This study analyses at which site, pre- or postsynaptic, the 5-HT1A ligands--8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and ipsapirone--induce their anxiolytic action.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
7606493-1	1995	This study analyses at which site, pre- or postsynaptic, the 5-HT1A ligands--8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and ipsapirone--induce their anxiolytic action.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
7712201-1	1995	We examined whether the selective 5-hydroxytryptamine 1A (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) injected systemically can act directly on sympathoexcitatory neurons located in the rostral ventrolateral medulla (RVLM) to cause the hypotensive effect of this agent in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
7712201-1	1995	We examined whether the selective 5-hydroxytryptamine 1A (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) injected systemically can act directly on sympathoexcitatory neurons located in the rostral ventrolateral medulla (RVLM) to cause the hypotensive effect of this agent in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-133	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
7712201-3	1995	Microinjections of spiperone and pindolol, 5-HT1A antagonists, into the RVLM inhibited the depressor response to 8-OH-DPAT intravenously injected or injected into the RVLM.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
8773241-7	1995	In RN neurons exhibiting a short-lasting inhibition in the response to 5-HT, the 5-HT1A agonist 8-hydroxy-2(di-n-propyl-amino)tetralin (8-OH-DPAT) induced inhibitory effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
8773241-7	1995	In RN neurons exhibiting a short-lasting inhibition in the response to 5-HT, the 5-HT1A agonist 8-hydroxy-2(di-n-propyl-amino)tetralin (8-OH-DPAT) induced inhibitory effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
7713361-17	1995	8-OH-DPAT, a full 5-HT1A receptor agonist, significantly increased transitions and locomotor activity but not % time.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	18-33
8748667-3	1995	In addition, a significant decrease (approximately 20%) in the binding of [3H]8-OH-DPAT to 5-HT1A receptors and of [125I]GTI to 5-HT1B receptors was also observed in the same spinal area in rhizotomized rats, suggesting that a small proportion of these receptors are also located on primary afferent fibres.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97
8748667-6	1995	Similarly, [3H]8-OH-DPAT binding to 5-HT1A receptors significantly increased (+26%) in the lumbar (but not the cervical) dorsal horn in rats whose noradrenergic systems had been lesioned by DSP-4.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
8903941-3	1995	In membranes containing 5-HT1Dbeta receptors, 5-CT and sumatriptan stimulated binding to a similar extent as 5-HT while yohimbine, metergoline and 8-OHDPAT were partial agonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	147-155	5-hydroxytryptamine receptor 1B	Homo sapiens	24-34
7731493-4	1995	8-Hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) or ipsapirone (10(-5) M) significantly stimulated LHRH release.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-39	gonadotropin releasing hormone 1	Rattus norvegicus	102-106
7731493-4	1995	8-Hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) or ipsapirone (10(-5) M) significantly stimulated LHRH release.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	gonadotropin releasing hormone 1	Rattus norvegicus	102-106
7731493-5	1995	Pharmacological studies have allowed to rule out the possible involvement of alpha 2- or beta-adrenoreceptors, or 5-HT uptake sites, in the stimulatory effect of 8-OH-DPAT on LHRH release, thus demonstrating the specific involvement of 5-HT1A receptors in the stimulation of LHRH release.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	gonadotropin releasing hormone 1	Rattus norvegicus	175-179
7731493-5	1995	Pharmacological studies have allowed to rule out the possible involvement of alpha 2- or beta-adrenoreceptors, or 5-HT uptake sites, in the stimulatory effect of 8-OH-DPAT on LHRH release, thus demonstrating the specific involvement of 5-HT1A receptors in the stimulation of LHRH release.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	5-hydroxytryptamine receptor 1A	Rattus norvegicus	236-242
7731493-5	1995	Pharmacological studies have allowed to rule out the possible involvement of alpha 2- or beta-adrenoreceptors, or 5-HT uptake sites, in the stimulatory effect of 8-OH-DPAT on LHRH release, thus demonstrating the specific involvement of 5-HT1A receptors in the stimulation of LHRH release.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	gonadotropin releasing hormone 1	Rattus norvegicus	275-279
7731493-9	1995	The effects of a pretreatment of cells by P on 8-OH-DPAT-induced LHRH release were tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	gonadotropin releasing hormone 1	Rattus norvegicus	65-69
7731493-10	1995	While 10(-7) M P alone did not stimulate LHRH release, this concentration of steroid potentiated the LHRH response to 10(-5) M 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	gonadotropin releasing hormone 1	Rattus norvegicus	101-105
7550544-0	1995	Attenuation of the fentanyl-induced muscle rigidity by the selective 5HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	69-74
7869825-4	1995	antagonized the hypothermia induced by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (0.5 mg/kg, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	67-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
7869825-4	1995	antagonized the hypothermia induced by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (0.5 mg/kg, s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
7550544-2	1995	The selective 5HT1A receptor agonist 8-OH-DPAT (0.1, 0.3 and 1.0 mg/kg ip) showed only a tendency to attenuate the natural muscle tone.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Homo sapiens	14-28
7777653-5	1995	The 5-HT1A agonist, 8-OH-DPAT, was able to attenuate the adrenocortical responses to acoustic stimulation, conditioned fear, IL-1 alpha, and cocaine administration, with ipsapirone also being effective in reducing the responses to acoustic stimulation and cocaine injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
7777653-5	1995	The 5-HT1A agonist, 8-OH-DPAT, was able to attenuate the adrenocortical responses to acoustic stimulation, conditioned fear, IL-1 alpha, and cocaine administration, with ipsapirone also being effective in reducing the responses to acoustic stimulation and cocaine injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	interleukin 1 alpha	Homo sapiens	125-135
7704614-1	1994	Proestrous rats were infused unilaterally into the median raphe nucleus with 200-2,000 ng of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	113-151	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
7705452-9	1994	Substantial (77%) blockade of [3H]WAY-100635 binding was achieved with the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), and the partial agonists, ipsapirone and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Homo sapiens	75-81
7889298-2	1994	The full and weak partial 5-HT1A agonist ligands [3H]-8-OH-DPAT and [3H]-BMY-7378 were used to characterize the binding parameters of pre- and postsynaptic 5-HT1A binding sites in bovine dorsal raphe and hippocampal membranes, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Bos taurus	156-162
7708935-3	1995	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a selective 5-HT1A agonist, dose dependently (0.25- 1.0 mg/kg i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	64-70
7708935-3	1995	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a selective 5-HT1A agonist, dose dependently (0.25- 1.0 mg/kg i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	64-70
7708935-15	1995	These findings demonstrate that chronic treatment of some antidepressants potentiates 8-OH-DPAT-induced increase in plasma corticosterone, by actions at 5-HT-1A receptors located postsynaptically on 5-HT neurones.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-160
7724701-6	1995	These results support the hypothesis that somatodendritic 5-HT1A autoreceptors within the midbrain raphe subserve the PPI-disruptive effects of systemically administered 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	170-179	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
7964736-9	1994	Moreover, the decrease of 5-HT in the median raphe region by low nanomolar concentrations of 8-OH-DPAT supports the notion that somatodendritic 5-HT release is subject to a local negative feedback mechanism through 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	215-221
7996433-1	1994	Treatment of rats with the serotonin 5-HT1A agonist 8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT, 1 mg/kg s.c.) markedly elevated plasma levels of corticosterone (CORT), adrenocorticotropic hormone (ACTH) and prolactin (PRL); the levels of growth hormone were unaffected.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
7996433-1	1994	Treatment of rats with the serotonin 5-HT1A agonist 8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT, 1 mg/kg s.c.) markedly elevated plasma levels of corticosterone (CORT), adrenocorticotropic hormone (ACTH) and prolactin (PRL); the levels of growth hormone were unaffected.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-91	cortistatin	Rattus norvegicus	169-173
7996433-1	1994	Treatment of rats with the serotonin 5-HT1A agonist 8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT, 1 mg/kg s.c.) markedly elevated plasma levels of corticosterone (CORT), adrenocorticotropic hormone (ACTH) and prolactin (PRL); the levels of growth hormone were unaffected.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
7996433-1	1994	Treatment of rats with the serotonin 5-HT1A agonist 8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT, 1 mg/kg s.c.) markedly elevated plasma levels of corticosterone (CORT), adrenocorticotropic hormone (ACTH) and prolactin (PRL); the levels of growth hormone were unaffected.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	cortistatin	Rattus norvegicus	169-173
7996433-3	1994	Prevention of EEDQ-induced 5-HT1A receptor inactivation by prior treatment with the reversible mixed 5-HT1A/beta-adrenergic antagonist (+/-)pinodolol (30 mg/kg s.c.) blocked the reduction of the CORT response to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	212-221	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
7898677-7	1994	Approximately one third were hyperpolarized by serotonin or the selective serotonin1A receptor agonist, (+/-)-8-hydroxy-2-(di-N-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-148	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-94
7886079-1	1994	It has been previously demonstrated that pretraining injection of 8-hydroxy-2-(di-n-propilamino)tetralin (8-OH-DPAT, a 5-HT1A agonist) impairs conditioned response (CR) in an autoshaping learning task.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
7886079-9	1994	The present data suggest that a) the pretraining effect of 8-OH-DPAT eliciting a decrease in CR can be eliminated by a food magazine training session; and b) presynaptic 5-HT1A receptors are involved in the effect of 8-OH-DPAT on the acquisition and consolidation of learning.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-176
7886079-9	1994	The present data suggest that a) the pretraining effect of 8-OH-DPAT eliciting a decrease in CR can be eliminated by a food magazine training session; and b) presynaptic 5-HT1A receptors are involved in the effect of 8-OH-DPAT on the acquisition and consolidation of learning.	8-Hydroxy-2-(di-n-propylamino)tetralin	217-226	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-176
7886629-6	1994	The specific binding of the radioligand in the hippocampal region, an area rich in 5-HT1A receptor density, was blocked by pretreatment with a dose of (+/-) 8-OH-DPAT (2 mg/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	157-166	5-hydroxytryptamine receptor 1A	Homo sapiens	83-98
7825906-0	1994	Social defeat impairs plasma corticosterone response to the 5-HT1A agonist 8-OH-DPAT in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
7698161-8	1994	p-Chloro-phenylalanine methyl ester was ineffective itself, but potentiated the antiaggressive effect of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamin)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	173-182	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	109-124
7996433-5	1994	Dose-response curves were obtained for 8-OH-DPAT (0.01-3 mg/kg s.c.)-induced elevation of plasma CORT, ACTH and PRL after treatment (24 hr earlier) with vehicle or EEDQ (6 mg/kg s.c.) and analyzed for the extent of receptor reserve.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	cortistatin	Rattus norvegicus	97-101
7996433-6	1994	Whereas substantial receptor reserves were observed for the 8-OH-DPAT rise in plasma CORT (80%) and ACTH (50%), no receptor reserve was seen for the increase in plasma PRL.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	cortistatin	Rattus norvegicus	85-89
7698161-9	1994	The beta-adrenoceptor/5-HT1A receptor antagonist, (-)-penbutolol, reversed the antiaggressive effects of 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-113	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-37
7698163-1	1994	The behavioural response of rats in the high light unfamiliar condition of the social interaction test of anxiety was observed following direct administration of the 5-HT1A receptor agonist, (+/-)-8-hydroxy-dipropylaminotetralin (8-OH-DPAT, 50, 100 or 200 ng) or antagonist tertatolol (3 micrograms) into the median raphe nucleus or dorsal hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	230-239	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
7897596-1	1994	The effects of single and multiple (5, 10, or 15 days) administration of the 5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) (3 mg kg-1, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	92-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
7698186-5	1994	5-HT1A (8-OH-DPAT) and 5-HT2 (DOI) receptor agonists decreased the frequency of attack 15 but not 55 min after i.c.v.	8-Hydroxy-2-(di-n-propylamino)tetralin	8-17	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
7855734-0	1994	5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6
7834389-2	1994	Using this technique together with recordings of tail flick latency (TFL) elicited from lightly anaesthetised rats we have found that the specific 5-HT1a agonist 8-OH DPAT (15, 150, 300 nmol) increases nociceptive responses recorded from single dorsal horn neurones and decreases TFL.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	5-hydroxytryptamine receptor 1A	Rattus norvegicus	147-153
7842512-1	1994	Repeated treatment of primary cultures of fetal rat septal neurons with 5-HT1A receptor agonists (8-OH-DPAT, ipsapirone, gepirone and buspirone) increased choline acetyltransferase activity after 6-7 days in culture.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
7842512-1	1994	Repeated treatment of primary cultures of fetal rat septal neurons with 5-HT1A receptor agonists (8-OH-DPAT, ipsapirone, gepirone and buspirone) increased choline acetyltransferase activity after 6-7 days in culture.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	choline O-acetyltransferase	Rattus norvegicus	155-180
7842512-4	1994	Autoradiographic investigations with [3H]8-OH-DPAT as radioligand and immunocytochemistry with specific anti-choline acetyltransferase antibodies and anti-rat 5-HT1A receptor antibodies showed that 5-HT1A receptors were expressed on septal neurons in culture, notably on the cholinergic neurons identified by their positive staining with anti-choline acetyltransferase antibodies.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	198-204
7843270-1	1994	Induction of lower lip retraction after local infusion of the selective 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the dorsal and median raphe nuclei was measured.	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
11224238-6	1994	For the 5-HT(1A) agonists, the order of potency for attenuating the AMPH discriminative stimulus was 8-OH-DPAT&gt;buspirone&gt;gepirone, similar to their binding affinities at 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Macaca mulatta	8-15
7529925-9	1994	Chronic testosterone propionate also caused an increase in the affinity of [3H]8-OH-DPAT for the 5-HT1A receptor but no corresponding change in the density of 5-HT1A binding sites in the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
7824554-3	1994	Both the unconditioned and conditioned emetic responses were dose-dependently blocked by 8-hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT) and LY228729, agonists at the 5-HT1A subtype of serotonin receptor, but not by the 5-HT3, antagonist tropisetron.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Homo sapiens	168-174
7824554-5	1994	NAN-190, a putative 5-HT1A partial agonist, produced both an antiemetic response when administered before DTG and also attenuated the antiemetic effects of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Homo sapiens	20-26
7532313-6	1994	The 5HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) (0.1-0.2 mg/kg), administered 10 min before testing in the elevated X-maze, had "anxiogenic" actions in non-stressed rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-9
7834355-3	1994	The expression study revealed that 5HT1A mRNA distribution in the hippocampus and prefrontal cortex was consistent with the data of the [3H]8-OH-DPAT binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Homo sapiens	35-40
7820591-4	1994	injection of the 5-HT1A receptor agonist, 8-OH-DPAT, during the dark phase (6 h after lights-off) significantly reduced the extracellular glutamate concentration in the SCN region from baseline levels (38.7 +/- 8.7 and 53.4 +/- 11.2%, respectively, of pretreatment values; P &lt; 0.05).	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Homo sapiens	17-32
7993956-7	1994	In conclusion, the present results confirm our previous results using 8-OH-DPAT as a challenge, and suggest that chronic 5-HT uptake inhibition results in adaptive changes leading to decreased function of the 5-HT1A receptor system.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Homo sapiens	209-224
7821351-0	1994	Role of 5-HT1A receptors in the antinociceptive action of 8-hydroxy-2-(di-n- propylamino)tetralin in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
7821351-1	1994	The role of 5-HT1A receptors in the antinociceptive action of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was investigated by using the shock titration test in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-18
7821351-1	1994	The role of 5-HT1A receptors in the antinociceptive action of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was investigated by using the shock titration test in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-18
7821351-5	1994	The results suggest that 8-OH-DPAT inhibits nociceptive responses by stimulating postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
7816892-1	1994	The densities of serotonin1A (5-HT1A) receptors, labeled with [3H]8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), were examined in the CNS of alcohol-naive adult male alcohol-preferring (P) and -nonpreferring (NP) rats using quantitative autoradiography.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
7862933-4	1994	In drug discrimination studies, pigeons were trained to discriminate injections of the 5-HT1A agonist 8-OH-DPAT (0.3 mg/kg) from saline.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Homo sapiens	87-93
7862933-9	1994	All compounds substituted for 8-OH-DPAT in the drug discrimination procedure, suggestive of 5-HT1A agonist activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98
7988650-3	1994	At 25 micrograms/kg, 8-hydroxy-2-(di-n-propylamino)tetralin, an agonist at 5-HT1A receptors, reduced cortical 5-HT output in controls but not in animals treated chronically with citalopram whereas 50 micrograms/kg reduced 5-HT output in both groups.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-59	5-hydroxytryptamine receptor 1A	Homo sapiens	75-81
7518496-6	1994	Adenylyl cyclase activity in CHO-K1 cells transiently transfected with GP2-7 was stimulated by several analogues of 5-HT with the following order of potency: 5-CT &gt; 5-HT = 5-MeOT &gt; dipropyl-5-CT &gt; 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	206-215	pancreatic secretory granule membrane major glycoprotein GP2	Cricetulus griseus	71-76
8071858-2	1994	Administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) dose-dependently increased ACh efflux and motor activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Cavia porcellus	22-28
8071858-3	1994	The effects of 8-OH-DPAT on ACh efflux may be mediated by activation of 5-HT1A receptors but are unlikely to be achieved through 5-HT1A receptors on cholinergic nerve terminals, because administering 8-OH-DPAT through the dialysis probe had no effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Cavia porcellus	72-78
7531300-6	1994	The hypothermic response to the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.15 mg/kg, s.c.) was significantly attenuated after chronic setraline treatment, whereas tianeptine was inactive at the 2 doses tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
7531300-6	1994	The hypothermic response to the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.15 mg/kg, s.c.) was significantly attenuated after chronic setraline treatment, whereas tianeptine was inactive at the 2 doses tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
7952867-2	1994	The effect of acute and repeated treatment with 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A receptor ligand, on excitatory amino acid-mediated synaptic transmission was examined in the stratum radiatum CA1 region of the dorsal hippocampus of alert, gently restrained, rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-86	carbonic anhydrase 1	Rattus norvegicus	219-222
7845547-9	1994	The 5-HT1A antagonist (S)-UH-301 [(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin] was without effect on avoidance performance but antagonized the effect of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	158-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7955334-4	1994	To investigate the role of 5-HT1A receptors in these differences, we labelled 5-HT1A binding sites autoradiographically with [3H]8-OH-DPAT 4 months after i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
7955347-7	1994	Both 5-HT1 (8-OH-DPAT, buspirone) and 5-HT2 agonists (DOI, alpha-methyl-5-HT) increased the RF but only the 5-HT1A agonist 8-OH-DPAT was efficient at submicromolar concentrations.	8-Hydroxy-2-(di-n-propylamino)tetralin	123-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
8021490-9	1994	Inhibition by metitepine is reversed by 5HT and by the selective 5HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Homo sapiens	65-79
7945981-4	1994	Both 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; the agonist of serotonin 5-HT1A receptors) and tropisetron (ICS 205-930, the antagonist of 5-HT3 receptors) reduced ETOH consumption in high-preferring, sham-lesioned rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	5-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
7945981-6	1994	Therefore, it seems that 5-HT1A autoreceptors are critically involved in 8-OH-DPAT action, while 5-HT3 receptor sites responsible for tropisetron action are located beyond the 5-HT system.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
7921613-10	1994	The locomotor activity increasing effect of 1.0 mg kg-1 8-OH-DPAT was blocked by the selective 5-HT1A antagonist (S)-UH-301 (3.0 and 10.0 mg kg-1), but not by (-)-alprenolol (15.0 mg kg-1).	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Cavia porcellus	95-101
7969810-6	1994	8-OH-DPAT induced depression of the reflex (IC50 0.85, 0.7-1.0 microM, geometric mean and 95% confidence limits) was blocked by spiperone (1 microM, apparent pA2 6.3) suggesting mediation via 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	192-198
7969811-2	1994	Selective 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), flesinoxan, buspirone and ipsapirone significantly decreased the power value of 7-9 Hz band activity and the median frequency of wr-RSA.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
7969811-2	1994	Selective 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), flesinoxan, buspirone and ipsapirone significantly decreased the power value of 7-9 Hz band activity and the median frequency of wr-RSA.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
7969811-4	1994	The 5-HT1A antagonists, (-)pindolol, (-)propranolol and spiperone, inhibited the effect of 8-OH-DPAT on wr-RSA.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7945962-2	1994	It was found that the 5-HT1A agonist 8-OH-DPAT and the alpha 2 adrenoceptor antagonist, yohimbine were effective in reversing the sexual inhibition resulting from sexual exhaustion.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
7953629-3	1994	injections of a combination of subthreshold doses of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (a 5-HT1A receptor agonist) at 30 micrograms/kg and mecamylamine (a nicotinic cholinergic receptor antagonist) a 2500 micrograms/kg greatly impaired WM navigation to a hidden platform and slightly, but not statistically significantly, impaired WM navigation to a visible platform.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	107-113
8014870-3	1994	Systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) produced complete reductions of 5-HT release.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
8014870-3	1994	Systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) produced complete reductions of 5-HT release.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-104	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
8014870-4	1994	The effects of systemic 8-OH-DPAT on 5-HT release were blocked completely by systemic administration of the 5-HT/beta adrenergic receptor antagonist, (-)-propranolol, but not by the beta-1 adrenergic receptor antagonist betaxolol or the beta-2 adrenergic receptor antagonist ICI-118,551.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	adrenoceptor beta 2	Rattus norvegicus	237-263
7532312-5	1994	Our findings tend to indicate that increased SWS after low doses of 8-OH-DPAT depends upon the activation of inhibitory somatodendritic 5-HT1A receptors, while increased W after higher doses of the compound is related to stimulation of postsynaptic receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
7862892-0	1994	Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
7862892-0	1994	Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
7522172-0	1994	Intracisternally injected galanin-(1-15) modulates the cardiovascular responses of galanin-(1-29) and the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Homo sapiens	106-121
8069671-2	1994	In the pharmacological study, the administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 60 micrograms/kg b.wt., i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	80-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
8069671-2	1994	In the pharmacological study, the administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 60 micrograms/kg b.wt., i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
8069671-11	1994	These studies indicate that the pre-synaptic mechanism of 8-OH-DPAT-induced hyperphagia may require specific circulating levels of insulin and glucose, which are regulated via post-synaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	190-196
8158130-3	1994	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 20 microM), a 5-HT1A agonist, increased ACh levels, whereas 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline (CGS-12066B; 100 microM), a 5-HT1B agonist, decreased it.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
8158130-3	1994	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 20 microM), a 5-HT1A agonist, increased ACh levels, whereas 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline (CGS-12066B; 100 microM), a 5-HT1B agonist, decreased it.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1B	Rattus norvegicus	210-216
8158130-3	1994	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 20 microM), a 5-HT1A agonist, increased ACh levels, whereas 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline (CGS-12066B; 100 microM), a 5-HT1B agonist, decreased it.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
8158130-3	1994	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 20 microM), a 5-HT1A agonist, increased ACh levels, whereas 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline (CGS-12066B; 100 microM), a 5-HT1B agonist, decreased it.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1B	Rattus norvegicus	210-216
8158132-2	1994	The changes in extracellular cAMP concentration were monitored in response to forskolin and the serotonin 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	130-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	96-121
8158133-1	1994	The selective serotonin (5-HT) agonist 8-hydroxydipropylaminotetralin (8-OH-DPAT) has been extensively used to characterize the physiological, biochemical, and behavioral features of the 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	187-193
8158133-3	1994	The saturation binding isotherms of [3H]8-OH-DPAT (free ligand from 200 pM to 160 nM) revealed high-affinity 5-HT1A receptors (KH = 0.7-0.8 nM) and low-affinity (KL = 22-36 nM) binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
8158133-5	1994	When the high-affinity sites were labeled with a 1 nM concentration of [3H]8-OH-DPAT, the competition curves of agonist and antagonist drugs were best fit to a two-site model, indicating the presence of two different 5-HT1A binding sites or, alternatively, two affinity states, tentatively designated as 5-HT1AHIGH and 5-HT1ALOW.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	217-223
7916383-4	1994	Moreover, the (+)-3-PPP effect was antagonized by the dopamine D2 antagonist sulpiride, whereas pretreatment with the 5-HT1A agonist 8-OH-DPAT and the alpha-adrenoceptor antagonist phenoxybenzamine did not exert any significant effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	133-142	5-hydroxytryptamine receptor 1A	Rattus norvegicus	118-124
7936105-8	1994	Forepaw treading and flat body posture responses to the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) were not altered by the stressors, but both of them slightly amplified 8-OH-DPAT-induced hypothermia.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
7936106-5	1994	The stereoselective antagonism by the pindolol enantiomers supports the proposal that 8-OH-DPAT-induced increase of waking and decrease of SWS depends on the activation of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	172-178
8084487-4	1994	This difference may have been due to a decrease in somatodendritic autoreceptor sensitivity, since the response to a low dose of the 5-HT1A agonist 8-OH-DPAT (25 micrograms/kg i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 1A	Rattus norvegicus	133-139
8155646-4	1994	The concentration of agonist producing half-maximal binding of [32P]-AA-GTP by G(i)alpha-3 [5-HT, 48 +/- 1 nM; 8-OH-DPAT, 28 +/- 1 nM; ipsapirone, 22 +/- 6 nM] compared to G(i)alpha-2 [5-HT, 124 +/- 38 nM; 8-OH-DPAT, 40 +/- 1 nM, ipsapirone, 82 +/- 7 nM] was lower with all agonists except rauwolscine, where the EC50"s were similar (G(i)alpha-2, 604 +/- 145 nM; Gi alpha-3, 708 +/- 130 nM).	8-Hydroxy-2-(di-n-propylamino)tetralin	206-215	G protein subunit alpha i3	Homo sapiens	79-90
7548638-5	1994	Also the selectivity of 8-OH-DPAT for the 5-HT1A receptor is accounted for.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Homo sapiens	42-57
7855220-1	1994	Administration of the serotonin (5-HT)1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) facilitates the expression of masculine sexual behavior in male and female rats as well as in male rhesus monkeys and inhibits lordosis behavior in female rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-49
7855220-1	1994	Administration of the serotonin (5-HT)1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) facilitates the expression of masculine sexual behavior in male and female rats as well as in male rhesus monkeys and inhibits lordosis behavior in female rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-49
7909554-4	1994	STFs elicited by the 5-HT1A agonist 8-OH-DPAT were potently blocked by the alpha 1-adrenoceptor antagonist prazosin, as well as by WB 4101 and 5-methylurapidil, antagonists with a preference for the alpha 1A-subtype of adrenoceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-27
7909555-4	1994	Whereas the 5-HT1A receptor agonists 8-OH-DPAT and WY 48,723 dose-dependently elicited STFs, (+)-flesinoxan was only weakly active and LY 165,163 was ineffective.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-18
7909555-6	1994	Nevertheless, (+)-flesinoxan and LY 165,163 mimicked 8-OH-DPAT and WY 48,723 in eliciting a pronounced rise in plasma corticosterone and a marked hypothermia: these actions were blocked by the 5-HT1A receptor antagonist, (-)-alprenolol, but they were not affected by the alpha 1-antagonist prazosin.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
8029267-3	1994	All drugs caused a dose-related decrease in USV, but only buspirone and 8-OH-DPAT induced a dose-related increase in CORT.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	cortistatin	Rattus norvegicus	117-121
8029267-4	1994	We suggest that the seemingly paradoxical effects of buspirone and 8-OH-DPAT, that is, the decrease in USV and the concomitant increase in plasma CORT, are due to the fact that these two drugs act as full agonists at both pre- and postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	cortistatin	Rattus norvegicus	146-150
8029267-4	1994	We suggest that the seemingly paradoxical effects of buspirone and 8-OH-DPAT, that is, the decrease in USV and the concomitant increase in plasma CORT, are due to the fact that these two drugs act as full agonists at both pre- and postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	244-250
8004461-4	1994	Concentration response curves for inhibition of electrically stimulated 5-HT overflow by 8-OH-DPAT (5-HT1a receptor agonist) or RU24969 (5-HT1b receptor agonist) in the DRN or SCN respectively were obtained in slices prepared from both groups of animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-106
8206109-1	1994	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) increases plasma glucose levels in conscious rats probably by stimulation of central 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
8206109-1	1994	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) increases plasma glucose levels in conscious rats probably by stimulation of central 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
8206109-10	1994	These results are consistent with previous suggestions that (R,S)-WAY100135 and (S)-WAY100135 are selective 5-HT1A receptor antagonists and that 8-OH-DPAT-induced hyperglycaemia is mediated by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
8200427-1	1994	The purpose of this study was to determine the effects of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide (8-OH-DPAT), on respiratory activity (phrenic nerve activity) following application to the ventral medullary surface in the cat.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-138	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77
8200427-1	1994	The purpose of this study was to determine the effects of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide (8-OH-DPAT), on respiratory activity (phrenic nerve activity) following application to the ventral medullary surface in the cat.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77
8204202-3	1994	In the present study on mice, the 5-HT1A receptor agonists (8-OH-DPAT), ipsapirone, and buspirone all antagonized the locomotor activity (LMA) stimulatory effect of ethanol (2.5 g/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	34-49
8138923-1	1994	Exposure of HeLa cells stably expressing cloned human 5-hydroxytryptamine (5-HT)1A receptors (HA7 cells) to the agonist 8-hydroxy-2-(di-N-propylamino)-tetralin (8-OH-DPAT) results in a loss of high-affinity binding sites and a desensitization of receptor-adenylate cyclase coupling, as measured by 5-HT1A-mediated inhibition of forskolin-stimulated adenylate cyclase activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-159	5-hydroxytryptamine receptor 1A	Homo sapiens	298-304
8138956-5	1994	Although forskolin-stimulated adenylate cyclase activity was significantly increased in hippocampal homogenates from cericlamine-treated rats, the reduction in this enzymatic activity due to 5-HT1A receptor stimulation by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was unchanged in these animals as compared with controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	222-260	5-hydroxytryptamine receptor 1A	Rattus norvegicus	191-197
8138956-5	1994	Although forskolin-stimulated adenylate cyclase activity was significantly increased in hippocampal homogenates from cericlamine-treated rats, the reduction in this enzymatic activity due to 5-HT1A receptor stimulation by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was unchanged in these animals as compared with controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	262-271	5-hydroxytryptamine receptor 1A	Rattus norvegicus	191-197
8138956-12	1994	They also suggest that the inhibitory influence of systemically administered direct 5-HT1A agonists such as 8-OH-DPAT and ipsapirone on the electrical and metabolic activity of serotoninergic neurons does not result solely from the stimulation of somatodendritic 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-90
8138956-12	1994	They also suggest that the inhibitory influence of systemically administered direct 5-HT1A agonists such as 8-OH-DPAT and ipsapirone on the electrical and metabolic activity of serotoninergic neurons does not result solely from the stimulation of somatodendritic 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	263-269
8007747-0	1994	Sex difference in the feeding responses of non-deprived rats to the 5-HT1A agonists 8-OH-DPAT and gepirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	68-74
8007747-1	1994	The aim of this study was to determine whether there was any difference in the feeding responses of male and female rats to the 5-HT1A agonists 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) and gepirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	144-181	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
8007747-1	1994	The aim of this study was to determine whether there was any difference in the feeding responses of male and female rats to the 5-HT1A agonists 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) and gepirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
7984269-1	1994	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces hypothermia and a flat body posture in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7984269-1	1994	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces hypothermia and a flat body posture in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7984270-5	1994	The rats then received as acute challenge, a 5-HT1A autoreceptor-active dose of the reference 5-HT1A agonist 8-OH-DPAT (0.025 mg/kg s.c.).	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
7984271-0	1994	Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
7984271-7	1994	The ACTH responses to d-fenfluramine and 8-OH-DPAT were inhibited in cocaine pretreated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	proopiomelanocortin	Homo sapiens	4-8
7984272-1	1994	Administration of the 5-HT1A receptor agonist (+-)-8-Hydroxy-dipropylaminotetralin (8-OH DPAT, 50 ng) into the dorsal raphe nucleus (DRN) increased social interaction but did not change the motor activity of rats tested in high light, thus indicating an anxiolytic response.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
7984273-1	1994	Low doses of the selective 5-HT1A agonist 8-OH-DPAT increase ethanol intake in a limited access paradigm following peripheral injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
7984273-7	1994	The selective 5-HT1A antagonist, (+)-WAY100135 (0.3, 1 and 3 mg/kg), blocked the effect of 8-OH-DPAT, showing that activation of 5-HT1A receptors underlies the ethanol drinking induced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
7984273-7	1994	The selective 5-HT1A antagonist, (+)-WAY100135 (0.3, 1 and 3 mg/kg), blocked the effect of 8-OH-DPAT, showing that activation of 5-HT1A receptors underlies the ethanol drinking induced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	129-135
7984273-7	1994	The selective 5-HT1A antagonist, (+)-WAY100135 (0.3, 1 and 3 mg/kg), blocked the effect of 8-OH-DPAT, showing that activation of 5-HT1A receptors underlies the ethanol drinking induced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	188-197	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
7984273-7	1994	The selective 5-HT1A antagonist, (+)-WAY100135 (0.3, 1 and 3 mg/kg), blocked the effect of 8-OH-DPAT, showing that activation of 5-HT1A receptors underlies the ethanol drinking induced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	188-197	5-hydroxytryptamine receptor 1A	Rattus norvegicus	129-135
7984279-3	1994	However, the common metabolite of these compounds, 1-PP (an alpha-2 adrenoceptor antagonist with low affinity for 5-HT1A receptors), also increased noradrenaline efflux whilst the 5-HT1A receptor agonist 8-OH-DPAT and MDL 73005EF, which are not metabolized to 1-PP, did not.	8-Hydroxy-2-(di-n-propylamino)tetralin	204-213	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
8008244-4	1994	Because pindolol blocked the effect of 5-HT and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) mimicked the effect of 5-HT, the inhibitory effect of 5-HT appeared to be mediated via the 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	190-205
8190769-4	1994	Brief (30 s) exposure of nonparasitized mice to a predator (a cat) induced marked, relatively short-lived analgesia that was insensitive to naloxone and blocked by the serotonin-1A (5-HT1A) agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	199-208	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	182-188
8208763-0	1994	Hypothalamic infusion of the 5-HT2/1C agonist, DOI, prevents the inhibitory actions of the 5-HT1A agonist, 8-OH-DPAT, on lordosis behavior.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97
8208768-1	1994	Administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.1 mg kg-1 SC) completely antagonised the catalepsy produced by the dopamine (DA) D2 receptor antagonist raclopride (16 mg kg-1 SC).	8-Hydroxy-2-(di-n-propylamino)tetralin	46-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
8208768-1	1994	Administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.1 mg kg-1 SC) completely antagonised the catalepsy produced by the dopamine (DA) D2 receptor antagonist raclopride (16 mg kg-1 SC).	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
8208768-2	1994	This effect by 8-OH-DPAT was in turn completely antagonised by treatment with the new 5-HT1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin [(S)-UH-301] (3.5 mg kg-1 SC), but not by the mixed 5-HT1 receptor/beta-adrenoceptor antagonist (-)pindolol (2.0 mg kg-1 SC).	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
7838929-1	1994	8-OH-DPAT, a selective 5-HT1A agonist, produced a hypothermic response in mice at a dosage of 0.5 mg/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	23-29
8208989-0	1994	The effect of chronic administration of antidepressants and electroconvulsive shock on the 5-HT1A receptor mediated hypothermic response induced by 8-OH-DPAT in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97
8208989-12	1994	These results suggest that the action site of 8-OH-DPAT is post-synaptic 5-HT1A receptors and that the chronic administration of some antidepressants and ECS has no direct action on these receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	73-79
8199864-6	1994	injection of the 5-HT1A receptor agonists, 8-OH-DPAT or buspirone, 30 min before the light pulse significantly inhibited the photic expression of Fos-LI (maximal suppression 45.7 +/- 8.1 and 43.0 +/- 1.3%, respectively, both P &lt; 0.01 vs. vehicle controls).	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	146-149
8199864-7	1994	Treatment with the 5-HT1A receptor antagonist, NAN-190, administered 15 min before 8-OH-DPAT injection prevented the inhibitory effect of 8-OH-DPAT (100.9 +/- 6.0% vs. controls, P &gt; 0.9).	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34
8199864-7	1994	Treatment with the 5-HT1A receptor antagonist, NAN-190, administered 15 min before 8-OH-DPAT injection prevented the inhibitory effect of 8-OH-DPAT (100.9 +/- 6.0% vs. controls, P &gt; 0.9).	8-Hydroxy-2-(di-n-propylamino)tetralin	138-147	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34
8199879-2	1994	After masking 5-HT1A receptors by 0.1 microM 8-OH-DPAT, the binding displaced by 0.1 microM 5-CT presumably represented 5-HT1D sites and the remaining binding 5-HT1E sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20
8013551-4	1994	A partial attenuation of fluoxetine-induced conditioned taste aversion was seen after pre-exposure to a high dose of the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 1 mg/kg), but not to lower doses.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-189	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	121-136
8013551-4	1994	A partial attenuation of fluoxetine-induced conditioned taste aversion was seen after pre-exposure to a high dose of the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 1 mg/kg), but not to lower doses.	8-Hydroxy-2-(di-n-propylamino)tetralin	191-200	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	121-136
8180795-0	1994	Estrogen-progesterone and 8-OH-DPAT attenuate the lordosis-inhibiting effects of the 5-HT1A agonist in the VMN.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-91
8162954-4	1994	These data provide the first demonstration of the antagonism, by a selective 5-HT1A receptor antagonist, of 8-OH-DPAT-induced feeding; an effect mediated via the somatodendritic 5-HT1A autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
8162954-4	1994	These data provide the first demonstration of the antagonism, by a selective 5-HT1A receptor antagonist, of 8-OH-DPAT-induced feeding; an effect mediated via the somatodendritic 5-HT1A autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	178-184
8113999-2	1994	5-HT-1A receptor agonists, such as 8-hydroxy-2-(di-n-propyl-amino)tetralin, increase the plasma prolactin concentration in rats, probably by an action in the brain that leads to an increase in prolactin release from the pituitary gland.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-7
8113999-2	1994	5-HT-1A receptor agonists, such as 8-hydroxy-2-(di-n-propyl-amino)tetralin, increase the plasma prolactin concentration in rats, probably by an action in the brain that leads to an increase in prolactin release from the pituitary gland.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-74	prolactin	Rattus norvegicus	96-105
8113999-2	1994	5-HT-1A receptor agonists, such as 8-hydroxy-2-(di-n-propyl-amino)tetralin, increase the plasma prolactin concentration in rats, probably by an action in the brain that leads to an increase in prolactin release from the pituitary gland.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-74	prolactin	Rattus norvegicus	193-202
8113999-8	1994	This effect of tandospirone is blocked by pretreatment with the 5-HT antagonists metergoline and NAN-190 and shows cross-desensitization with the 5-HT-1A agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-201	5-hydroxytryptamine receptor 1A	Rattus norvegicus	146-153
8146221-3	1994	This effect was very similar to that produced by the selective 5-HT1A agonist 8-OH-DPAT, both in terms of potency and time-effect relationship, and was blocked by the selective 5-HT1A antagonist NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
8146221-3	1994	This effect was very similar to that produced by the selective 5-HT1A agonist 8-OH-DPAT, both in terms of potency and time-effect relationship, and was blocked by the selective 5-HT1A antagonist NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	177-183
7512426-1	1994	The aim of the present study was to evaluate whether galanin-(1-29) and galanin-(1-15) can modulate the 5-hydroxytryptamine1A (5-HT1A) receptors using [3H]8-OH-2-(di-n-propylamino)-tetralin ([3H]8-OH-DPAT) as a radioligand.	8-Hydroxy-2-(di-n-propylamino)tetralin	191-204	5-hydroxytryptamine receptor 1A	Rattus norvegicus	127-133
8129683-2	1994	The present paper deals with the acute effect of 8-OH-DPAT (a 5-HT1A agonist) administered to rats before or after training in an autoshaped lever-press response (a model of associative learning).	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
8275340-4	1994	8-OH-DPAT blockade of this nicotine effect was reversed by spiperone, a 5-HT1A/2 antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	72-78
8082044-3	1994	In malnourished rats, 5-HT1A receptors assayed with [3H]8-OH-DPAT were decreased by 20% in CA3.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
8082044-3	1994	In malnourished rats, 5-HT1A receptors assayed with [3H]8-OH-DPAT were decreased by 20% in CA3.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	carbonic anhydrase 3	Rattus norvegicus	91-94
7826569-0	1994	The 5-HT1A receptor antagonist (S)-UH-301 blocks the qR)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7826569-4	1994	consistently reversed the inhibition of DRN-5-HT cells produced by the selective 5-HT1A receptor agonist (R)-8-OH-DPAT (0.5 microgram/kg i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	105-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
8301575-4	1994	The spontaneous tail-flicks, flat-body posture and hypothermia mediated by an action of the 5-HT1A agonist 8-OH-DPAT at postsynaptic 5-HT1A receptors were dose-dependently and completely antagonized by S 14489, S 15535 and S15931 at doses of 0.63 to 10.0 and 2.5 to 40.0 mg/kg for s.c. and oral administration, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98
8301575-4	1994	The spontaneous tail-flicks, flat-body posture and hypothermia mediated by an action of the 5-HT1A agonist 8-OH-DPAT at postsynaptic 5-HT1A receptors were dose-dependently and completely antagonized by S 14489, S 15535 and S15931 at doses of 0.63 to 10.0 and 2.5 to 40.0 mg/kg for s.c. and oral administration, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	133-139
8148368-3	1994	The density of 5-HT1A receptors, labelled with [3H]8-OH-DPAT, in the rat hippocampus was enhanced after citalopram, imipramine, mianserin and levoprotiline, but not altered after fluoxetine administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
7968222-4	1994	Pretreatment of rats with the selective 5-HT1A agonist (+/-)-8-OH-DPAT effectively blocked the retention of radioactivity in brain regions known to contain high densities of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
7968222-4	1994	Pretreatment of rats with the selective 5-HT1A agonist (+/-)-8-OH-DPAT effectively blocked the retention of radioactivity in brain regions known to contain high densities of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	174-180
7800163-2	1994	A large number of binding sites for [3H]8-OH-DPAT were observed in the hippocampus, especially the dentate gyrus, CA1+CA2 field, dorsal raphe nucleus and septum.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	carbonic anhydrase 1	Rattus norvegicus	114-117
7800163-2	1994	A large number of binding sites for [3H]8-OH-DPAT were observed in the hippocampus, especially the dentate gyrus, CA1+CA2 field, dorsal raphe nucleus and septum.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	carbonic anhydrase 2	Rattus norvegicus	118-121
8183439-1	1994	The selective 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT, 0.5-35 micrograms kg-1 i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	53-91	5-hydroxytryptamine receptor 1A	Cavia porcellus	14-35
8183439-1	1994	The selective 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT, 0.5-35 micrograms kg-1 i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	53-91	5-hydroxytryptamine receptor 1A	Cavia porcellus	37-43
8115414-0	1994	The 5-HT1A agonist 8-OH-DPAT increases attachment maintenance but decreases suckling-related intake in 17-18-day-old rat pups.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8309982-2	1994	This hypothesis predicts that nociceptive dorsal horn units inhibited by NRM stimulation or iontophoretic 5-HT application would also be inhibited by iontophoresis of the selective 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	197-235	5-hydroxytryptamine receptor 1A	Rattus norvegicus	181-187
8309982-2	1994	This hypothesis predicts that nociceptive dorsal horn units inhibited by NRM stimulation or iontophoretic 5-HT application would also be inhibited by iontophoresis of the selective 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	237-246	5-hydroxytryptamine receptor 1A	Rattus norvegicus	181-187
7981767-2	1994	Its effect on the 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced behavioral syndrome (flat body posture and reciprocal forepaw treading) in reserpine-pretreated rats, the stimulus effect in a drug discrimination model in rats, the lower lip retraction in rats, the hypothermia in mice and secretion of corticosterone in rats, i.e. responses mediated by 5-HT1A receptors, were examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	365-371
7981767-2	1994	Its effect on the 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced behavioral syndrome (flat body posture and reciprocal forepaw treading) in reserpine-pretreated rats, the stimulus effect in a drug discrimination model in rats, the lower lip retraction in rats, the hypothermia in mice and secretion of corticosterone in rats, i.e. responses mediated by 5-HT1A receptors, were examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	365-371
7506312-3	1993	The affinity of the compounds for the 5-HT1A receptors was evaluated by competition experiments with [3H]-8-OH-DPAT in rat hippocampal and cortical tissue.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
8136041-6	1993	This effect was reversed by bilateral microinjection of zimelidine (20 and 100 nmol), a 5-HT re-uptake blocker, or 8-OH-DPAT (3 nmol), a 5-HT1A agonist, into the dorsal hippocampus immediately after restraint.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	137-143
8118681-0	1993	Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97
8118681-2	1993	Hormone responses to the 5-HT1A agonist, 8-OH-DPAT, were evaluated after long-term exposure to two antidepressants, the 5-HT uptake blocker, fluoxetine, and the norepinephrine uptake blocker, desipramine (DMI).	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-31
8118681-9	1993	Chronic injections of fluoxetine inhibited the ACTH, corticosterone and oxytocin responses to 8-OH-DPAT, suggesting reduced 5-HT1A receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	124-130
8111640-1	1993	Cigarette smoke passed through the nasal cavity of atenolol pre-treated anesthetized spontaneously breathing rabbits caused a bradycardia which was significantly modified by intracisternal application of the 5-HT1A receptor ligands 8-OH-DPAT (50 micrograms.kg-1) and buspirone (200 micrograms.kg-1).	8-Hydroxy-2-(di-n-propylamino)tetralin	232-241	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	208-214
8005619-4	1993	Dialysis of this extract (SBDS) against buffer containing 25% ethylene glycol produced a stable, reconstituted and active preparation (SBDSE) of vesicles which upon centrifugal separation followed by gentle resuspension retained 95-100% [3H] 8-OH-DPAT binding activity as well as 60% [3H] GppNHp binding and adenylate cyclase activities of SBDSE.	8-Hydroxy-2-(di-n-propylamino)tetralin	242-251	SBDS ribosome maturation factor	Homo sapiens	26-30
11224231-0	1993	Neuroanatomical basis for the antidepressant-like effects of the 5-HT(1A) receptor agonists 8-OH-DPAT and ipsapirone in the rat forced swimming test.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-72
11224231-1	1993	In the rat forced swimming test, systemic application of the serotonin 1A (5-HT(1A)) receptor agonist 8-OH-DPAT reduced immobility (ID(50) 0.17-1.37mg/kg, depending on route of application and application schedule).	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-82
8111224-7	1993	These results indicate that differences exist between male and female guinea pigs in the adaptive responses to prolonged treatment with the selective 5-HT1A agonist 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	165-173	5-hydroxytryptamine receptor 1A	Cavia porcellus	150-156
7904566-1	1993	In rats, the 5-HT1A receptor full agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the 5-HT1A receptor partial agonists ipsapirone and buspirone dose dependently and completely inhibited shock-induced ultrasonic vocalization after systemic injection and after microinjection into the dorsal raphe nucleus, a brain region rich in somatodendritic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
7904566-8	1993	It is suggested that both presynaptic and (possibly to a lesser extent) postsynaptic 5-HT1A receptors are involved in the anxiolytic effects of ipsapirone, buspirone, and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-91
8313165-2	1993	In this study we examined the ingestive response of rats with AP/mNTS-lesions after treatment with 8-OH-DPAT, a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
8005619-9	1993	Since no known cell line contains the serotonin 5-HT1A receptor (5-HT1A-R), stable transfection of the selected cell lines with a DNA construct encoding the human 5-HT1A-R was carried out and this resulted in a late increase of [3H] 8-OH-DPAT binding in the stationary phase only in the cell lines of neural origin.	8-Hydroxy-2-(di-n-propylamino)tetralin	233-242	5-hydroxytryptamine receptor 1A	Homo sapiens	163-171
8282017-4	1993	The higher potency of the latter compound was also noted at the level of presynaptic 5-HT1A receptors where both (+)-WAY 100 135 and SDZ 216-525 prevented the negative influence of 5-HT1A receptor agonists (8-OH-DPAT, flesinoxan or lesopitron) on the nerve impulse flow within dorsal raphe nucleus 5-HT neurones in brain stem slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	207-216	5-hydroxytryptamine receptor 1A	Rattus norvegicus	181-187
8201242-4	1993	Using measurements of rodent behaviour in the mouse light and dark test box and rat social interaction, anxiolytic agents such as diazepam and putative anxiolytic agents such as the 5-HT1A and 5-HT3 receptor ligands 8-OH-DPAT and low doses of tropisetron release behaviour suppressed by the aversive situation.	8-Hydroxy-2-(di-n-propylamino)tetralin	216-225	5-hydroxytryptamine receptor 3A	Rattus norvegicus	193-207
8297925-1	1993	The effects of 5-HT1A antagonists spiperone, methiothepin and BMY 7378 on [3H]-8-OH-DPAT binding were determined in vitro and ex vivo in rat hippocampus CA3 membrane preparations, and ex vivo in tissue sections of CA1 and CA3 subfields using quantitative autoradiography.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
8276064-0	1993	The effects of long-term treatment with the 5-HT1A receptor agonist 8-OH-DPAT and the 5-HT2/1C receptor agonist DOI in the neonatal rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
8276064-3	1993	The reduction induced by 8-OH-DPAT and DOI was antagonized by the 5-HT1A antagonist (S)-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin ((S)-UH-301) and the 5-HT2 antagonist ketanserin, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
11224215-4	1993	Two 5-HT(1A) agonists, buspirone and 8-OH-DPAT, had different effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
11224215-7	1993	Differences between the behavioral effects of buspirone and 8-OH-DPAT may reflect differential activity at the 5-HT(1A) receptor or the dopaminergic properties of buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-118
8265698-2	1993	The 5-HT1A agonist (R)-8-hydroxy-2-(di-propylamino)- tetralin (8-OH-DPAT) (1.3-13 nmol on each side) produced a dose-dependent depression of vacuous chewing movements (VCMs) that lasted about 20 min.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8265698-2	1993	The 5-HT1A agonist (R)-8-hydroxy-2-(di-propylamino)- tetralin (8-OH-DPAT) (1.3-13 nmol on each side) produced a dose-dependent depression of vacuous chewing movements (VCMs) that lasted about 20 min.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8265698-3	1993	The (R)-8-OH-DPAT-induced depression of VCMs was blocked by the simultaneous intranigral infusion of a specific 5-HT1A antagonist [(-)-(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin HCl (UH-301)], which had no effect when given alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-17	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
8265706-1	1993	The selective 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) activates raphe somatodendritic autoreceptors, leading to an inhibition of 5-HT neuronal activity and reduced synthesis and release of 5-HT in forebrain terminal areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-35
8265706-1	1993	The selective 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) activates raphe somatodendritic autoreceptors, leading to an inhibition of 5-HT neuronal activity and reduced synthesis and release of 5-HT in forebrain terminal areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
8265706-1	1993	The selective 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) activates raphe somatodendritic autoreceptors, leading to an inhibition of 5-HT neuronal activity and reduced synthesis and release of 5-HT in forebrain terminal areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-35
8265706-1	1993	The selective 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) activates raphe somatodendritic autoreceptors, leading to an inhibition of 5-HT neuronal activity and reduced synthesis and release of 5-HT in forebrain terminal areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
8271204-11	1993	Spiperone reversibly antagonized the response to 5-HT and 8-OHDPAT (8-hydroxy-2-(di-n-propylamino)tetralin) mimicked the response indicating that the receptor activated was of the 5-HT1A subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
8271204-11	1993	Spiperone reversibly antagonized the response to 5-HT and 8-OHDPAT (8-hydroxy-2-(di-n-propylamino)tetralin) mimicked the response indicating that the receptor activated was of the 5-HT1A subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
8255909-1	1993	Saturable [3H]8-OHDPAT binding to recognition sites of 5-HT1A receptors was shown to be higher in cortical membranes of alcohol-preferring (P) than in membranes of alcohol-nonpreferring (NP) rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
8219034-1	1993	To determine the impact on food intake of the 5-HT1A agonist, 8-OH-DPAT, administered at various times throughout the nocturnal cycle, rats were implanted with cannulae in either the dorsal or median raphe nuclei and injected with saline or 8-OH-DPAT (0.4, 0.8 or 1.6 nmol) immediately following dark onset, or during the mid or late dark periods.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-52
8374797-5	1993	The 5HT1A agonist 8-OH-DPAT given systemically again decreased extracellular levels of ACh, and the effect was dose-dependent.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-9
8374797-6	1993	The 5-HT1A effect was probably exerted in the NAC, because local infusion of 8-OH-DPAT mimicked systemic injections.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8405187-3	1993	The inhibitory effects of 5-CT and the 5-HT1A selective agent 8-hydroxy-2-(di-n-propyl-amino) tetralin (8-OH-DPAT) on forskolin stimulated adenylate cyclase activity are greater in isolated ciliary processes than in the iris musculature.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-102	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	39-45
8405187-3	1993	The inhibitory effects of 5-CT and the 5-HT1A selective agent 8-hydroxy-2-(di-n-propyl-amino) tetralin (8-OH-DPAT) on forskolin stimulated adenylate cyclase activity are greater in isolated ciliary processes than in the iris musculature.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	39-45
8248853-3	1993	Pharmacol., 37:231-237] have shown that a large receptor reserve exists for the inhibition of serotonin synthesis in rat cortex and hippocampus by the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT), whereas little or no reserve exists for the lower efficacy agonists ipsapirone and BMY 7378.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-203	5-hydroxytryptamine receptor 1A	Rattus norvegicus	151-157
8223894-3	1993	In contrast, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) (0.1 mg/kg s.c.) and the partial agonists BMY 7378 (1.0 mg/kg s.c.) and buspirone (5 mg/kg s.c.) significantly decreased hippocampal 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
8223894-4	1993	Pretreatment with (+/-)-WAY100135 (at 10 mg/kg s.c.) and (+)-WAY100135 (at 1.0-10 mg/kg s.c.) completely blocked the 8-OH-DPAT-induced decrease in 5-HT release demonstrating that these compounds are antagonists at the somatodendritic 5-HT1A autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	234-240
8223895-3	1993	The 5-HT3/5-HT4 receptor antagonist tropisetron and the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) had similar inhibitory potencies to cocaine (pKi values of 6.58 +/- 0.04, 6.47 +/- 0.14 and 6.45 +/- 0.12 respectively).	8-Hydroxy-2-(di-n-propylamino)tetralin	71-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
8223895-3	1993	The 5-HT3/5-HT4 receptor antagonist tropisetron and the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) had similar inhibitory potencies to cocaine (pKi values of 6.58 +/- 0.04, 6.47 +/- 0.14 and 6.45 +/- 0.12 respectively).	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
8248853-3	1993	Pharmacol., 37:231-237] have shown that a large receptor reserve exists for the inhibition of serotonin synthesis in rat cortex and hippocampus by the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT), whereas little or no reserve exists for the lower efficacy agonists ipsapirone and BMY 7378.	8-Hydroxy-2-(di-n-propylamino)tetralin	205-214	5-hydroxytryptamine receptor 1A	Rattus norvegicus	151-157
8374738-0	1993	Apparent regional differences in 5-HT1A binding may reflect [3H]8-OH-DPAT labeling of serotonin uptake sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Bos taurus	33-39
8374738-1	1993	The binding of [3H]8-OH-DPAT and [3H]paroxetine to 5-HT1A and 5-HT uptake sites (respectively) was examined in membranes prepared from bovine dorsal raphe and hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-28	5-hydroxytryptamine receptor 1A	Bos taurus	51-63
8405111-4	1993	As 8-OH-DPAT and to a lesser extent eltoprazine affect 5-HT1A receptors, it is proposed that a general reduction of serotonergic neurotransmission by activation of somatodendritic serotonergic autoreceptor leads to a non-specific reduction of aggression.	8-Hydroxy-2-(di-n-propylamino)tetralin	3-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
8336817-0	1993	Comparative effects of chronic 8-OH-DPAT, gepirone and ipsapirone treatment on the sensitivity of somatodendritic 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
8415816-3	1993	Pretreatment with desipramine and mianserin in combination induced the most intense 5-HT syndrome and the greatest fall in colonic temperature after injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	181-220	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
7694781-5	1993	In contrast, the agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 5-HT1A agonist) and alpha-CH3-5-HT (5-HT1C and 5-HT2) only caused a decrease in HR, while the agonist 2-CH3-5-HT (5-HT3) was devoid of cardiovascular effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
8222726-3	1993	This effect is also induced by the 5-HT receptor agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propyl-amino] tetralin, RU 24969 (5-methoxy-3-[1,2,3,6, tetrahydro-4-pyridinyl]-1-indole) and ipsapirone, suggesting the involvement of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	223-229
8101215-5	1993	Both serotonin and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a selective 5-HT1A receptor agonist, were moderately potent, receptor-mediated inhibitors of tyrosine hydroxylation in synaptosomes, with EC50 values of 8.4 and 7.0 microM, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
8101215-5	1993	Both serotonin and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a selective 5-HT1A receptor agonist, were moderately potent, receptor-mediated inhibitors of tyrosine hydroxylation in synaptosomes, with EC50 values of 8.4 and 7.0 microM, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
8361577-0	1993	Assessment of 8-OH-DPAT induced spontaneous tailflicks as an in vivo model of 5-HT1A function in young rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
8361577-2	1993	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), induced dose-related increases in spontaneous tailflicks in adult (&gt; 60 days) male rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
8361577-2	1993	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), induced dose-related increases in spontaneous tailflicks in adult (&gt; 60 days) male rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
8361577-7	1993	Thus 8-OH-DPAT induced spontaneous tailflicks reflect in vivo activation of 5-HT1A receptors in adult and 30 day old male rats but are inappropriate for the study of 5-HT1A mediated behaviour in younger animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	5-14	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
8332619-4	1993	In Experiment 1, rats received 0- to 4.0-mg/kg IP injections of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a selective 5-HT1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
8332619-4	1993	In Experiment 1, rats received 0- to 4.0-mg/kg IP injections of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a selective 5-HT1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
8364729-3	1993	Stress, but not antidepressant, depressed 5-HT1A sites labelled with [3H]8-hydroxy-DPAT in hippocampal fields CA3, CA4 and dentate gyrus.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
11224195-4	1993	Drugs with affinity for 5-HT(1A) receptors (i.e. 8-OHDPAT, flesinoxan, ipsapirone, buspirone, gepirone, NAN-190) abolished the vocalization irrespective of their efficacy.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-31
8361548-6	1993	In addition, by blocking the 5-HT1B sites with 100 nM CP 93129, the remaining population of [125I]GTI binding sites could be studied and was found to have high affinity for PAPP, rauwolscine and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	195-204	5-hydroxytryptamine receptor 1B	Rattus norvegicus	29-35
8101137-1	1993	This study examined the effects of kainic acid and NMDA microinjections into the lateral tegmental field on the sympatholytic effect of the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	155-164	5-hydroxytryptamine receptor 1A	Homo sapiens	140-146
8336822-8	1993	The activation of this receptor using the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), leads to a reduction in NMDA-induced behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-109	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	42-48
8336822-8	1993	The activation of this receptor using the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), leads to a reduction in NMDA-induced behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	42-48
8330206-4	1993	Microinjection of kainic or ibotenic acid into the dorsal and ventral hippocampus reduced the density of 5-HT1A receptors labelled with [3H]8-OH-DPAT (approximately -45%) as expected from their known location on intrinsic neuronal cell bodies and/or dendrites.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
8330213-3	1993	The goals of this study were to characterize the effects of 8-OH-DPAT, a selective 5-HT1A agonist, on the firing characteristics and membrane properties of PAG neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
8334526-3	1993	Oxytocin responses to 8-OH-DPAT were significantly attenuated by pretreatment with the 5-HT1A receptor antagonist NAN-190 while responses to DOI were blocked by pretreatment with the 5-HT2/5-HT1C receptor antagonist ritanserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
8319749-5	1993	The memory impairment by tandospirone was mimicked by the 5-HT1A receptor agonist 8-OH-DPAT (8-hydroxy-dipropylaminotetralin HBr) and blocked by the 5-HT1A receptor antagonist BMY7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspirol-[4]- decane-7,9-dione).	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	58-73
8098761-1	1993	Recently, we found that the beta 1/beta 2 adrenoceptor blocking agent (-)penbutolol prevents behavioral and biochemical actions of the specific serotonin (5-HT)1A agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-215	adrenoceptor beta 1	Homo sapiens	28-54
8098761-8	1993	Furthermore, (-)penbutolol, but not its (+)antipode, prevented the decrease of 5-HT release induced by the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-175	5-hydroxytryptamine receptor 1A	Homo sapiens	107-122
7686633-2	1993	(+/-) Tertatolol bound with high affinity (Ki = 38 nM) to 5-HT1A sites labelled by [3H]8-OH-DPAT in hippocampal membranes.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
8496807-4	1993	The selective 5-HT1A receptor agonist ipsapirone substituted completely for 8-OH-DPAT (ED50, 1.52 mg/kg) and 5-OMe-DMT substituted partially for 8-OH-DPAT, whereas 8-OH-DPAT (ED50, 0.07 mg/kg) and ipsapirone (ED50, 4.15 mg/kg) substituted completely for 5-OMe-DMT.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
8496807-4	1993	The selective 5-HT1A receptor agonist ipsapirone substituted completely for 8-OH-DPAT (ED50, 1.52 mg/kg) and 5-OMe-DMT substituted partially for 8-OH-DPAT, whereas 8-OH-DPAT (ED50, 0.07 mg/kg) and ipsapirone (ED50, 4.15 mg/kg) substituted completely for 5-OMe-DMT.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
8496807-4	1993	The selective 5-HT1A receptor agonist ipsapirone substituted completely for 8-OH-DPAT (ED50, 1.52 mg/kg) and 5-OMe-DMT substituted partially for 8-OH-DPAT, whereas 8-OH-DPAT (ED50, 0.07 mg/kg) and ipsapirone (ED50, 4.15 mg/kg) substituted completely for 5-OMe-DMT.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
8496807-5	1993	These results suggest that the discriminative stimulus properties of both 8-OH-DPAT and 5-OMe-DMT are 5-HT1A receptor mediated, although 5-OMe-DMT may involve an additional interaction with other 5-HT receptor subtypes.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-108
7686633-4	1993	As expected of a 5-HT1A antagonist, (-)tertatolol prevented in a concentration-dependent manner (Ki = 24 nM) the inhibitory effect of 8-OH-DPAT on forskolin-stimulated adenylate cyclase activity in rat hippocampal homogenates.	8-Hydroxy-2-(di-n-propylamino)tetralin	134-143	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
7686633-7	1993	), (-)tertatolol prevented the inhibitory effects of the 5-HT1A receptor agonists 8-OH-DPAT, ipsapirone and lesopitron on the firing rate of serotoninergic neurones within the dorsal raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
7693136-3	1993	The effects of intrastriatal administration of IPSA were mimicked by 8-OH-DPAT (0.5 mM), another agonist of 5-HT1A receptors, and were antagonized by the peripheral administration of metergoline (5 mg/kg ip) and intrastriatal administration of NAN-190 (0.5 mM).	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
8481797-4	1993	Inhibition of 5-HT neurons following administration of the 5-HT1A autoreceptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) increased the accumulation of DOPA in the DMN and the concentrations of DOPAC in the MZI and DMN, indicating an activation of catecholaminergic neurons in these regions.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
8516375-6	1993	[3H]8-OH-DPAT binding with 5-HT1A receptors was not altered by bulbectomy in any brain area in C57Bl/6j mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	27-33
8097721-2	1993	The effect of 5 micrograms 8-OH-DPAT on retention latencies was completely antagonized by 1 microgram/microliter spiroxatrine, a 5-HT1A receptor antagonist, infused into the dorsal hippocampus 5 min before 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	129-135
8481797-4	1993	Inhibition of 5-HT neurons following administration of the 5-HT1A autoreceptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) increased the accumulation of DOPA in the DMN and the concentrations of DOPAC in the MZI and DMN, indicating an activation of catecholaminergic neurons in these regions.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
8472759-0	1993	Working memory deficits induced by intrahippocampal administration of 8-OH-DPAT, a 5-HT1A receptor agonist, in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
8482325-9	1993	Binding studies with [3H]8-OH-DPAT indicated that the affinity and Bmax of 5-HT1A receptors was increased in vitamin B6-deficient hypertensive rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-81
8490207-12	1993	Next we found that the 5-HT1A agonist 8-OH-DPAT, and to a lesser extent the 5-HT1A-1B agonist RU 24969, mimicked the effects of quipazine during the subjective daytime, whereas the 5-HT1A antagonist NAN-190 blocked quipazine"s effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Homo sapiens	23-29
8474003-4	1993	Such in situ injection of either toxin in the dorsal hippocampus decreased by about 90% the responsiveness of CA3 pyramidal neurons to microiontophoretic applications onto their cell body of 5-HT and 8-OH-DPAT, but not of GABA.	8-Hydroxy-2-(di-n-propylamino)tetralin	200-209	carbonic anhydrase 3	Rattus norvegicus	110-113
8474032-3	1993	administration of the 5-hydroxytryptamine (5-HT)1A antagonist spiperone (1 mg/kg) antagonized the suppressant effect of microiontophoretic applications of 5-HT and of the selective 5-HT1A agonist 8-OH-DPAT on the firing activity of the rat dorsal raphe 5-HT neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	196-205	5-hydroxytryptamine receptor 1A	Rattus norvegicus	181-187
7690117-6	1993	Lastly, pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine prevented the immediate inhibitory effect of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) upon cold-induced TSH release, but it amplified the late release of TSH in cold-exposed 8-OH-DPAT-injected rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	160-198	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
7690117-6	1993	Lastly, pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine prevented the immediate inhibitory effect of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) upon cold-induced TSH release, but it amplified the late release of TSH in cold-exposed 8-OH-DPAT-injected rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	200-209	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
7690117-6	1993	Lastly, pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine prevented the immediate inhibitory effect of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) upon cold-induced TSH release, but it amplified the late release of TSH in cold-exposed 8-OH-DPAT-injected rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	299-308	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
8476611-2	1993	Addition of the specific 1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) to the culture, at concentrations similar to that needed for transactivation of the prodynorphin gene, also significantly increases cAMP levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-75	prodynorphin	Rattus norvegicus	172-184
8497336-7	1993	These effects were similar to those produced by the tricyclic antidepressant desipramine and the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103
8510763-0	1993	The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8472759-1	1993	In a test of working memory using a three-panel runway task, the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), at 1.0 mg/kg i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
8472759-1	1993	In a test of working memory using a three-panel runway task, the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), at 1.0 mg/kg i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
8472759-4	1993	The effect of intrahippocampal 8-OH-DPAT (10 micrograms/side) on working memory was blocked by the 5-HT1A receptor antagonist, (-)-propranolol, at 5 mg/kg i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
8459396-1	1993	Synthesis and structure-activity relationships of C-1- or C-3-substituted derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-127	T cell receptor gamma constant 1	Homo sapiens	50-53
8459396-1	1993	Synthesis and structure-activity relationships of C-1- or C-3-substituted derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-127	complement C3	Homo sapiens	58-61
8459396-2	1993	The synthesis and structure-activity relationships (SAR) of C-1- or C-3-substituted derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) are described.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-137	T cell receptor gamma constant 1	Homo sapiens	60-63
8459396-2	1993	The synthesis and structure-activity relationships (SAR) of C-1- or C-3-substituted derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) are described.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-137	complement C3	Homo sapiens	68-71
8459396-2	1993	The synthesis and structure-activity relationships (SAR) of C-1- or C-3-substituted derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) are described.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	T cell receptor gamma constant 1	Homo sapiens	60-63
8459396-2	1993	The synthesis and structure-activity relationships (SAR) of C-1- or C-3-substituted derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) are described.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	complement C3	Homo sapiens	68-71
8459396-12	1993	Overall, the SAR study showed that cis C-1 substitution maintains the 5-HT1A agonist activity of 8-OH-DPAT whereas trans C-1 substitution displays somewhat diminished activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	T cell receptor gamma constant 1	Homo sapiens	39-42
8459396-12	1993	Overall, the SAR study showed that cis C-1 substitution maintains the 5-HT1A agonist activity of 8-OH-DPAT whereas trans C-1 substitution displays somewhat diminished activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76
8462008-3	1993	The inhibitions were mimicked in 5/7 cells by iontophoresis of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 10-30 nA) whilst excitation was produced in 3/5 cells by iontophoresis of the 5-HT2 agonist alpha-methyl-5-HT (10-30 nA).	8-Hydroxy-2-(di-n-propylamino)tetralin	82-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
8462008-3	1993	The inhibitions were mimicked in 5/7 cells by iontophoresis of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 10-30 nA) whilst excitation was produced in 3/5 cells by iontophoresis of the 5-HT2 agonist alpha-methyl-5-HT (10-30 nA).	8-Hydroxy-2-(di-n-propylamino)tetralin	123-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
8461029-4	1993	For both radioligands the binding sites labelled have the properties of 5HT1A receptors and most antagonists show roughly equal affinities for the receptors labelled by either [3H]8-OH-DPAT or [3H]spiperone.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	5-hydroxytryptamine receptor 1A	Homo sapiens	72-77
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-75	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28
8385783-7	1993	The affinities of DPAT, yohimbine, and NAN-190 for the 5-HT1A and alpha 2-adrenergic receptors, respectively, were sufficiently high to lead to some ambiguity of interpretation of the behavioral data.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-75	tachykinin precursor 1	Homo sapiens	130-133
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	tachykinin precursor 1	Homo sapiens	130-133
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	thyrotropin releasing hormone	Homo sapiens	210-213
8479545-3	1993	In addition, differentiation of 5-HT1D receptors was achieved by incubation of the tissues with [3H]-5-HT in the presence of 100 nmol/l 8-OH-DPAT together with 100 nmol/l mesulergine.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine receptor 1D	Cavia porcellus	32-38
8467355-0	1993	Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	81-87
8467355-6	1993	Other selective 5-HT1A receptor ligands (0.3-30 mg kg-1, s.c.) either mimicked the 8-OH-DPAT response (ipsapirone, at 10 and 30 mg kg-1, s.c.) or were inactive (buspirone and gepirone).	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	16-31
8467355-30	1993	We conclude that 8-OH-DPAT produces an antidepressant-like effect in the Porsolt test which is mediated via postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	121-127
8386213-5	1993	5-HT, 8-OH-DPAT (both at 10 nmol/l) and DOI (at higher concentrations) blunted the stimulatory effect of CRH.	8-Hydroxy-2-(di-n-propylamino)tetralin	6-15	corticotropin releasing hormone	Rattus norvegicus	105-108
8386213-6	1993	The suppressive effects of 8-OH-DPAT and DOI on CRH-stimulated ACTH release were antagonized by (-)propranolol, a beta-adrenergic receptor antagonist which binds the 5-HT1A receptor with elevated affinity, and ketanserin, a 5-HT2 receptor antagonist respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	corticotropin releasing hormone	Rattus norvegicus	48-51
8094756-3	1993	As seen with the prototypical 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin, (+/-)-S 20244, (+)-S 20499 and (-)-S 20500 inhibited forskolin-activated adenylate cyclase in hippocampal homogenates with potencies corresponding to their respective affinities for 5-HT1A sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
8450471-2	1993	Administered s.c., 8-hydroxy-(2-di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), an agonist at both pre- and postsynaptic 5-HT1A receptors, elicited pronounced hypothermia.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
8450471-2	1993	Administered s.c., 8-hydroxy-(2-di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), an agonist at both pre- and postsynaptic 5-HT1A receptors, elicited pronounced hypothermia.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
8450471-4	1993	Similarly, 8-OH-DPAT was more efficacious than BMY 7378 in eliciting corticosterone secretion, a response mediated by postsynaptic 5-HT1A receptors, whereas BMY 7378 was as efficacious as 8-OH-DPAT in inhibiting striatal accumulation of 5-hydroxytryptophan, a response mediated by presynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-20	5-hydroxytryptamine receptor 1A	Rattus norvegicus	131-137
8384569-5	1993	SDZ 216-525 potently antagonised the effects of 8-OH-DPAT (8-hydroxy-2-[N-dipropyl-amino]-tetralin) on 5-HT1A receptors (pKB = 10) and displayed no intrinsic activity in this test, whereas it behaved at best as a weak antagonist on the other receptor models (pKB values &lt; 6.9).	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Bos taurus	103-109
8444282-1	1993	Interactions between central 5-HT1A receptors and the enantiomers of LY-41, a 2-aminotetralin derivative related to 8-OH-DPAT (8-hydroxy-2-(dipropylamino)tetralin), were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
8450176-3	1993	The purpose of these studies was to assess and characterize hypotensive responses to a 5-HT1A agonist, (8-hydroxy-dipropylaminotetraline, 8-OH-DPAT), administered to the ventral medulla of the rat, to correlate the responsive ventral medullary sites with the distribution of 3H-8-OH-DPAT binding sites, and to assess the role of serotonergic systems in mediating the hypotensive responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	138-147	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
8450176-3	1993	The purpose of these studies was to assess and characterize hypotensive responses to a 5-HT1A agonist, (8-hydroxy-dipropylaminotetraline, 8-OH-DPAT), administered to the ventral medulla of the rat, to correlate the responsive ventral medullary sites with the distribution of 3H-8-OH-DPAT binding sites, and to assess the role of serotonergic systems in mediating the hypotensive responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	278-287	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
8450176-5	1993	The hypotensive response to 8-OH-DPAT was attenuated by pretreatment with the 5-HT1A antagonists, spiperone or NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
8446668-7	1993	It is hypothesized that the Fawn Hood (FH) rat, which is reported to be resistant to hypothermia induced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), has an abnormality of 5-HT1A receptor activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-146	5-hydroxytryptamine receptor 1A	Rattus norvegicus	182-188
8382063-4	1993	Full inhibition was observed with 5-HT1A receptor agonists: N,N-dipropyl-8-hydroxy-2-aminotetralin (8-OH-DPAT) and flesinoxan, and non-selective 5-HT receptor agonists: d-lysergic acid diethylamide (d-LSD), RU 24,969, bufotenine, methysergide and tryptamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine receptor 1A	Homo sapiens	34-49
8431766-0	1993	Female sexual behavior following intracerebral infusion of the 5-HT1A agonist, 8-OH-DPAT, into the medial preoptic area.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
8431766-1	1993	The effects of intracerebral infusions of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), on sexual behaviors of intact, proestrous rats were examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-52
8381359-2	1993	In vivo, S 15535 (0.16-10 mg/kg s.c.) acted as an antagonist at postsynaptic 5-HT1A receptors in completely blocking the flat-body posture and hypothermia elicited by the 5-HT1A receptor agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	196-205	5-hydroxytryptamine receptor 1A	Homo sapiens	77-83
8444282-6	1993	However, it is noteworthy that the stereoselective interaction of 5-HT1A receptors with LY-41 was opposite to that of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
8430834-13	1993	Radioligand binding studies with the specific 5-HT1A receptor ligand [3H]8-OH-DPAT confirmed the presence of 5-HT1A receptor binding sites in bulk-isolated rat medullary TAL.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	46-61
8430834-13	1993	Radioligand binding studies with the specific 5-HT1A receptor ligand [3H]8-OH-DPAT confirmed the presence of 5-HT1A receptor binding sites in bulk-isolated rat medullary TAL.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	109-124
8491267-7	1993	The inhibitory effects in biphasic cells, and in cells that showed a pure inhibition in response to 5-HT, were blocked by pindobind-5-HT and mimicked by 8-hydroxy-2-(di-n-propylamino)-tetralin indicating the involvement of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	153-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	223-229
7906241-22	1993	These results show that the 5-HT1A receptor agonists 8-OH-DPAT, flesinoxan, 5-methyl-urapidil and MDL 75,608A show antihypertensive properties in conscious SHR after iv or icv injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
7906241-23	1993	However, the mechanism of action of the compounds differs: 8-OH-DPAT and flesinoxan may act predominantly as 5-HT1A receptor agonists, where as 5-methyl-urapidil and MDL 75,608A also seem to have an effect on peripheral alpha 1-adrenoceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
7510111-0	1993	Gonadotropin and prolactin secretion in prepubertal female rats treated with 8-hydroxy-2-(di-n-propylamino) tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-116	prolactin	Rattus norvegicus	17-26
7510111-7	1993	In addition, the simultaneous increase in serum and pituitary prolactin content suggests that 8-OH-DPAT enhances prolactin synthesis.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	prolactin	Rattus norvegicus	62-71
7510111-7	1993	In addition, the simultaneous increase in serum and pituitary prolactin content suggests that 8-OH-DPAT enhances prolactin synthesis.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	prolactin	Rattus norvegicus	113-122
8217055-3	1993	Seizure discharge activity was attenuated by the microinjection of the 5-HT1A agonist, 8-hydroxy-2-(di-N-propylamino)tetralin(8-(OH)-DPAT) and augmented by the specific 5-HT1A antagonist, spiroxatrine in the contralateral hippocampal CA-3 region.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
8217055-3	1993	Seizure discharge activity was attenuated by the microinjection of the 5-HT1A agonist, 8-hydroxy-2-(di-N-propylamino)tetralin(8-(OH)-DPAT) and augmented by the specific 5-HT1A antagonist, spiroxatrine in the contralateral hippocampal CA-3 region.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
8423555-7	1993	In contrast, the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)- tetralin (8-OH-DPAT), continued to evoke STFs.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
8423555-7	1993	In contrast, the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)- tetralin (8-OH-DPAT), continued to evoke STFs.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
8391081-7	1993	In autoradiographic binding studies of animals treated with volkensin, binding in deep neocortical layers of [3H]8-hydroxy-2-(n-dipropylamino) tetralin ([3H]8-OH-DPAT) to 5-HT1A but not of [3H]ketanserin to 5-HT2 receptors was significantly reduced.	8-Hydroxy-2-(di-n-propylamino)tetralin	153-166	5-hydroxytryptamine receptor 1A	Rattus norvegicus	171-177
8445996-1	1993	5-HT-1A receptor agonists suppress the rat hind paw licking reaction on a hot-plate and unpunished drinking in thirsty rats with the order of potency: 8-OH-DPAT &gt; Ru 24.969 &gt; buspirone &gt; gepirone &gt; ipsapirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-7
8492637-1	1993	The antidepressant-like effect of 8-hydroxy-2-(di-n-propylamino)tetralin(8-OH-DPAT), a selective 5-HT1A receptor agonist, was studied in the forced swimming wheel test in reserpine-treated mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-72	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	97-112
8492637-7	1993	This enhanced effect of 8-OH-DPAT was blocked by pretreatment with the 5-HT1A receptor antagonists, (-)-propranolol (3 mg/kg, i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	71-86
8492637-11	1993	These results suggest that the effect of 8-OH-DPAT in increasing the number of turns of the wheel made by mice was exerted through a 5-HT1A receptor and that this effect did not reflect only changes in the locomotor activity of the mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	133-148
7862825-8	1993	These results indicate that the mechanism by which 8-OH-DPAT induces a conditioned place preference involves activation of raphe somatodendritic 5-HT1A autoreceptors, leading to a reduction in 5-HT neurotransmission.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-151
8510803-5	1993	Under pentobarbital anesthesia, central administration of the selective 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and ipsapirone decreased plasma CS levels, relative to saline-treated control rats, at all doses tested (0.001-20 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	89-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
8510803-5	1993	Under pentobarbital anesthesia, central administration of the selective 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and ipsapirone decreased plasma CS levels, relative to saline-treated control rats, at all doses tested (0.001-20 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
8510803-8	1993	In contrast, intraperitoneal injection of 8-OH-DPAT (2 mumol/kg) increased plasma CS concentrations, but this was not prevented by prior intracerebroventricular administration of the 5-HT1A antagonist, NAN-190 (5 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	183-189
8510803-12	1993	Since intra-PVN injections of 8-OH-DPAT to pentobarbital-anesthetized rats also decreased hypothalamo-pituitary-adrenocortical activity, it appears that a component of the inhibitory effect of 5-HT1A receptor activation is mediated by a direct effect at the level of the PVN, and presumably involves CRF-secreting neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
7680787-4	1993	Serotonin release was reduced by the systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	92-130	5-hydroxytryptamine receptor 1A	Homo sapiens	68-83
7680787-4	1993	Serotonin release was reduced by the systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	132-141	5-hydroxytryptamine receptor 1A	Homo sapiens	68-83
7862825-9	1993	This demonstration of the rewarding properties of 8-OH-DPAT, together with previous results showing increased feeding and sexual behaviour following 8-OH-DPAT treatment, strongly suggests an important role for brain 5-HT systems in reward and reinforcement processes.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	POU class 6 homeobox 1	Rattus norvegicus	210-217
7862825-9	1993	This demonstration of the rewarding properties of 8-OH-DPAT, together with previous results showing increased feeding and sexual behaviour following 8-OH-DPAT treatment, strongly suggests an important role for brain 5-HT systems in reward and reinforcement processes.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	POU class 6 homeobox 1	Rattus norvegicus	210-217
7870899-3	1993	5-HT1A agonists (BAY R 1531, 8-OHDPAT, flesinoxan, gepirone, 5MeO DMT, buspirone, ipsapirone, BMY 14802) completely inhibit the aggressive behaviour irrespective of their intrinsic activities.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-37	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-6
7870905-3	1993	The 5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) produced an increase in locomotor activity that was independent of DA neurotransmission.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7870905-3	1993	The 5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) produced an increase in locomotor activity that was independent of DA neurotransmission.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7870907-1	1993	Rats were trained to self-administer cocaine (0.5 mg/kg/infusion) and were then pretreated with the 5-HT1A agonist 8-OH-DPAT (0.125, 0.25 or 0.5 mg/kg, SC).	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-106
7531851-3	1993	In contrast, the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) induced forepaw treading, flat body posture, hypothermia and hyperactivity which were not significantly different in aged compared to mature rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
7531851-3	1993	In contrast, the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) induced forepaw treading, flat body posture, hypothermia and hyperactivity which were not significantly different in aged compared to mature rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
7531851-7	1993	8-OH-DPAT reduced 5-HIAA in both regions examined in mature rats, an effect which was attenuated in the aged rats, suggesting an age-related reduction in presynaptic 5-HT1A receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
7870907-8	1993	This effect may be due to the effects at the 5-HT1A receptor, since 8-OH-DPAT produced a similar effect on cocaine self-administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
7870936-5	1993	During combination tests, the selective 5HT1A agonist, 8-OH-DPAT (0.001-3.2 mg/kg), dose-dependently attenuated the discriminative stimulus effects of 5.6 mg/kg U50,488 and 3.2 mg/kg spiradoline.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Homo sapiens	40-45
7871009-3	1993	Previously it has been found that the prototypical 5-HT1A receptor agonist, 8-OH-DPAT, increases avoidance, apparently by increasing general activity, after repeated administration but not on acute administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	51-57
7870997-0	1993	Ipsapirone and 8-OH-DPAT reduce ethanol preference in rats: involvement of presynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
7870997-8	1993	Local application of 8-OH-DPAT (10 micrograms, 0.5 microliters) into the dorsal raphe nucleus (DRN, a brain area rich in somatodendritic 5-HT1A autoreceptors), reduced the EtOH preference significantly as compared to the saline injection in the same animal (-12%, 8:00-12:00 P.M.).	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	137-143
7871000-0	1993	Cross-familiarisation conditioned taste aversion procedure as a method to reveal stimulus resemblance between drugs: studies on the 5-HT1A agonist 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	147-155	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	132-138
7871000-1	1993	In the present study a cross-familiarisation conditioned taste aversion (CTA) paradigm was utilized to reveal stimulus resemblance between the selective 5-HT1A agonist 8-OHDPAT and a variety of serotonergic and non-serotonergic drugs.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-176	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	153-159
8388111-2	1993	However, the effects of the 5-HT1a agonist 8-OH-DPAT on these two paradigms are probably mediated by different mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
8388111-5	1993	This suggests that, among its various possible mechanisms of action, 8-OH-DPAT induces an increase of food intake in rats by activating presynaptic 5-HT1a autoreceptors in the raphe nuclei, where most serotonergic fibers originate, while its effect on plasma ACTH concentration occurs through activation of postsynaptic 5-HT1a receptors in the PVN, where some serotonergic fibers terminate.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	148-154
8388111-5	1993	This suggests that, among its various possible mechanisms of action, 8-OH-DPAT induces an increase of food intake in rats by activating presynaptic 5-HT1a autoreceptors in the raphe nuclei, where most serotonergic fibers originate, while its effect on plasma ACTH concentration occurs through activation of postsynaptic 5-HT1a receptors in the PVN, where some serotonergic fibers terminate.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	320-326
1473002-6	1992	A functional index of 5-HT terminal damage was also implied by the impaired short-term feeding responses IC-5,7-DHT rats showed to the systemic administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) when tested between 3 and 4 weeks after IC treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	182-221	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
1473002-6	1992	A functional index of 5-HT terminal damage was also implied by the impaired short-term feeding responses IC-5,7-DHT rats showed to the systemic administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) when tested between 3 and 4 weeks after IC treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	223-232	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
11224163-5	1992	The selective 5-HT(1A) agonist 8-OH-DPAT produced effects only at 1.0mg/kg, with evidence of an anxiolytic/sedative action at this dose.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-21
1369587-3	1992	In this report, microinjection of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a selective 5-HT1A agonist, into the PVN increased rat plasma ACTH concentration in a dose-related manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
1369587-3	1992	In this report, microinjection of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a selective 5-HT1A agonist, into the PVN increased rat plasma ACTH concentration in a dose-related manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
1369587-5	1992	(+/-)-Pindolol, known to have 5-HT1A antagonist properties, blocked the effect induced by an optimal dose of 8-OH-DPAT after injection into the PVN.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
1369587-6	1992	This same dose of 8-OH-DPAT also induced a decrease of hypothalamic CRH concentration, which was completely antagonized as well by pretreatment injection of (+/-)-pindolol into the PVN.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	corticotropin releasing hormone	Rattus norvegicus	68-71
1468487-4	1992	The compound was found to counteract, in a stereospecific fashion, not only the behavioural and hypothermic but also the in vivo 5-HT synthesis/turnover-reducing effects of the specific 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	210-248	5-hydroxytryptamine receptor 1A	Homo sapiens	186-201
1468487-4	1992	The compound was found to counteract, in a stereospecific fashion, not only the behavioural and hypothermic but also the in vivo 5-HT synthesis/turnover-reducing effects of the specific 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	250-259	5-hydroxytryptamine receptor 1A	Homo sapiens	186-201
1487113-11	1992	8-OH-DPAT selectively depressed MSR (IC50 1.1 microM), IPSI SLOW and CON SLOW (IC50 5.7-7.6 microM), while methylsergide depressed only MSR (IC50 26 nM).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Rattus norvegicus	32-35
1432685-5	1992	Reduction of prepulse inhibition by 8-OHDPAT was antagonized by (-)propranolol, a 5-HT1a receptor antagonist, and partially by haloperidol, a dopamine D2 receptor antagonist, but not by ketanserin or methysergide, 5-HT2 receptor antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
1331764-11	1992	8-OH-DPAT-induced cAMP accumulation could be blocked by ICS 205-930 but not by the 5-HT1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-pthalimido)butyl]piperazine hydrobromide, distinguishing the SM cell 5-HT receptor from 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Bos taurus	217-223
1361965-9	1992	also significantly inhibited the food intake, induced by the 5-HT1A agonist 8-OH-DPAT (0.25 mg/kg, i.p.).	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
1475018-1	1992	Chronic treatment with electroconvulsive shock or antidepressant drugs has been reported to attenuate the hypothermia induced by 8-hydroxy-2-(di-n-propyl)aminotetralin (8-OH-DPAT), a serotonin1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	183-203
1475018-1	1992	Chronic treatment with electroconvulsive shock or antidepressant drugs has been reported to attenuate the hypothermia induced by 8-hydroxy-2-(di-n-propyl)aminotetralin (8-OH-DPAT), a serotonin1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	169-178	5-hydroxytryptamine receptor 1A	Rattus norvegicus	183-203
1475019-4	1992	The drug [3H]8-OH-DPAT was used to label 5-HT1A receptors and the Kd values for frontal cortex, hippocampus, striatum, hypothalamus and brainstem were similar in all three strains of rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
7871012-0	1993	Chronic lithium treatment enhances the postsynaptic 5-HT1A receptor-mediated 5-HT behavioral syndrome induced by 8-OH-DPAT in rats via catecholaminergic systems.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	52-58
7871012-1	1993	The effects of antimanic agents, including lithium, carbamazepine, clonazepam and zotepine, on the postsynaptic 5-HT1A receptor-mediated behavioral and hypothermic responses induced by 8-OH-DPAT in rats, and on [3H]8-OH-DPAT binding to 5-HT1A receptors in the rat hippocampus were examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	185-194	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
1448492-0	1992	Estradiol modulation of the hyperphagia induced by the 5-HT1A agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
1426017-1	1992	The affinities of a range of antipsychotic drugs at human hippocampal 5-HT1A receptors, defined by specific [3H]8-OH-DPAT binding, were determined.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76
1333974-1	1992	The 5-HT receptor agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) produced dose-dependent increases in plasma adrenocorticotropin (ACTH) in the male rat by activation of 5-HT1A and 5-HT2 receptors respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	239-251
1357094-6	1992	The selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin at 0.1 microM did not modify the electrically evoked release of [3H]5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	5-hydroxytryptamine receptor 1A	Homo sapiens	14-29
1436121-0	1992	Differential coupling of 5-HT1A receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Homo sapiens	25-31
1336851-1	1992	In rats anaesthetised with urethane, iontophoretic application of 5-hydroxytryptamine (5-HT) and the 5-HT1A agonists buspirone, flesinoxan and 8-hydroxy-2-(di-n-propylamino)-tetralin inhibited ongoing or amino-acid-evoked activity of neurons in the rostral ventrolateral medulla (RVLM) including barosensitive cells with spinally projecting axons.	8-Hydroxy-2-(di-n-propylamino)tetralin	143-182	5-hydroxytryptamine receptor 1A	Rattus norvegicus	101-107
1359573-4	1992	Partial, irreversible 5-HT1A receptor inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) (1 mg/kg) reduced the maximal hypothermic effect of 8-OH-DPAT (to 53% of control) without altering its ED50 (0.96 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	160-169	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	22-37
1359573-7	1992	The results demonstrate that 8-OH-DPAT-induced hypothermia in mice is mediated by a 5-HT1A receptor whose synaptic localization is uncertain but that has no receptor reserve.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	84-99
1446239-10	1992	Iontophoretic application of the 5HT1A agonists, 8-OH-DPAT and ipsapirone, mimic the suppressive action of serotonin in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Homo sapiens	33-38
1358403-1	1992	The binding profile of [3H]8-hydroxy-2-(di-N-propylamino)-tetralin ([3H]8-OH-DPAT) to serotonin1A (5-HT1A) sites in rat hippocampal, frontocortical and striatal membranes has been compared.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
1330157-9	1992	Thus, 8-OH-DPAT inhibition of VIP (30 nM)-stimulated cyclic AMP production decreased with increasing passage number of the cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	6-15	vasoactive intestinal peptide	Rattus norvegicus	30-33
1436390-0	1992	Desensitization of 5-HT1A autoreceptors by chronic administration of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	19-25
1436390-1	1992	The function of 5-HT1A autoreceptors was examined by measuring the ability of the 5-HT1A receptor agonist 8-OH-DPAT to reduce 5-HT release in the striatum using in vivo microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Homo sapiens	16-22
1436390-1	1992	The function of 5-HT1A autoreceptors was examined by measuring the ability of the 5-HT1A receptor agonist 8-OH-DPAT to reduce 5-HT release in the striatum using in vivo microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Homo sapiens	82-97
1422568-0	1992	Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	63-69
1422568-17	1992	), abolished the response to 8-OH-DPAT indicating that the 5-HT1A receptors involved were located on 5-HT neurones.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	59-65
1422568-24	1992	In conclusion, these data confirm that 8-OH-DPAT-induced hypothermia is mediated by 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	84-90
10607047-0	1992	Dose-dependent effects of the 5-HT1A receptor agonist 8-OH-DPAT on sleep and wakefulness in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
10607047-8	1992	The opposite effects, observed on the waking EEG after activation of either serotonin autoreceptors or postsynaptic 5-HT1A receptors with adequate doses of 8-OH-DPAT, tend to indicate an active role for the 5-HT1A receptor in the control of the waking state.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-122
10607047-8	1992	The opposite effects, observed on the waking EEG after activation of either serotonin autoreceptors or postsynaptic 5-HT1A receptors with adequate doses of 8-OH-DPAT, tend to indicate an active role for the 5-HT1A receptor in the control of the waking state.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Rattus norvegicus	207-213
1357765-4	1992	[3H]8-hydroxy-2-(di-n-propylamino)-tetralin ([3H]8-OH-DPAT), a ligand specific for the 5-HT1A site, has been used successfully to label these sites using both membrane binding assays and autoradiography.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
1385172-3	1992	Treatment with the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.5-1 mg/kg), 3-5 h after the end of cold exposure triggered less intense flat body posture and forepaw treading in cold-exposed rats than in controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
1448177-0	1992	Long lasting attenuation of 8-OH-DPAT-induced corticosterone secretion after a single injection of a 5-HT1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	101-107
1448177-2	1992	The 5-HT1A receptors mediating the corticosterone secretion appear to be postsynaptic to the 5-HT neurons, since the response to 8-OH-DPAT was not decreased but potentiated by depletion of 5-HT with p-chlorophenylalanine pretreatment of the animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1448177-4	1992	Thus, 1 mg/kg s.c. of 8-OH-DPAT attenuated the response of a challenge dose (0.1 mg/kg s.c.) of this compound within 4 h lasting between 7 and 14 d. The development of the subsensitivity was antagonized by pretreatment of the rats with the 5-HT1A receptor antagonist S-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin ((-)-UH 301).	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	240-246
1448178-2	1992	A transfected clonal cell line which expresses 900 +/- 36 fmol 5-HT1A receptor/mg protein (designated CHO-5-HT1A/WT-27) responded to 5-HT and/or 8-OH-DPAT by coupling to several second messenger pathways.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Homo sapiens	63-78
1448178-2	1992	A transfected clonal cell line which expresses 900 +/- 36 fmol 5-HT1A receptor/mg protein (designated CHO-5-HT1A/WT-27) responded to 5-HT and/or 8-OH-DPAT by coupling to several second messenger pathways.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69
1513320-7	1992	The rank order of potency of ligands to compete for the [3H]5-HT-labeled site best matched the binding profile of the pharmacologically defined 5-HT1E binding site, 5-HT greater than methysergide greater than ergotamine greater than 8-hydroxy-2-(di-n-propylamino)tetralin greater than 5-carboxyamidotryptamine greater than ketanserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	233-271	5-hydroxytryptamine receptor 1E	Homo sapiens	144-150
1425937-1	1992	Pigeons were trained to discriminate 0.3 mg/kg of the 5-HT1A receptor agonist 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT) from saline.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-60
1386220-8	1992	The effect of highly selective 5-HT-1A receptor agonist, 8-OHDPAT, on ET-OH consumption in the high preference group was antagonized by cyanopindolol, a nonselective antagonist of 5-HT-1 receptor subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-38
1387027-10	1992	BMY 7378 (8 mg kg-1, s.c.) inhibited another effect of activation of postsynaptic 5-HT1A receptors, i.e., the induction of components of the 5-HT syndrome by 8-OH-DPAT (0.5, 1.0 mg kg-1, s.c.) which suggests that BMY 7378 has antagonistic as well as agonistic effects at these sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	158-167	5-hydroxytryptamine receptor 1A	Homo sapiens	82-88
1391763-2	1992	administration of the selective 5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) (100 micrograms kg-1) has been investigated by in vivo 5-hydroxyindole electrochemical (peak 3) detection in the nucleus raphe magnus (NRM) and medullary dorsal horn (MDH) of acute anaesthetized and unanaesthetized freely moving rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
1357574-2	1992	The serotonin1A receptor agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OHDPAT) increased concentrations of prolactin in plasma rapidly and in a dose-related manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-24
1357574-2	1992	The serotonin1A receptor agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OHDPAT) increased concentrations of prolactin in plasma rapidly and in a dose-related manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-72	prolactin	Rattus norvegicus	112-121
1357574-2	1992	The serotonin1A receptor agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OHDPAT) increased concentrations of prolactin in plasma rapidly and in a dose-related manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-24
1357574-2	1992	The serotonin1A receptor agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OHDPAT) increased concentrations of prolactin in plasma rapidly and in a dose-related manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-82	prolactin	Rattus norvegicus	112-121
1357574-3	1992	Concentrations of prolactin peaked within 9 min after intravenous injection of 8-OHDPAT and returned to baseline values within 30 min.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-87	prolactin	Rattus norvegicus	18-27
1357674-2	1992	We trained different groups of rats to discriminate the benzodiazepine chlordiazepoxide (CDP, 20 mg/kg) or the 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (0.4 mg/kg) from saline by means of the CTA procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	150-188	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-132
1357674-2	1992	We trained different groups of rats to discriminate the benzodiazepine chlordiazepoxide (CDP, 20 mg/kg) or the 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (0.4 mg/kg) from saline by means of the CTA procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	150-188	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-140
1409788-0	1992	The 5-HT1A agonist 8-OH-DPAT attenuates the satiating action of cholecystokinin.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
1409788-0	1992	The 5-HT1A agonist 8-OH-DPAT attenuates the satiating action of cholecystokinin.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	cholecystokinin	Homo sapiens	64-79
1393558-0	1992	Phase-resetting effect of 8-OH-DPAT, a serotonin1A receptor agonist, on the circadian rhythm of firing rate in the rat suprachiasmatic nuclei in vitro.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-59
1393558-6	1992	Besides, it is reported that the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetraline hydrobromide (8-OH-DPAT) affected a circadian rhythm of hamster wheel-running activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	33-39
1393558-7	1992	In the present study we investigated whether the 5-HT1A agonist 8-OH-DPAT can reset the phase of the SCN clock when it is isolated in vitro.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
1391763-5	1992	With reference to similar in vivo studies demonstrating differential responsiveness of ascending serotonergic systems to 8-OH-DPAT, it is concluded that the serotonergic NRM-dorsal horn system is slightly affected by this 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	222-228
1391765-2	1992	The 5-HT1A agonist, 8-OH-DPAT, significantly inhibited lordosis in 5,7-DHT-treated and non-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1407394-0	1992	The putative 5-HT1A antagonist BMY 7378 blocks 8-OH-DPAT-induced changes in local cerebral glucose utilization in the conscious rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
1407394-1	1992	It has previously been shown that the 5-HT1A agonist, 8-OH-DPAT, caused discrete changes in cerebral glucose utilization in the rat, as assessed by quantitative 2-deoxyglucose autoradiography.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
1407394-8	1992	These data are consistent with the hypothesis that the effects of 8-OH-DPAT on regional cerebral glucose utilization are mediated by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	133-139
1385662-3	1992	The inhibitory response of single 5-HT neurons in the dorsal raphe (DR) to (-)-cocaine, the 5-HT uptake inhibitor fluoxetine or the 5-HT1A agonist 8-hydroxy-2-[di-N-propylamino]tetralin (8-OHDPAT) was significantly enhanced in cocaine-treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	147-185	5-hydroxytryptamine receptor 1A	Rattus norvegicus	132-138
1533667-5	1992	Contractions induced by 8-hydroxy-2-(di-n-propylamino)-tetralin or alpha-methylserotonin maleate were attenuated by pretreatment with S(-)propranolol (2.6 microM), a relatively selective 5-HT1A and 5-HT1B receptor antagonist, and ketanserin (0.3 microM), a selective 5-HT2 receptor antagonist, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-63	5-hydroxytryptamine receptor 1A	Bos taurus	187-199
1534843-7	1992	In cortical areas, Par1/Par2 [3H]8-OH-DPAT binding was significantly reduced (2 and 6 ng animals) in both superficial and deeper cortical layers, but quantitative histological analysis has not been performed.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	coagulation factor II (thrombin) receptor	Rattus norvegicus	19-23
1534843-7	1992	In cortical areas, Par1/Par2 [3H]8-OH-DPAT binding was significantly reduced (2 and 6 ng animals) in both superficial and deeper cortical layers, but quantitative histological analysis has not been performed.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	F2R like trypsin receptor 1	Rattus norvegicus	24-28
1350068-2	1992	The purposes of the present studies were to determine if nicotine, morphine and the serotonin1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) utilize a common synaptic pathway to release prolactin and, if so, to establish the serial order of the receptors involved.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-151	prolactin	Rattus norvegicus	209-218
1350068-5	1992	In the saline-treated animals, administration of nicotine, morphine, 8-OH-DPAT and haloperidol resulted in significant increases in plasma prolactin levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	prolactin	Rattus norvegicus	139-148
1350068-11	1992	These data indicate that nicotine, morphine and 8-OH-DPAT act to release prolactin via a common synaptic pathway expressing nicotinic cholinergic, opiate, and 5-HT1A receptors at synapses arranged serially in that functional order.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	prolactin	Rattus norvegicus	73-82
1356248-3	1992	Completely analogous effects were found at the somatodendritic 5-HT1A autoreceptor in the raphe nuclei, mediating inhibition of the synthesis of serotonin (5-HT); the full agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the partial agonist, buspirone were utilized to inhibit the synthesis of 5-HT, as measured by changes in levels of L-5-hydroxytryptophan (5-HTP).	8-Hydroxy-2-(di-n-propylamino)tetralin	181-219	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69
1356248-3	1992	Completely analogous effects were found at the somatodendritic 5-HT1A autoreceptor in the raphe nuclei, mediating inhibition of the synthesis of serotonin (5-HT); the full agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the partial agonist, buspirone were utilized to inhibit the synthesis of 5-HT, as measured by changes in levels of L-5-hydroxytryptophan (5-HTP).	8-Hydroxy-2-(di-n-propylamino)tetralin	221-230	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69
1388247-4	1992	In whole mouse brains, the histamine turnover was significantly inhibited by the 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (greater than 0.5 mg/kg) and buspirone (greater than 2 mg/kg) injected s.c. 10 min before pargyline treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	138-147	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	81-87
1388255-1	1992	In the mouse, administration of corticosterone-21-acetate (30 mg/kg, s.c. daily) for 3 and 10 days produced an attenuation of the hypothermic response to the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), which was not present after administration for 1 day.	8-Hydroxy-2-(di-n-propylamino)tetralin	182-220	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	158-173
1388255-5	1992	The serotonin syndrome was also induced in mice using 8-OH-DPAT; this increased in a dose-dependent manner and could be significantly decreased by pre-treatment with 1-(2-methoxyphenyl)-4-(4-phthalimidobutyl)-piperazine (NAN-190 5 mg/kg, i.p., 30 min prior to administration of 8-OH-DPAT), a 5-HT1A receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	292-307
1388278-8	1992	The behavioral syndrome induced by a selective 5-HT1A agonist [8-hydroxy-2-(di-n-propyl-amino)-tetralin (8-OH-DPAT)] was clearly antagonized by administration of (-)-alprenolol, indicating that (-)-alprenolol was an efficient 5-HT1A blocker.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
1388278-8	1992	The behavioral syndrome induced by a selective 5-HT1A agonist [8-hydroxy-2-(di-n-propyl-amino)-tetralin (8-OH-DPAT)] was clearly antagonized by administration of (-)-alprenolol, indicating that (-)-alprenolol was an efficient 5-HT1A blocker.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	226-232
1388278-8	1992	The behavioral syndrome induced by a selective 5-HT1A agonist [8-hydroxy-2-(di-n-propyl-amino)-tetralin (8-OH-DPAT)] was clearly antagonized by administration of (-)-alprenolol, indicating that (-)-alprenolol was an efficient 5-HT1A blocker.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
1388278-8	1992	The behavioral syndrome induced by a selective 5-HT1A agonist [8-hydroxy-2-(di-n-propyl-amino)-tetralin (8-OH-DPAT)] was clearly antagonized by administration of (-)-alprenolol, indicating that (-)-alprenolol was an efficient 5-HT1A blocker.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	226-232
1316283-5	1992	The phase advance induced by 8-OH-DPAT was blocked by pretreatment with (-)-pindolol, a 5-HT1A receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Homo sapiens	88-103
1579785-4	1992	The 5-HT2 receptor agonist DOI and the 5-HT1a receptor agonist 8 OH-DPAT induced a dose-related increase in wakefulness; treatment with RP 62203 reversed the enhancement of wakefulness produced by DOI but not that produced by 8 OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	226-235	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-9
1534769-4	1992	8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin; 1 and 10 micrograms), a specific 5-HT1A agonist, affected neither aggression nor any other behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-90
1385752-0	1992	8-Hydroxy-2-(di-n-propylamino)tetralin impairs spatial learning in a water maze: role of postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-108
1385752-2	1992	The effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, on place navigation was studied by use of two spatial tasks in a water maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
1385752-14	1992	The results suggest that, at doses causing no apparent changes in motor behaviour or motivation, 8-OH-DPAT impairs spatial navigation by stimulating postsynaptic 5-HT1A receptors in the rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	162-168
1353126-4	1992	However, 5-HT1A receptor binding sites labeled with [3H]8-OH-DPAT in hippocampal membranes did not differ significantly in either the total number of binding sites (Bmax) or dissociation constant (Kd) between the two groups.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	9-24
1535691-4	1992	The pharmacological profiles of the binding (determined with [3H]8-OH-DPAT) and the calcium response (measured using Fura-2) were clearly of the 5-HT1A type.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-74	5-hydroxytryptamine receptor 1A	Homo sapiens	145-151
1355147-9	1992	8-OH-DPAT, a full agonist of 5-HT1A receptors, was also effective in this test with a high potency.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
1357637-1	1992	The effect of 8-OH-DPAT, a 5-HT1A receptor agonist, on the locomotor activity was analyzed in Albino Swiss mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-23	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	27-42
1357637-3	1992	The hypoactivity induced by 8-OH-DPAT (1.5 mg/kg) was abolished by the dopamine (D1 and D2) receptor antagonist-haloperidol (0.00125 and 0.0025 mg/kg, but not in higher doses) and by the D2 antagonist with affinity for 5-HT1A and 5-HT2 receptors-spiperone (0.0025 and 0.005 mg/kg, but not in higher doses).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	dopamine receptor D1	Mus musculus	81-100
1357637-3	1992	The hypoactivity induced by 8-OH-DPAT (1.5 mg/kg) was abolished by the dopamine (D1 and D2) receptor antagonist-haloperidol (0.00125 and 0.0025 mg/kg, but not in higher doses) and by the D2 antagonist with affinity for 5-HT1A and 5-HT2 receptors-spiperone (0.0025 and 0.005 mg/kg, but not in higher doses).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	219-225
1584831-11	1992	Relative to vehicle-exposed controls, withdrawal from cocaine treatment enhanced the inhibitory potency of the 5-HT1A agonist (+-)-8-hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) on DOI-induced HTR.	8-Hydroxy-2-(di-n-propylamino)tetralin	175-184	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	111-117
1535597-1	1992	The hypothermia induced by the serotonin (5-HT)1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was attenuated in rats that had received a course of six electroconvulsive shocks (ECS) over a two-week period.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-58
1535597-1	1992	The hypothermia induced by the serotonin (5-HT)1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was attenuated in rats that had received a course of six electroconvulsive shocks (ECS) over a two-week period.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-58
1535320-1	1992	The effects of various subcutaneous doses (30, 100 and 300 micrograms/kg) of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a serotonin (5-HT)1A receptor agonist, were studied on the performance of rats in a one-trial passive avoidance task.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	131-158
1530868-5	1992	Similarly, systemic administration of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (0.1 mg/kg, s.c., 60 min before death) blocked the reserpine-induced elevation of brain 5-HT synthesis.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-114	POU class 6 homeobox 1	Rattus norvegicus	197-204
1531359-1	1992	The purported serotonin (5-HT)1A antagonists BMY-7378 and NAN-190 were examined in pigeons for their potential to block the effects of the prototypical 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on punished ("conflict") and unpunished behavior and for their binding affinity at the 5-HT1A receptor site labeled by [3H]-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	167-205	5-hydroxytryptamine receptor 1A	Homo sapiens	152-158
1370841-11	1992	The second response was not blocked by a variety of 5-HT receptor antagonists but was reproduced by (+/-)-8-hydroxy-DPAT HBr (8-OH-DPAT), a reputed 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Bos taurus	148-154
1535317-7	1992	The 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), did not increase any of these parameters.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1374613-8	1992	pretreatment with the 5-HT1A-agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	37-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
1374613-8	1992	pretreatment with the 5-HT1A-agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
1389001-2	1992	In the present study the excitatory action of nicotine was inhibited by treatment with the selective 5-HT re-uptake inhibitor citalopram or the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine receptor 1A	Homo sapiens	144-159
1387164-2	1992	Daily injection for 30 consecutive days of 10 mg/kg ip 8-OH-DPAT (pre- and post-synaptic 5-HT1A agonist) significantly decreased 8-OH-DPAT-evoked flat body posture, forelimb myoclonus, and hypothermia compared to chronic vehicle injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
1387164-2	1992	Daily injection for 30 consecutive days of 10 mg/kg ip 8-OH-DPAT (pre- and post-synaptic 5-HT1A agonist) significantly decreased 8-OH-DPAT-evoked flat body posture, forelimb myoclonus, and hypothermia compared to chronic vehicle injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	89-95
1318516-3	1992	The 5-HT1A receptor agonist, 8-OH-DPAT, and the adenyl cyclase activator, forskolin administered together, produced an additive hyperalgesia, suggesting that the 5-HT1A receptor in peripheral terminals of the primary afferent neurons is positively coupled to the cAMP second messenger system in producing hyperalgesia.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Homo sapiens	162-177
1351756-5	1992	These results closely resemble those we found after administration of two other 5-HT1A agonists, 8-OH-DPAT and MDL 73005EF (NeuroReport, 1, 267-270, 1990).	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	80-86
1740965-5	1992	The combination of the 5-HT-1a agonist 8-OH-DPAT and the 5-HT-1b agonist CGS-12066B, however, did inhibit d-amphetamine-stimulated locomotor activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	23-30
1667606-8	1991	The regional distribution of 5-HT1A receptors labelled by [3H]rauwolscine is in agreement with previous studies using [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Homo sapiens	29-35
1535232-0	1992	Effects of the 5HT1A agonist, 8-OH-DPAT, on operant food intake in non-deprived rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-20
1357711-0	1992	Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-83
1357711-1	1992	Previous studies have shown that discriminative stimulus control established with the 5HT1A receptor agonist, 8-OH-DPAT, generalizes to other 5HT1A agonists and partial agonists but also to the alpha 2-adrenoceptor antagonist, yohimbine.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-91
1357711-1	1992	Previous studies have shown that discriminative stimulus control established with the 5HT1A receptor agonist, 8-OH-DPAT, generalizes to other 5HT1A agonists and partial agonists but also to the alpha 2-adrenoceptor antagonist, yohimbine.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-147
1357711-7	1992	Furthermore, there were statistically significant positive correlations between drug affinity for 5HT1A sites and their ED50 values for both substitution for 8-OH-DPAT and potency to decrease response rates.	8-Hydroxy-2-(di-n-propylamino)tetralin	158-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-103
1357711-8	1992	These results are consistent with the view that the 8-OH-DPAT cue, like the ability of the compounds tested to decrease rates of responding, is largely mediated by activity at 5HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	176-181
1365647-1	1992	8-OH-DPAT, a selective 5-HT1A agonist, has variously been found to impair, have no effect on or enhance the conditioned avoidance response (CAR).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	23-29
1410130-4	1992	Direct administration into the PAG of either 5-carboxamidotryptamine (5-CT) or 8-hydroxy-2-(di-n-propylamino) tetralin (8-OHDPAT) produced behaviours (decreased exploratory rearing, dose related onset of flat body posture) indicative of 5-HT1A receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	237-243
1410130-4	1992	Direct administration into the PAG of either 5-carboxamidotryptamine (5-CT) or 8-hydroxy-2-(di-n-propylamino) tetralin (8-OHDPAT) produced behaviours (decreased exploratory rearing, dose related onset of flat body posture) indicative of 5-HT1A receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	237-243
1410132-5	1992	In the tail-flick analgesiometric test, administration of the 5-HT1A agonists 8-OH-DPAT and ipsapirone and the 5-HT1B agonists RU24969 and mCPP resulted in a significant dose-dependent increase in tail-flick latencies when compared to predrug baseline values, indicating a decrease in nociceptive sensitivity to noxious thermal stimuli.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Homo sapiens	62-68
1839984-3	1991	In low Mg2+ concentrations, the inhibitory actions of 5-HT and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) but not meta-trifluoromethyl phenyl piperazine (TFMPP) on Purkinje cells were significantly reduced; whereas the excitatory actions to the physiologic agonist 5-HT were enhanced.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-102	mucin 7, secreted	Homo sapiens	7-10
1666334-1	1991	Serotonin1A receptor agonists, 8-hydroxy-2-(di-n-propylamino)tetralin and 10-methyl-11-hydroxyaporphine, inhibited electrical stimulation-induced contraction of the guinea-pig ileum.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-20
1836757-5	1991	Transient expression of this clone demonstrated high-affinity binding of [3H]5-HT with a pharmacological profile corresponding to that of the 5-HT1B subtype: 5-CT, 5-HT greater than propranolol greater than methysergide greater than rauwolscine greater than 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	258-267	5-hydroxytryptamine receptor 1B	Rattus norvegicus	142-148
1688012-7	1991	Activity was also seen with the 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, at 0.05 and 0.25 mg/kg), and 5-methoxy-N,N-dimethyltryptamine (5-MeODMT at 3 mg/kg) as well as with the muscarinic agonist oxotremorine (0.1 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	48-86	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-38
1688012-7	1991	Activity was also seen with the 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, at 0.05 and 0.25 mg/kg), and 5-methoxy-N,N-dimethyltryptamine (5-MeODMT at 3 mg/kg) as well as with the muscarinic agonist oxotremorine (0.1 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-38
1834802-2	1991	[3H]5-HT competition studies using selective 5-HT1A receptor ligands indicated that approximately 25% of high-affinity synaptosomal [3H]5-HT binding was inhibited by 5-HT1A-selective compounds, an estimate consistent with [3H](+-)-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) saturation experiments in which 5-HT1A receptors were directly labeled.	8-Hydroxy-2-(di-n-propylamino)tetralin	271-284	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
1834802-2	1991	[3H]5-HT competition studies using selective 5-HT1A receptor ligands indicated that approximately 25% of high-affinity synaptosomal [3H]5-HT binding was inhibited by 5-HT1A-selective compounds, an estimate consistent with [3H](+-)-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) saturation experiments in which 5-HT1A receptors were directly labeled.	8-Hydroxy-2-(di-n-propylamino)tetralin	271-284	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
1762063-7	1991	Drug-appropriate responding occurred in pigeons trained at the lower dose of imipramine with the 5-HT1A compounds 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide and gepirone; partial substitution occurred in pigeons trained with the higher dose of imipramine.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-165	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103
1839498-4	1991	The long-term treatments with imipramine and ECS, but not with paroxetine, increased the responsiveness of postsynaptic CA3 hippocampus pyramidal neurons to the microiontophoretic application of 5-HT and to that of the selective 5-HT1A receptor ligand 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	252-261	carbonic anhydrase 3	Rattus norvegicus	120-123
1687762-5	1991	The 5-HT1A receptor agonist, 8-OH DPAT, also exhibited anxiolytic-like action between doses of 0.0005 to 3.16 mg/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-19
1840083-0	1991	Gender and estrous cycle differences in the response to the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
1840083-6	1991	These findings suggest that postsynaptic 5-HT1A sites involved in 8-OH-DPAT-induced hypothermia do not vary during the estrous cycle.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
1838579-4	1991	In competition studies, the rank order of drug affinities was suggestive of a 5-HT1A binding site: 5-HT greater than 8-OH-DPAT, RU24969 greater than methysergide, methiothepin, 1-2,5-dimethoxy-4-iodophenyl aminopropane (DOI), ketanserin greater than mianserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Homo sapiens	78-84
1838408-3	1991	Systemic administration of the putative 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) led to a 50-80% reduction in 5-HT levels in hippocampal dialysates from both intact and raphe grafted hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
1838408-3	1991	Systemic administration of the putative 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) led to a 50-80% reduction in 5-HT levels in hippocampal dialysates from both intact and raphe grafted hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
1838408-4	1991	Since 8-OH-DPAT normally reduces 5-HT release from the nerve terminal via activation at the somatodendritic 5-HT1A autoreceptor and subsequent inhibition of impulse flow, the results indicate that 5-HT output from both medullary and mesencephalic raphe grafts can be regulated by autoreceptors and is dependent on serotoninergic neuronal activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	6-15	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
11224077-1	1991	Rats were trained to discriminate the stimulus properties of the selective 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.4mg/kg i.p.)	8-Hydroxy-2-(di-n-propylamino)tetralin	92-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-82
11224077-6	1991	Other drugs with high affinity for 5-HT(1A) receptors, such as the azapirones gepirone, ipsapirone and buspirone, produced selective reductions of saccharin preference in rats trained to discriminate 8-OH-DPAT from saline but not in controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	200-209	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-42
11224080-0	1991	Modification of the discriminative stimulus effects of 8-OH-DPAT, buspirone and the beta-adrenoreceptor antagonist pindolol after chronic administration of the 5-HT(1A) agonist 8-OH-DPAT in the pigeon.	8-Hydroxy-2-(di-n-propylamino)tetralin	177-186	5-hydroxytryptamine receptor 1A	Homo sapiens	160-167
11224080-6	1991	Chronic administration of 8-OH-DPAT resulted in a heightened sensitivity not only to the 5-HT(1A) agonists 8-OH-DPAT and buspirone, but also to what appear to be partial agonist effects of pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Homo sapiens	89-96
11224080-6	1991	Chronic administration of 8-OH-DPAT resulted in a heightened sensitivity not only to the 5-HT(1A) agonists 8-OH-DPAT and buspirone, but also to what appear to be partial agonist effects of pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	89-96
11224080-7	1991	This approach represents a first step in the in vivo characterization of changes in 5-HT(1A) sensitivity after chronic administration of 8-OH-DPAT using the drug discrimination procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	137-146	5-hydroxytryptamine receptor 1A	Homo sapiens	84-91
1837848-2	1991	Superfusion of either serotonin or 8-OH-DPAT in the bath was found to inhibit population responses in a dose-dependent manner in both regions, with a greater effect in the CA1.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	carbonic anhydrase 1	Rattus norvegicus	172-175
1819150-6	1991	In contrast, the selective 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan decrease blood pressure and heart rate by a centrally-mediated decrease in sympathetic tone and an increase in vagal tone.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Homo sapiens	27-42
1725157-2	1991	To this end we analysed the interactions between galanin and the 5-HT1A receptor agonist 8-OH-2-(di-n-propylamino)-tetralin (8-OH-DPAT) in central cardiovascular regulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
1725157-6	1991	The vasodepressor action of 8-OH-DPAT was counteracted by the 5-HT1A receptor antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine (NAN-190).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
1797349-2	1991	5-HT1A mRNA was visualized using a 910 bp cRNA probe synthesised from a BalI-PvuII fragment of the rat 5-HT1A reetor gene, while 5-HT1A receptors were labelled with the 5-HT1A-selective ligand 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	193-202	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
1839282-0	1991	Effects of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective agonist of 5-HT1A receptors, on the cough reflex in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
1839282-1	1991	The effects of the agonist of 5-HT1A receptors, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), on the capsaicin-induced cough reflex in rats were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
1839282-1	1991	The effects of the agonist of 5-HT1A receptors, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), on the capsaicin-induced cough reflex in rats were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
1839282-12	1991	These results suggest that the antitussive action of 8-OH-DPAT may be related to the enhancement of the function of 5-HT1A receptors, and that antitussives interact with the 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-122
1839283-3	1991	A 5-HT1 agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (10 microM), reduced the release of TRH.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-55	thyrotropin releasing hormone	Rattus norvegicus	92-95
1839137-2	1991	Agents that have high and selective affinity for the 5-HT1A site such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and N,N-dipropyl-5-carboxamidotryptamine (DP5CT) inhibited the responses to field stimulation in guinea-pig ileum preparations; the inhibitory effects were antagonized by methiothepin and spiperone, consistent with effects at the 5-HT1A site.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-111	5-hydroxytryptamine receptor 1A	Cavia porcellus	53-59
1839148-0	1991	Low doses of the 5-HT1A receptor agonist 8-OH-DPAT increase ingestive behavior in late preweanling and postweanling, but not neonatal rat pups.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
1839148-4	1991	To the extent that low doses of 8-OH-DPAT increase feeding via preferential stimulation of 5-HT1A autoreceptors, these data suggest that neonates may lack functional 5-HT1A autoreceptors, with these receptors maturing by the late preweanling period.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97
1839137-2	1991	Agents that have high and selective affinity for the 5-HT1A site such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and N,N-dipropyl-5-carboxamidotryptamine (DP5CT) inhibited the responses to field stimulation in guinea-pig ileum preparations; the inhibitory effects were antagonized by methiothepin and spiperone, consistent with effects at the 5-HT1A site.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-111	5-hydroxytryptamine receptor 1A	Cavia porcellus	354-360
1839137-2	1991	Agents that have high and selective affinity for the 5-HT1A site such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and N,N-dipropyl-5-carboxamidotryptamine (DP5CT) inhibited the responses to field stimulation in guinea-pig ileum preparations; the inhibitory effects were antagonized by methiothepin and spiperone, consistent with effects at the 5-HT1A site.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Cavia porcellus	53-59
1839567-6	1991	Both the nonselective 5-HT agonist 5-MeODMT (1.25 mg/kg) and the more selective 5-HT1A agonist 8-OH-DPAT (2 mg/kg) disrupted spontaneous alternation.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-104	5-hydroxytryptamine receptor 1A	Homo sapiens	80-86
1664803-1	1991	The aim of the present study was to assess the effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and flesinoxan in ring preparations of human basilar artery.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-124	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77
1664803-1	1991	The aim of the present study was to assess the effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and flesinoxan in ring preparations of human basilar artery.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77
1664803-9	1991	We conclude from the relative rank order of antagonist potency that 8-OH-DPAT and 5-HT produce contraction of the human basilar artery by activation of the same receptor, a 5-HT1-like receptor distinct from the 5-HT1A receptor subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Homo sapiens	211-226
1686254-6	1991	Thus, the vasodilator effect of the 5-HT1A receptor agonists urapidil, 5-methyl-urapidil, ipsapirone, flesinoxan and 8-OH-DPAT in the noradrenaline-perfused rat kidney appears to be mediated by their concomitant alpha 1A-adrenoceptor blockade.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
1686254-6	1991	Thus, the vasodilator effect of the 5-HT1A receptor agonists urapidil, 5-methyl-urapidil, ipsapirone, flesinoxan and 8-OH-DPAT in the noradrenaline-perfused rat kidney appears to be mediated by their concomitant alpha 1A-adrenoceptor blockade.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	adrenoceptor alpha 1A	Rattus norvegicus	212-233
1838499-0	1991	The novel 5-HT1A receptor antagonist (S)-UH-301 antagonizes 8-OH-DPAT-induced effects on male as well as female rat copulatory behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
1838499-1	1991	The 5-HT1A receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) facilitates male rat copulatory behaviour but inhibits female rat copulatory behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1838499-1	1991	The 5-HT1A receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) facilitates male rat copulatory behaviour but inhibits female rat copulatory behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1838499-2	1991	The effect of the novel 5-HT1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin [S)-UH-301) on these 8-OH-DPAT-induced responses was tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
1715390-2	1991	Administration of 8-OH-DPAT, a 5-HT1A receptor agonist that decreases 5-HT neuronal activity, decreased extracellular 5-HT in both brain areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	31-46
1861158-11	1991	Immunostaining of cells by the anti-idiotypic antibodies was inhibited by appropriate pharmacological agents: immunostaining of cells expressing 5-HT1C receptors was blocked by mesulergine (but not ketanserin, 8-OH-DPAT, or spiperone), whereas that of cells expressing 5-HT2 receptors was blocked by ketanserin or spiperone (but not mesulergine or 8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	348-357	5-hydroxytryptamine receptor 2C	Homo sapiens	145-151
1682008-6	1991	The 5-HT1A receptor agonists, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), buspirone and gepirone caused consistent reduction in the firing rate of cells depressed by 5-HT while they did not change the firing activity of cells excited by 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1838334-1	1991	The effects of 5-HT1A receptor agonists such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), BP-554 and buspirone on the serum corticosterone level were significantly more pronounced in female than in male mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-86	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	15-30
1838334-2	1991	A similar sex difference was observed for the effect of 8-OH-DPAT on the plasma ACTH level.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	pro-opiomelanocortin-alpha	Mus musculus	80-84
1833017-2	1991	Parallel series of experiments were carried out in the rat and mouse in order to investigate the mechanism(s) underlying the hypothermia induced in rodents by the selective 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	198-236	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	173-188
1838983-6	1991	The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.5-16 nmol) also caused dose-dependent dilator responses in preconstricted rat kidneys.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1838983-6	1991	The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.5-16 nmol) also caused dose-dependent dilator responses in preconstricted rat kidneys.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1838983-9	1991	Both 8-OH-DPAT and tertatolol (1-30 microM) significantly reduced the vasoconstrictor responses to angiotensin II (20 pmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	5-14	angiotensinogen	Rattus norvegicus	99-113
1833017-13	1991	These data are consistent with the hypothesis that 8-OH-DPAT-induced hypothermia is mediated by presynaptic autoreceptors in the mouse and by postsynaptic 5-HT1A receptors in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	155-161
1658007-1	1991	1 We have examined the actions of the 5-HT1A-receptor ligand 8-OH-DPAT at alpha 2-adrenoceptor ligand binding sites in human platelet and rat kidney membranes and at functional pre- and postjunctional alpha 2-adrenoceptors in rat atrium and human saphenous vein, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	38-53
1681986-4	1991	The 5-HT1A/1B agonists 5-CT and 8-OH-DPAT and the 5-HT1B/1C agonist TFMPP reduced the synaptic responses as well, with an IC50 of 0.26, 2.2 and 0.28 microM, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1834306-1	1991	Quantitative autoradiographic analysis of serotonin 5-HT1A receptors in the human brain, using [3H]8-OH-DPAT as a ligand, reveals region-specific decreases in receptor labeling with age in several cortical and hippocampal regions and in the raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	52-58
1830099-1	1991	The selective 5-hydroxytryptamine (5-HT1A) receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) induces a large number of pharmacological effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
1830099-1	1991	The selective 5-hydroxytryptamine (5-HT1A) receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) induces a large number of pharmacological effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
1838412-0	1991	Effects of the 5-HT1A agonist, 8-OH-DPAT, on sexual behaviors of the proestrous rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
1838412-1	1991	The effects of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), were examined in intact, proestrous rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
1683291-7	1991	Similarly we have previously observed spiperone reversal of the sympatholytic effects of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) but failed to affect nerve activity when given alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99
1683291-7	1991	Similarly we have previously observed spiperone reversal of the sympatholytic effects of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) but failed to affect nerve activity when given alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-157	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99
1835441-4	1991	The results show that single-dose pretreatment with the reference 5-HT1A receptor agonist 8-hydroxy-2-(din-propylamino)tetralin, 8-OH-DPAT, (i) did not significantly alter the baseline output of 5-HT in the rat ventral hippocampus 24 h later, and (ii) did not alter the release-reducing response to 5-HT1A agonist (8-OH-DPAT, ipsapirone or BMY 7378) challenge under the same conditions.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
1835441-5	1991	These observations indicate that the functional responsiveness of the 5-HT release-controlling 5-HT1A autoreceptors is maintained after bolus 8-OH-DPAT pretreatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-101
1835441-6	1991	When related to the acute 8-OH-DPAT-induced reduction in raphe 5-HT1A radioligand binding density recently reported by others, the present results are consistent with a large functional overcapacity of this 5-HT1A receptor population.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
1835441-6	1991	When related to the acute 8-OH-DPAT-induced reduction in raphe 5-HT1A radioligand binding density recently reported by others, the present results are consistent with a large functional overcapacity of this 5-HT1A receptor population.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	207-213
1828347-2	1991	The affinity of DMT for 5-HT1A sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) was decreased in the presence of 10(-4) M GTP, suggesting agonist activity of DMT at this receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
1828859-0	1991	Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-116
1835098-2	1991	Acutely, in naive rats, both the putative 5-HT2 agonist DOI and 5-HT1A agonist 8-OH-DPAT induced some behaviors of the "serotonin syndrome" but the two drugs could be differentiated.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	64-70
1680714-6	1991	Detailed autoradiographic investigations allowed the detection of 5-HT1A sites labelled by both [3H]5-methyl-urapidil and [3H]8-OH-DPAT in the posterior raphe nuclei (pallidus and obscurus) which are possibly involved in the hypotensive action of 5-methyl-urapidil.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
1833209-1	1991	Infusion of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (2.5-20 micrograms in 1 microliter during 15 min), into the paraventricular nucleus of the hypothalamus (PVN) in the rat dose dependently increased plasma adrenaline and corticosterone concentrations, without affecting plasma noradrenaline concentrations.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	16-22
1833209-1	1991	Infusion of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (2.5-20 micrograms in 1 microliter during 15 min), into the paraventricular nucleus of the hypothalamus (PVN) in the rat dose dependently increased plasma adrenaline and corticosterone concentrations, without affecting plasma noradrenaline concentrations.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Rattus norvegicus	16-22
1826520-1	1991	Previous studies on central 5-hydroxytryptamine1A (5-HT1A) receptors have consistently shown the existence of a GTP-insensitive component of agonist binding, i.e., binding of [3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) that persists in the presence of 0.1 mM GTP or guanylylimidodiphosphate (GppNHp).	8-Hydroxy-2-(di-n-propylamino)tetralin	219-232	5-hydroxytryptamine receptor 1A	Rattus norvegicus	51-57
1826520-8	1991	These data suggest that the appearance of GTP-insensitive [3H]8-OH-DPAT specific binding occurs as a result of the (spontaneous) oxidation of essential -SH groups (different from those preferentially inactivated by N-ethylmaleimide) on the R[5-HT1A]-G protein complex.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	242-248
1831424-1	1991	The effects of long-term treatment with a low dose of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on steroid hormone-dependent copulatory behaviour in female rats, the lordosis response, and on the hypothermic response of female rats were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
1831424-1	1991	The effects of long-term treatment with a low dose of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on steroid hormone-dependent copulatory behaviour in female rats, the lordosis response, and on the hypothermic response of female rats were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
11224054-4	1991	The autoradiographic binding pattern of 4nM [(3)H]lisuride in rat brain showed high densities of sites displaceable by the 5-HT(1A) agonist 8-OH-DPAT in hippocampus, lateral septal nucleus and amygdala, as well as those displaceable by the D(2) antagonist sulpiride in striatum, nucleus accumbens and olfactory tubercle.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-130
1830235-6	1991	A single dose of Cl-Imip significantly reduced the effect of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylaminotetralin) (8-OH-DPAT, 0.1 mg kg-1, s.c.), which nearly doubled the cortical ACh release in control animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-118	5-hydroxytryptamine receptor 1A	Cavia porcellus	65-71
1830235-6	1991	A single dose of Cl-Imip significantly reduced the effect of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylaminotetralin) (8-OH-DPAT, 0.1 mg kg-1, s.c.), which nearly doubled the cortical ACh release in control animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Cavia porcellus	65-71
1848278-9	1991	Moreover, the inhibitory effect of 8-OH-DPAT on the carbachol response was blocked by 10 microM quinacrine (a phospholipase A2 inhibitor) but not by BW 755C (100 microM), a cyclooxygenase and lipoxygenase inhibitor.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	phospholipase A2 group IB	Rattus norvegicus	110-126
1826928-2	1991	administration of serotonin (5-HT) and the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	68-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
1826928-8	1991	These results suggest that stimulation of central nervous system 5-HT1A receptors with low doses of 8-OH-DPAT produces cardiovascular activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
1678728-3	1991	Lisuride was found to strongly inhibit the bindings of [3H]8-OH-DPAT to 5-HT1A receptors in the raphe nucleus, hippocampus, cortex, amygdala and hypothalamus of rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-78
1830134-2	1991	([3H]8-OH-DPAT), a serotonergic agonist, to 5-HT1A receptors was determined in membranes from the brain of the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	5-14	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
1829611-5	1991	Clonidine (an alpha 2-agonist) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, a 5-HT1A agonist) induced hyperphagia and 1-(3-trifluoromethylphenyl)piperazine (TFMPP, a 5-HT1B agonist) induced hypophagia dose-dependently in both rat lines.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
1829611-5	1991	Clonidine (an alpha 2-agonist) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, a 5-HT1A agonist) induced hyperphagia and 1-(3-trifluoromethylphenyl)piperazine (TFMPP, a 5-HT1B agonist) induced hypophagia dose-dependently in both rat lines.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-73	5-hydroxytryptamine receptor 1B	Rattus norvegicus	176-182
1829611-5	1991	Clonidine (an alpha 2-agonist) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, a 5-HT1A agonist) induced hyperphagia and 1-(3-trifluoromethylphenyl)piperazine (TFMPP, a 5-HT1B agonist) induced hypophagia dose-dependently in both rat lines.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
1829611-5	1991	Clonidine (an alpha 2-agonist) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, a 5-HT1A agonist) induced hyperphagia and 1-(3-trifluoromethylphenyl)piperazine (TFMPP, a 5-HT1B agonist) induced hypophagia dose-dependently in both rat lines.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1B	Rattus norvegicus	176-182
1829365-13	1991	Facilitation by 8-OH-DPAT of the male rat copulatory performance after median raphe injections is probably due to stimulation of 5-HT1A autoreceptors in this brainstem region.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	5-hydroxytryptamine receptor 1A	Rattus norvegicus	129-135
1682325-2	1991	In the isolated perfused mesenteric bed of the rat, bolus administration or infusion of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propyl-amino) tetralin (8-OH-DPAT; bolus 0.3-90 nmoles, infusion 0.03-30 microM) caused dose-related decreases in phenylephrine-induced tone.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	102-108
1682325-8	1991	The potency of 8-OH-DPAT, flesinoxan, ipsapirone, sumatriptan and phentolamine, at decreasing phenylephrine-induced tone in the mesentery correlated closely with antagonist potency at alpha 1-adrenoceptors (r = 0.99) but not with affinity at 5-HT1A binding sites (r = -0.2).	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	242-248
1672380-4	1991	The selective 5-HT1A agonist, (+-)-8-hydroxy-diprolaminotetralin HBr (8-OH-DPAT), dose-dependently antagonized morphine-induced antinociception (MIA) without affecting the latency to respond when applied alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-20
1672380-9	1991	The antagonism of MIA by 8-OH-DPAT was mimicked by additional drugs acting as high efficacy 5-HT1A agonists: lisuride, 5-methoxy-N,N-dimethyltryptamine hydrogen oxalate, RU 24969 [methoxy-3-(1,2,3.6-tetrahydropyridin-4-yl)-1H-indole] and d-lysergic acid diethylamide.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	92-98
1826033-4	1991	In rats restrained in horizontal cylinders, the selective 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin HBr (8-OH-DPAT), dose-dependently (0.04-10.0 mg/kg s.c.) elicited spontaneous tail-flicks (STFs).	8-Hydroxy-2-(di-n-propylamino)tetralin	119-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
1826033-9	1991	beta-Blockers with 5-HT1A affinity i.e., (-)-alprenolol, (+/-)-isamoltane and, stereoselectivity, (-)-but not (+)-pindolol, blocked the action of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
1826033-10	1991	Spiperone and spiroxatrine, D2 antagonists with high 5-HT1A affinity, also inhibited 8-OH-DPAT-induced STFs.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
1648748-2	1991	Three of these drugs (Compounds A, B, and C) are extremely potent (i.e., Ki values less than 1.0 nM) at 5-hydroxytryptamine1A (5-HT1A) sites labeled by [3H] 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	198-207	5-hydroxytryptamine receptor 1A	Rattus norvegicus	127-133
1829040-1	1991	Cardiovascular and behavioral responses induced by intravenous administration of the serotonin (5-HT)1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), were studied in conscious normotensive rats either after a single administration, after repeated subcutaneous treatments (1 mg/kg daily for 3 days), or after chronic intravenous infusion (200 micrograms/kg per h for 72 h).	8-Hydroxy-2-(di-n-propylamino)tetralin	122-160	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-112
1675996-1	1991	Microinfusion of the selective 5-HT1A receptor agonist, 8-hydroxy-(di-N-propylamino)tetralin (8-OHDPAT), into the dorsal raphe nucleus (DRN) produced a marked behavioural hypoactivity and flat body posture.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
1675996-4	1991	The behavioural profiles of other 5-HT1A selective compounds, gepirone and BMY7378 were found to be similar to 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
1828770-0	1991	Is NAN-190 an effective antagonist of the hypothermia and hyperglycemia induced by the 5-HT1A receptor agonist, 8-OH-DPAT?	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	87-102
1828770-2	1991	The responses studied were hypothermia- and hyperglycemia-induced by the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	89-127	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	73-79
1828770-2	1991	The responses studied were hypothermia- and hyperglycemia-induced by the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	129-138	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	73-79
1674364-3	1991	The inhibition produced by buspirone was unaffected by flumazenil, but was mimicked by the selective 5-HT1A receptor agonist, 8-OH DPAT and prevented by the 5-HT receptor antagonist spiperone [10(-6) M].	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Bos taurus	101-107
1829231-2	1991	The selective 5-HT1A agonist 8-OH-DPAT (0.03-1.0 mg/kg) resulted in dose-dependent increases in responding on the key correlated with imipramine administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20
1829232-8	1991	Quantitative autoradiographic studies 5 weeks after 5,7-DHT treatment revealed a significant increase in radioligand binding to 5-HT1A, 5-HT1B and 5-HT1C sites in many brain regions studied, except for the raphe nuclei where [3H]8-OH-DPAT binding to 5-HT1A sites was markedly reduced.	8-Hydroxy-2-(di-n-propylamino)tetralin	229-238	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-134
1831945-2	1991	8-OH-DPAT, known to be a central 5-HT1A receptor agonist, can induce a clonic seizure.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	33-48
1675912-1	1991	The prototypical 5-HT1A agonist, 8-OH-DPAT, dose-dependently (0.16-10.0 mg/kg, s.c.) elicited a pronounced antinociception in the hot-plate test in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	17-23
1826942-1	1991	A conditioned place preference paradigm was used to examine the motivational effects of the putative 5-hydroxytryptamine 1A (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propyl amino)tetralin (DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	150-189	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
1826942-3	1991	Pretreatment with the 5-HT1A/D2 dopamine (DA) receptor antagonist spiperone or the D1 DA receptor antagonist SCH-23390 abolished the DPAT-induced preferences.	8-Hydroxy-2-(di-n-propylamino)tetralin	133-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
1826942-5	1991	These data demonstrate that DPAT is an appetitive reinforcer and that this effect results from an interaction with 5-HT1A and D1 DA receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-32	5-hydroxytryptamine receptor 1A	Rattus norvegicus	115-121
1829040-1	1991	Cardiovascular and behavioral responses induced by intravenous administration of the serotonin (5-HT)1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), were studied in conscious normotensive rats either after a single administration, after repeated subcutaneous treatments (1 mg/kg daily for 3 days), or after chronic intravenous infusion (200 micrograms/kg per h for 72 h).	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-112
1772068-12	1991	Hyperpolarizing responses are also elicited by the 5-HT1A agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Homo sapiens	51-57
1832809-18	1991	The experiments with 8-OH-DPAT suggest that serotonergic mechanisms in thermoregulation are mediated via receptors of the 5-HT1A type.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
1832809-19	1991	The 8-OH-DPAT-induced effects on sexual behavior, spontaneous motor activity and on forebrain 5-HT synthesis suggests a specific functional role for 5-HT1A receptors in the MR.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	149-155
1837683-7	1991	Thus, 5-HT1A agonists (8-OH-DPAT, buspirone, gepirone etc.)	8-Hydroxy-2-(di-n-propylamino)tetralin	23-32	5-hydroxytryptamine receptor 1A	Rattus norvegicus	6-12
1675146-2	1991	The effects of pretreatment with two novel and relatively specific alpha 2-adrenoceptor antagonists on the hypothermic and hyperglycaemic responses induced by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) were investigated in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	187-225	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	163-178
2015508-3	1991	The dt rats were 6-fold more sensitive to the ability of the 5-HT1A agonist 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT) to produce the 5-HT behavioral syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
1673344-1	1991	The administration of the 5-HT1A agonist 8-OH-DPAT, 0.1 mg kg-1 sc-20 min, produced a moderate suppression of conditioned avoidance behavior (60% of controls) in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
1826841-0	1991	5-HT1A agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain-stimulation reward.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
1834089-1	1991	In order to establish whether the 5-HT1A or the 5HT1B agonists, 8-OH-DPAT or TFMPP, produce their facilitatory or inhibitory actions on masculine sexual behaviour via a mechanism involving: (a) the serotonin synthesis or release; (b) the stimulation of presynaptic receptors, or (c) the stimulation of somatodendritic receptors, three series of experiments were performed.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1B	Rattus norvegicus	48-53
1886079-2	1991	In our attempt to develop new agents that would interact selectively at certain 5-HT receptors, especially the 5-HT1A subtype, 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT) served as a template for the design of novel agents sharing aspects of the pharmacophore of 8-OH-DPAT and 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-164	5-hydroxytryptamine receptor 1A	Homo sapiens	111-117
1886079-2	1991	In our attempt to develop new agents that would interact selectively at certain 5-HT receptors, especially the 5-HT1A subtype, 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT) served as a template for the design of novel agents sharing aspects of the pharmacophore of 8-OH-DPAT and 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-175	5-hydroxytryptamine receptor 1A	Homo sapiens	111-117
1886079-3	1991	5-HT contains no center of asymmetry, and 8-OH-DPAT shows only very modest stereospecificity for 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103
1886079-4	1991	To develop agents having enhanced potency and selectivity for the 5-HT1A site, several ring systems offering enhanced conformational rigidity which approximate the oxygen to nitrogen interatomic distances of 8-OH-DPAT and (to a lesser extent) 5-HT were synthesized.	8-Hydroxy-2-(di-n-propylamino)tetralin	208-217	5-hydroxytryptamine receptor 1A	Homo sapiens	66-72
1824956-4	1991	The [3H]8-OH-DPAT bindings to the prefrontal cortex and hippocampus were potently inhibited by serotonin (IC50 = 6.3 x 10(-9) M) and 5-HT1A agonists (IC50 = 5.0 x 10(-9) - 2.3 x 10(-7) M), while other neurotransmitters, 5-HT2 and 5-HT3 related compounds did not inhibit the binding (IC50 greater than 10(-5) M).	8-Hydroxy-2-(di-n-propylamino)tetralin	8-17	5-hydroxytryptamine receptor 1A	Homo sapiens	133-139
1834090-1	1991	The density of 5-HT1A binding using 3H-8-hydroxy-2-(di-n-propyl-amino) tetralin (8-OH-DPAT) as binding ligand, was studied in human frontal cortex of suicide victims and normal controls who died due to medical disease or accidentally.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	15-21
1825686-5	1991	The 5-HT1A receptor agonist 8-OH-DPAT competitively inhibited carbachol-stimulated inositol phospholipid breakdown with pA2 values of 5.78 (IMR-32) and 5.61 (SK-N-MC).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
1825686-5	1991	The 5-HT1A receptor agonist 8-OH-DPAT competitively inhibited carbachol-stimulated inositol phospholipid breakdown with pA2 values of 5.78 (IMR-32) and 5.61 (SK-N-MC).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	hedgehog acyltransferase	Homo sapiens	158-162
1828519-1	1991	The 5-HT1A receptor agonists buspirone and 8-OH-DPAT have strong effects on serotoninergic systems.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
20504708-2	1991	[(3)H]8-OH-DPAT, [(125)I]ICYP, [(3)H]mesulergine and [(3)H]ketanserin are radiolabeled ligands for 5-HT(1A), 5-HT(1B), 5-HT(1C) and 5-HT(2) sites, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	6-15	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-106
1678895-5	1991	Thus, 1-PP has been evaluated alone (0.06-4 mg/kg/day) or in combination with a selective 5-HT1A agonist 8-OH-DPAT (0.25 mg/kg/day) which is not metabolized to 1-PP and buspirone (0.5 mg/kg/day).	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	90-96
2052135-3	1991	In 1983 the very selective, high affinity 5-HT1A agonist 8-OH-DPAT was developed which allowed the pharmacology and distribution of the 5-HT1A receptor in the central nervous system of the rat and man to be extensively characterized.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
2052135-3	1991	In 1983 the very selective, high affinity 5-HT1A agonist 8-OH-DPAT was developed which allowed the pharmacology and distribution of the 5-HT1A receptor in the central nervous system of the rat and man to be extensively characterized.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Homo sapiens	136-151
1829235-5	1991	The application of 5-HT or the 5-HT1A agonist 8-OH-DPAT into the DR produced a marked decrease in core temperature, whereas injections into the MR had no effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
1829235-7	1991	The fact that the 5-HT1A agonist 8-OH-DPAT produced a decrease in core temperature, together with the observation that administration of the 5-HT1 antagonist (-)pindolol antagonized the 5-HT as well as the 8-OH-DPAT-induced decrease, indicates the involvement of DR 5-HT1A receptors in rat thermoregulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
1829235-7	1991	The fact that the 5-HT1A agonist 8-OH-DPAT produced a decrease in core temperature, together with the observation that administration of the 5-HT1 antagonist (-)pindolol antagonized the 5-HT as well as the 8-OH-DPAT-induced decrease, indicates the involvement of DR 5-HT1A receptors in rat thermoregulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	266-272
1829235-7	1991	The fact that the 5-HT1A agonist 8-OH-DPAT produced a decrease in core temperature, together with the observation that administration of the 5-HT1 antagonist (-)pindolol antagonized the 5-HT as well as the 8-OH-DPAT-induced decrease, indicates the involvement of DR 5-HT1A receptors in rat thermoregulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	206-215	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
1839064-3	1991	The ED50 for the 5-HT1A receptor mediated, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)-induced LLR showed an increase from 0.07 mg/kg in placebo pretreated rats to 0.13 in 8-OH-DPAT (1 mg/kg/day) pretreated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
1839064-3	1991	The ED50 for the 5-HT1A receptor mediated, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)-induced LLR showed an increase from 0.07 mg/kg in placebo pretreated rats to 0.13 in 8-OH-DPAT (1 mg/kg/day) pretreated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
1839064-3	1991	The ED50 for the 5-HT1A receptor mediated, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)-induced LLR showed an increase from 0.07 mg/kg in placebo pretreated rats to 0.13 in 8-OH-DPAT (1 mg/kg/day) pretreated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
1839064-8	1991	The monoamine oxidase (MAO) inhibitor tranylcypromine (4 mg/kg/day) given for 10 days caused an increase in the ED50 for 8-OH-DPAT induced LLR (ED50 values were 0.06 and 0.14 mg/kg, respectively, in placebo--and tranylcypromine--pretreated rats) and attenuated MK 212 (0.22 and 0.46 mg/kg)-induced PE.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	monoamine oxidase A	Rattus norvegicus	4-21
1839064-8	1991	The monoamine oxidase (MAO) inhibitor tranylcypromine (4 mg/kg/day) given for 10 days caused an increase in the ED50 for 8-OH-DPAT induced LLR (ED50 values were 0.06 and 0.14 mg/kg, respectively, in placebo--and tranylcypromine--pretreated rats) and attenuated MK 212 (0.22 and 0.46 mg/kg)-induced PE.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	monoamine oxidase A	Rattus norvegicus	23-26
2150776-5	1990	Pituitary stalk transection (PST), as well as pretreatment with rabbit serum hyperimmune against rat corticotropin-releasing hormone (CRH, TS-6) completely abolished beta-End-LI response to 8-OH-DPAT and attenuated the responses by about 60% to DOI.	8-Hydroxy-2-(di-n-propylamino)tetralin	190-199	corticotropin releasing hormone	Rattus norvegicus	101-132
2150776-5	1990	Pituitary stalk transection (PST), as well as pretreatment with rabbit serum hyperimmune against rat corticotropin-releasing hormone (CRH, TS-6) completely abolished beta-End-LI response to 8-OH-DPAT and attenuated the responses by about 60% to DOI.	8-Hydroxy-2-(di-n-propylamino)tetralin	190-199	corticotropin releasing hormone	Rattus norvegicus	134-137
1964908-4	1990	MDL 73005EF failed to alter basal plasma adrenocorticotropin (ACTH) levels but, in common with pindolol, attenuated the ACTH response to the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	166-204	5-hydroxytryptamine receptor 1A	Rattus norvegicus	141-147
2150818-7	1990	The mixed 5-HT1C/2 receptor antagonists, ritanserin and ICI 169,369, did not modify the action of 8-OH-DPAT alone but abolished the potentiation of 8-OH-DPAT-induced tail-flicks by DOI and TFMPP.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 2C	Rattus norvegicus	10-16
2150818-9	1990	A common property of those drugs potentiating 8-OH-DPAT-induced tail-flicks is an agonist action at 5-HT1C receptors and the data indicate that it is this mechanism which underlies the facilitation of tail-flicks.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-55	5-hydroxytryptamine receptor 2C	Rattus norvegicus	100-106
1963847-4	1990	Administration of the 5-HT1A agonists, 8-OH-DPAT (1 mg/kg) and ipsapirone (4 mg/kg), to rats resulted in activation of the HPA axis as evidenced by increased plasma ACTH and corticosterone concentrations in acutely treated rats and increased plasma corticosterone concentrations in both acutely and chronically treated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
2178032-3	1990	The reductions of GABA-depolarizations which were produced by 1.0 microM 5-HT were mimicked by the 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-(n-dipropylamino)tetralin) and ipsapirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Homo sapiens	99-105
2178032-6	1990	The presumptive 5-HT1A receptor-mediated effects of 1.0 microM 5-HT and 8-OH-DPAT appeared to result from a direct action on afferent terminals because the reduction of GABA responses was unchanged by addition of TTX to the Ringer"s solution.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Homo sapiens	16-31
2282513-8	1990	The 5-HT1A agonists, serotonin (5-HT) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) competed with equal affinities regardless of the radioligand used to label the 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2282513-8	1990	The 5-HT1A agonists, serotonin (5-HT) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) competed with equal affinities regardless of the radioligand used to label the 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	172-178
1702155-5	1990	As expected from unchanged postsynaptic 5-HT1A receptors, inhibition of forskolin-stimulated adenylate cyclase by 5-HT1A agonists (8-hydroxy-2-(di-n-propylamino)tetralin, ipsapirone) exhibited the same characteristics in hippocampal homogenates from both control and ipsapirone-treated animals.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-169	5-hydroxytryptamine receptor 1A	Rattus norvegicus	114-120
2150180-9	1990	Forepaw treading in rats induced by the 5-HT1A-agonist 8-OH-DPAT was attenuated by the 5-HT1C-agonists MK 212 and mCPP.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
2150180-9	1990	Forepaw treading in rats induced by the 5-HT1A-agonist 8-OH-DPAT was attenuated by the 5-HT1C-agonists MK 212 and mCPP.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 2C	Rattus norvegicus	87-93
2150180-10	1990	The 5-HT1C-agonist TFMPP had a bimodal effect: at low doses (less than 1 mg kg-1) it potentiated, and at higher doses (greater than 2.2 mg kg-1) it attenuated forepaw treading, the mixed 5-HT2/1C-agonist DOI produced 5-HT2-related behaviours and potentiated 8-OH-DPAT-induced forepaw treading.	8-Hydroxy-2-(di-n-propylamino)tetralin	258-267	5-hydroxytryptamine receptor 2C	Rattus norvegicus	4-10
2136217-2	1990	The putative 5-HT1A receptor agonists buspirone, gepirone, ipsapirone and 8-OH-DPAT all produced anxiolytic-like effects in narrow low dose-ranges, while in higher doses the behavior returned towards that seen in controls and, after the highest doses of buspirone and gepirone, was suppressed below that of controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28
2150862-15	1990	The 5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin hydrobromide (8-OH-DPAT) mimicked the hyperpolarizing response.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2150862-15	1990	The 5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin hydrobromide (8-OH-DPAT) mimicked the hyperpolarizing response.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1982341-0	1990	Diminished corticotropin and enhanced prolactin responses to 8-hydroxy-2(di-n-propylamino)tetralin in methylenedioxymethamphetamine pretreated rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-98	prolactin	Rattus norvegicus	38-47
1982341-2	1990	In the present study, a blunted corticotropin and an enhanced prolactin response to the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH DPAT) was found in rats treated two weeks previously with a single dose of MDMA (2.0 or 20.0 mg/kg, sc).	8-Hydroxy-2-(di-n-propylamino)tetralin	103-140	prolactin	Rattus norvegicus	62-71
1982341-2	1990	In the present study, a blunted corticotropin and an enhanced prolactin response to the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH DPAT) was found in rats treated two weeks previously with a single dose of MDMA (2.0 or 20.0 mg/kg, sc).	8-Hydroxy-2-(di-n-propylamino)tetralin	103-140	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
1982341-2	1990	In the present study, a blunted corticotropin and an enhanced prolactin response to the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH DPAT) was found in rats treated two weeks previously with a single dose of MDMA (2.0 or 20.0 mg/kg, sc).	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	prolactin	Rattus norvegicus	62-71
1982341-2	1990	In the present study, a blunted corticotropin and an enhanced prolactin response to the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH DPAT) was found in rats treated two weeks previously with a single dose of MDMA (2.0 or 20.0 mg/kg, sc).	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
1983358-0	1990	Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	35-41
1979459-13	1990	Local stereotactic injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) caused a decrease in mean arterial blood pressure (MAP) and heart rate (HR).	8-Hydroxy-2-(di-n-propylamino)tetralin	51-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
1979459-13	1990	Local stereotactic injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) caused a decrease in mean arterial blood pressure (MAP) and heart rate (HR).	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
2148816-3	1990	Immunoautoradiographic labelling of rat brain sections with the anti-peptide antiserum was superimposed with the autoradiographic distribution of 5-HT1A sites labelled by the selective radioligand [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	201-210	5-hydroxytryptamine receptor 1A	Rattus norvegicus	146-152
2148726-7	1990	This indicates that blockade of 8-OH-DPAT-induced LLR is only possible by selective blockade of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Rattus norvegicus	96-102
2282513-8	1990	The 5-HT1A agonists, serotonin (5-HT) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) competed with equal affinities regardless of the radioligand used to label the 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2255331-1	1990	Recent results have indicated that the 5-HT1A receptor subtype mediates the adrenaline-releasing and hyperglycemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-164	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
2078274-17	1990	Hyperpolarizing responses are also elicited by the 5-HT1A agonists, 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) and 5-carboxyamidotryptamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Homo sapiens	51-57
2123971-5	1990	The putative 5-HT1A antagonist, (+/-) pindolol, attenuated the reversal of catalepsy by 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
1701842-4	1990	In the control animals, systemic stimulation of somatodendritic 5-HT1A receptors with the 5-HT1A receptor agonist 8-OH-DPAT, inhibited the release of 5-HT presumably via inhibitory feedback autoregulation; an effect also seen in animals treated acutely with ritanserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	64-70
1701842-4	1990	In the control animals, systemic stimulation of somatodendritic 5-HT1A receptors with the 5-HT1A receptor agonist 8-OH-DPAT, inhibited the release of 5-HT presumably via inhibitory feedback autoregulation; an effect also seen in animals treated acutely with ritanserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	90-96
2259248-4	1990	We have observed that a range of 5-HT1A agonists, including 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), inhibit 5-HT release in hippocampus, most probably by acting on somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	33-39
2259248-4	1990	We have observed that a range of 5-HT1A agonists, including 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), inhibit 5-HT release in hippocampus, most probably by acting on somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
2259248-4	1990	We have observed that a range of 5-HT1A agonists, including 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), inhibit 5-HT release in hippocampus, most probably by acting on somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	33-39
2259248-4	1990	We have observed that a range of 5-HT1A agonists, including 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), inhibit 5-HT release in hippocampus, most probably by acting on somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
2149874-2	1990	The excitability of spinal motoneurons was markedly enhanced after intravenous administration of the selective 5-HT1A ligand 8-hydroxy-2-(di-n-propylamino) tetralin (DPAT) in rats with acute spinal transections at C1.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-164	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
2145051-6	1990	Pretreatment with the 5-HT2/5-HT1C antagonist ICI 170,809 (0.25-5 mg kg-1) also enhanced the behavioural syndrome induced by 8-OH-DPAT or 5-MeODMT.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	5-hydroxytryptamine receptor 2C	Rattus norvegicus	28-34
2145051-8	1990	The 5-HT2/alpha 1-adrenoceptor antagonist ketanserin in a low dose (0.25 mg kg-1) significantly increased the 5-HT behavioural syndrome induced by 8-OH-DPAT or 5-MeODMT, while in a higher dose (2.5 mg kg-1) this drug decreased the response.	8-Hydroxy-2-(di-n-propylamino)tetralin	147-156	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-30
2148812-3	1990	The 8-OH-DPAT-induced increase in serum corticosterone was not antagonized by metergoline, the most potent antagonist of the quipazine effect, but was antagonized by pindolol or penbutolol, 5-HT1A receptor antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	190-196
2148813-2	1990	Application of the selective 5-HT1A agonist, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT; 10(-6) M) or d-lysergic acid diethylamide (d-LSD; 10(-6) M), produced only a hyperpolarizing response which was larger than the response to 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
2166901-4	1990	On the other hand, treatment with Boc-Cys(Npys) inhibited the effect of several GTP analogs (GTP gamma S, guanylyl-imidodiphosphate, guanylyl)-(beta, gamma-methylene)-diphosphate, and GTP) on [3H]8-OH-DPAT and [3H]clonidine binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	196-205	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	93-187
2149874-2	1990	The excitability of spinal motoneurons was markedly enhanced after intravenous administration of the selective 5-HT1A ligand 8-hydroxy-2-(di-n-propylamino) tetralin (DPAT) in rats with acute spinal transections at C1.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-170	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
2149874-8	1990	However, the marked increase in firing of motoneurons that was caused by intravenous administration of DPAT in spinal transected rats, suggests that 5-HT1A receptors in the spinal cord may participate in 5-HT-induced enhancement of somatomotor outflow, at sites presynaptic to the motoneurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-107	5-hydroxytryptamine receptor 1A	Rattus norvegicus	149-155
1981665-1	1990	The aim of the present experiments was to investigate whether 8-OH-DPAT, a selective 5-HT1A agonist, could induce vasoconstriction in vivo and, if so, the type of receptors functionally involved.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-91
1981665-12	1990	(-)Propranolol (5 mg/kg), a beta-blocker with a 5-HT1A antagonistic action, affected the 8-OH-DPAT-induced blood pressure elevation (37% reduction).	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	48-54
1981665-18	1990	Our data suggest that the 5-HT1A agonistic property of 8-OH-DPAT cannot account for this pressor effect which seems to depend on the activation of the vascular 5-HT2 receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
2151467-3	1990	These results, together with literature data, indicate that the presynaptic 5-HT1A receptors involved in the 8-OH-DPAT-induced feeding are not affected by long-term antidepressant administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
2144824-8	1990	The results suggest that 8-OH-DPAT activates 5-HT1A receptors in the dorsal raphe nucleus to cause hypotension and bradycardia.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
1698505-6	1990	Behaviorally, rats treated with 3-AP were 2.5-fold more sensitive to the ability of the 5-HT1A agonist 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.33-3.3 mg/kg) to produce the 5-HT syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	138-147	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
1698505-10	1990	Quantitative autoradiographic analysis of the density of 5-HT1A receptors labeled with [3H]8-OH-DPAT revealed that these sites were unchanged in regions of the brain (frontal cortex, hippocampus and brain stem) and in the spinal cord.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
1696545-2	1990	injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) caused hypothermia and increased the concentrations of serum corticosterone and plasma ACTH in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-51	pro-opiomelanocortin-alpha	Mus musculus	151-155
1696545-2	1990	injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) caused hypothermia and increased the concentrations of serum corticosterone and plasma ACTH in mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	pro-opiomelanocortin-alpha	Mus musculus	151-155
1973935-2	1990	At this point, the somatodendritic 5-HT1A autoreceptor had desensitized, as indicated by the reduced effectiveness of intravenous lysergic acid diethylamide (LSD) and of microiontophoretic applications of 5-HT, LSD, 8-hydroxy-2-(N,N-propylamino) tetralin (8-OH-DPAT), and gepirone, but not of gamma-aminobutyric acid in depressing the firing activity of 5-HT neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	256-265	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
2142096-6	1990	The cardiovascular responses to flesinoxan and 8-OH-DPAT in the anaesthetized Wistar were inhibited by the putative 5-HT1A antagonists methiothepin, buspirone, spiroxatrine and 8-MeO-C1EPAT (8-methoxy-2-(N-2-cholroethyl-N-n-propylamino)tetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	47-56	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-122
2142096-10	1990	This study confirms the involvement of central 5-HT1A receptors in the cardiovascular effects of flesinoxan and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
2117776-5	1990	The effects of serotonin on baseline and IL-2-activated NK cells were mimicked by the 5-HT1A receptor-specific agonists 8-OH-DPAT and (+)-ALK.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	interleukin 2	Homo sapiens	41-45
2117776-5	1990	The effects of serotonin on baseline and IL-2-activated NK cells were mimicked by the 5-HT1A receptor-specific agonists 8-OH-DPAT and (+)-ALK.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Homo sapiens	86-101
2141988-0	1990	Antidepressant-like action of 8-OH-DPAT, a 5-HT1A agonist, in the learned helplessness paradigm: evidence for a postsynaptic mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
2141988-9	1990	These results suggest that the ability of 8-OH-DPAT to reverse helpless behaviour probably involved the stimulation of postsynaptic rather than presynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	156-162
2142614-2	1990	Effects of the prototype selective 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-dipropylamino)tetralin (8-OH-DPAT), were studied on the glycaemia and insulinaemia in conscious spontaneously hypertensive (SH) rats concurrently with blood pressure (BP) and heart rate (HR); underlying mechanism(s) were investigated in anaesthetized and pithed SH rats and in the perfused rat pancreas.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
1971022-3	1990	The 5-HT-1A agonists 8-hydroxy-2-(di-n-propylamino)tetralin and 5-methoxy-N,N-dimethyltryptamine preferentially increased the firing rate of slowly firing DA neurons, but did not alter the responsiveness of these cells to quinpirole-induced inhibition of firing rate.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
2140514-5	1990	Using acutely isolated, patch-clamped dorsal raphe neurons, we found that low concentrations of 5-HT and the 5-HT1A-selective agonist 8-OH-DPAT reversibly decrease whole-cell calcium current.	8-Hydroxy-2-(di-n-propylamino)tetralin	134-143	5-hydroxytryptamine receptor 1A	Homo sapiens	109-115
2349270-1	1990	Buspirone was studied to determine whether the detailed profile of male sexual behavior observed following treatment with the prototypical 5-HT1A ligand, 8-OH-DPAT, can be generalized to other 5-HT1A agonist drugs.	8-Hydroxy-2-(di-n-propylamino)tetralin	154-163	5-hydroxytryptamine receptor 1A	Rattus norvegicus	139-145
1970497-0	1990	Heterogeneity of alpha 2-adrenoceptors in rat cortex but not human platelets can be defined by 8-OH-DPAT, RU 24969 and methysergide.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-104	adrenoceptor alpha 2A	Rattus norvegicus	17-38
1972893-7	1990	Subcutaneous injection of the 5-HT1a receptor antagonists spiroxatrine or spiperone inhibited the cardiovascular response to 8-OH-DPAT and 5-MU.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	30-45
1974300-1	1990	The administration of the 5-HT1A agonist 8-OH-DPAT (0.8 mumols kg-1 s.c.-40 min) produced an increase in dopamine (DA) turnover, estimated by the quotient (DOPAC + HVA) DA-1, in the ventral striatum of the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	41-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
1970616-0	1990	Evidence that 5-HT1A receptors are involved in the adrenaline-releasing effects of 8-OH-DPAT in the conscious rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
1970616-1	1990	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A receptor-selective agonist that has recently been reported to trigger adrenal catecholamine release and hyperglycemia.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
1970616-1	1990	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A receptor-selective agonist that has recently been reported to trigger adrenal catecholamine release and hyperglycemia.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
1970616-9	1990	The data suggest that the adrenaline-releasing and a major part of the hyperglycemic effects of 8-OH-DPAT are mediated by activation of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
2138459-3	1990	In contrast, both 5-HT1A agonists tested, 8-OH-DPAT and ipsapirone, produced an increase in respiratory rate at all doses tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
2140607-5	1990	The results of the present study indicate similarity between the discriminative stimulus effects of flesinoxan and the stimulus produced by the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	159-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	144-150
1691712-1	1990	8-Hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT) has antidepressant-like effects in rats and selectively reduces presynaptic 5-HT1A function a day after administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
1691712-7	1990	These results confirm the ability of 8-OH-DPAT to desensitise presynaptic 5-HT1A receptors and suggest that this may lead to a loss of feedback control so that, on neuronal stimulation, the increase of 5-HT function is enhanced.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
2139613-1	1990	The long-term effects of low doses of the 5-HT1A-agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), were studied to assess differences in the development of subsensitivity in 8-OH-DPAT-induced behavioural responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
1692973-5	1990	The cis-1-methylated 8-OH-DPAT analogue (+)ALK-3 was comparable to the parent compound in reducing the 5-HT output from rat ventral hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	bone morphogenetic protein receptor type 1A	Rattus norvegicus	43-48
1692973-9	1990	In summary, the data indicate that (+)ALK-3, like 8-OH-DPAT, is a very potent 5-HT receptor agonist which inhibits terminal 5-HT release in rat hippocampus, probably via activation of somatodendritic 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	bone morphogenetic protein receptor type 1A	Rattus norvegicus	38-43
2139188-11	1990	Indeed, the 5-HT1A agonist, 8-OH-DPAT, was reported to attenuate morphine-evoked antinociception in mice (Berge et al., 1985).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	12-18
1980361-4	1990	8-OH-DPAT, a selective agonist of 5-HT1A receptors, used in a dose of 5 mg/kg sc was less effective, having accelerated noradrenaline disappearance in the cortex and hypothalamus, and having increased only the level of homovanillic acid in the striatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
1970424-6	1990	The increase in the behavioural deficit induced by 8-OH-DPAT, was likely to have resulted from stimulation of 5-HT1A receptors, since it was impaired by pretreatment with penbutolol, a beta-adrenergic-blocking drug, also known to bind to 5-HT1 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	110-116
1970269-13	1990	The anti-conflict effects of MDL 73005EF were reversed by low doses of the 5-HT1A receptor agonist, 8-OH-DPAT; those of buspirone were neither antagonised nor mimicked by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	75-81
2138222-4	1990	8-OH-DPAT (0.0625-4.0 micrograms) produced dose-dependent hypotension and bradycardia, which were antagonized by the 5-HT1A antagonists spiperone and spiroxatrine.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	117-123
1691832-0	1990	Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
1691832-0	1990	Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Rattus norvegicus	127-133
1691832-1	1990	The effects of repeated treatment of rats with 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 1.0 mg/kg, subcutaneously, twice daily for 7 days, on the stimulation of post- and presynaptic 5-HT1A receptors were examined.	8-Hydroxy-2-(di-n-propylamino)tetralin	47-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	194-200
1691832-6	1990	The kinetic properties of 5-HT1A receptors in the cerebral cortex and hippocampus, hippocampus alone, hypothalamus and medulla oblongata were determined with [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
2137565-2	1990	In the present study, specific binding of the 5-HT1A-specific ligand, [3H]8-OH-DPAT, was determined in sections of the rat medulla oblongata using autoradiographic techniques.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-52
1968842-0	1990	Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapirone in vitro.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Homo sapiens	59-65
2252308-9	1990	5-HT1D receptors show high to intermediate affinities to compounds such as PAPP, DP-5-CT, 8-OH-DPAT, yohimbine and rauwolscine, whereas 5-HT1B receptors have very low affinities for these compounds.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1D	Homo sapiens	0-6
2136995-5	1990	Conversely, attempts to prevent the dissociation of R[5-HT1A]-G by treatment of CHAPS soluble hippocampal extracts with the cross-linking reagent disuccinimidyl suberate (0.1 mM) resulted in a significant increase (+70%) in [3H]8-OH-DPAT binding activity associated with the appearance of a new sedimenting material with a higher coefficient (16.5 S).	8-Hydroxy-2-(di-n-propylamino)tetralin	228-237	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-60
2136995-6	1990	Furthermore, [3H]8-OH-DPAT binding became almost completely insensitive to guanine nucleotides as expected from the irreversible coupling by disuccinimidyl suberate of R[5-HT1A] with G protein(s).	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-176
1691944-14	1990	The 5-HT behavioural syndrome induced by injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was unaltered by either acute injection of felodipine (35 mg kg-1) or administration of felodipine twice daily for 3 days.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
1688708-0	1990	Hippocampal 5-hydroxytryptamine synthesis is greater in female rats than in males and more decreased by the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	123-132	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
1688708-4	1990	The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 1 mg/kg sc) caused comparable decreases of 5-HT synthesis rate in both sexes and in all regions studied except the hippocampus where the percentage decrease was twice as large in the females (-64%) as in the males (-32%) so that the sex difference in 5-HT synthesis in this region largely disappeared.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
1688708-4	1990	The 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 1 mg/kg sc) caused comparable decreases of 5-HT synthesis rate in both sexes and in all regions studied except the hippocampus where the percentage decrease was twice as large in the females (-64%) as in the males (-32%) so that the sex difference in 5-HT synthesis in this region largely disappeared.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2136705-4	1990	These nonhydrolyzable GTP analogues were used to characterize the effects of persistent alterations in G proteins on [3H]8-OH-DPAT binding to 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-148
2136705-8	1990	These results indicate that GTP gamma S and GppNHp induce persistent changes in 5-HT1A receptor-G protein interactions that are reflected as a decrease in the density of binding sites labeled by [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	199-208	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
2125080-4	1990	While non-5-HT1A sites, defined as specific [3H]5-HT binding in the presence of 100 nM 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), were not affected by lithium treatment in either brain region, chronic lithium administration reduced significantly the density of 5-HT1A sites labeled with [3H]8-OH-DPAT only in the hippocampus, but not in the cerebral cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
2125080-4	1990	While non-5-HT1A sites, defined as specific [3H]5-HT binding in the presence of 100 nM 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), were not affected by lithium treatment in either brain region, chronic lithium administration reduced significantly the density of 5-HT1A sites labeled with [3H]8-OH-DPAT only in the hippocampus, but not in the cerebral cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	271-277
2137548-1	1990	Saturable [3H]-8OHDPAT binding to 5HT-1A receptors in membranes prepared from hippocampus and frontal cerebral cortex of alcohol-preferring P rats and of alcohol-nonpreferring NP rats has been compared.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
1969119-4	1990	The effects of 8-OH-DPAT and SM-3997 on the hippocampal RSA were blocked by pindolol, which has 5-HT1A antagonistic activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	96-102
1969119-6	1990	These findings indicated that 8-OH-DPAT and SM-3997 inhibited the hippocampal RSA by acting on hippocampal 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	107-113
20504589-2	1990	Computer nonlinear regression analysis of competition studies employing 8-OH-DPAT indicated that this 5-HT(1A) selective agonist demonstrated high affinity competition (K(i = 1.3 nM)) for 24.6 +/- 0.7% of the total [(3)H]5-HT binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-109
20504589-3	1990	Competition studies employing the 5-HT(1B) selective agonist RU24969, in the presence of 100 nM 8-OH-DPAT, indicated that RU24969 demonstrated high affinity (K(i = 1.1 nM)) competitive inhibition for 26.2 +/- 1.4% of all [(3)H]5-HT binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1B	Rattus norvegicus	34-41
20504590-3	1990	In electrophysiological studies, iontophoretic administration of either the 5-HT(1A) agonist 8-OH-DPAT (43.8 +/- 5.4 nA) or BMY 7378 (46.3 +/- 5.2 nA) significantly inhibited the firing rate of wide-dynamic-range dorsal horn units indicating that BMY 7378 demonstrates significant intrinsic activity at spinal cord 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-83
2138331-5	1990	Furthermore, pretreatment with a partial 5-HT1A agonist (+/-)pindolol blocked the inhibitory effects of 8-OH-DPAT to the level of inhibition produced by (+/-)pindolol itself.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
1971447-1	1990	The role of 5-HT1A autoreceptors in the discriminative stimulus properties of 8-OH-DPAT (0.1 mg/kg, SC) in rats, was investigated.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	12-18
1975107-2	1990	The 5-HT1A agonists 8-OH-DPAT (0.125-1.0 mg/kg, SC) and tandospirone (SM-3997) (5-20 mg/kg, SC) both produced dose-related decreases in immobility time following subchronic treatment in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2137632-2	1990	The hypothesis that this effect is mediated by 5-HT1A receptors was tested by investigating the abilities of the putative 5-HT1A antagonists metergoline, propranolol and spiperone to prevent 8-OH-DPAT-induced eating.	8-Hydroxy-2-(di-n-propylamino)tetralin	191-200	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
2137943-4	1990	The selective 5-HT1A agonist 8-OH-DPAT produced a gradual decrease in the height of the 300 mV oxidation peak in the dorsal raphe and in the frontal cortex, reaching a maximum of 60% 3 h after the i.v.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
34970573-8	2021	Results: 5-HT1A receptor agonist (8-OH-DPAT) increased corneal fluorescein sodium staining spots and 5-HT1A receptor antagonist (WAY-100635) decreased them.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	9-24
1702486-3	1990	Gepirone and 8-OH-DPAT, two 5-HT1A agonists, when administered intravenously or applied by microiontophoresis, dose-dependently decreased the firing rate of these 5-HT neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
1702488-1	1990	An attempt to determine the central site of the sympathoinhibitory effects of 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, has been made in normotensive anesthetized dogs.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-117	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	133-148
1702488-1	1990	An attempt to determine the central site of the sympathoinhibitory effects of 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, has been made in normotensive anesthetized dogs.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-128	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	133-148
1702488-9	1990	These results suggested that 8-OH-DPAT has a direct effect on 5-HT1A receptors located in the VLPA in dogs.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	62-68
1702490-3	1990	However, the central sympathoinhibition observed with 5-HT1A agonists such as 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is not uniform for all regional sympathetic outflows, renal outflow being the most sensitive.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Homo sapiens	54-60
1702490-3	1990	However, the central sympathoinhibition observed with 5-HT1A agonists such as 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is not uniform for all regional sympathetic outflows, renal outflow being the most sensitive.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-127	5-hydroxytryptamine receptor 1A	Homo sapiens	54-60
26315784-2	2015	Earlier work showed that the 5-hydroxy-tryptamine 1a (5HT1a) receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) protects retinal pigment epithelium (RPE) cells from hydrogen peroxide treatment and mouse retinas from oxidative insults including light injury.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-117	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-69
26315784-2	2015	Earlier work showed that the 5-hydroxy-tryptamine 1a (5HT1a) receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) protects retinal pigment epithelium (RPE) cells from hydrogen peroxide treatment and mouse retinas from oxidative insults including light injury.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-128	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-69
26315784-5	2015	In mice treated with 8-OH-DPAT, the same genes (MT1, HO1, NqO1, Cat, Sod1) were induced in the neural retina, but the drug did not affect the expression of Sod2, the gene for manganese superoxide dismutase.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	metallothionein 1	Mus musculus	48-51
26315784-5	2015	In mice treated with 8-OH-DPAT, the same genes (MT1, HO1, NqO1, Cat, Sod1) were induced in the neural retina, but the drug did not affect the expression of Sod2, the gene for manganese superoxide dismutase.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	heme oxygenase 1	Mus musculus	53-56
26315784-5	2015	In mice treated with 8-OH-DPAT, the same genes (MT1, HO1, NqO1, Cat, Sod1) were induced in the neural retina, but the drug did not affect the expression of Sod2, the gene for manganese superoxide dismutase.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	NAD(P)H dehydrogenase, quinone 1	Mus musculus	58-62
26315784-5	2015	In mice treated with 8-OH-DPAT, the same genes (MT1, HO1, NqO1, Cat, Sod1) were induced in the neural retina, but the drug did not affect the expression of Sod2, the gene for manganese superoxide dismutase.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	catalase	Mus musculus	64-67
26315784-5	2015	In mice treated with 8-OH-DPAT, the same genes (MT1, HO1, NqO1, Cat, Sod1) were induced in the neural retina, but the drug did not affect the expression of Sod2, the gene for manganese superoxide dismutase.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	superoxide dismutase 1, soluble	Mus musculus	69-73
25363799-2	2015	EXPERIMENTAL APPROACH: In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) of 5-HT1A receptors in membranes obtained from rat brainstem or human 5-HT1A CHO cells, using [(35)S]-GTPgammaS and 8-[(3)H]-OH-DPAT binding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-126	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-148
25363799-2	2015	EXPERIMENTAL APPROACH: In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) of 5-HT1A receptors in membranes obtained from rat brainstem or human 5-HT1A CHO cells, using [(35)S]-GTPgammaS and 8-[(3)H]-OH-DPAT binding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-148
25363799-2	2015	EXPERIMENTAL APPROACH: In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) of 5-HT1A receptors in membranes obtained from rat brainstem or human 5-HT1A CHO cells, using [(35)S]-GTPgammaS and 8-[(3)H]-OH-DPAT binding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Homo sapiens	209-215
12552358-0	2003	The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
12552358-1	2003	RATIONALE: The present experiments evaluated the potential of the 5-HT(1A )agonist, 8-OH-DPAT (DPAT), which reduces serotonin availability, to interfere with both the establishment and with the expression of lithium-induced conditioned rejection reactions (experiment 1) and lithium-induced taste avoidance (experiment 2).	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-73
8082505-1	1994	Effect of selective 5HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-25
8082505-5	1994	The serotonin 5HT1A agonist 8-OH-DPAT dramatically and dose-dependently increased the frequency of long-duration, high-amplitude waves in the transverse and distal colon, and concurrently promoted defecation; these effects were prevented by the putative 5HT1A antagonist pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-19
8082505-5	1994	The serotonin 5HT1A agonist 8-OH-DPAT dramatically and dose-dependently increased the frequency of long-duration, high-amplitude waves in the transverse and distal colon, and concurrently promoted defecation; these effects were prevented by the putative 5HT1A antagonist pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	254-259
8082505-6	1994	We conclude that 5HT1A agonists such as 8-OH-DPAT may promote defecation and occurrence of propulsive waves through the same serotoninergic mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-22
1467958-1	1992	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a potent 5-HT1A receptor agonist, was infused in the dorsal hippocampus of rats and its effect on acquisition and performance of a 2-platform spatial discrimination task was studied using a water maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
1467958-1	1992	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a potent 5-HT1A receptor agonist, was infused in the dorsal hippocampus of rats and its effect on acquisition and performance of a 2-platform spatial discrimination task was studied using a water maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
1467958-5	1992	Intrahippocampal administration of 1 microgram spiroxatrine, a 5-HT1A receptor antagonist, antagonized the effect of 5 micrograms 8-OH-DPAT on accuracy and choice latency with no significant effect on the errors of omission on days 1 and 2 of training.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
34512276-7	2021	We then locally activated the 5-HT1A receptor through iontophoretic application of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	30-45
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	interleukin 6	Mus musculus	105-118
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	interleukin 6	Mus musculus	120-124
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	tumor necrosis factor	Mus musculus	127-154
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	tumor necrosis factor	Mus musculus	156-165
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	chemokine (C-C motif) ligand 2	Mus musculus	168-196
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	chemokine (C-C motif) ligand 2	Mus musculus	198-202
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	chemokine (C-X-C motif) ligand 10	Mus musculus	208-239
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	chemokine (C-X-C motif) ligand 10	Mus musculus	241-247
34970573-11	2021	8-OH-DPAT significantly enhanced the expression of LC3B-I/II and ATG5 by disrupting ROS levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	microtubule-associated protein 1 light chain 3 beta	Mus musculus	51-55
34970573-11	2021	8-OH-DPAT significantly enhanced the expression of LC3B-I/II and ATG5 by disrupting ROS levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	autophagy related 5	Mus musculus	65-69
34726306-0	2022	The 5-HT1A receptor agonist, 8-OH-DPAT, Attenuates Long-Lasting Pain in Imiquimod-Induced Psoriasis in Mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-19
35595026-3	2022	The present paper investigates the phenomenon called state-dependent memory (SDM) induced by ACPA (a selective cannabinoid CB1 receptor agonist) and 8-OH-DPAT (a nonselective 5-HT1A receptor agonist) with special focus on the role of the 5-HT1A receptor in the effects of both ACPA and 8-OH-DPAT SDM and cross state-dependent memory retrieval between ACPA and 8-OH-DPAT in a step-down inhibitory avoidance task.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	175-190
35595026-3	2022	The present paper investigates the phenomenon called state-dependent memory (SDM) induced by ACPA (a selective cannabinoid CB1 receptor agonist) and 8-OH-DPAT (a nonselective 5-HT1A receptor agonist) with special focus on the role of the 5-HT1A receptor in the effects of both ACPA and 8-OH-DPAT SDM and cross state-dependent memory retrieval between ACPA and 8-OH-DPAT in a step-down inhibitory avoidance task.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	238-253
35595026-11	2022	Pre-test administration of a 5-HT1A receptor antagonist, (S)-WAY 100135 (0.25 and 0.5 mug/mouse), 5 min before ACPA and 8-OH-DPAT dose-dependently inhibited ACPA- and 8-OH-DPAT-induced SDM, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	167-176	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	29-44
35595026-13	2022	Overall, the data revealed that dorsal hippocampal 5-HT1A receptor mechanisms play a pivotal role in modulating cross state-dependent memory retrieval between ACPA and 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	51-66
35301424-7	2022	This effect was accompanied by a decreased inhibitory response of 5-HT neurons to microiontophoretic applications of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-N,N-dipropyl-2-aminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	121-127
35234992-8	2022	Local 5-HT1A receptors blockade produces opposite effects and suppresses the effect by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	6-12
2533334-0	1989	Apparent hyperalgesic action of the 5-HT1A agonist, 8-OH-DPAT, in the rat reflects induction of spontaneous tail-flicks.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
35434766-5	2022	When administered in combination, pretreatment with HAL and QUIN worsened 8-OH-DPAT-induced maternal disruption and induced a decrease in the pup preference ratio.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	histidine ammonia lyase	Rattus norvegicus	52-55
35434766-6	2022	Accordingly, 8-OH-DPAT enhanced QUIN" and HAL"s disruption of pup retrieval and pup preference, reversed the increase in hovering over pups induced by HAL.	8-Hydroxy-2-(di-n-propylamino)tetralin	13-22	histidine ammonia lyase	Rattus norvegicus	42-45
2533334-1	1989	The 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), induced a dose-dependent reduction in latency to withdraw the tail from noxious hot water (48 degrees C).	8-Hydroxy-2-(di-n-propylamino)tetralin	20-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2533334-1	1989	The 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), induced a dose-dependent reduction in latency to withdraw the tail from noxious hot water (48 degrees C).	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2576226-1	1989	The mixed beta-adrenoceptor and 5-HT1A receptor antagonists, (-)-pindolol and propranolol, enhance rather than inhibit the hyperlocomotion induced in rats by the 5-HT1A receptor agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	187-196	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
2576226-1	1989	The mixed beta-adrenoceptor and 5-HT1A receptor antagonists, (-)-pindolol and propranolol, enhance rather than inhibit the hyperlocomotion induced in rats by the 5-HT1A receptor agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	187-196	5-hydroxytryptamine receptor 1A	Rattus norvegicus	162-168
2533557-0	1989	Partial postsynaptic 5-HT1A agonist properties of the novel stereoselective 8-OH-DPAT analogue (+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin, (+)ALK-3.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-27
2533557-1	1989	The present study assessed the pharmacological activity of the stereoisomers of the novel 8-OH-DPAT analogue cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin, ALK-3, at postsynaptic 5-HT1A receptors involved in 5-HT-mediated behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	bone morphogenetic protein receptor type 1A	Rattus norvegicus	162-167
2533557-5	1989	Following pretreatment, (+)ALK-3 dose dependently, but partially, attenuated the effect of (+)8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	bone morphogenetic protein receptor type 1A	Rattus norvegicus	27-32
2533557-6	1989	(-)ALK-3 did not elicit 5-HT behaviours per se, and only very weakly antagonized the behavioural actions of (+)8-OH-DPAT at the highest dose tried.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	bone morphogenetic protein receptor type 1A	Rattus norvegicus	3-8
2530993-1	1989	The influence of the centrally active 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on the exploration of objects was studied in hamsters, using a radioactographic method.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-91	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44
2530993-1	1989	The influence of the centrally active 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on the exploration of objects was studied in hamsters, using a radioactographic method.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44
2574066-2	1989	We have previously found that the putative 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) decreases hippocampal 5-hydroxytryptamine (5-HT) release in the anaesthetized rat, as measured by brain microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
2574066-2	1989	We have previously found that the putative 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) decreases hippocampal 5-hydroxytryptamine (5-HT) release in the anaesthetized rat, as measured by brain microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
2481192-10	1989	These results establish that the 5-HT1A receptor agonists flesinoxan and 8-OH-DPAT elicited a systemic and regional hemodynamic profile that differs from that of the alpha 2-adrenoceptor agonist clonidine.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	33-48
2531256-4	1989	In addition, 5,7-DHT treatment produced a two-fold shift to the left of the dose-response curve of the 5-HT1A agonists 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT) or 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) in producing the 5-HT syndrome indicating the development of denervation supersensitivity following the destruction of 5-HT neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-157	5-hydroxytryptamine receptor 1A	Rattus norvegicus	103-109
2531256-4	1989	In addition, 5,7-DHT treatment produced a two-fold shift to the left of the dose-response curve of the 5-HT1A agonists 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT) or 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) in producing the 5-HT syndrome indicating the development of denervation supersensitivity following the destruction of 5-HT neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	159-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	103-109
2533325-4	1989	In addition, 5-HT1A and 5-HT1C sites were directly visualized with the more selective radioligands [3H]8-OH-DPAT and [3H]mesulergine, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Homo sapiens	13-19
2533325-4	1989	In addition, 5-HT1A and 5-HT1C sites were directly visualized with the more selective radioligands [3H]8-OH-DPAT and [3H]mesulergine, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 2C	Homo sapiens	24-30
2533336-3	1989	Stimulation of 5-HT1A receptors with 8-hydroxy-di-N,N-propylaminotetralin (8-OH-DPAT) and blockade of 5-HT1B receptors with cyanopindolol resulted in seizure protection.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
2529951-1	1989	Previous studies indicate that the selective 5-HT1A agonist, 8-OH DPAT, acts in the central nervous system to inhibit sympathetic nerve activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	45-51
2529951-12	1989	Rather, the data suggest that 8-OH DPAT acts postsynaptically on 5-HT1A receptors located on central sympathetic neurons to inhibit sympathetic nerve activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	65-71
2478259-5	1989	Reciprocally, 5-HT was significantly reduced to about half of control levels with either local administration of tetrodotoxin, zero calcium dialysis solution, or systemic administration of 8-hydroxy-2-(di-n-propylamino)tetralin, a 5-HT1A agonist that suppresses 5-HT neuronal activity via activation of the somatodendritic autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	189-227	5-hydroxytryptamine receptor 1A	Rattus norvegicus	231-237
2574684-2	1989	Indicative of anxiolytic effects the 5-HT1A agonists, buspirone, gepirone and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) all significantly increased social interaction time and open arm exploration time in the social interaction and elevated plus maze procedures, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-117	5-hydroxytryptamine receptor 1A	Homo sapiens	37-43
2574684-2	1989	Indicative of anxiolytic effects the 5-HT1A agonists, buspirone, gepirone and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) all significantly increased social interaction time and open arm exploration time in the social interaction and elevated plus maze procedures, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-128	5-hydroxytryptamine receptor 1A	Homo sapiens	37-43
2530985-1	1989	A liquid chromatographic method using electrochemical detection is described for the assay of brain concentrations of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), centrally acting serotonin agonists selective for the 5HT-1A subtype of serotonin receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-156	5-hydroxytryptamine receptor 1A	Rattus norvegicus	224-230
2795604-3	1989	In addition, the ability of the compounds to displace [3H]-8-OH-DPAT from 5-HT1A binding sites was evaluated.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
2575564-4	1989	The central 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produced hypotension and decreases in sympathetic nerve activity (SNA).	8-Hydroxy-2-(di-n-propylamino)tetralin	36-75	5-hydroxytryptamine receptor 1A	Homo sapiens	12-27
2575564-4	1989	The central 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produced hypotension and decreases in sympathetic nerve activity (SNA).	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Homo sapiens	12-27
2533688-5	1989	Similar experiments conducted with 1 mg/kg (IP) 8-hydroxy-2(di-N-propylamino) tetralin (DPAT) demonstrated that this 5-HT1A agonist also enhanced the attenuating effects of fluoxetine on ethanol intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	117-123
2533688-5	1989	Similar experiments conducted with 1 mg/kg (IP) 8-hydroxy-2(di-N-propylamino) tetralin (DPAT) demonstrated that this 5-HT1A agonist also enhanced the attenuating effects of fluoxetine on ethanol intake.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	117-123
2622983-9	1989	In phenelzine- and isocarboxazid-treated rats the disruption of FR-40 responses by LSD and 8-OHDPAT were significantly reduced during Period 1, Period 2 and Washout Period.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-99	period circadian regulator 1	Rattus norvegicus	134-142
2547897-4	1989	The 5-HT1A [5-hydroxytryptamine (serotonin) type 1A] receptor agonists 8-hydroxy-2-(di-n-propylamino)tetralin and buspirone mimic the serotonin response in reducing the forskolin-stimulated cyclic AMP levels, as do the indole derivatives 5-methoxytryptamine, 5-hydroxtryptophan, and tryptamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-109	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	4-10
2533356-1	1989	The repeated administration of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 3 mg/kg, twice daily for 14 days) significantly diminished hypothermia and corticosterone secretion induced by an acute challenge with the 5-HT1A agonist 8-OH-DPAT (0.1 mg/kg) when compared to the responses in animals treated chronically with the solvent vehicle.	8-Hydroxy-2-(di-n-propylamino)tetralin	229-238	5-hydroxytryptamine receptor 1A	Homo sapiens	214-220
2533356-5	1989	These data are consistent with other evidence that these physiological effects of 8-OH-DPAT and MK-212 are mediated by 5-HT1A and 5-HT2 receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Homo sapiens	119-145
2530985-1	1989	A liquid chromatographic method using electrochemical detection is described for the assay of brain concentrations of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), centrally acting serotonin agonists selective for the 5HT-1A subtype of serotonin receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	158-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	224-230
2526217-7	1989	8-Hydroxy-2-(di-n-propylamino)tetralin, a selective 5-HT1A receptor ligand, also inhibited the DSP, but only produced about 65% of the maximal 5-CT or 5-HT response (EC50 = 50 nM).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	52-58
2526217-10	1989	The response to 8-hydroxy-2-(di-n-propylamino) tetralin was antagonized by pretreatment with the 5-HT1A antagonist spiperone (1 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	16-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
2746511-3	1989	Direct 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)tetralin and 5-methoxy-N,N-dimethyltryptamine and the 5-HT precursor 5-hydroxytryptophan all increased the reinforcement rate.	8-Hydroxy-2-(di-n-propylamino)tetralin	23-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	7-13
2570505-4	1989	In arteries from both species the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), only caused weak contraction.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
2470860-9	1989	Injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (0.5 and 2.5 micrograms) into the dorsal raphe nucleus caused a dose-related fall in hippocampal output of 5-HT compared to saline-injected controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
2732950-6	1989	The selective 5-HT1A agonist, 8-hydroxy-2(di-n-propylamino)tetralin, was the least potent but elicited a more intense vasoconstriction.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-67	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20
2530590-0	1989	Stimulation of corticosterone secretion by the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
2530590-0	1989	Stimulation of corticosterone secretion by the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
2530590-1	1989	The selective 5-HT1A receptor agonist 8-OH-DPAT increased serum corticosterone concentration in rats in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
2530590-3	1989	The corticosterone response to 8-OH-DPAT was also antagonized by spiperone, (+/-)- and (-)-pindolol and (+/-)-propranolol, all of which have been shown to have a high affinity for 5-HT1A receptors, though in most cases no complete blockade was found.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
2530590-7	1989	It is concluded that 8-OH-DPAT-induced increase in serum corticosterone concentration results from its action at a site different than the adrenal cortex and is mediated by postsynaptic 5-HT1A receptors, whereas other subtypes (5-HT1B, 5-HT2, 5-HT3) of 5-HT receptors do not participate in this response.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	186-192
2530590-7	1989	It is concluded that 8-OH-DPAT-induced increase in serum corticosterone concentration results from its action at a site different than the adrenal cortex and is mediated by postsynaptic 5-HT1A receptors, whereas other subtypes (5-HT1B, 5-HT2, 5-HT3) of 5-HT receptors do not participate in this response.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1B	Rattus norvegicus	228-234
2530729-1	1989	[3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) is thought to label a single population of serotonin (5-HT)1A receptor, but some reports implicate multiple binding sites exist.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-129
2570505-4	1989	In arteries from both species the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), only caused weak contraction.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
2566495-8	1989	The actions of 8-OH-DPAT and buspirone, but not of RU 24969 and idazoxan, were blocked by the 5-HT1A receptor antagonist, spiroperidol.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	94-109
2522991-3	1989	In addition, the ability of the enantiomers of 1-4 to displace [3H]-8-OH DPAT from 5-HT1A binding sites was evaluated.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	83-89
2522986-3	1989	The affinity of CM 57493 for 5-HT1A sites labeled by [3H]-8-OH-DPAT in hippocampal membranes was enhanced by Mn++ and reduced by GTP, as expected for an agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
2526270-6	1989	OM-853 had more potent inhibitory effect on the binding of [3H]8-hydroxy-2-(di-n-propylamino)tetralin (8-hydroxy DPAT) to 5-HT1A receptors and/or 5-HT autoreceptors than that of [3H]-ketanserin to 5-HT2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-117	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
2524677-4	1989	In contrast, the selective 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) and ipsapirone (2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3 -(2H) one-1,1-dioxidehydrochloride) did not increase levels of prolactin in plasma at any dose.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
2524677-4	1989	In contrast, the selective 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) and ipsapirone (2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3 -(2H) one-1,1-dioxidehydrochloride) did not increase levels of prolactin in plasma at any dose.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-33
2524392-5	1989	The proaversive effect of 8-OH-DPAT and the antiaversive effect of mCPP suggest that 5-HT1A and non-5-HT1a (5-HT1B or 5-HT1C) receptors play distinct roles in mechanisms of aversion, perhaps at different locations in the CNS.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	85-91
2524390-3	1989	The putative 5-HT1B agonist, 1-(3-trifluoromethylphenyl)piperazine (TFMPP), had a weak effect on the responses to DOI or 8-OHDPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-129	5-hydroxytryptamine receptor 1B	Rattus norvegicus	13-19
2523813-13	1989	These results indicate that the central sympatho-inhibitory effects of 8-OH-DPAT were due to the stimulation of 5-HT1A receptors located in the ventrolateral pressor area.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	112-118
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Homo sapiens	34-49
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Homo sapiens	34-40
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	34-49
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	34-40
2466516-6	1989	Under these conditions the putative 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) caused a dose-dependent (5-250 micrograms kg-1, s.c.) reduction of 5-HT in hippocampal dialysates.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
2466516-6	1989	Under these conditions the putative 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) caused a dose-dependent (5-250 micrograms kg-1, s.c.) reduction of 5-HT in hippocampal dialysates.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
2527161-0	1989	Median raphe, but not dorsal raphe, application of the 5-HT1A agonist 8-OH-DPAT stimulates rat motor activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
2523754-1	1989	The intravenous administration of low doses of lysergic acid diethylamide (LSD) or of the selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) depresses the firing activity of dorsal raphe 5-HT-containing neurons, presumably via the activation of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-186	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-121
2523754-1	1989	The intravenous administration of low doses of lysergic acid diethylamide (LSD) or of the selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) depresses the firing activity of dorsal raphe 5-HT-containing neurons, presumably via the activation of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-186	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
2526950-2	1989	The 8-OHDPAT cue was mimicked by the 5-HT1A agonists ipsapirone, buspirone, gepirone and partially by 5-methoxy-N,N-dimethyltryptamine and d-LSD.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
2527161-1	1989	Local application of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the median raphe of rats caused locomotor stimulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-88	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
2527161-1	1989	Local application of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the median raphe of rats caused locomotor stimulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
2527161-4	1989	By activating somatodendritic 5-HT1A autoreceptors in the median raphe, 8-OH-DPAT may disinhibit locomotor-enforcing neural pathways that receive 5-HT afferents from this nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
2702482-9	1989	Regularly firing neurons were completely inhibited by low doses of the 5-HT1A agonist 8-hydroxy-dipropylamino-tetralin (8-OH-DPAT) (i.e. 2 micrograms/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77
2521252-1	1989	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a selective 5-HT1A serotonin agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
11224034-4	1989	The 5HT(1A) agonists 8-OH-DPAT and MDL-72832 produced similar disruptions in the performance of a step-down passive avoidance response (i.e. decreased latencies), with 8-OH-DPAT giving rise to a bell-shaped dose-response curve.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
11224034-4	1989	The 5HT(1A) agonists 8-OH-DPAT and MDL-72832 produced similar disruptions in the performance of a step-down passive avoidance response (i.e. decreased latencies), with 8-OH-DPAT giving rise to a bell-shaped dose-response curve.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2569497-6	1989	The antagonism by pindolol of 8-OH-DPAT-induced effects on male rat sexual behavior suggests an involvement of 5-HT1A receptors in the facilitation of this behavior produced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
2569497-6	1989	The antagonism by pindolol of 8-OH-DPAT-induced effects on male rat sexual behavior suggests an involvement of 5-HT1A receptors in the facilitation of this behavior produced by 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	177-186	5-hydroxytryptamine receptor 1A	Rattus norvegicus	111-117
2547173-4	1989	The selective 5-HT1A agonist 8-hydroxy-2(di-n-propylamino) tetralin (8-OHDPAT) increased 3H-5-HT release from aged rat spinal cord slices similar to results previously obtained from adult rat spinal cord slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
2547173-4	1989	The selective 5-HT1A agonist 8-hydroxy-2(di-n-propylamino) tetralin (8-OHDPAT) increased 3H-5-HT release from aged rat spinal cord slices similar to results previously obtained from adult rat spinal cord slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
2471984-7	1989	Acute administration of the 5-HT1A receptor ligand 8-OH-DPAT (3.0 mg/kg) resulted in large decreases in 5-HIAA levels that persisted throughout the period of chronic administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43
2526947-0	1989	Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
2479937-2	1989	The reduced 5-HIAA level and 5-HIAA/5-HT ratio after the 5-HT1A selective agonist 8-OH-DPAT was not antagonized by pretreatment with ipsapirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
2748869-9	1989	Single injections of 5-HT1A agonists (8-OH-DPAT, buspirone, ipsapirone, gepirone) but not of benzodiazepine anxiolytics have similar effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-27
2498921-3	1989	Several 5-HT1A agonists (8-OH-DPAT, ipsapirone, buspirone, 5-Me-ODMT) and a 5-HT uptake blocker (fluvoxamine) also reduced aggression.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	8-14
2524855-0	1989	5HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), inhibits non-opioid analgesia in defeated mice: influence of route of administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-53	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-5
2524855-0	1989	5HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), inhibits non-opioid analgesia in defeated mice: influence of route of administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-5
2524855-2	1989	In the present study, we have examined the influence of the 5-HT1A receptor agonist, 8-OH-DPAT, on basal nociception and defeat analgesia in male DBA/2 mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	60-75
2528157-3	1989	The EB- or EB plus P-activated lordosis was also suppressed by administration of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	119-157	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-101
2528157-3	1989	The EB- or EB plus P-activated lordosis was also suppressed by administration of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	159-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-101
2531902-1	1989	Feeding elicited by the 5HT1A agonist 8-OH-DPAT was blocked by pretreatment with the DA antagonists SCH-23390 and sulpiride, in two experiments conducted in non-deprived rats and in three experiments conducted after 4 h food deprivation.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-29
2521959-2	1989	5-HT1A and 5-HT1C binding sites were pharmacologically blocked using 100 nM 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) and 100 nM mesulergine, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-114	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6
2521959-2	1989	5-HT1A and 5-HT1C binding sites were pharmacologically blocked using 100 nM 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) and 100 nM mesulergine, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6
2521959-6	1989	Drug interactions with putative 5-HT1D binding sites in bovine caudate membranes correlated significantly with their affinities for human membrane recognition sites labeled by 3H-5-HT in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine.	8-Hydroxy-2-(di-n-propylamino)tetralin	210-219	5-hydroxytryptamine receptor 1D	Homo sapiens	32-38
2532423-3	1989	The present study was undertaken to quantify 5-HT1A sites in the rat brain by autoradiography and membrane binding, using the selective ligand [3H]8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT), following long-term antidepressant treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	187-196	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
2535033-5	1989	5HT-1A receptor sites were detected by displacement experiments and by direct labeling with [3H]8-hydroxy-2(di-n-propylamino) tetralin 8OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-143	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15
2521252-1	1989	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a selective 5-HT1A serotonin agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
2521252-3	1989	A series of N-phenylalkyl derivatives of 8-methoxy-2-aminotetralin was evaluated at [3H]-8-OH-DPAT-labeled 5-HT1A sites in rat brain hippocampal membranes.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	107-113
2849052-5	1988	Two selective 5-HT1A agonists: 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and ipsapirone, could not stimulate adenylate cyclase.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-70	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-20
2975608-0	1988	8-Hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist, reduces the immobility of rats in the forced swimming test by acting on the nucleus raphe dorsalis.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	52-72
2907586-0	1988	[3H]8-OH-DPAT labels the 5-hydroxytryptamine uptake recognition site and the 5-HT1A binding site in the rat striatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
2907586-8	1988	Thus [3H]8-OH-DPAT labels the 5-HT transporter in the rat striatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	solute carrier family 6 member 4	Rattus norvegicus	30-46
2907586-9	1988	Unlike [3H]imipramine binding, the binding of [3H]8-OH-DPAT to the 5-HT transporter was independent of external sodium ions.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-59	solute carrier family 6 member 4	Rattus norvegicus	67-83
2907586-10	1988	It is therefore suggested that 8-OH-DPAT acts as substrate for the 5-HT transporter and labels the 5-HT recognition site of the transporter complex.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-40	solute carrier family 6 member 4	Rattus norvegicus	67-83
2469021-1	1988	The present study was undertaken in an attempt to assess whether the effects of the potent and selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, on cerebral 5-hydroxytryptamine (5-HT) neurochemistry in vivo are mediated via 5-HT autoreceptors on the cell bodies or on the terminals, and or via postsynaptic 5-HT receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	129-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
2972829-7	1988	The widening effect produced by 8-OH-DPAT (a putative 5-HT1A agonist) was not blocked by any antagonist tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	54-60
2972829-9	1988	These results suggest the 5-HT receptors mediating 5-HT action potential narrowing in these cells are of the 5-HT1A subtype, but that they differ from the 5-HT1A receptors described in other tissues in which 8-OH-DPAT is an agonist or a partial agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	208-217	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	109-115
2972829-9	1988	These results suggest the 5-HT receptors mediating 5-HT action potential narrowing in these cells are of the 5-HT1A subtype, but that they differ from the 5-HT1A receptors described in other tissues in which 8-OH-DPAT is an agonist or a partial agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	208-217	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	155-161
2469021-1	1988	The present study was undertaken in an attempt to assess whether the effects of the potent and selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, on cerebral 5-hydroxytryptamine (5-HT) neurochemistry in vivo are mediated via 5-HT autoreceptors on the cell bodies or on the terminals, and or via postsynaptic 5-HT receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	169-178	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
2469021-6	1988	These findings provide direct neurochemical evidence that by preferentially stimulating somatodendritic 5-HT1A receptors, 8-OH-DPAT inhibits the 5-HT neuronal impulse flow, thereby effectuating decreased terminal 5-HT synthesis and release.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-110
2971097-2	1988	Kinetic analyses of [3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) binding indicated that the 5-HT1A sites exhibit the same properties in the soluble form as in the membrane-bound form.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
2906877-3	1988	Azaspirodecanediones have high affinity for the 5-HT1A serotonin receptor, however, the specific 5-HT1A agonist, 8-hydroxy-2-(di-n-propyl-amino)-tetralin (8-OH-DPAT) had no effect on strychnine seizure in naive rats (CD50 = 2.0 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	155-164	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
2971097-3	1988	Furthermore, a positive correlation (r = 0.988) was found between the respective pIC50 values of a series of agonists and antagonists to inhibit [3H]8-OH-DPAT binding to either soluble or membrane-bound 5-HT1A sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-158	5-hydroxytryptamine receptor 1A	Rattus norvegicus	203-209
2976671-7	1988	In addition, the 5-HT1A receptor antagonist, spiperone, inhibited the 5-HT syndrome elicited by 8-OH-DPAT, while the dopamine receptor antagonist, haloperidol, affected only the head weaving.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	17-32
3234480-1	1988	The effect of chronic administration of various monoamine oxidase (MAO) inhibitors on the ability of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to inhibit forskolin-stimulated adenylate cyclase activity was studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-139	monoamine oxidase A	Rattus norvegicus	48-65
3234480-1	1988	The effect of chronic administration of various monoamine oxidase (MAO) inhibitors on the ability of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to inhibit forskolin-stimulated adenylate cyclase activity was studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-139	monoamine oxidase A	Rattus norvegicus	67-70
3234480-1	1988	The effect of chronic administration of various monoamine oxidase (MAO) inhibitors on the ability of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to inhibit forskolin-stimulated adenylate cyclase activity was studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	monoamine oxidase A	Rattus norvegicus	48-65
3234480-1	1988	The effect of chronic administration of various monoamine oxidase (MAO) inhibitors on the ability of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to inhibit forskolin-stimulated adenylate cyclase activity was studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	monoamine oxidase A	Rattus norvegicus	67-70
2971358-3	1988	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased forskolin-stimulated adenylate cyclase activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
2971358-3	1988	The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased forskolin-stimulated adenylate cyclase activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
2976671-8	1988	These results suggest that 8-OH-DPAT-induced behaviour in mice is mediated by the postsynaptic 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	95-110
2976673-0	1988	NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	94-132	5-hydroxytryptamine receptor 1A	Homo sapiens	79-85
2976673-0	1988	NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	134-143	5-hydroxytryptamine receptor 1A	Homo sapiens	79-85
2457083-3	1988	The reduced 5-HT turnover probably resulted from the stimulation of 5-HT1A autoreceptors within the anterior raphe nuclei as in vitro tests [( 3H]-8-hydroxy-2-[di-n-propylamino]tetralin binding and adenylate cyclase assays) demonstrated that ipsapirone was a 5-HT1A agonist almost as potent as 8-OH-DPAT, and the same decrease in 5-hydroxytryptophan accumulation could be induced by the i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	147-185	5-hydroxytryptamine receptor 1A	Rattus norvegicus	68-74
2972552-1	1988	The ability of 5-hydroxytryptamine (5-HT) and the 5-HT1A selective agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to modulate adenylate cyclase activity was measured in rat hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-56
2972552-1	1988	The ability of 5-hydroxytryptamine (5-HT) and the 5-HT1A selective agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to modulate adenylate cyclase activity was measured in rat hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-56
2972934-5	1988	The antagonistic effect of 8-OHDPAT suggests a secondary, modulating role for 5-HT1A receptor mediated events in both types of catalepsy.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
2905661-3	1988	The hypothermic response to the 5-HT1A agonist, 8-OH-DPAT, was unaltered by any of the atypical neuroleptics tested.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
2898533-3	1988	Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM).	8-Hydroxy-2-(di-n-propylamino)tetralin	329-338	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
2458945-1	1988	The present study was undertaken to investigate the hyperphagic responses to the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), in young and adult rats fed either a powder diet or pellets.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
2458945-1	1988	The present study was undertaken to investigate the hyperphagic responses to the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), in young and adult rats fed either a powder diet or pellets.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-87
2905470-1	1988	Under several behavioral procedures, such as punished responding and drug discrimination, the effects of the atypical anxiolytic buspirone are similar to those of its analogue gepirone, and to those of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	230-239	5-hydroxytryptamine receptor 1A	Homo sapiens	206-221
2970974-0	1988	Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
2970974-1	1988	The 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) at a dose of 1 mg/kg s.c. increased food intake in free feeding rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2970974-1	1988	The 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) at a dose of 1 mg/kg s.c. increased food intake in free feeding rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2970974-2	1988	8-OH-DPAT-induced feeding was blocked by metergoline which has comparable affinity for 5-HT1A, 5-HT1B, 5-HT1C and 5-HT2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
2970974-2	1988	8-OH-DPAT-induced feeding was blocked by metergoline which has comparable affinity for 5-HT1A, 5-HT1B, 5-HT1C and 5-HT2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1B	Rattus norvegicus	95-101
2970974-2	1988	8-OH-DPAT-induced feeding was blocked by metergoline which has comparable affinity for 5-HT1A, 5-HT1B, 5-HT1C and 5-HT2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	103-109
2970974-9	1988	These results indicate that 8-OH-DPAT-induced feeding is mediated by 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
2967376-3	1988	In addition, the ability of the cis- and trans-8-hydroxy-3-methyl-2-(di-n-propylamino)tetralins (15 and 11) to displace [3H]-8-OH-DPAT from 5-HT1A binding sites was evaluated.	8-Hydroxy-2-(di-n-propylamino)tetralin	125-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	140-146
2975354-6	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103
2969083-0	1988	8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-39	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-73
3399126-5	1988	5-HT1D sites were defined as the binding sites remaining when both 8-OH-DPAT and mesulergine were added to the incubation medium.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1D	Homo sapiens	0-6
2969083-1	1988	The selective serotonin1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) was studied for its ability to reverse haloperidol-induced catalepsy in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-82	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-34
2969083-1	1988	The selective serotonin1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) was studied for its ability to reverse haloperidol-induced catalepsy in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-34
2966313-0	1988	Serotonin-1A receptor activation in hippocampal CA1 neurons by 8-hydroxy-2-(di-n-propylamino)tetralin, 5-methoxytryptamine and 5-hydroxytryptamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-101	carbonic anhydrase 1	Homo sapiens	48-51
2969339-3	1988	spiperone, but not LY53837 (a 5-HT2 antagonist), antagonized the inhibition induced by 5-HT1A agonists 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) and buspirone in the dorsal raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine receptor 1A	Homo sapiens	87-93
2855237-6	1988	In contrast, the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin, the 5-HT1B agonists 1-(m-trifluoromethylphenyl)piperazine and 1-(m-chlorophenyl)-piperazine and the 5-HT3 agonist 2-methyl-5-HT were inactive.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
2965244-1	1988	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a serotonergic agonist with high affinity and selectivity for a particular population of central serotonin (5-HT) binding sites (i.e., 5-HT1A sites).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	189-195
2965244-1	1988	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a serotonergic agonist with high affinity and selectivity for a particular population of central serotonin (5-HT) binding sites (i.e., 5-HT1A sites).	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Rattus norvegicus	189-195
2966310-1	1988	In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77
2966310-1	1988	In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	5-hydroxytryptamine receptor 2C	Homo sapiens	82-88
2966310-1	1988	In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	5-hydroxytryptamine receptor 1B	Homo sapiens	234-240
2966310-1	1988	In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified.	8-Hydroxy-2-(di-n-propylamino)tetralin	152-191	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77
2966310-1	1988	In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified.	8-Hydroxy-2-(di-n-propylamino)tetralin	152-191	5-hydroxytryptamine receptor 2C	Homo sapiens	82-88
2966310-5	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103
2828913-11	1988	Its main differences with the 5-HT1A receptor in hippocampal neurons are as follows: 1) 8-OH-DPAT was only a poor partial agonist in cortical neurons, whereas it was the best full agonist in hippocampal neurons; and 2) metergoline and methysergide as well as the anxiolytic drugs, ipsapirone and buspirone, which were potent agonists in hippocampal neurons, were competitive antagonists in cortical neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	30-45
2967189-0	1988	Hyperinsulinemia of the genetically obese (fa/fa) rat is decreased by a low dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	112-150	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
2967189-0	1988	Hyperinsulinemia of the genetically obese (fa/fa) rat is decreased by a low dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	152-161	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
2967189-2	1988	and obese (fa/fa) rats after acute administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	81-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
2895033-13	1988	A 5-HT1A agonist (8-OH-DPAT) blocked WDS, but like putative 5-HT1B (RU 24969) and 5-HT2 (DOI) agonists and the 5-HT antagonists methysergide (non-selective), ritanserin (5-HT2 selective), and l-propranolol (5-HT1 selective), it did not block other antagonists behavioural effects of MK-771.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	2-8
2961850-6	1988	Of special interest was the observation that 5-HT1A agonists such as serotonin, 8-OH-DPAT, and ipsapirone competed with equal high affinities for [3H]spiroxatrine or [3H]8-OH-DPAT-labelled 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
2961850-6	1988	Of special interest was the observation that 5-HT1A agonists such as serotonin, 8-OH-DPAT, and ipsapirone competed with equal high affinities for [3H]spiroxatrine or [3H]8-OH-DPAT-labelled 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	189-195
2961850-6	1988	Of special interest was the observation that 5-HT1A agonists such as serotonin, 8-OH-DPAT, and ipsapirone competed with equal high affinities for [3H]spiroxatrine or [3H]8-OH-DPAT-labelled 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	170-179	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
2961850-7	1988	[3H]Spiroxatrine and [3H]8-OH-DPAT binding to 5-HT1A receptors was inhibited by guanosine 5"-(beta,gamma-imido)triphosphate (a nonhydrolyzable analog of GTP) in a concentration-dependent manner whereas adenosine 5"-(beta,gamma-imido)triphosphate (a nonhydrolyzable analog of ATP) had no effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-52
2961850-8	1988	The similarities in the 5-HT1A receptor radiolabelling properties of [3H]spiroxatrine and [3H]8-OH-DPAT, i.e., the high affinities of agonists and the guanyl nucleotide sensitivity, indicate that [3H]spiroxatrine has "agonist-like" binding properties in its interaction with the 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
2961850-8	1988	The similarities in the 5-HT1A receptor radiolabelling properties of [3H]spiroxatrine and [3H]8-OH-DPAT, i.e., the high affinities of agonists and the guanyl nucleotide sensitivity, indicate that [3H]spiroxatrine has "agonist-like" binding properties in its interaction with the 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	279-285
2965963-3	1988	Like its parent compound, the agonist 8-hydroxy-2-(di-n-propylamino)tetralin or 8-OH-DPAT, [125I]-BH-8-MeO-N-PAT, exhibits a high affinity and excellent selectivity for 5-HT1A sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	169-175
2965963-3	1988	Like its parent compound, the agonist 8-hydroxy-2-(di-n-propylamino)tetralin or 8-OH-DPAT, [125I]-BH-8-MeO-N-PAT, exhibits a high affinity and excellent selectivity for 5-HT1A sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	80-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	169-175
2901381-9	1988	The prototype 5HT1A agonist 8OH-DPAT may also have potential anxiolytic effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-36	5-hydroxytryptamine receptor 1A	Homo sapiens	14-19
2976387-6	1988	8-Hydroxy-2-(di-n-propylamino)tetralin</compound-id> (8-OH-DPAT) and 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) decreased the MSR and increased the PSR in spinal rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Rattus norvegicus	127-130
2897609-4	1988	Especially, 8-OH-DPAT, a 5-HT-1A selective agonist, bound with the highest affinity to these binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	12-21	5-hydroxytryptamine receptor 1A	Rattus norvegicus	25-32
2961966-0	1988	The 5-HT1A receptor probe [3H]8-OH-DPAT labels the 5-HT transporter in human platelets.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
2961966-0	1988	The 5-HT1A receptor probe [3H]8-OH-DPAT labels the 5-HT transporter in human platelets.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	solute carrier family 6 member 4	Homo sapiens	51-67
2961966-7	1988	These results suggest that the human platelet site labeled by [3H]8-OH-DPAT is pharmacologically different from the neuronal site and probably is a component of the 5-HT transporter.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-75	solute carrier family 6 member 4	Homo sapiens	165-181
3340274-5	1988	The 5-HT 1A agonist 8-OH-DPAT potently stimulated prolactin at doses of 1 and 5 nmol.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
3352865-4	1988	The pEC40 values of 5-HT agonists tested, determined from release assays, significantly correlated with the relative affinities (pKD"s) of these compounds for the binding of [3H]5-HT to the 5-HT1B receptor subtype in the presence of 2 microM 8-OHDPAT, as determined from radioligand binding studies (r = 0.98, P = 0.003).	8-Hydroxy-2-(di-n-propylamino)tetralin	242-250	5-hydroxytryptamine receptor 1B	Rattus norvegicus	190-196
3352865-5	1988	Conversely, the potencies of the 5-HT1A agonists 5-MeODMT and 8-OHDPAT, at the 5-HT autoreceptor, were negatively correlated (r = -0.77, P less than 0.10) with their potencies at displacing [3H]5-HT from the 5-HT1A subsite (binding of [3H]5-HT in the presence of 1 microM mCPP).	8-Hydroxy-2-(di-n-propylamino)tetralin	62-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	33-39
3352865-5	1988	Conversely, the potencies of the 5-HT1A agonists 5-MeODMT and 8-OHDPAT, at the 5-HT autoreceptor, were negatively correlated (r = -0.77, P less than 0.10) with their potencies at displacing [3H]5-HT from the 5-HT1A subsite (binding of [3H]5-HT in the presence of 1 microM mCPP).	8-Hydroxy-2-(di-n-propylamino)tetralin	62-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	208-214
2469047-6	1988	The 5-HT1A agonist, 8-OH-DPAT, was an inefficient competitor for 3H-5-HT binding in frontal cortex of females treated with chlordecone.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2834759-3	1988	Antidepressant treatments also attenuate the temperature response to the 5-HT1A agonist 8-OH-DPAT but 5-HT2-receptor number and function are both decreased by antidepressant drugs but increased by ECS.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	73-79
2973613-0	1988	Specific effect of putative 5-HT1A agonists, 8-OH-DPAT and gepirone, to increase hypertonic saline consumption in the rat: evidence against a general hyperdipsic action.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
2976944-3	1988	In support of this, 8-OH-DPAT (a selective 5-HT1A agonist), which inhibits serotonergic activity at small doses via an autoreceptor mechanism, enhanced sucrose sham-feeding and reversed the suppressant effect of d-fenfluramine.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	43-49
2894704-0	1988	Potential anxiolytic properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin 1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-108
2894704-1	1988	The effects of a selective serotonin 1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), were studied in two animal models of anxiety.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-48
2894704-1	1988	The effects of a selective serotonin 1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), were studied in two animal models of anxiety.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine receptor 1A	Rattus norvegicus	27-48
2964672-0	1988	The 5-HT1A agonist 8-OH-DPAT increases consumption of palatable wet mash and liquid diets in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2964672-1	1988	The 5-HT1A agonist 8-OH-DPAT, at a dose of 30 micrograms/kg, enhanced the consumption of sweetened wet mash and sweetened milk in non-deprived rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2965396-0	1988	Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	31-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
2965396-3	1988	The 5HT-1a agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), at doses of 0.3-3 mg/kg SC, induced robust contralateral rotational behavior (RB) in 6-OHDA-lesioned rats that had been preselected on the basis of high responsiveness to the atypical DA agonists 3-PPP and SKF 38393.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2965396-3	1988	The 5HT-1a agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), at doses of 0.3-3 mg/kg SC, induced robust contralateral rotational behavior (RB) in 6-OHDA-lesioned rats that had been preselected on the basis of high responsiveness to the atypical DA agonists 3-PPP and SKF 38393.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2970649-1	1988	There have been recent claims that the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) elicits chewing and eating of solid but not liquid foods.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
2970649-1	1988	There have been recent claims that the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) elicits chewing and eating of solid but not liquid foods.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-103	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
3145525-3	1988	Food intake was significantly decreased when the 5-HT1A agonist 8-OH-DPAT was given systemically (1 mg/kg SC) to rats previously deprived of food but was unaffected when 8-OH-DPAT (1 microgram) was infused into the paraventricular nucleus of both food-deprived and free feeding rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
3293039-5	1988	8-OH DPAT and TFMPP also serve as training drugs; the 8-OH DPAT-stimulus generalizes to other 5-HT1A agonists, but not to 5-HT1B or 5-HT2 agonists, whereas the TFMPP-stimulus generalizes to other 5-HT1B agonists, but not to 5-HT1A or 5-HT2 agonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	94-100
3293039-5	1988	8-OH DPAT and TFMPP also serve as training drugs; the 8-OH DPAT-stimulus generalizes to other 5-HT1A agonists, but not to 5-HT1B or 5-HT2 agonists, whereas the TFMPP-stimulus generalizes to other 5-HT1B agonists, but not to 5-HT1A or 5-HT2 agonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1B	Rattus norvegicus	196-202
3293039-5	1988	8-OH DPAT and TFMPP also serve as training drugs; the 8-OH DPAT-stimulus generalizes to other 5-HT1A agonists, but not to 5-HT1B or 5-HT2 agonists, whereas the TFMPP-stimulus generalizes to other 5-HT1B agonists, but not to 5-HT1A or 5-HT2 agonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	224-230
3293039-8	1988	Animals trained to discriminate such agents from saline might be useful for the identification and/or investigation of novel site-selective agonists and antagonists (for example, the 8-OH DPAT-stimulus generalizes to members of a new class of anxiolytics that display high affinity for 5-HT1A binding sites), and might also aid in the overall understanding of central serotonergic mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	183-192	5-hydroxytryptamine receptor 1A	Rattus norvegicus	286-292
2961414-2	1987	Drug competition studies were performed using 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) to compete selectively for 5-HT1A sites, RU 24969 to compete for 5-HT1B sites and mesulergine to compete for 5-HT1C sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	124-130
2963752-0	1987	Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-77	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-111
2963752-1	1987	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a selective serotonin1A receptor agonist, was studied for its anti-immobility activity in the forced swimming test after different schedules of treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	64-84
2826757-0	1987	5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
3443977-8	1987	Spiperone is the most effective antagonist of the response and the selective 5-HT1A agonist, 8-OHDPAT, behaves as a partial agonist at this receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	77-83
2961583-0	1987	Hypothermia induced by the putative 5-HT1A agonists LY165163 and 8-OH-DPAT is not prevented by 5-HT depletion.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
2449711-0	1987	Influence of route of administration on potency of the selective 5HT-1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
2961583-6	1987	Results indicate that the hypothermia induced by the putative 5-HT1A agonists LY165163 and 8-OH-DPAT in the rat is not dependent on presynaptic 5-HT stores and is therefore probably mediated by postsynaptic 5-HT receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
2889611-1	1987	Using iontophoretic techniques we observed that in vivo isapirone (TVX Q 7821), a selective ligand for the 5-HT1A binding site, at low ejection currents (5-30 nA) antagonised 5-HT and 8-hydroxy-2-(di-n-propylamino) tetralin (DPAT)-induced suppression of hippocampal unit activity, with little effect on baseline firing rate itself.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-223	5-hydroxytryptamine receptor 1A	Rattus norvegicus	107-113
3119155-3	1987	A hyperpolarization associated with an increased conductance state and insensitive to 5-HT2 antagonists was observed in 26% of the neurons and could be mimicked by the selective 5-HT1A agonist (+/-)-8-hydroxy-2-(di-N-propyl-amino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	194-238	5-hydroxytryptamine receptor 1A	Homo sapiens	178-184
3119155-3	1987	A hyperpolarization associated with an increased conductance state and insensitive to 5-HT2 antagonists was observed in 26% of the neurons and could be mimicked by the selective 5-HT1A agonist (+/-)-8-hydroxy-2-(di-N-propyl-amino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	240-249	5-hydroxytryptamine receptor 1A	Homo sapiens	178-184
2889611-1	1987	Using iontophoretic techniques we observed that in vivo isapirone (TVX Q 7821), a selective ligand for the 5-HT1A binding site, at low ejection currents (5-30 nA) antagonised 5-HT and 8-hydroxy-2-(di-n-propylamino) tetralin (DPAT)-induced suppression of hippocampal unit activity, with little effect on baseline firing rate itself.	8-Hydroxy-2-(di-n-propylamino)tetralin	225-229	5-hydroxytryptamine receptor 1A	Rattus norvegicus	107-113
2894736-0	1987	[Behavioural effects of 8-OH-DPAT, a 5-HT1A agonist in rats and effects on the behaviour of antimanic drugs].	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
2894736-3	1987	These results indicate that 8-OH-DPAT-induced forepaw treading is produced by the direct stimulation of 5-HT1A receptor postsynaptically and also that this behaviour is not mediated by monoaminergic neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-110
2959487-2	1987	As expected from these observations, the tritiated derivative [3H]5-MeO-DPAC bound to a single class of specific sites which exhibited the same pharmacological properties as 5-HT1A sites labelled by [3H]8-OH-DPAT in hippocampal and cortical membranes.	8-Hydroxy-2-(di-n-propylamino)tetralin	203-212	5-hydroxytryptamine receptor 1A	Rattus norvegicus	174-180
2958302-7	1987	These results suggested that the hypotension and bradycardia induced by 5-MeODMT and 8-OH-DPAT are due to the stimulation of "5-HT1-like" receptors and probably to the 5-HT1A subtype; the 5-MeODMT-induced hypertension being ascribed to the stimulation of 5-HT2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	168-174
2958301-4	1987	Two 5-HT1A ligands, LY165163 and 8-OH-DPAT, mimicked the effect of serotonin, although with slower kinetics.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
2889156-6	1987	In contrast the hypothermic response which follows injection of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin-(8-OHDPAT) is attenuated not only after a range of diverse antidepressant drugs but also electroconvulsive shock.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-130	5-hydroxytryptamine receptor 1A	Homo sapiens	68-82
2889156-6	1987	In contrast the hypothermic response which follows injection of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin-(8-OHDPAT) is attenuated not only after a range of diverse antidepressant drugs but also electroconvulsive shock.	8-Hydroxy-2-(di-n-propylamino)tetralin	132-140	5-hydroxytryptamine receptor 1A	Homo sapiens	68-82
2887435-6	1987	The similar stimulus properties of 8-OHDPAT and the novel anxiolytics (buspirone, ipsapirone) are mirrored by the common abilities of these agents to selectively inhibit 5-HT1A binding and release punished responding.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-43	5-hydroxytryptamine receptor 1A	Homo sapiens	170-176
2956114-3	1987	The corticosterone and beta-END responses to 8-OH-DPAT were antagonized by spiperone and (-)-pindolol, both of which have been shown to have high affinity for the 5-HT1A binding site.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	163-169
3496228-6	1987	The corresponding values for the 5HT1A selective agonists 8-OH-DPAT and ipsapirone were 1.3 and 33 nmol/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Homo sapiens	33-38
2951504-2	1987	The addition of either the 5-HT1A-selective drug 8-OH-DPAT (100 nM) or the 5-HT1C-selective drug mesulergine (100 nM) to the assay resulted in a 5-10% decrease in specific 3H-5-HT binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Bos taurus	27-33
2951504-5	1987	5-HT1A selective agents such as 8-OH-DPAT, ipsapirone, and buspirone display micromolar affinities for these sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Bos taurus	0-6
2883013-2	1987	Therefore, rats were restrained for 2 h and injected with vehicle or 60-1,000 micrograms/kg of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) s.c. Vehicle-treated restrained rats showed reduced locomotor activity and increased defaecation in an open field test the day after the end of restraint.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-153	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
2883013-2	1987	Therefore, rats were restrained for 2 h and injected with vehicle or 60-1,000 micrograms/kg of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) s.c. Vehicle-treated restrained rats showed reduced locomotor activity and increased defaecation in an open field test the day after the end of restraint.	8-Hydroxy-2-(di-n-propylamino)tetralin	155-164	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
2883013-5	1987	Evidence suggests that the above action of 8-OH-DPAT is mediated by 5-HT1A receptors since it was antagonised by the 5-HT1A antagonist spiperone but not by the 5-HT2 antagonist ketanserin and was not mimicked by the 5-HT1B agonist RU 24969.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	68-74
2883013-5	1987	Evidence suggests that the above action of 8-OH-DPAT is mediated by 5-HT1A receptors since it was antagonised by the 5-HT1A antagonist spiperone but not by the 5-HT2 antagonist ketanserin and was not mimicked by the 5-HT1B agonist RU 24969.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	117-123
2883013-5	1987	Evidence suggests that the above action of 8-OH-DPAT is mediated by 5-HT1A receptors since it was antagonised by the 5-HT1A antagonist spiperone but not by the 5-HT2 antagonist ketanserin and was not mimicked by the 5-HT1B agonist RU 24969.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1B	Rattus norvegicus	216-222
2884586-2	1987	The potencies of the drugs were determined at 5-HT1A binding sites labelled by [3H]8-OH-DPAT in hippocampal membranes from the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-52
2881789-0	1987	Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
2881789-0	1987	Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
2881789-1	1987	Male Sprague-Dawley rats were trained to discriminate the putative 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) from saline in a 2-lever operant drug discrimination paradigm.	8-Hydroxy-2-(di-n-propylamino)tetralin	92-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
2881789-3	1987	In contrast, both buspirone and TVX Q 7821, which like 8-OH-DPAT have high affinity and selectivity for the 5-HT1A recognition site, generalized to the 8-OH-DPAT cue in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
2881789-3	1987	In contrast, both buspirone and TVX Q 7821, which like 8-OH-DPAT have high affinity and selectivity for the 5-HT1A recognition site, generalized to the 8-OH-DPAT cue in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	152-161	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
2881789-7	1987	In view of the fact that 8-OH-DPAT has negligible affinity for the 5-HT1B site, the above results are consistent with its discriminative stimulus properties being mediated by the putative 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	188-194
22158750-0	1987	The 5-HT1A agonists 8-OH-DPAT, buspirone and ipsapirone attenuate stress-induced anorexia in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2958885-8	1987	The present results taken in light of 8-OH-DPAT"s preferential binding to 5-HT1A receptors, the high density of these receptors in hippocampus, and the observation that the number of 5-HT1A receptors is decreased in Alzheimer"s disease, suggest a possible role for this serotonergic receptor subtype in memory.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-80
3025366-3	1987	The 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin did not cause stimulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-56	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
2957498-2	1987	We have first designed a photoaffinity ligand containing the structure of 8-OH-DPAT, a potent and specific agonist of 5-HT1A sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	118-124
2954178-0	1987	Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat.	8-Hydroxy-2-(di-n-propylamino)tetralin	143-152	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
2954178-1	1987	The hypothermia and motor behavioural syndrome produced in rats by injection of the 5-HT1A ligand 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) has been studied following administration of electroconvulsive shock under halothane anaesthesia (ECS) and during the administration of antidepressant drugs.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-136	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-90
2954178-1	1987	The hypothermia and motor behavioural syndrome produced in rats by injection of the 5-HT1A ligand 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) has been studied following administration of electroconvulsive shock under halothane anaesthesia (ECS) and during the administration of antidepressant drugs.	8-Hydroxy-2-(di-n-propylamino)tetralin	138-147	5-hydroxytryptamine receptor 1A	Rattus norvegicus	84-90
2957721-7	1987	Thus, while other 5-HT1A agonists such as 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) cause stereotypy, this does not occur with LY165163, probably because the drug blocks DA receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
2947981-3	1986	In the latter case, it was shown that 3H-5-HT binding to 5-HT1A sites corresponded to that displaceable by 0.1 microM 8-OH-DPAT or 1 microM spiperone.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
2947981-4	1986	The "non-5-HT1A" sites labeled by 3H-5-HT in the presence of 0.1 microM 8-OH-DPAT corresponded mainly to 5-HT1B sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	9-15
2947981-4	1986	The "non-5-HT1A" sites labeled by 3H-5-HT in the presence of 0.1 microM 8-OH-DPAT corresponded mainly to 5-HT1B sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1B	Rattus norvegicus	105-111
2951611-6	1986	In contrast, administration of the putative 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) resulted in marked, dose-related hypothermic responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-97	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
2951611-6	1986	In contrast, administration of the putative 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) resulted in marked, dose-related hypothermic responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
2430815-1	1986	Administration of 60 micrograms/kg s.c. of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), a dose previously shown to cause hyperphagia in satiated rats (but not to cause the 5-HT behavioural syndrome) decreased 5-HIAA and 5-HIAA/5-HT ratio in several brain regions, the most marked effects being in pons + medulla oblongata, a region containing 5-HT cell bodies and ascending 5-HT axons.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
2430815-1	1986	Administration of 60 micrograms/kg s.c. of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), a dose previously shown to cause hyperphagia in satiated rats (but not to cause the 5-HT behavioural syndrome) decreased 5-HIAA and 5-HIAA/5-HT ratio in several brain regions, the most marked effects being in pons + medulla oblongata, a region containing 5-HT cell bodies and ascending 5-HT axons.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
3780861-12	1986	The effect of chronic MAO inhibitor treatment on 5-HT1A receptors was associated with a decrease in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin and the decrease in 5-HT2 binding was related to a small reduction in the sensitivity of the inositol phosphate system to stimulation by 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-166	monoamine oxidase A	Rattus norvegicus	22-25
3780861-12	1986	The effect of chronic MAO inhibitor treatment on 5-HT1A receptors was associated with a decrease in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin and the decrease in 5-HT2 binding was related to a small reduction in the sensitivity of the inositol phosphate system to stimulation by 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-166	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
2877677-2	1986	Three drugs that facilitate seminal emissions and/or ejaculations [8-hydroxy-2-n-propylaminotetralin (8-OH-DPAT), 5-methoxy-dimethyltryptamine, and RDS-127] are potent and selective inhibitors of [3H]8-OH-DPAT binding to 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Rattus norvegicus	221-227
2946344-0	1986	Effect of chronic treatment with 5-HT1 agonist (8-OH-DPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine (serotonin) receptor 5A	Mus musculus	145-156
2946344-10	1986	Chronic treatment with 8-OH-DPAT (5 mg kg-1, s.c.) produced a modest enhancement of the 5-HT2 receptor-mediated head-twitch behaviour initiated by 5-hydroxytryptophan injection while chronic isapirone decreased this behavioural response.	8-Hydroxy-2-(di-n-propylamino)tetralin	23-32	hypothermia due to alcohol sensitivity 2	Mus musculus	90-93
2946344-11	1986	5-HT2 receptor number in frontal cortex was unaltered by isapirone treatment but markedly decreased (34%) by chronic 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	hypothermia due to alcohol sensitivity 2	Mus musculus	2-5
2946344-13	1986	7 The data further demonstrate that chronic treatment with 8-OH-DPAT and isapirone alter postsynaptic 5-HT2 receptor function although 5-HT2 receptor number in the frontal cortex did not correlate with the behavioural change.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	hypothermia due to alcohol sensitivity 2	Mus musculus	104-107
22158750-2	1987	The selective 5-HT(1A) agonists 8-hydroxy-2-(di- n-propylamino)tetralin (8-OH-DPAT), buspirone and ipsapirone, when injected 2 h after the termination of stress, attenuated stress-induced anor exia and body weight loss.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-21
22158750-3	1987	The effects of 8-OH-DPAT on stress-induced anorexia were blocked by the 5-HT(1A) antagonist spiperone but not by the 5-HT(2) antagonist ketanserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-79
22158750-7	1987	The data suggest that 8-OH-DPAT, buspirone and ipsapirone attenuate stress-induced anorexia in rodents by a hyperphagic action on 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	130-137
2947249-8	1986	Previous studies have shown that 8-OH-DPAT stimulates central serotonergic receptors, and shows selectivity for the 5-HT1A recognition site.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	116-122
2944752-4	1986	Under UV irradiation (lambda = 366 nm), 8-methoxy-3"-NAP-amino-PAT produced an irreversible blockade of 5-HT1A sites which could be prevented by prior site occupancy by a saturating concentration (10 microM) of reversible 5-HT ligands such as 5-HT itself, 8-OH-DPAT or LSD.	8-Hydroxy-2-(di-n-propylamino)tetralin	256-265	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-110
2944129-1	1986	Using a two-lever operant procedure, eleven rats were trained to discriminate 0.2 mg/kg of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT) from saline using a variable-interval 15 sec schedule of reinforcement.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-148	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-101
2942638-3	1986	Therefore, non-5-HT1A binding in rat frontal cortex was defined as specific [3H]5-HT binding observed in the presence of 100 nM 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	15-21
2942638-8	1986	A homogeneous population of 5-HT1A sites can be directly labeled using [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-76	5-hydroxytryptamine receptor 1B	Sus scrofa	8-14
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-76	5-hydroxytryptamine receptor 2C	Rattus norvegicus	19-25
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-120	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-120	5-hydroxytryptamine receptor 1B	Sus scrofa	8-14
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-120	5-hydroxytryptamine receptor 2C	Rattus norvegicus	19-25
2944129-0	1986	Discriminative stimulus properties of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	57-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
2944129-0	1986	Discriminative stimulus properties of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
3013203-0	1986	Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(DI-n-propylamino)tetralin ([3H]-8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	115-129	5-hydroxytryptamine receptor 1A	Homo sapiens	29-35
3013203-1	1986	Nucleotide interactions were examined at 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	5-hydroxytryptamine receptor 1A	Homo sapiens	41-62
3013203-1	1986	Nucleotide interactions were examined at 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	5-hydroxytryptamine receptor 1A	Homo sapiens	64-70
3016581-8	1986	[3H]8-OH-DPAT HL binding sites were particularly abundant in the hippocampus, septum and cerebral cortex, and exhibited pharmacological properties typical of the postsynaptic 5-HT1A subsites previously characterized with [3H]5-HT as the ligand.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	175-181
2942413-0	1986	[3H]8-OH-DPAT labels the serotonin transporter in the rat striatum.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	solute carrier family 6 member 4	Rattus norvegicus	25-46
3720831-4	1986	The tetralin derivative 8-OH-DPAT, a drug with selective affinity for 5-HT1A binding sites, was a weak partial agonist on veins and completely devoid of any activity on the platelets.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76
2871177-7	1986	On the contrary, the 5-HT1A agonist 8-hydroxy-2-di-N-propylamino)tetralin activated the presynaptic heteroreceptors (pEC30 = 7.98), but was ineffective as a 5-HT autoreceptor agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-73	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-27
2940798-0	1986	A central serotonin receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, has different effects on prolactin secretion in male and female rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	prolactin	Rattus norvegicus	103-112
2940798-1	1986	Male and female rats were compared with respect to alterations in prolactin secretion induced by the serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	128-166	prolactin	Rattus norvegicus	66-75
2940798-1	1986	Male and female rats were compared with respect to alterations in prolactin secretion induced by the serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	prolactin	Rattus norvegicus	66-75
2940798-4	1986	In females, in contrast, 0.1 mg/kg of 8-OH-DPAT tended to decrease serum levels of prolactin, while 0.3, 1, and 3 mg/kg elevated them in a dose dependent manner to maximally 700% of control values.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	prolactin	Rattus norvegicus	83-92
2940798-6	1986	In males, but not in females, pretreatment with 8-OH-DPAT (1 mg/kg) reduced the 5-MeODMT-induced elevation of serum prolactin levels.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	prolactin	Rattus norvegicus	116-125
2940798-7	1986	The mechanism underlying the sexually differentiated effects of 8-OH-DPAT on prolactin secretion is discussed.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	prolactin	Rattus norvegicus	77-86
2942782-2	1986	5-HT and the preferential 5-HT1A receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] concentration-dependently inhibited the evoked 3H overflow.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41
2942782-2	1986	5-HT and the preferential 5-HT1A receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] concentration-dependently inhibited the evoked 3H overflow.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-99	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41
2937644-1	1986	A subcutaneous injection of 0.5 mg/kg 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a drug with high affinity for 5-hydroxytryptamine (5-HT1A) binding sites, substantially increased eating in non-deprived rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	141-147
2937644-1	1986	A subcutaneous injection of 0.5 mg/kg 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a drug with high affinity for 5-hydroxytryptamine (5-HT1A) binding sites, substantially increased eating in non-deprived rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	141-147
2943219-7	1986	These receptors are probably of the 5-HT1A subtype as 8-OH-DPAT has a high affinity for this receptor and other putative 5-HT1A agonist (i.e. buspirone, TVX Q 7821) also elicit feeding.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
3028726-6	1986	The putative agonist for the 5-HT1A receptor 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produces a hypothermic response in mice, apparently by acting as an agonist at presynaptic 5-HT1 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-84	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	29-44
3028726-6	1986	The putative agonist for the 5-HT1A receptor 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produces a hypothermic response in mice, apparently by acting as an agonist at presynaptic 5-HT1 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	29-44
2949056-8	1986	The 5-HT1A agonist 8-OHDPAT inhibited pergolide-induced circling only.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-27	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2944129-1	1986	Using a two-lever operant procedure, eleven rats were trained to discriminate 0.2 mg/kg of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT) from saline using a variable-interval 15 sec schedule of reinforcement.	8-Hydroxy-2-(di-n-propylamino)tetralin	150-159	5-hydroxytryptamine receptor 1A	Rattus norvegicus	95-101
2936976-0	1986	The beta 2-adrenoceptor agonists clenbuterol and salbutamol enhance the hypothermic action of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice by a central mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	94-132	adrenergic receptor, beta 2	Mus musculus	4-23
2936976-0	1986	The beta 2-adrenoceptor agonists clenbuterol and salbutamol enhance the hypothermic action of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice by a central mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	134-143	adrenergic receptor, beta 2	Mus musculus	4-23
2936976-1	1986	The hypothermic response of mice to injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was enhanced by injection of the beta 2-adrenoceptor agonist clenbuterol with an ED50 of 0.4 mg/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-87	adrenergic receptor, beta 2	Mus musculus	133-152
2936976-1	1986	The hypothermic response of mice to injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was enhanced by injection of the beta 2-adrenoceptor agonist clenbuterol with an ED50 of 0.4 mg/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	adrenergic receptor, beta 2	Mus musculus	133-152
2942955-1	1986	The peripheral administration of the serotonin type 1A (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT) inhibited lordosis behavior in ovariectomized rats primed with estradiol benzoate.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
2942955-1	1986	The peripheral administration of the serotonin type 1A (5-HT1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT) inhibited lordosis behavior in ovariectomized rats primed with estradiol benzoate.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	56-62
2941817-6	1986	In rats the hypothermia induced by 8-OH-DPAT was partially antagonised by TVX Q 7821 while the behavioural "serotonin syndrome" induced by 8-OH-DPAT (a possible post-synaptic 5-HT1B-mediated effect) was unaffected by TVX Q 7821 as was the locomotion induced by RU 24969.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	5-hydroxytryptamine receptor 1B	Rattus norvegicus	175-181
2947256-2	1986	The treatment of rats for 4 or 7 days with nialamide (40 mg/kg, twice daily) resulted in a suppression of the hypothermic effect of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.05-0.25 mg/kg, SC).	8-Hydroxy-2-(di-n-propylamino)tetralin	151-190	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
2949333-0	1986	The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Rattus norvegicus	34-40
2935410-2	1985	[3H]8-OH-DPAT bound in rat and pig cortex to the 5-HT1A recognition site characterized by high affinity for 5-CT (5-carboxamido-tryptamine), 8-OH-DPAT, 5-HT (5-hydroxytryptamine, serotonin) and low affinity for pirenperone, ketanserin and mesulergine.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
2935410-2	1985	[3H]8-OH-DPAT bound in rat and pig cortex to the 5-HT1A recognition site characterized by high affinity for 5-CT (5-carboxamido-tryptamine), 8-OH-DPAT, 5-HT (5-hydroxytryptamine, serotonin) and low affinity for pirenperone, ketanserin and mesulergine.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
2935410-4	1985	[3H]Mesulergine bound in pig choroid plexus and in rat cortex (besides binding to 5-HT2 sites in rat cortex) to the 5-HT1C recognition site characterized by high affinity for metergoline, mesulergine, 5-HT and methergine and low affinity for (-)21-009, ICYP, 8-OH-DPAT and spiroperidol.	8-Hydroxy-2-(di-n-propylamino)tetralin	259-268	5-hydroxytryptamine receptor 2C	Rattus norvegicus	116-122
3002805-9	1985	The low affinity of 5-HT1B recognition sites for some 5-HT1A, 5-HT1C and 5-HT2 selective compounds (e.g. 8-OH-DPAT, mesulergine, ketanserin) suggests that 5-HT1B recognition sites are pharmacologically different from 5-HT1A, 5-HT1C and 5-HT2 recognition sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1B	Rattus norvegicus	20-26
2931606-2	1985	Recently a new drug, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), has been identified which shows high selectivity for binding to 5-HT1 (possibly 5-HT1A) receptors and which binds to presynaptic serotonin autoreceptors in some regions of rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	137-142
2931606-2	1985	Recently a new drug, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), has been identified which shows high selectivity for binding to 5-HT1 (possibly 5-HT1A) receptors and which binds to presynaptic serotonin autoreceptors in some regions of rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-159
2931606-2	1985	Recently a new drug, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), has been identified which shows high selectivity for binding to 5-HT1 (possibly 5-HT1A) receptors and which binds to presynaptic serotonin autoreceptors in some regions of rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	137-142
2931606-2	1985	Recently a new drug, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), has been identified which shows high selectivity for binding to 5-HT1 (possibly 5-HT1A) receptors and which binds to presynaptic serotonin autoreceptors in some regions of rat brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-159
4041865-2	1985	5-HT1A binding sites were directly labeled with [3H]8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) in bovine hippocampal membranes.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Bos taurus	0-6
3160596-0	1985	Differential selectivities of RU 24969 and 8-OH-DPAT for the purported 5-HT1A and 5-HT1B binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	71-77
3160596-0	1985	Differential selectivities of RU 24969 and 8-OH-DPAT for the purported 5-HT1A and 5-HT1B binding sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1B	Rattus norvegicus	82-88
3160596-4	1985	Following addition of spiperone (1 microM) as a selective ligand for the putative 5-HT1A recognition site of [3H]5-HT, the displacement curve of RU 24969 underwent a leftward shift, whereas spiperone induced a shift to the right for the displacement curve of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	259-268	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
3160596-9	1985	Based on the proposal that the 5-HT1A site corresponds to the high affinity site of 8-OH-DPAT and the low affinity site of RU 24969, it is hypothesized that the late depressor phase of 5-HT agonists in rats is mediated by activation of peripheral (vascular) 5-HT receptors which have similarities with the 5-HT1A subtype of central 5-HT1 recognition site.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
2580582-2	1985	These techniques have also indicated that certain drugs appear to show sub-type specificity: 8-hydroxy-2-(di-n-propylamino)tetralin(8-OH-DPAT), a 5-HT1A agonist; 5-methoxy-3(1,2,3,6-tetrahydropyridin-4-yl)1-H indole (RU 24969), a 5-HT1B agonist; and ritanserin, a 5-HT2 antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	132-141	5-hydroxytryptamine receptor 1B	Rattus norvegicus	230-236
6238235-2	1984	Experiments have been carried out to provide direct evidence for the proposed presynaptic 5-HT autoreceptor agonist activity of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) a compound with selectivity for the 5-HT1A subtype of the 5-HT1 binding site.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-167	5-hydroxytryptamine receptor 1A	Rattus norvegicus	216-222
2933490-5	1986	Spiperone and 8-hydroxy-2-(di-n-propylamino)tetralin, two compounds that discriminate [3H]5-HT binding to 5-HT1A and 5-HT1B sites, inhibited [3H]PAPP binding in accordance with their much higher affinities for the 5-HT1A receptor subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-123
2933490-5	1986	Spiperone and 8-hydroxy-2-(di-n-propylamino)tetralin, two compounds that discriminate [3H]5-HT binding to 5-HT1A and 5-HT1B sites, inhibited [3H]PAPP binding in accordance with their much higher affinities for the 5-HT1A receptor subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	14-52	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
6241568-1	1984	The centrally active 5-HT receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) has a high affinity for the 5-HT1A subtype of the 5-HT1 recognition site in cerebral membranes and, in the rat, induces most aspects of the "5-HT behavioural syndrome" including hyperlocomotion, head weaving, a flat body posture and reciprocal forepaw treading.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-81	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
6241568-1	1984	The centrally active 5-HT receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) has a high affinity for the 5-HT1A subtype of the 5-HT1 recognition site in cerebral membranes and, in the rat, induces most aspects of the "5-HT behavioural syndrome" including hyperlocomotion, head weaving, a flat body posture and reciprocal forepaw treading.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
6241568-7	1984	The residual behavioural effects of 8-OH-DPAT in reserpinised rats may, therefore, reflect the consequences of stimulation of the putative 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	139-145
6238235-2	1984	Experiments have been carried out to provide direct evidence for the proposed presynaptic 5-HT autoreceptor agonist activity of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) a compound with selectivity for the 5-HT1A subtype of the 5-HT1 binding site.	8-Hydroxy-2-(di-n-propylamino)tetralin	169-178	5-hydroxytryptamine receptor 1A	Rattus norvegicus	216-222
6238235-9	1984	Moreover, the fact that 8-OH-DPAT is inactive at the autoreceptor at concentrations selective for the 5-HT1A recognition site suggests that this subtype of the 5-HT1 binding site may not correspond to the 5-HT autoreceptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-108
34030210-8	2021	In vitro, apigenin behaved as a positive allosteric modulator (PAM) to increase the efficacy (stimulation of [35 S] GTPgammaS binding) of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-175	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	142-157
33607166-3	2021	galanin did not impair retention in the passive avoidance (PA) test 24 h after training, but attenuated the retention deficit caused by subcutaneous (s.c.) administration of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	202-211	galanin and GMAP prepropeptide	Mus musculus	0-7
33607166-3	2021	galanin did not impair retention in the passive avoidance (PA) test 24 h after training, but attenuated the retention deficit caused by subcutaneous (s.c.) administration of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	202-211	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	178-193
33854099-11	2021	We screened 5 reported neuroprotectants and provide the first report that serotonin is antiapoptotic in a stroke model and the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) is neuroprotective in PC12 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	142-181	5-hydroxytryptamine receptor 1A	Rattus norvegicus	127-133
33384591-6	2020	The [3H]-8-OH-DPAT binding assay was used to determine the pharmacological interaction of CBD with 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	5-hydroxytryptamine receptor 1A	Homo sapiens	99-105
33058959-10	2021	TKO mice also showed increased responsiveness of DRN 5-HT-1A autoreceptors, measured as a reduced dose of the 5-HT-1A agonist 8-OH-DPAT necessary to inhibit DRN 5-HT firing activity by 50%.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	53-60
32352556-8	2020	By contrast, the 5-HT1A agonist R(+)-8-OH-DPAT inhibited evoked EPSCs in saline, but not CFA-injected rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
32396921-5	2020	The results show that intra-mPFC infusion of the 5-HT1A receptor agonist 8-OH-DPAT induces rapid and long-lasting antidepressant-like effects in the forced swim, novelty-suppressed feeding, female urine sniffing, and chronic unpredictable stress tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	49-64
32396921-6	2020	In addition, the results demonstrate that the antidepressant-like effects of intra-mPFC infusion of 8-OH-DPAT are blocked by co-infusion of an AMPA receptor antagonist or an anti-BDNF neutralizing antibody.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	brain derived neurotrophic factor	Homo sapiens	179-183
32396921-7	2020	In addition, mPFC infusion of 8-OH-DPAT increased the phosphorylation of signaling proteins downstream of BDNF, including mTOR, ERK, 4EBP1, and p70S6K.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	brain derived neurotrophic factor	Homo sapiens	106-110
32396921-7	2020	In addition, mPFC infusion of 8-OH-DPAT increased the phosphorylation of signaling proteins downstream of BDNF, including mTOR, ERK, 4EBP1, and p70S6K.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	mechanistic target of rapamycin kinase	Homo sapiens	122-126
32396921-7	2020	In addition, mPFC infusion of 8-OH-DPAT increased the phosphorylation of signaling proteins downstream of BDNF, including mTOR, ERK, 4EBP1, and p70S6K.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	mitogen-activated protein kinase 1	Homo sapiens	128-131
32396921-7	2020	In addition, mPFC infusion of 8-OH-DPAT increased the phosphorylation of signaling proteins downstream of BDNF, including mTOR, ERK, 4EBP1, and p70S6K.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	nuclear factor kappa B subunit 1	Homo sapiens	134-138
32396921-7	2020	In addition, mPFC infusion of 8-OH-DPAT increased the phosphorylation of signaling proteins downstream of BDNF, including mTOR, ERK, 4EBP1, and p70S6K.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	ribosomal protein S6 kinase B1	Homo sapiens	144-150
32533210-7	2020	RESULTS: Perinatal FLX exposure shortened the free-running tau in response to the 5-HT1A/7 agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-90
32561651-10	2020	In vitro, chrysin (0.1-10 nM) increased the maximum effect (Emax, shown as stimulation of [35S] GTPgammaS binding) of 8-OH-DPAT, a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	131-137
32733195-10	2020	These effects of J147 were blocked by pretreatment with a 5-HT1A antagonist NAD-299 and enhanced by a 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	102-108
32312154-6	2020	RESULTS: Social isolation led to a pronounced increase in aggressive behaviour, which was dose-dependently inhibited by the 5-HT1AR agonist 8-OH-DPAT (0.1, 0.3 and 1 mg/kg intraperitoneally (i.p.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	124-131
32312154-8	2020	The effects of 8-OH-DPAT on aggression, huddling and grooming were blocked by pretreatment with a selective 5-HT1AR antagonist (WAY-100635; 0.1 mg/kg i.p.).	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	108-115
32229140-7	2020	treatment with 8-OH-DPAT alone or together with basic fibroblast growth factor (FGF2) significantly increased FGFR1-5-HT1AR heterocomplexes in the GFAP positive cells, especially in the polyformic layer of the dentate gyrus (PoDG) but also in the CA3 area upon combined treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	fibroblast growth factor 2	Homo sapiens	80-84
31634501-9	2020	Although inhibiting 5-HT7 receptors with SB266990 did not affect locomotor pattern organization, activating 5-HT1A receptors with 8-OH-DPAT specifically deteriorated extensor phase motor burst activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
32229140-7	2020	treatment with 8-OH-DPAT alone or together with basic fibroblast growth factor (FGF2) significantly increased FGFR1-5-HT1AR heterocomplexes in the GFAP positive cells, especially in the polyformic layer of the dentate gyrus (PoDG) but also in the CA3 area upon combined treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	fibroblast growth factor receptor 1	Homo sapiens	110-115
32229140-7	2020	treatment with 8-OH-DPAT alone or together with basic fibroblast growth factor (FGF2) significantly increased FGFR1-5-HT1AR heterocomplexes in the GFAP positive cells, especially in the polyformic layer of the dentate gyrus (PoDG) but also in the CA3 area upon combined treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	glial fibrillary acidic protein	Homo sapiens	147-151
32229140-7	2020	treatment with 8-OH-DPAT alone or together with basic fibroblast growth factor (FGF2) significantly increased FGFR1-5-HT1AR heterocomplexes in the GFAP positive cells, especially in the polyformic layer of the dentate gyrus (PoDG) but also in the CA3 area upon combined treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	carbonic anhydrase 3	Homo sapiens	247-250
32315693-4	2020	Additionally, to establish a correlation between the behavioral effects in drug discrimination and changes in dopamine (DA) and gamma-aminobutyric acid (GABA) concentrations, we evaluated the effect of systemic administration of low or high doses of the 5-HT1A receptor agonist 8-OH-DPAT and of the 5-HT1A receptor antagonist WAY100135 on DA and GABA extracellular concentrations in the nucleus accumbens (nAcc) and ventral tegmental area (VTA), respectively, using cerebral microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	278-287	5-hydroxytryptamine receptor 1A	Homo sapiens	254-269
31637976-8	2020	In the dorsal raphe caudal subnucleus, animals were injected with kainic acid, WAY-100635 or the serotonin 1A receptor agonist 8-OH-DPAT ((+-)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide) and tested in the elevated T-maze.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-196	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-118
32315693-0	2020	Administration of low doses of the 5-HT1A receptor agonist 8-OH-DPAT attenuates the discriminative signal of amphetamine in the conditioned taste aversion procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	35-50
32315693-1	2020	Several studies have reported that low doses of the 5-HT1A receptor agonist 8-OH-DPAT reduce cocaine-induced locomotor activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Homo sapiens	52-67
32315693-3	2020	This study aimed to evaluate the effects of low and high doses of the 5-HT1A agonist 8-OH-DPAT on the discriminative signal of AMPH using conditioned taste aversion as a drug discrimination procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76
32256369-9	2020	In vitro, isorhynchophylline (0.1-10 nM) increased the Emax (stimulation of [35S] GTPgammaS binding) of 8-OH-DPAT, a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	117-123
32194374-7	2020	TAAR5-KO mice also showed significant decreases in the tissue levels of serotonin and its metabolite in several brain areas and were more sensitive to the hypothermic action of serotonin 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propilamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	251-260	trace amine-associated receptor 5	Mus musculus	0-5
28951000-6	2020	Treatment of nos1-/- zebrafish with the 5-HT receptor 1A agonist 8-OH-DPAT rescues aggression and some aspects of anxiety-like behaviour.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-74	nitric oxide synthase 1 (neuronal)	Danio rerio	13-17
31823197-3	2020	The activity of 5-HT1A receptors was assessed by (+)-8-OH-DPAT-induced hypothermia and [35S]GTPgammaS binding autoradiography.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-62	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	16-22
31377402-7	2019	Threshold to induce NMDA receptor (NMDAr)-dependent long-term potentiation (LTP) was declined in VCD-mice with elevation of CaMKII phosphorylation, which was sensitive to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	35-40
31377402-9	2019	In addition, NMDAr-independent long-term depression (LTD) could not be induced in VCD-mice, which was rescued by the co-application of 8-OH-DPAT with DOI or the GABAA receptor agonist muscimol.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	13-18
31289857-4	2019	The 5-HT1A agonist 8-OH-DPAT (0.0125-0.1 mg/kg subcutaneous) increased impulsive action at low doses, but decreased it at higher doses, on the novel paced variable consecutive number with discriminative stimulus task (VCN).	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10
31289857-7	2019	We hypothesize that the biphasic effect of 8-OH-DPAT is due to actions on presynaptic raphe 5-HT1A autoreceptors, and also postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98
31289857-7	2019	We hypothesize that the biphasic effect of 8-OH-DPAT is due to actions on presynaptic raphe 5-HT1A autoreceptors, and also postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	136-142
30858018-6	2019	Likewise, intra-dlPAG injection of the 5-HT1A receptor agonist 8-OH-DPAT (3.2 nmol/0.2 u L) also reduced anxiety-like behavior, a response prevented by intra-dlPAG injection of AM251 (100 pmol/0.2 microL).	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Homo sapiens	39-54
31377402-7	2019	Threshold to induce NMDA receptor (NMDAr)-dependent long-term potentiation (LTP) was declined in VCD-mice with elevation of CaMKII phosphorylation, which was sensitive to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	20-33
31555094-6	2019	The same analysis was conducted in hyposerotonergic mice with concomitant administration of the 5-HT1 A receptor agonist, 8-Hydroxy-2-(di-n- propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	122-162	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	96-112
31555094-6	2019	The same analysis was conducted in hyposerotonergic mice with concomitant administration of the 5-HT1 A receptor agonist, 8-Hydroxy-2-(di-n- propylamino) tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	164-173	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	96-112
31555094-8	2019	Seven-day treatment with 8-OH-DPAT reestablished the expression of pro-BDNF modified by PCPA, and induced an increase in the expression of p75 receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	brain derived neurotrophic factor	Mus musculus	71-75
31555094-8	2019	Seven-day treatment with 8-OH-DPAT reestablished the expression of pro-BDNF modified by PCPA, and induced an increase in the expression of p75 receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	nerve growth factor receptor (TNFR superfamily, member 16)	Mus musculus	139-142
31130845-5	2019	In addition, the high expression of GS and EAAT2 induced by glaucoma was downregulated by the 5-HT1A receptor agonist 8-OH-DPAT and the 5-HT1A receptor antagonist WAY-100635, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	118-127	solute carrier family 1 member 2	Rattus norvegicus	43-48
30789290-3	2019	AIMS: The aim of the present study was to investigate: 1) 8-OH-DPAT (5-HT1A agonist), AS19 (5-HT7 agonist) and muscimol (GABA-A agonist) on memory retrieval and state of memory, 2) cross state-dependent learning between 8-OH-DPAT and/or AS19 and muscimol.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	69-75
30789290-13	2019	Pre-test administration of a selective GABA-A receptor antagonist, bicuculline, 5 min before muscimol, 8-OH-DPAT and AS19 dose-dependently inhibited muscimol-, 8-OH-DPAT- and AS19-induced SDL, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	39-45
30789290-13	2019	Pre-test administration of a selective GABA-A receptor antagonist, bicuculline, 5 min before muscimol, 8-OH-DPAT and AS19 dose-dependently inhibited muscimol-, 8-OH-DPAT- and AS19-induced SDL, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	160-169	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	39-45
30789290-14	2019	CONCLUSIONS: The results strongly revealed a cross SDL among 8-OH-DPAT and/or AS19 and muscimol in the dorsal hippocampal CA1 regions.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	carbonic anhydrase 1	Mus musculus	122-125
31378723-13	2019	CONCLUSION: It may be concluded that buspirone and 8-OHDPAT improves extrapyramidal symptoms in a haloperidol-induced Parkinsonism model probably via activation of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	164-170
30902681-6	2019	Moreover, the 5-HT1A agonist 8-OH-DPAT induced a reduction of fEPSP amplitude similar to that induced by 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
31130845-8	2019	In summary, 8-OH-DPAT decreases and increases GS and EAAT2 expression of glaucomatous retina, respectively, while decreasing sEPSC and mEPSC frequency.	8-Hydroxy-2-(di-n-propylamino)tetralin	12-21	solute carrier family 1 member 2	Rattus norvegicus	53-58
30607822-5	2019	Mice with or without mTBI received intracerebroventricular injections of 5-HT1A receptor agonist (8-OH-DPAT) or antagonist (WAY-100635) for 5 days, then animals were subjected to behavioral tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	73-88
30607822-8	2019	Activation of 5-HT1A receptor by a subthreshold dose of 8-OH-DPAT led to a significant decrease in depression-like behaviors, whereas blockade of 5-HT1A receptor by a subthreshold dose of WAY-100635 resulted in a considerable increase in depression-like phenotypes in mTBI-induced mice.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	14-29
30541912-2	2019	However, the neuroprotective functional implications and synaptic mechanism of 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT), a serotonin receptor (5-HT1A) agonist, in an adult male Wistar rat model of chronic glaucoma model remain unknown.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-119	5-hydroxytryptamine receptor 1A	Rattus norvegicus	155-161
30460515-11	2019	Co-administration of a cannabinoid agonist and the 5-HT1A agonist 8-OH-DPAT results in a synergistic effect on LLR.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	51-57
30541912-2	2019	However, the neuroprotective functional implications and synaptic mechanism of 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT), a serotonin receptor (5-HT1A) agonist, in an adult male Wistar rat model of chronic glaucoma model remain unknown.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	155-161
30541912-4	2019	The protective effects of 8-OH-DPAT were blocked by intravitreal administration of the selective 5-HT1A antagonist WAY-100635 or the selective GABAA receptor antagonist SR95531.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
30541912-8	2019	The 8-OH-DPAT-induced changes at the synaptic level were enhanced by PKA inhibition by H-89 and blocked by PKA activation with bucladesine.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	69-72
30541912-8	2019	The 8-OH-DPAT-induced changes at the synaptic level were enhanced by PKA inhibition by H-89 and blocked by PKA activation with bucladesine.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	107-110
30541912-9	2019	Furthermore, the density of phosphorylated PKA (p-PKA)/PKA was significantly increased in glaucomatous retinas and 8-OH-DPAT significantly decreased p-PKA/PKA expression, which led to the inhibition of PKA phosphorylation upon relieving neurotransmitter GABA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	43-46
30541912-9	2019	Furthermore, the density of phosphorylated PKA (p-PKA)/PKA was significantly increased in glaucomatous retinas and 8-OH-DPAT significantly decreased p-PKA/PKA expression, which led to the inhibition of PKA phosphorylation upon relieving neurotransmitter GABA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	50-53
30541912-9	2019	Furthermore, the density of phosphorylated PKA (p-PKA)/PKA was significantly increased in glaucomatous retinas and 8-OH-DPAT significantly decreased p-PKA/PKA expression, which led to the inhibition of PKA phosphorylation upon relieving neurotransmitter GABA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	50-53
30541912-9	2019	Furthermore, the density of phosphorylated PKA (p-PKA)/PKA was significantly increased in glaucomatous retinas and 8-OH-DPAT significantly decreased p-PKA/PKA expression, which led to the inhibition of PKA phosphorylation upon relieving neurotransmitter GABA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	50-53
30541912-9	2019	Furthermore, the density of phosphorylated PKA (p-PKA)/PKA was significantly increased in glaucomatous retinas and 8-OH-DPAT significantly decreased p-PKA/PKA expression, which led to the inhibition of PKA phosphorylation upon relieving neurotransmitter GABA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	50-53
30541912-9	2019	Furthermore, the density of phosphorylated PKA (p-PKA)/PKA was significantly increased in glaucomatous retinas and 8-OH-DPAT significantly decreased p-PKA/PKA expression, which led to the inhibition of PKA phosphorylation upon relieving neurotransmitter GABA release.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	50-53
30541912-12	2019	Therefore, phosphorylated protein kinase A (PKA) inhibition upon release of the neurotransmitter GABA was eliminated by 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT), which led to increased levels of GABAergic mIPSCs in ON- and OFF-type RGCs, thus enhancing RGC viability and function.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-160	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	26-42
30541912-12	2019	Therefore, phosphorylated protein kinase A (PKA) inhibition upon release of the neurotransmitter GABA was eliminated by 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT), which led to increased levels of GABAergic mIPSCs in ON- and OFF-type RGCs, thus enhancing RGC viability and function.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-160	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	44-47
30541912-12	2019	Therefore, phosphorylated protein kinase A (PKA) inhibition upon release of the neurotransmitter GABA was eliminated by 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT), which led to increased levels of GABAergic mIPSCs in ON- and OFF-type RGCs, thus enhancing RGC viability and function.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	26-42
30541912-12	2019	Therefore, phosphorylated protein kinase A (PKA) inhibition upon release of the neurotransmitter GABA was eliminated by 8-hydroxy-2- (di-n-propylamino) tetralin (8-OH-DPAT), which led to increased levels of GABAergic mIPSCs in ON- and OFF-type RGCs, thus enhancing RGC viability and function.	8-Hydroxy-2-(di-n-propylamino)tetralin	162-171	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	44-47